| SemMedDB Concept | ERG | PC | Shared | Score | Mean CP | Mean Odds | Hierarchy |
|---|
| SemMedDB Concept | Observed | Expected | Odds Ratio | P-value | Corrected P-value |
|---|---|---|---|---|---|
| Gland structure:0 | 12/867 | 17,877/26,262,527 | 20.60 | 2.03e-12 | 4.15e-11 |
| TRANSCRIPTION FACTOR:0 | 58/867 | 73,851/26,262,527 | 25.42 | 1.85e-58 | 2.02e-56 |
| Fusion Gene:0 | 50/867 | 3,748/26,262,527 | 428.77 | 4.09e-111 | 8.38e-109 |
| Genomic Instability:0 | 5/867 | 3,926/26,262,527 | 38.80 | 2.72e-07 | 3.42e-06 |
| CAP - NOS:0 | 13/867 | 2,768/26,262,527 | 144.41 | 4.32e-24 | 1.57e-22 |
| DNA Binding:0 | 7/867 | 8,694/26,262,527 | 24.58 | 2.43e-08 | 3.62e-07 |
| Glutaminase:0 | 7/867 | 754/26,262,527 | 283.50 | 1.16e-15 | 3.18e-14 |
| Reporter:0 | 7/867 | 11,671/26,262,527 | 18.31 | 1.75e-07 | 2.29e-06 |
| epitheliasin|TMPRSS2:0 | 36/867 | 246/26,262,527 | 4624.86 | 9.41e-117 | 2.20e-114 |
| epitheliasin:0 | 3/867 | 20/26,262,527 | 4559.46 | 6.35e-11 | 1.21e-09 |
| Specimen from prostate:0 | 38/867 | 1,141/26,262,527 | 1055.02 | 1.19e-99 | 2.16e-97 |
| ERG:0 | 4/867 | 33/26,262,527 | 3688.68 | 7.78e-14 | 1.77e-12 |
| Proto-Oncogenes:0 | 7/867 | 8,723/26,262,527 | 24.50 | 2.49e-08 | 3.67e-07 |
| Chromosomal Rearrangement:0 | 18/867 | 1,838/26,262,527 | 302.92 | 1.68e-38 | 1.06e-36 |
| Malignant neoplasm of prostate:0 | 427/867 | 129,049/26,262,527 | 196.52 | 0.00e+00 | 0.00e+00 |
| Urine:0 | 31/867 | 29,355/26,262,527 | 33.14 | 1.10e-35 | 6.19e-34 |
| DELETION:0 | 13/867 | 20,760/26,262,527 | 19.24 | 5.80e-13 | 1.23e-11 |
| Enhancer:0 | 7/867 | 7,241/26,262,527 | 29.51 | 7.05e-09 | 1.13e-07 |
| Transcription factor genes:0 | 10/867 | 1,385/26,262,527 | 221.25 | 1.04e-20 | 3.28e-19 |
| Prostate-Specific Antigen:0 | 22/867 | 14,799/26,262,527 | 46.18 | 6.28e-29 | 2.78e-27 |
| Prostate cancer metastatic:0 | 22/867 | 7,354/26,262,527 | 92.95 | 1.67e-35 | 9.13e-34 |
| elk-1 protein:0 | 5/867 | 100/26,262,527 | 1523.34 | 3.73e-15 | 9.40e-14 |
| Cancer Model:0 | 7/867 | 4,416/26,262,527 | 48.40 | 2.40e-10 | 4.32e-09 |
| Infantile fibrosarcoma:0 | 3/867 | 349/26,262,527 | 261.28 | 2.56e-07 | 3.25e-06 |
| Epithelial Cells:0 | 18/867 | 126,298/26,262,527 | 4.39 | 4.03e-07 | 5.03e-06 |
| PCA3:0 | 23/867 | 189/26,262,527 | 3786.67 | 2.26e-73 | 3.09e-71 |
| Fluorescent in Situ Hybridization:0 | 49/867 | 14,341/26,262,527 | 109.64 | 3.54e-80 | 5.28e-78 |
| Gel Shift Analysis:0 | 3/867 | 188/26,262,527 | 485.05 | 4.08e-08 | 5.86e-07 |
| Transcription, Genetic:0 | 47/867 | 90,323/26,262,527 | 16.61 | 1.38e-39 | 9.84e-38 |
| Gene Fusion:0 | 13/867 | 311/26,262,527 | 1285.45 | 2.73e-36 | 1.60e-34 |
| Immunohistochemistry:0 | 26/867 | 40,249/26,262,527 | 20.14 | 8.01e-25 | 3.05e-23 |
| Prostatic Intraepithelial Neoplasias:0 | 7/867 | 1,354/26,262,527 | 157.87 | 6.78e-14 | 1.56e-12 |
| Tumor stage:0 | 6/867 | 3,763/26,262,527 | 48.63 | 4.54e-09 | 7.43e-08 |
| Common Carcinoma:0 | 3/867 | 205/26,262,527 | 444.82 | 5.27e-08 | 7.38e-07 |
| Prostatic epithelium:0 | 7/867 | 924/26,262,527 | 231.34 | 4.78e-15 | 1.17e-13 |
| Transcript:0 | 11/867 | 20,496/26,262,527 | 16.45 | 1.74e-10 | 3.20e-09 |
| Aggressive behavior:0 | 10/867 | 27,698/26,262,527 | 11.05 | 4.72e-08 | 6.66e-07 |
| ETV5:0 | 9/867 | 1,240/26,262,527 | 222.15 | 8.53e-19 | 2.59e-17 |
| Raised prostate specific antigen:0 | 7/867 | 829/26,262,527 | 257.85 | 2.25e-15 | 5.84e-14 |
| ETS Variant Gene 6 Protein|ETV6:0 | 5/867 | 220/26,262,527 | 692.43 | 1.77e-13 | 3.92e-12 |
| ETS Family Gene:0 | 6/867 | 37/26,262,527 | 4946.32 | 7.75e-21 | 2.49e-19 |
| Androgen therapy:0 | 6/867 | 5,391/26,262,527 | 33.94 | 3.74e-08 | 5.42e-07 |
| ETV2:0 | 3/867 | 166/26,262,527 | 549.33 | 2.82e-08 | 4.12e-07 |
| Gene Rearrangement:0 | 8/867 | 1,607/26,262,527 | 152.19 | 1.47e-15 | 3.88e-14 |
| Neoplasm progression:0 | 41/867 | 37,131/26,262,527 | 35.06 | 1.58e-47 | 1.29e-45 |
| Transcriptional Regulation:0 | 8/867 | 9,809/26,262,527 | 24.93 | 2.19e-09 | 3.70e-08 |
| SPOP:0 | 3/867 | 117/26,262,527 | 779.39 | 1.00e-08 | 1.55e-07 |
| integral to membrane:0 | 27/867 | 13,201/26,262,527 | 63.91 | 7.61e-39 | 4.98e-37 |
| Transfection:0 | 10/867 | 17,763/26,262,527 | 17.24 | 7.45e-10 | 1.28e-08 |
| Carcinogens:0 | 15/867 | 29,931/26,262,527 | 15.43 | 2.29e-13 | 4.93e-12 |
| Prostatectomy:0 | 9/867 | 3,080/26,262,527 | 89.43 | 2.85e-15 | 7.28e-14 |
| Prostatic secretions:0 | 3/867 | 461/26,262,527 | 197.80 | 5.86e-07 | 7.11e-06 |
| Ets Variant Protein 1|ETV1:0 | 4/867 | 107/26,262,527 | 1137.63 | 7.04e-12 | 1.41e-10 |
| Prostatic Neoplasms:0 | 26/867 | 3,143/26,262,527 | 258.30 | 4.49e-53 | 4.33e-51 |
| Neoplasm Metastasis:0 | 18/867 | 100,066/26,262,527 | 5.54 | 1.35e-08 | 2.05e-07 |
| ETV1 gene|ETV1:0 | 19/867 | 379/26,262,527 | 1552.56 | 7.70e-54 | 7.88e-52 |
| NKX3-1 gene|NKX3-1:0 | 4/867 | 278/26,262,527 | 437.86 | 3.02e-10 | 5.37e-09 |
| Acute Erythroblastic Leukemia:0 | 9/867 | 7,204/26,262,527 | 38.23 | 5.24e-12 | 1.06e-10 |
| Tissue specimen:0 | 15/867 | 20,806/26,262,527 | 22.21 | 1.29e-15 | 3.47e-14 |
| ETS1 gene|ETS1:0 | 61/867 | 3,178/26,262,527 | 625.35 | 6.93e-145 | 1.89e-142 |
| Chicken Cells:0 | 4/867 | 1,872/26,262,527 | 65.02 | 5.78e-07 | 7.06e-06 |
| Digital Rectal Examination:0 | 4/867 | 1,378/26,262,527 | 88.33 | 1.72e-07 | 2.27e-06 |
| DNA Sequence:0 | 25/867 | 102,730/26,262,527 | 7.56 | 3.50e-14 | 8.18e-13 |
| Tissue specimen from prostate:0 | 4/867 | 282/26,262,527 | 431.65 | 3.20e-10 | 5.62e-09 |
| 5q21:0 | 3/867 | 107/26,262,527 | 852.23 | 7.72e-09 | 1.20e-07 |
| ETV6 gene|ETV6:0 | 10/867 | 843/26,262,527 | 363.51 | 7.58e-23 | 2.70e-21 |
| Needle biopsy procedure:0 | 10/867 | 5,778/26,262,527 | 53.03 | 1.42e-14 | 3.41e-13 |
| SPINK1 gene|SPINK1:0 | 6/867 | 642/26,262,527 | 285.06 | 1.26e-13 | 2.81e-12 |
| Carcinogenesis:0 | 23/867 | 60,832/26,262,527 | 11.74 | 4.10e-17 | 1.18e-15 |
| Biopsy:0 | 47/867 | 137,987/26,262,527 | 10.85 | 1.43e-31 | 6.67e-30 |
| Prostate carcinoma:0 | 20/867 | 10,986/26,262,527 | 56.42 | 3.71e-28 | 1.60e-26 |
| ETV4:0 | 15/867 | 556/26,262,527 | 831.58 | 7.45e-39 | 4.98e-37 |
| ETS1 protein, human|ETS1:0 | 3/867 | 104/26,262,527 | 876.82 | 7.10e-09 | 1.13e-07 |
| PTEN gene|PTEN:0 | 45/867 | 16,075/26,262,527 | 89.38 | 7.06e-70 | 8.89e-68 |
| TMPRSS2 gene|TMPRSS2:0 | 148/867 | 267/26,262,527 | 20246.67 | 0.00e+00 | 0.00e+00 |
| AR gene|AR:0 | 23/867 | 4,311/26,262,527 | 165.99 | 9.00e-43 | 6.70e-41 |
| TNM category pT:0 | 3/867 | 107/26,262,527 | 852.23 | 7.72e-09 | 1.20e-07 |
| Chromosomal translocation:0 | 21/867 | 6,997/26,262,527 | 93.14 | 5.52e-34 | 2.82e-32 |
| FLVCR1:0 | 10/867 | 2,066/26,262,527 | 148.32 | 5.50e-19 | 1.70e-17 |
| ELK1 gene|ELK1:0 | 10/867 | 1,051/26,262,527 | 291.57 | 6.75e-22 | 2.30e-20 |
| Ewings sarcoma:0 | 6/867 | 8,391/26,262,527 | 21.80 | 4.89e-07 | 6.06e-06 |
| PROSTATE SPECIFIC:0 | 4/867 | 196/26,262,527 | 621.05 | 7.59e-11 | 1.43e-09 |
| Specimen:0 | 7/867 | 6,593/26,262,527 | 32.41 | 3.73e-09 | 6.16e-08 |
| GA-Binding Protein Transcription Factor:0 | 3/867 | 53/26,262,527 | 1720.55 | 9.92e-10 | 1.69e-08 |
| ETV4 gene|ETV4:0 | 15/867 | 120/26,262,527 | 3853.05 | 1.63e-48 | 1.49e-46 |
| Tumor Suppressor Genes:0 | 12/867 | 33,756/26,262,527 | 10.91 | 2.58e-09 | 4.32e-08 |
| Pathologic stage:0 | 4/867 | 1,244/26,262,527 | 97.85 | 1.15e-07 | 1.55e-06 |
| Androgens:0 | 40/867 | 38,318/26,262,527 | 33.10 | 1.87e-45 | 1.46e-43 |
| Transcriptional Activation:0 | 11/867 | 17,807/26,262,527 | 18.94 | 4.02e-11 | 7.74e-10 |
| High-Risk Cancer:0 | 6/867 | 7,468/26,262,527 | 24.50 | 2.49e-07 | 3.19e-06 |
| Serum Response Factor:0 | 6/867 | 2,279/26,262,527 | 80.30 | 2.34e-10 | 4.26e-09 |
| Adenocarcinoma of prostate:0 | 11/867 | 2,164/26,262,527 | 155.94 | 5.62e-21 | 1.84e-19 |
| fluorouracil/methotrexate protocol:0 | 5/867 | 321/26,262,527 | 474.56 | 1.14e-12 | 2.37e-11 |
| Utrophin|UTRN:0 | 4/867 | 711/26,262,527 | 171.20 | 1.25e-08 | 1.91e-07 |
| Prostate:0 | 214/867 | 82,025/26,262,527 | 104.60 | 0.00e+00 | 0.00e+00 |
| Tumorigenesis:0 | 34/867 | 42,358/26,262,527 | 25.27 | 4.31e-35 | 2.28e-33 |
| [M]Unspecified tumor cell NOS:0 | 25/867 | 75,073/26,262,527 | 10.36 | 3.23e-17 | 9.43e-16 |
| Erythroblastosis:0 | 3/867 | 507/26,262,527 | 179.86 | 7.78e-07 | 9.23e-06 |
| KLK3 gene|KLK3:0 | 17/867 | 9,016/26,262,527 | 58.24 | 2.09e-24 | 7.79e-23 |
| cohort:0 | 45/867 | 121,378/26,262,527 | 11.79 | 8.54e-32 | 4.11e-30 |
| SP1 gene|SP1:0 | 7/867 | 8,423/26,262,527 | 25.37 | 1.96e-08 | 2.95e-07 |
| epitheliasin|ERG:0 | 16/867 | 36/26,262,527 | 13715.89 | 1.79e-59 | 2.09e-57 |
| Trans-Activation (Genetics):0 | 6/867 | 7,069/26,262,527 | 25.88 | 1.81e-07 | 2.36e-06 |
| leukemia:0 | 21/867 | 53,501/26,262,527 | 12.16 | 4.58e-16 | 1.27e-14 |
| Retroviridae:0 | 8/867 | 14,532/26,262,527 | 16.82 | 4.43e-08 | 6.31e-07 |
| PCA3 gene|PCA3:0 | 10/867 | 100/26,262,527 | 3064.46 | 6.82e-32 | 3.38e-30 |
| High-Grade Prostatic Intraepithelial Neoplasia:0 | 17/867 | 1,431/26,262,527 | 367.03 | 7.43e-38 | 4.50e-36 |
| Tumor focality:0 | 9/867 | 228/26,262,527 | 1208.24 | 2.47e-25 | 9.87e-24 |
| Proto-Oncogene Proteins c-ets:0 | 51/867 | 672/26,262,527 | 2442.51 | 4.29e-151 | 1.41e-148 |
| Family member:0 | 11/867 | 19,277/26,262,527 | 17.49 | 9.20e-11 | 1.71e-09 |
| Adenocarcinoma:0 | 19/867 | 90,559/26,262,527 | 6.48 | 4.59e-10 | 8.00e-09 |
| Binding Sites:0 | 20/867 | 59,087/26,262,527 | 10.47 | 3.43e-14 | 8.14e-13 |
| ERG gene|ERG:0 | 178/867 | 1,893/26,262,527 | 3583.90 | 0.00e+00 | 0.00e+00 |
| Prostatic Tissue:0 | 16/867 | 5,110/26,262,527 | 96.61 | 1.57e-26 | 6.59e-25 |
| ETS Family Protein:0 | 29/867 | 391/26,262,527 | 2324.38 | 3.38e-86 | 5.53e-84 |
| overdiagnosis:0 | 3/867 | 278/26,262,527 | 328.02 | 1.30e-07 | 1.73e-06 |
| SLC45A3:0 | 4/867 | 15/26,262,527 | 8115.11 | 4.57e-15 | 1.13e-13 |
| White American:0 | 3/867 | 500/26,262,527 | 182.38 | 7.47e-07 | 8.92e-06 |
| Leukemia, Myelocytic, Acute:0 | 14/867 | 65,224/26,262,527 | 6.59 | 6.64e-08 | 9.21e-07 |
| Gleason grading system for prostatic cancer:0 | 6/867 | 887/26,262,527 | 206.32 | 8.59e-13 | 1.80e-11 |
| Candidate Disease Gene:0 | 17/867 | 53,728/26,262,527 | 9.76 | 7.95e-12 | 1.57e-10 |
| Oncogene Proteins:0 | 17/867 | 8,427/26,262,527 | 62.31 | 6.76e-25 | 2.64e-23 |
| Oncogenes:0 | 9/867 | 9,037/26,262,527 | 30.47 | 3.81e-11 | 7.43e-10 |
| Radical prostatectomy:0 | 33/867 | 15,642/26,262,527 | 66.39 | 1.34e-47 | 1.16e-45 |
| ELF3 gene|ELF3:0 | 4/867 | 600/26,262,527 | 202.87 | 6.37e-09 | 1.03e-07 |
| Cancer Diagnosis:0 | 17/867 | 3,927/26,262,527 | 133.73 | 1.83e-30 | 8.30e-29 |
| Amino Acids|ASAH1:0 | 2/867 | 29/26,262,527 | 2093.88 | 5.06e-07 | 6.23e-06 |
| cDNA Library:0 | 8/867 | 16,096/26,262,527 | 15.19 | 9.59e-08 | 1.32e-06 |
| Chromosomes, Human, Pair 11:0 | 5/867 | 3,274/26,262,527 | 46.52 | 1.12e-07 | 1.52e-06 |
| Tissue Microarray:0 | 10/867 | 2,648/26,262,527 | 115.72 | 6.43e-18 | 1.91e-16 |
| Endopeptidases:0 | 24/867 | 40,740/26,262,527 | 18.32 | 4.12e-22 | 1.43e-20 |
| Fusion Protein:0 | 16/867 | 23,054/26,262,527 | 21.40 | 2.62e-16 | 7.41e-15 |
| Androgen Receptor|AR:0 | 17/867 | 13,713/26,262,527 | 38.28 | 2.25e-21 | 7.51e-20 |
| Disease Progression:0 | 9/867 | 28,836/26,262,527 | 9.54 | 7.30e-07 | 8.79e-06 |
| Promoter Regions (Genetics):0 | 6/867 | 6,625/26,262,527 | 27.62 | 1.24e-07 | 1.67e-06 |
| ETS2 Protein:0 | 2/867 | 18/26,262,527 | 3373.48 | 2.07e-07 | 2.66e-06 |
| Chromosomes, Human, Pair 21:0 | 14/867 | 2,920/26,262,527 | 147.60 | 5.86e-26 | 2.40e-24 |
| Aggressive cancer:0 | 7/867 | 1,584/26,262,527 | 134.94 | 2.01e-13 | 4.39e-12 |
| SemMedDB Concept | Observed | Expected | Odds Ratio | P-value | Corrected P-value |
|---|---|---|---|---|---|
| Antithymoglobulin:0 | 7/138,393 | 8,973/26,262,527 | 0.15 | 8.72e-13 | 9.87e-12 |
| Entire genitourinary tract:0 | 64/138,393 | 709/26,262,527 | 17.14 | 1.06e-53 | 4.92e-52 |
| Arteriosclerosis:0 | 6/138,393 | 5,697/26,262,527 | 0.20 | 2.95e-07 | 2.03e-06 |
| Nephritis:0 | 2/138,393 | 7,208/26,262,527 | 0.05 | 4.87e-14 | 6.06e-13 |
| hepatoma cell:0 | 10/138,393 | 7,691/26,262,527 | 0.25 | 2.23e-08 | 1.74e-07 |
| Prior Chemotherapy:0 | 35/138,393 | 1,195/26,262,527 | 5.56 | 2.86e-15 | 3.84e-14 |
| Deformity:0 | 8/138,393 | 18,641/26,262,527 | 0.08 | 1.36e-31 | 3.60e-30 |
| Mammary Neoplasms:0 | 237/138,393 | 21,389/26,262,527 | 2.10 | 2.42e-24 | 4.93e-23 |
| PIM-1 Serine/Threonine Kinase|PIM1:0 | 17/138,393 | 314/26,262,527 | 10.28 | 4.58e-12 | 4.92e-11 |
| Left atrial structure:0 | 2/138,393 | 10,491/26,262,527 | 0.04 | 3.02e-21 | 5.45e-20 |
| Cerebral Ischemia:0 | 3/138,393 | 16,214/26,262,527 | 0.04 | 1.65e-32 | 4.49e-31 |
| Etoposide:0 | 224/138,393 | 20,728/26,262,527 | 2.05 | 7.84e-22 | 1.45e-20 |
| HIF1alpha protein:0 | 101/138,393 | 5,793/26,262,527 | 3.31 | 1.14e-23 | 2.25e-22 |
| Disseminated carcinoma:0 | 19/138,393 | 269/26,262,527 | 13.41 | 2.93e-15 | 3.93e-14 |
| Cyclin D1|CCND1:0 | 247/138,393 | 12,653/26,262,527 | 3.71 | 7.67e-64 | 4.34e-62 |
| procalcitonin:0 | 1/138,393 | 6,565/26,262,527 | 0.03 | 7.18e-14 | 8.82e-13 |
| SLC43A1 gene|SLC43A1:0 | 5/138,393 | 9/26,262,527 | 105.43 | 7.62e-09 | 6.24e-08 |
| Levamisole:0 | 2/138,393 | 6,229/26,262,527 | 0.06 | 7.59e-12 | 8.02e-11 |
| Puncture biopsy:0 | 94/138,393 | 1,334/26,262,527 | 13.38 | 5.73e-69 | 3.49e-67 |
| teleost:0 | 1/138,393 | 3,504/26,262,527 | 0.05 | 4.47e-07 | 3.00e-06 |
| Technetium Tc 99m Medronate:0 | 28/138,393 | 718/26,262,527 | 7.40 | 1.98e-15 | 2.67e-14 |
| Teams:0 | 45/138,393 | 17,095/26,262,527 | 0.50 | 2.51e-07 | 1.74e-06 |
| Nerve Fibers:0 | 11/138,393 | 8,342/26,262,527 | 0.25 | 8.38e-09 | 6.81e-08 |
| Clients:0 | 13/138,393 | 13,213/26,262,527 | 0.19 | 2.40e-16 | 3.41e-15 |
| Vasodilator Agents:0 | 1/138,393 | 6,551/26,262,527 | 0.03 | 7.07e-14 | 8.69e-13 |
| Rivers:0 | 1/138,393 | 3,764/26,262,527 | 0.05 | 1.01e-07 | 7.30e-07 |
| Leuprolide Acetate|PGR|PR@|PRH2|TMEM37|ERVK-10:0 | 21/138,393 | 25/26,262,527 | 159.43 | 7.87e-36 | 2.41e-34 |
| Energy, Physics:0 | 90/138,393 | 46,134/26,262,527 | 0.37 | 3.65e-29 | 8.90e-28 |
| histone deacetylase activity:0 | 13/138,393 | 366/26,262,527 | 6.74 | 1.66e-07 | 1.17e-06 |
| Esthesia:0 | 11/138,393 | 9,091/26,262,527 | 0.23 | 3.88e-10 | 3.56e-09 |
| Thrombocytopenia:0 | 57/138,393 | 25,242/26,262,527 | 0.43 | 1.81e-13 | 2.15e-12 |
| small molecule:0 | 266/138,393 | 16,058/26,262,527 | 3.15 | 2.56e-55 | 1.23e-53 |
| NDRG1 gene|NDRG1:0 | 24/138,393 | 493/26,262,527 | 9.24 | 1.93e-15 | 2.61e-14 |
| Chromosomal Rearrangement:0 | 28/138,393 | 1,838/26,262,527 | 2.89 | 1.37e-06 | 8.69e-06 |
| Octreotide|BGLAP:0 | 9/138,393 | 40/26,262,527 | 42.70 | 5.08e-12 | 5.45e-11 |
| Cytoplasmic Granules:0 | 11/138,393 | 7,812/26,262,527 | 0.27 | 4.80e-08 | 3.59e-07 |
| Persistent infection:0 | 7/138,393 | 8,704/26,262,527 | 0.15 | 2.26e-12 | 2.48e-11 |
| Radiotherapy planning:0 | 26/138,393 | 393/26,262,527 | 12.56 | 1.18e-19 | 1.98e-18 |
| Endocytosis:0 | 35/138,393 | 13,815/26,262,527 | 0.48 | 1.26e-06 | 8.06e-06 |
| Flow Cytometry:0 | 259/138,393 | 23,238/26,262,527 | 2.12 | 1.09e-26 | 2.44e-25 |
| ^103^Palladium:0 | 21/138,393 | 31/26,262,527 | 128.57 | 2.11e-34 | 6.10e-33 |
| Critical Illness:0 | 4/138,393 | 48,155/26,262,527 | 0.02 | 2.83e-102 | 2.51e-100 |
| Prostate cancer metastatic:0 | 4,113/138,393 | 7,354/26,262,527 | 109.35 | 0.00e+00 | 0.00e+00 |
| Non-alcoholic fatty liver:0 | 4/138,393 | 43,876/26,262,527 | 0.02 | 1.59e-92 | 1.28e-90 |
| Rats, Inbred WKY:0 | 1/138,393 | 6,516/26,262,527 | 0.03 | 1.08e-13 | 1.31e-12 |
| magnetic resonance spectroscopic imaging:0 | 49/138,393 | 206/26,262,527 | 45.15 | 6.08e-60 | 3.22e-58 |
| Cancer Model:0 | 568/138,393 | 4,416/26,262,527 | 24.51 | 0.00e+00 | 0.00e+00 |
| Immunologic Deficiency Syndromes:0 | 142/138,393 | 16,838/26,262,527 | 1.60 | 2.18e-07 | 1.51e-06 |
| Soy bean product:0 | 13/138,393 | 132/26,262,527 | 18.69 | 1.37e-12 | 1.53e-11 |
| Urine cytology:0 | 28/138,393 | 747/26,262,527 | 7.11 | 5.07e-15 | 6.70e-14 |
| TRANCE protein:0 | 54/138,393 | 2,523/26,262,527 | 4.06 | 6.38e-17 | 9.41e-16 |
| Interleukin-17:0 | 17/138,393 | 13,901/26,262,527 | 0.23 | 6.43e-15 | 8.42e-14 |
| Bacillus subtilis:0 | 1/138,393 | 12,731/26,262,527 | 0.01 | 1.02e-27 | 2.37e-26 |
| Peripheral Nerves:0 | 12/138,393 | 12,001/26,262,527 | 0.19 | 8.04e-15 | 1.05e-13 |
| Not significant:0 | 46/138,393 | 3,312/26,262,527 | 2.64 | 1.15e-08 | 9.18e-08 |
| KLF6:0 | 20/138,393 | 479/26,262,527 | 7.92 | 5.75e-12 | 6.13e-11 |
| Transgenic Model:0 | 213/138,393 | 4,452/26,262,527 | 9.09 | 2.58e-122 | 2.79e-120 |
| Oxidative Stress:0 | 261/138,393 | 81,493/26,262,527 | 0.61 | 2.55e-18 | 4.03e-17 |
| Hypothalamic structure:0 | 30/138,393 | 53,237/26,262,527 | 0.11 | 5.02e-81 | 3.55e-79 |
| Oxalates:0 | 1/138,393 | 3,293/26,262,527 | 0.06 | 1.33e-06 | 8.49e-06 |
| Brain-Derived Neurotrophic Factor:0 | 7/138,393 | 25,919/26,262,527 | 0.05 | 2.66e-48 | 1.13e-46 |
| Antibiotic therapy:0 | 15/138,393 | 8,668/26,262,527 | 0.33 | 3.28e-07 | 2.24e-06 |
| ORALIT:0 | 39/138,393 | 2,406/26,262,527 | 3.08 | 2.70e-09 | 2.31e-08 |
| Pepsinogens:0 | 1/138,393 | 4,064/26,262,527 | 0.05 | 2.42e-08 | 1.87e-07 |
| Gingivitis:0 | 2/138,393 | 3,880/26,262,527 | 0.10 | 5.97e-07 | 3.96e-06 |
| Stromal Cells:0 | 477/138,393 | 26,512/26,262,527 | 3.42 | 1.83e-109 | 1.73e-107 |
| VTN gene|VTN:0 | 11/138,393 | 62/26,262,527 | 33.67 | 2.17e-13 | 2.56e-12 |
| Oncolytic Virotherapy:0 | 12/138,393 | 261/26,262,527 | 8.73 | 3.41e-08 | 2.59e-07 |
| Jaundice, Obstructive:0 | 7/138,393 | 7,977/26,262,527 | 0.17 | 6.16e-11 | 6.05e-10 |
| Spinal Fusion:0 | 2/138,393 | 3,772/26,262,527 | 0.10 | 1.26e-06 | 8.08e-06 |
| integral to membrane:0 | 187/138,393 | 13,201/26,262,527 | 2.69 | 3.67e-31 | 9.63e-30 |
| Complement System Proteins:0 | 102/138,393 | 40,770/26,262,527 | 0.47 | 1.73e-17 | 2.61e-16 |
| Transcript:0 | 183/138,393 | 20,496/26,262,527 | 1.70 | 5.91e-11 | 5.81e-10 |
| Sodium Channel:0 | 8/138,393 | 8,283/26,262,527 | 0.18 | 8.74e-11 | 8.48e-10 |
| Diethylstilbestrol:0 | 361/138,393 | 10,507/26,262,527 | 6.53 | 8.87e-162 | 1.31e-159 |
| Hemophilia A:0 | 12/138,393 | 16,702/26,262,527 | 0.14 | 8.80e-24 | 1.76e-22 |
| Myocardial Contraction:0 | 4/138,393 | 6,121/26,262,527 | 0.12 | 9.06e-10 | 8.07e-09 |
| Kidney Transplantation:0 | 38/138,393 | 21,569/26,262,527 | 0.33 | 4.13e-16 | 5.79e-15 |
| Corneal endothelial cell:0 | 1/138,393 | 3,558/26,262,527 | 0.05 | 3.02e-07 | 2.07e-06 |
| Cancer of Urethra:0 | 15/138,393 | 246/26,262,527 | 11.57 | 1.67e-11 | 1.71e-10 |
| Focal Adhesion Protein-Tyrosine Kinases:0 | 92/138,393 | 9,239/26,262,527 | 1.89 | 3.58e-08 | 2.71e-07 |
| tissue polypeptide specific antigen:0 | 12/138,393 | 371/26,262,527 | 6.14 | 1.26e-06 | 8.04e-06 |
| Entire thumb:0 | 3/138,393 | 6,485/26,262,527 | 0.09 | 2.28e-11 | 2.31e-10 |
| circulating cancer cell:0 | 34/138,393 | 233/26,262,527 | 27.70 | 1.05e-35 | 3.20e-34 |
| Fatty Acids, Omega-6:0 | 44/138,393 | 2,127/26,262,527 | 3.93 | 1.33e-13 | 1.60e-12 |
| estromustine:0 | 9/138,393 | 23/26,262,527 | 74.26 | 7.52e-14 | 9.22e-13 |
| Cholesterol:0 | 183/138,393 | 78,273/26,262,527 | 0.44 | 1.10e-36 | 3.48e-35 |
| RAC-Alpha Serine/Threonine Kinase|AKT1:0 | 73/138,393 | 7,395/26,262,527 | 1.87 | 1.16e-06 | 7.45e-06 |
| Structure of arteriole:0 | 10/138,393 | 12,160/26,262,527 | 0.16 | 1.59e-16 | 2.28e-15 |
| Structure of articular cartilage:0 | 1/138,393 | 11,844/26,262,527 | 0.02 | 1.27e-25 | 2.73e-24 |
| Partial excision of liver NOS:0 | 2/138,393 | 3,982/26,262,527 | 0.10 | 4.37e-07 | 2.94e-06 |
| Sleeplessness:0 | 18/138,393 | 11,804/26,262,527 | 0.29 | 8.09e-11 | 7.86e-10 |
| Spontaneous abortion:0 | 5/138,393 | 12,463/26,262,527 | 0.08 | 7.93e-22 | 1.47e-20 |
| Vagotomy:0 | 1/138,393 | 3,680/26,262,527 | 0.05 | 1.43e-07 | 1.02e-06 |
| Endoscopic Retrograde Cholangiopancreatography:0 | 2/138,393 | 4,975/26,262,527 | 0.08 | 3.07e-09 | 2.60e-08 |
| Free Calcium:0 | 9/138,393 | 11,738/26,262,527 | 0.15 | 1.36e-16 | 1.96e-15 |
| trichostatin A:0 | 84/138,393 | 7,897/26,262,527 | 2.02 | 9.47e-09 | 7.66e-08 |
| Seeds:0 | 57/138,393 | 19,557/26,262,527 | 0.55 | 1.14e-06 | 7.35e-06 |
| Androgen Metabolism:0 | 39/138,393 | 158/26,262,527 | 46.85 | 1.35e-48 | 5.73e-47 |
| Endometriosis, site unspecified:0 | 58/138,393 | 34,669/26,262,527 | 0.32 | 1.02e-26 | 2.27e-25 |
| MAP2K4:0 | 24/138,393 | 945/26,262,527 | 4.82 | 9.12e-10 | 8.12e-09 |
| Cell Death:0 | 980/138,393 | 74,554/26,262,527 | 2.51 | 5.79e-136 | 7.05e-134 |
| Heparin:0 | 50/138,393 | 50,120/26,262,527 | 0.19 | 2.72e-58 | 1.39e-56 |
| Metals, Heavy:0 | 19/138,393 | 10,804/26,262,527 | 0.33 | 1.12e-08 | 9.01e-08 |
| Penicillamine:0 | 2/138,393 | 9,391/26,262,527 | 0.04 | 1.05e-18 | 1.68e-17 |
| Hyperthermia, Local:0 | 25/138,393 | 569/26,262,527 | 8.34 | 4.70e-15 | 6.22e-14 |
| FRAGMENTS:0 | 57/138,393 | 25,411/26,262,527 | 0.43 | 1.12e-13 | 1.35e-12 |
| Epstein-Barr Virus Infections:0 | 5/138,393 | 5,434/26,262,527 | 0.17 | 1.51e-07 | 1.07e-06 |
| Glycosylation End Products, Advanced:0 | 9/138,393 | 7,861/26,262,527 | 0.22 | 2.85e-09 | 2.43e-08 |
| Acute Disease:0 | 1/138,393 | 6,031/26,262,527 | 0.03 | 1.44e-12 | 1.60e-11 |
| Transferrin|TF:0 | 13/138,393 | 10,504/26,262,527 | 0.23 | 1.97e-11 | 2.01e-10 |
| Linear accelerator electrons procedure:0 | 17/138,393 | 283/26,262,527 | 11.40 | 9.59e-13 | 1.08e-11 |
| GRPR gene|GRPR:0 | 31/138,393 | 99/26,262,527 | 59.44 | 1.02e-41 | 3.71e-40 |
| Fracture Fixation, Internal:0 | 9/138,393 | 18,502/26,262,527 | 0.09 | 2.23e-30 | 5.68e-29 |
| Reperfusion Injury:0 | 2/138,393 | 30,360/26,262,527 | 0.01 | 9.97e-66 | 5.81e-64 |
| Proto-Oncogene Protein pp60 (c-src)|SRC:0 | 168/138,393 | 14,960/26,262,527 | 2.13 | 3.32e-18 | 5.21e-17 |
| Breast adenocarcinoma:0 | 51/138,393 | 2,999/26,262,527 | 3.23 | 2.13e-12 | 2.34e-11 |
| Potassium:0 | 5/138,393 | 31,281/26,262,527 | 0.03 | 7.60e-63 | 4.23e-61 |
| Streptokinase:0 | 3/138,393 | 10,656/26,262,527 | 0.05 | 2.65e-20 | 4.57e-19 |
| Cholecystokinin:0 | 2/138,393 | 10,734/26,262,527 | 0.04 | 1.05e-21 | 1.93e-20 |
| branched chain fatty acid:0 | 23/138,393 | 513/26,262,527 | 8.51 | 3.79e-14 | 4.75e-13 |
| Castration Cell:0 | 150/138,393 | 314/26,262,527 | 90.75 | 3.89e-218 | 8.02e-216 |
| Buffers:0 | 46/138,393 | 32,719/26,262,527 | 0.27 | 7.34e-30 | 1.84e-28 |
| PA2024:0 | 6/138,393 | 9/26,262,527 | 126.52 | 9.97e-11 | 9.64e-10 |
| Positioning - therapy:0 | 22/138,393 | 420/26,262,527 | 9.94 | 6.78e-15 | 8.87e-14 |
| clopidogrel:0 | 4/138,393 | 14,299/26,262,527 | 0.05 | 5.15e-27 | 1.16e-25 |
| Methadone:0 | 4/138,393 | 8,566/26,262,527 | 0.09 | 1.05e-14 | 1.36e-13 |
| Acetaldehyde:0 | 2/138,393 | 6,592/26,262,527 | 0.06 | 1.28e-12 | 1.43e-11 |
| Transforming Growth Factor beta Receptors:0 | 32/138,393 | 2,244/26,262,527 | 2.71 | 1.01e-06 | 6.54e-06 |
| Bicarbonates:0 | 5/138,393 | 12,959/26,262,527 | 0.07 | 6.65e-23 | 1.29e-21 |
| Entire periprostatic tissue:0 | 26/138,393 | 56/26,262,527 | 88.12 | 6.34e-39 | 2.13e-37 |
| Local Anesthetics:0 | 9/138,393 | 9,049/26,262,527 | 0.19 | 1.76e-11 | 1.80e-10 |
| Uterus:0 | 226/138,393 | 77,192/26,262,527 | 0.55 | 1.81e-22 | 3.43e-21 |
| sexual dimorphism:0 | 1/138,393 | 3,312/26,262,527 | 0.06 | 8.67e-07 | 5.67e-06 |
| Dental Pulp:0 | 1/138,393 | 9,713/26,262,527 | 0.02 | 7.62e-21 | 1.35e-19 |
| Senile Plaques:0 | 13/138,393 | 37,771/26,262,527 | 0.07 | 1.39e-66 | 8.22e-65 |
| CK2:0 | 20/138,393 | 341/26,262,527 | 11.13 | 1.52e-14 | 1.94e-13 |
| Factor VIII-Related Antigen:0 | 10/138,393 | 14,034/26,262,527 | 0.14 | 2.61e-20 | 4.50e-19 |
| Carcinoma, Neuroendocrine:0 | 45/138,393 | 2,981/26,262,527 | 2.87 | 1.48e-09 | 1.29e-08 |
| VIM gene|VIM:0 | 78/138,393 | 3,030/26,262,527 | 4.89 | 1.71e-28 | 4.07e-27 |
| Repression:0 | 43/138,393 | 3,460/26,262,527 | 2.36 | 8.06e-07 | 5.29e-06 |
| Gastric Emptying:0 | 1/138,393 | 9,920/26,262,527 | 0.02 | 2.51e-21 | 4.53e-20 |
| Tartrates:0 | 12/138,393 | 337/26,262,527 | 6.76 | 4.77e-07 | 3.19e-06 |
| Chromatography:0 | 29/138,393 | 20,808/26,262,527 | 0.26 | 1.11e-19 | 1.86e-18 |
| Varicocele:0 | 9/138,393 | 7,200/26,262,527 | 0.24 | 4.77e-08 | 3.57e-07 |
| Dexmedetomidine:0 | 2/138,393 | 6,931/26,262,527 | 0.05 | 2.07e-13 | 2.45e-12 |
| Right ventricular structure:0 | 4/138,393 | 19,424/26,262,527 | 0.04 | 4.43e-38 | 1.45e-36 |
| Cystine:0 | 2/138,393 | 4,000/26,262,527 | 0.09 | 4.53e-07 | 3.04e-06 |
| Nutritional Support:0 | 4/138,393 | 5,254/26,262,527 | 0.14 | 5.27e-08 | 3.91e-07 |
| SLC25A4 protein, human|SLC25A4:0 | 56/138,393 | 1,744/26,262,527 | 6.10 | 2.83e-25 | 5.98e-24 |
| Platelet rich plasma:0 | 1/138,393 | 4,287/26,262,527 | 0.04 | 8.26e-09 | 6.72e-08 |
| basolateral membrane:0 | 4/138,393 | 7,022/26,262,527 | 0.11 | 1.50e-11 | 1.55e-10 |
| Dyslipidemias:0 | 26/138,393 | 19,927/26,262,527 | 0.25 | 6.44e-20 | 1.09e-18 |
| Hydroxyl Radical:0 | 8/138,393 | 7,062/26,262,527 | 0.21 | 2.09e-08 | 1.63e-07 |
| Psychotic symptom:0 | 1/138,393 | 3,255/26,262,527 | 0.06 | 1.25e-06 | 8.03e-06 |
| anti-apoptosis:0 | 101/138,393 | 5,946/26,262,527 | 3.23 | 6.99e-23 | 1.35e-21 |
| ABNORMAL GROWTH:0 | 30/138,393 | 790/26,262,527 | 7.21 | 3.99e-16 | 5.60e-15 |
| Endocarditis:0 | 4/138,393 | 15,316/26,262,527 | 0.05 | 3.44e-29 | 8.39e-28 |
| Posterior lobe of prostate:0 | 5/138,393 | 8/26,262,527 | 118.61 | 4.92e-09 | 4.09e-08 |
| Ectopic Expression:0 | 56/138,393 | 2,216/26,262,527 | 4.80 | 1.38e-20 | 2.42e-19 |
| Latex:0 | 1/138,393 | 4,783/26,262,527 | 0.04 | 6.46e-10 | 5.83e-09 |
| Creatinine:0 | 38/138,393 | 15,682/26,262,527 | 0.46 | 7.07e-08 | 5.19e-07 |
| Gonadal Steroid Hormones:0 | 154/138,393 | 9,516/26,262,527 | 3.07 | 9.28e-32 | 2.47e-30 |
| Radium therapy:0 | 8/138,393 | 129/26,262,527 | 11.77 | 7.82e-07 | 5.14e-06 |
| Retinitis Pigmentosa:0 | 1/138,393 | 7,459/26,262,527 | 0.03 | 6.09e-16 | 8.45e-15 |
| Electroconvulsive Therapy:0 | 8/138,393 | 11,171/26,262,527 | 0.14 | 2.25e-16 | 3.21e-15 |
| Eligard:0 | 9/138,393 | 16/26,262,527 | 106.75 | 5.66e-15 | 7.46e-14 |
| PTH protein, human|PTH:0 | 37/138,393 | 22,807/26,262,527 | 0.31 | 1.40e-18 | 2.25e-17 |
| Kidney Tubules, Proximal:0 | 18/138,393 | 21,142/26,262,527 | 0.16 | 1.15e-27 | 2.67e-26 |
| Neoplastic Processes:0 | 23/138,393 | 1,074/26,262,527 | 4.06 | 4.20e-08 | 3.16e-07 |
| Gout:0 | 10/138,393 | 8,951/26,262,527 | 0.21 | 1.14e-10 | 1.10e-09 |
| Gammaretrovirus:0 | 36/138,393 | 219/26,262,527 | 31.20 | 2.25e-39 | 7.65e-38 |
| Support Groups:0 | 18/138,393 | 516/26,262,527 | 6.62 | 1.01e-09 | 8.92e-09 |
| Heart Transplantation:0 | 8/138,393 | 10,854/26,262,527 | 0.14 | 1.28e-15 | 1.75e-14 |
| DNA Repair:0 | 124/138,393 | 12,898/26,262,527 | 1.83 | 1.32e-09 | 1.16e-08 |
| FLVCR1:0 | 369/138,393 | 2,066/26,262,527 | 33.98 | 0.00e+00 | 0.00e+00 |
| Carcinoma:0 | 4,988/138,393 | 144,987/26,262,527 | 6.74 | 0.00e+00 | 0.00e+00 |
| Cystic Fibrosis:0 | 8/138,393 | 67,785/26,262,527 | 0.02 | 1.28e-139 | 1.62e-137 |
| Neuraminidase:0 | 17/138,393 | 12,347/26,262,527 | 0.26 | 2.72e-12 | 2.96e-11 |
| Teacher:0 | 3/138,393 | 4,938/26,262,527 | 0.12 | 3.28e-08 | 2.49e-07 |
| Cyproterone Acetate:0 | 236/138,393 | 3,875/26,262,527 | 11.58 | 5.34e-157 | 7.59e-155 |
| Xenograft Model:0 | 604/138,393 | 9,453/26,262,527 | 12.17 | 0.00e+00 | 0.00e+00 |
| enterodiol:0 | 11/138,393 | 249/26,262,527 | 8.38 | 1.85e-07 | 1.29e-06 |
| Finasteride 5 MG:0 | 5/138,393 | 30/26,262,527 | 31.63 | 1.13e-06 | 7.26e-06 |
| Lung excision:0 | 6/138,393 | 5,590/26,262,527 | 0.20 | 3.89e-07 | 2.64e-06 |
| Dimethyl Sulfoxide:0 | 25/138,393 | 15,807/26,262,527 | 0.30 | 1.39e-13 | 1.67e-12 |
| Urease:0 | 1/138,393 | 4,611/26,262,527 | 0.04 | 1.30e-09 | 1.14e-08 |
| Peptic Ulcer:0 | 6/138,393 | 21,161/26,262,527 | 0.05 | 2.66e-39 | 8.98e-38 |
| Argipressin|AVP:0 | 2/138,393 | 16,931/26,262,527 | 0.02 | 1.87e-35 | 5.64e-34 |
| Stem cells:0 | 596/138,393 | 66,239/26,262,527 | 1.71 | 4.41e-33 | 1.23e-31 |
| Telomerase|EREG|ESR1:0 | 4/138,393 | 12/26,262,527 | 63.26 | 1.31e-06 | 8.33e-06 |
| Pathologic stage:0 | 294/138,393 | 1,244/26,262,527 | 44.94 | 0.00e+00 | 0.00e+00 |
| GDF15 gene|GDF15:0 | 22/138,393 | 509/26,262,527 | 8.20 | 2.69e-13 | 3.16e-12 |
| Androgen replacement therapy:0 | 15/138,393 | 237/26,262,527 | 12.01 | 1.01e-11 | 1.06e-10 |
| California:0 | 59/138,393 | 2,000/26,262,527 | 5.60 | 9.21e-25 | 1.91e-23 |
| Chronic inflammatory disorder:0 | 8/138,393 | 8,441/26,262,527 | 0.18 | 4.60e-11 | 4.57e-10 |
| Pads:0 | 117/138,393 | 7,003/26,262,527 | 3.17 | 1.18e-25 | 2.54e-24 |
| Immunoglobulin A:0 | 2/138,393 | 3,820/26,262,527 | 0.10 | 8.57e-07 | 5.61e-06 |
| Open Reading Frames:0 | 36/138,393 | 14,222/26,262,527 | 0.48 | 9.67e-07 | 6.28e-06 |
| Bariatric Surgery:0 | 3/138,393 | 6,842/26,262,527 | 0.08 | 3.93e-12 | 4.24e-11 |
| Electric Countershock:0 | 1/138,393 | 6,410/26,262,527 | 0.03 | 1.47e-13 | 1.76e-12 |
| Cardiovascular Physiology:0 | 1/138,393 | 4,097/26,262,527 | 0.05 | 1.63e-08 | 1.29e-07 |
| Myocardial Ischemia:0 | 45/138,393 | 46,323/26,262,527 | 0.18 | 7.16e-55 | 3.41e-53 |
| Cancer Cell Growth Regulation:0 | 5/138,393 | 12/26,262,527 | 79.07 | 2.32e-08 | 1.80e-07 |
| Glomerulonephritis:0 | 3/138,393 | 15,803/26,262,527 | 0.04 | 1.45e-31 | 3.85e-30 |
| Graft acceptance:0 | 3/138,393 | 6,321/26,262,527 | 0.09 | 4.51e-11 | 4.48e-10 |
| Ulcer of rectum:0 | 16/138,393 | 236/26,262,527 | 12.87 | 7.88e-13 | 8.93e-12 |
| Radionuclide therapy:0 | 36/138,393 | 955/26,262,527 | 7.16 | 6.20e-19 | 1.01e-17 |
| Paralysed:0 | 31/138,393 | 13,974/26,262,527 | 0.42 | 3.16e-08 | 2.41e-07 |
| Caucasoid Race:0 | 519/138,393 | 48,558/26,262,527 | 2.03 | 6.21e-47 | 2.56e-45 |
| PCGEM1:0 | 13/138,393 | 44/26,262,527 | 56.07 | 4.46e-18 | 6.95e-17 |
| Bone neoplasms:0 | 71/138,393 | 3,563/26,262,527 | 3.78 | 4.33e-20 | 7.38e-19 |
| Gangliosides:0 | 11/138,393 | 10,781/26,262,527 | 0.19 | 2.69e-13 | 3.16e-12 |
| Binding protein 3:0 | 11/138,393 | 278/26,262,527 | 7.51 | 5.26e-07 | 3.51e-06 |
| epitheliasin|ERG:0 | 16/138,393 | 36/26,262,527 | 84.35 | 2.82e-24 | 5.73e-23 |
| Shunt Device:0 | 2/138,393 | 3,820/26,262,527 | 0.10 | 8.57e-07 | 5.61e-06 |
| Cardiomyopathy, Dilated:0 | 2/138,393 | 19,531/26,262,527 | 0.02 | 2.41e-41 | 8.65e-40 |
| Dermatitis:0 | 5/138,393 | 11,495/26,262,527 | 0.08 | 7.37e-20 | 1.24e-18 |
| Eyelid structure:0 | 1/138,393 | 3,793/26,262,527 | 0.05 | 1.06e-07 | 7.61e-07 |
| Major Depressive Disorder:0 | 15/138,393 | 43,686/26,262,527 | 0.07 | 7.95e-77 | 5.34e-75 |
| invasive treatment:0 | 93/138,393 | 2,708/26,262,527 | 6.52 | 4.57e-43 | 1.72e-41 |
| CEP 701:0 | 9/138,393 | 72/26,262,527 | 23.72 | 5.55e-10 | 5.03e-09 |
| Seminal Vesicles:0 | 529/138,393 | 7,044/26,262,527 | 14.30 | 0.00e+00 | 0.00e+00 |
| Urethral sphincter:0 | 15/138,393 | 580/26,262,527 | 4.91 | 9.62e-07 | 6.25e-06 |
| Sulfhydryl Compounds:0 | 24/138,393 | 18,089/26,262,527 | 0.25 | 5.39e-18 | 8.37e-17 |
| Xenopus oocyte:0 | 2/138,393 | 8,132/26,262,527 | 0.05 | 4.53e-16 | 6.33e-15 |
| CD2 gene|CD2:0 | 7/138,393 | 7,515/26,262,527 | 0.18 | 4.34e-10 | 3.98e-09 |
| Enterotoxins:0 | 1/138,393 | 4,062/26,262,527 | 0.05 | 2.41e-08 | 1.86e-07 |
| CDKN1A gene|CDKN1A:0 | 89/138,393 | 4,171/26,262,527 | 4.05 | 1.06e-26 | 2.37e-25 |
| Gingiva:0 | 13/138,393 | 24,837/26,262,527 | 0.10 | 2.34e-39 | 7.92e-38 |
| DNA Methylation:0 | 149/138,393 | 11,446/26,262,527 | 2.47 | 8.75e-22 | 1.62e-20 |
| PAWR protein:0 | 21/138,393 | 884/26,262,527 | 4.51 | 2.97e-08 | 2.27e-07 |
| Diazepam:0 | 2/138,393 | 18,569/26,262,527 | 0.02 | 4.23e-39 | 1.42e-37 |
| Integrase:0 | 2/138,393 | 4,830/26,262,527 | 0.08 | 6.23e-09 | 5.13e-08 |
| Endothelin-1:0 | 71/138,393 | 27,482/26,262,527 | 0.49 | 1.92e-11 | 1.96e-10 |
| Macrophages, Alveolar:0 | 2/138,393 | 22,007/26,262,527 | 0.02 | 6.50e-47 | 2.67e-45 |
| DAB2IP gene|DAB2IP:0 | 9/138,393 | 30/26,262,527 | 56.93 | 5.49e-13 | 6.31e-12 |
| Alveolar:0 | 14/138,393 | 25,114/26,262,527 | 0.11 | 6.60e-39 | 2.21e-37 |
| Interleukin-6:0 | 362/138,393 | 92,684/26,262,527 | 0.74 | 2.46e-09 | 2.11e-08 |
| Simple atrophy:0 | 6/138,393 | 28/26,262,527 | 40.67 | 2.46e-08 | 1.90e-07 |
| Naloxone:0 | 4/138,393 | 23,701/26,262,527 | 0.03 | 1.64e-47 | 6.84e-46 |
| Eczema:0 | 1/138,393 | 7,811/26,262,527 | 0.02 | 1.56e-16 | 2.24e-15 |
| GALACTOSYLGALACTOSYLGLUCOSYLCERAMIDASE:0 | 21/138,393 | 371/26,262,527 | 10.74 | 6.55e-15 | 8.58e-14 |
| PARP1|COL11A2:0 | 88/138,393 | 5,132/26,262,527 | 3.26 | 2.08e-20 | 3.62e-19 |
| Chemoembolisation:0 | 9/138,393 | 9,779/26,262,527 | 0.17 | 6.89e-13 | 7.83e-12 |
| Diagnostic Neoplasm Staging:0 | 50/138,393 | 1,285/26,262,527 | 7.39 | 3.08e-26 | 6.77e-25 |
| Neuroendocrine Cell:0 | 175/138,393 | 3,362/26,262,527 | 9.89 | 2.02e-106 | 1.85e-104 |
| Retina:0 | 16/138,393 | 125,111/26,262,527 | 0.02 | 8.67e-255 | 2.14e-252 |
| Light, Visible:0 | 4/138,393 | 11,660/26,262,527 | 0.07 | 2.75e-21 | 4.97e-20 |
| Ependymoma:0 | 4/138,393 | 4,873/26,262,527 | 0.16 | 2.79e-07 | 1.93e-06 |
| Germ-Line Mutation:0 | 130/138,393 | 8,355/26,262,527 | 2.95 | 1.29e-25 | 2.77e-24 |
| Purkinje Cells:0 | 5/138,393 | 9,374/26,262,527 | 0.10 | 1.77e-15 | 2.40e-14 |
| Bone structure of humerus:0 | 4/138,393 | 6,431/26,262,527 | 0.12 | 2.33e-10 | 2.18e-09 |
| Taxol:0 | 123/138,393 | 10,303/26,262,527 | 2.27 | 1.67e-15 | 2.26e-14 |
| Cell Cycle:0 | 604/138,393 | 32,670/26,262,527 | 3.52 | 3.95e-143 | 5.09e-141 |
| Conn Syndrome:0 | 1/138,393 | 5,936/26,262,527 | 0.03 | 1.95e-12 | 2.15e-11 |
| Phospholipids:0 | 87/138,393 | 62,101/26,262,527 | 0.27 | 6.88e-56 | 3.35e-54 |
| Poorly Differentiated Prostate Adenocarcinoma:0 | 7/138,393 | 11/26,262,527 | 120.77 | 3.29e-12 | 3.56e-11 |
| Reflux:0 | 11/138,393 | 19,243/26,262,527 | 0.11 | 6.07e-30 | 1.52e-28 |
| Oxidopamine:0 | 1/138,393 | 10,311/26,262,527 | 0.02 | 2.67e-22 | 5.01e-21 |
| Percutaneous insertion of nephrostomy tube:0 | 26/138,393 | 879/26,262,527 | 5.61 | 7.77e-12 | 8.20e-11 |
| Somatostatin analog|GRHL3:0 | 10/138,393 | 8/26,262,527 | 237.23 | 6.60e-19 | 1.07e-17 |
| Muscular Dystrophies:0 | 2/138,393 | 7,295/26,262,527 | 0.05 | 3.47e-14 | 4.35e-13 |
| Maintenance therapy:0 | 13/138,393 | 11,064/26,262,527 | 0.22 | 2.37e-12 | 2.59e-11 |
| Cyanides:0 | 2/138,393 | 5,643/26,262,527 | 0.07 | 1.29e-10 | 1.24e-09 |
| Acute respiratory failure:0 | 1/138,393 | 6,487/26,262,527 | 0.03 | 1.02e-13 | 1.25e-12 |
| MULTISECTION:FINDING:POINT IN TIME:PROSTATE:NARRATIVE:MRI:0 | 13/138,393 | 17/26,262,527 | 145.13 | 2.49e-22 | 4.67e-21 |
| DNA ploidy analysis:0 | 12/138,393 | 169/26,262,527 | 13.48 | 3.38e-10 | 3.12e-09 |
| Thyroid Hormones:0 | 17/138,393 | 20,514/26,262,527 | 0.16 | 4.21e-27 | 9.56e-26 |
| Lysophosphatidylcholines:0 | 3/138,393 | 5,125/26,262,527 | 0.11 | 1.74e-08 | 1.37e-07 |
| Imipramine:0 | 1/138,393 | 12,831/26,262,527 | 0.01 | 7.38e-28 | 1.72e-26 |
| Mercury:0 | 6/138,393 | 16,451/26,262,527 | 0.07 | 2.78e-29 | 6.81e-28 |
| Cancer Risk:0 | 12/138,393 | 185/26,262,527 | 12.31 | 8.91e-10 | 7.95e-09 |
| POTED:0 | 8/138,393 | 52/26,262,527 | 29.20 | 1.14e-09 | 1.01e-08 |
| Hematopoietic Stem Cell Transplantation:0 | 7/138,393 | 13,726/26,262,527 | 0.10 | 2.15e-22 | 4.05e-21 |
| Blood - brain barrier function:0 | 3/138,393 | 12,822/26,262,527 | 0.04 | 5.71e-25 | 1.19e-23 |
| Prostatic Urethra:0 | 283/138,393 | 942/26,262,527 | 57.13 | 0.00e+00 | 0.00e+00 |
| Prostatic radiotherapies:0 | 82/138,393 | 113/26,262,527 | 137.79 | 1.32e-131 | 1.55e-129 |
| histone methylation:0 | 13/138,393 | 346/26,262,527 | 7.13 | 8.91e-08 | 6.48e-07 |
| Suicidal:0 | 2/138,393 | 5,922/26,262,527 | 0.06 | 3.07e-11 | 3.09e-10 |
| Gene Silencing:0 | 58/138,393 | 3,941/26,262,527 | 2.79 | 1.91e-11 | 1.95e-10 |
| Motor Cortex:0 | 2/138,393 | 9,858/26,262,527 | 0.04 | 7.90e-20 | 1.33e-18 |
| Bupivacaine:0 | 9/138,393 | 13,970/26,262,527 | 0.12 | 5.94e-21 | 1.06e-19 |
| Disks:0 | 6/138,393 | 8,515/26,262,527 | 0.13 | 1.09e-12 | 1.22e-11 |
| Tissue Recombination:0 | 12/138,393 | 83/26,262,527 | 27.44 | 1.57e-13 | 1.88e-12 |
| Peptide Hydrolases|OMA1:0 | 31/138,393 | 1,818/26,262,527 | 3.24 | 3.60e-08 | 2.72e-07 |
| Asymptomatic:0 | 386/138,393 | 38,353/26,262,527 | 1.91 | 2.26e-30 | 5.75e-29 |
| Ryanodine:0 | 1/138,393 | 3,746/26,262,527 | 0.05 | 9.97e-08 | 7.21e-07 |
| Psychiatric inpatient:0 | 4/138,393 | 8,111/26,262,527 | 0.09 | 8.34e-14 | 1.02e-12 |
| Entire limb:0 | 10/138,393 | 35,911/26,262,527 | 0.05 | 3.62e-66 | 2.13e-64 |
| Proctitis:0 | 54/138,393 | 1,184/26,262,527 | 8.66 | 2.15e-31 | 5.67e-30 |
| Chickenpox:0 | 1/138,393 | 4,398/26,262,527 | 0.04 | 3.85e-09 | 3.25e-08 |
| Mammary Gland Parenchyma:0 | 106/138,393 | 10,997/26,262,527 | 1.83 | 1.69e-08 | 1.33e-07 |
| ANXA3 gene|ANXA3:0 | 8/138,393 | 42/26,262,527 | 36.15 | 2.52e-10 | 2.35e-09 |
| Agitation:0 | 2/138,393 | 6,924/26,262,527 | 0.05 | 2.05e-13 | 2.43e-12 |
| Crisis:0 | 4/138,393 | 5,534/26,262,527 | 0.14 | 1.36e-08 | 1.08e-07 |
| MG 132|ATF6B|GNA13:0 | 8/138,393 | 11/26,262,527 | 138.02 | 4.09e-14 | 5.11e-13 |
| Gonadorelin|BRD2:0 | 108/138,393 | 47/26,262,527 | 436.40 | 5.33e-207 | 1.03e-204 |
| Nomograms:0 | 22/138,393 | 172/26,262,527 | 24.28 | 1.57e-22 | 2.99e-21 |
| Prostate manipulation:0 | 24/138,393 | 94/26,262,527 | 48.46 | 7.99e-31 | 2.07e-29 |
| Granuloma:0 | 23/138,393 | 13,506/26,262,527 | 0.32 | 5.74e-11 | 5.65e-10 |
| Prostate-Specific Antigen|PGR|PR@|PRH2|TMEM37|ERVK-10:0 | 7/138,393 | 20/26,262,527 | 66.42 | 8.81e-11 | 8.54e-10 |
| Arthralgia:0 | 3/138,393 | 4,706/26,262,527 | 0.12 | 9.10e-08 | 6.62e-07 |
| Lipid Bilayers:0 | 6/138,393 | 6,907/26,262,527 | 0.16 | 1.12e-09 | 9.87e-09 |
| Anchorage-Independent Growth:0 | 125/138,393 | 3,285/26,262,527 | 7.23 | 6.38e-62 | 3.51e-60 |
| Secretory Cell:0 | 104/138,393 | 2,987/26,262,527 | 6.61 | 1.84e-48 | 7.79e-47 |
| Phenylalanine:0 | 24/138,393 | 16,821/26,262,527 | 0.27 | 8.67e-16 | 1.19e-14 |
| Carp, fish:0 | 1/138,393 | 4,511/26,262,527 | 0.04 | 2.84e-09 | 2.42e-08 |
| Surgeon:0 | 290/138,393 | 26,085/26,262,527 | 2.11 | 1.31e-29 | 3.24e-28 |
| Tissue Kallikrein:0 | 88/138,393 | 2,553/26,262,527 | 6.54 | 5.77e-41 | 2.05e-39 |
| Chronic gastritis NOS:0 | 1/138,393 | 4,440/26,262,527 | 0.04 | 4.08e-09 | 3.43e-08 |
| Glycine:0 | 36/138,393 | 24,989/26,262,527 | 0.27 | 1.22e-22 | 2.33e-21 |
| Nkx-3.1 protein|NKX3-1:0 | 57/138,393 | 135/26,262,527 | 80.16 | 1.65e-81 | 1.17e-79 |
| Chloroquine:0 | 21/138,393 | 13,786/26,262,527 | 0.29 | 2.05e-12 | 2.25e-11 |
| Mammals:0 | 56/138,393 | 42,175/26,262,527 | 0.25 | 4.49e-40 | 1.56e-38 |
| Integrins:0 | 263/138,393 | 28,396/26,262,527 | 1.76 | 5.98e-17 | 8.83e-16 |
| Glandular proliferation:0 | 13/138,393 | 111/26,262,527 | 22.23 | 1.80e-13 | 2.14e-12 |
| Cistern:0 | 8/138,393 | 5,949/26,262,527 | 0.26 | 1.50e-06 | 9.47e-06 |
| Blind Vision:0 | 5/138,393 | 17,053/26,262,527 | 0.06 | 1.09e-31 | 2.89e-30 |
| Mitotic arrest:0 | 42/138,393 | 1,110/26,262,527 | 7.18 | 7.10e-22 | 1.32e-20 |
| Graft-vs-Host Disease:0 | 3/138,393 | 7,697/26,262,527 | 0.07 | 5.69e-14 | 7.03e-13 |
| Tumor cells, malignant:0 | 2,361/138,393 | 49,808/26,262,527 | 9.13 | 0.00e+00 | 0.00e+00 |
| Entire arteriole:0 | 1/138,393 | 5,256/26,262,527 | 0.04 | 4.94e-11 | 4.89e-10 |
| Beta-glucuronidase:0 | 11/138,393 | 8,353/26,262,527 | 0.25 | 5.84e-09 | 4.83e-08 |
| Hyperammonemia:0 | 1/138,393 | 3,856/26,262,527 | 0.05 | 7.24e-08 | 5.31e-07 |
| Vesicle:0 | 99/138,393 | 63,707/26,262,527 | 0.29 | 8.02e-52 | 3.63e-50 |
| 6-Phosphofructokinase:0 | 1/138,393 | 3,478/26,262,527 | 0.05 | 4.28e-07 | 2.89e-06 |
| Calcitriol:0 | 123/138,393 | 9,538/26,262,527 | 2.45 | 6.81e-18 | 1.05e-16 |
| Chromosomes, Human, Pair 8:0 | 41/138,393 | 2,017/26,262,527 | 3.86 | 1.49e-12 | 1.65e-11 |
| Male urethral structure:0 | 18/138,393 | 650/26,262,527 | 5.26 | 3.10e-08 | 2.37e-07 |
| Simplexvirus:0 | 14/138,393 | 10,879/26,262,527 | 0.24 | 1.78e-11 | 1.83e-10 |
| 3-Iodobenzylguanidine:0 | 8/138,393 | 7,671/26,262,527 | 0.20 | 1.14e-09 | 1.00e-08 |
| Leuprolide Acetate|HSD3B1:0 | 11/138,393 | 1/26,262,527 | 2087.61 | 9.80e-25 | 2.03e-23 |
| tomography:0 | 646/138,393 | 97,084/26,262,527 | 1.26 | 1.14e-08 | 9.13e-08 |
| Dapsone:0 | 2/138,393 | 5,433/26,262,527 | 0.07 | 3.79e-10 | 3.48e-09 |
| AZIN2|GADL1:0 | 23/138,393 | 1,068/26,262,527 | 4.09 | 3.81e-08 | 2.87e-07 |
| Phantoms, Imaging:0 | 363/138,393 | 20,059/26,262,527 | 3.44 | 2.09e-84 | 1.54e-82 |
| liarozole:0 | 19/138,393 | 253/26,262,527 | 14.25 | 1.03e-15 | 1.41e-14 |
| Carcinoma, Non-Small-Cell Lung:0 | 282/138,393 | 85,737/26,262,527 | 0.62 | 1.41e-17 | 2.14e-16 |
| Nicotinic Receptors:0 | 2/138,393 | 16,069/26,262,527 | 0.02 | 1.47e-33 | 4.16e-32 |
| Aptosyn:0 | 5/138,393 | 19/26,262,527 | 49.94 | 1.55e-07 | 1.09e-06 |
| Tonsillectomy:0 | 3/138,393 | 4,967/26,262,527 | 0.11 | 3.39e-08 | 2.58e-07 |
| atrasentan:0 | 41/138,393 | 366/26,262,527 | 21.26 | 1.76e-38 | 5.80e-37 |
| RNA, Untranslated:0 | 47/138,393 | 3,168/26,262,527 | 2.82 | 1.11e-09 | 9.78e-09 |
| Cell Transplantation:0 | 3/138,393 | 6,329/26,262,527 | 0.09 | 4.54e-11 | 4.51e-10 |
| Nickel:0 | 9/138,393 | 8,923/26,262,527 | 0.19 | 3.42e-11 | 3.43e-10 |
| PROSTATE ABNORMAL:0 | 19/138,393 | 29/26,262,527 | 124.35 | 4.67e-31 | 1.22e-29 |
| PCAT4:0 | 6/138,393 | 36/26,262,527 | 31.63 | 9.26e-08 | 6.73e-07 |
| Pravastatin:0 | 4/138,393 | 7,570/26,262,527 | 0.10 | 1.41e-12 | 1.58e-11 |
| Malignant neoplasm of prostate:0 | 56,120/138,393 | 129,049/26,262,527 | 138.13 | 0.00e+00 | 0.00e+00 |
| Barrett Esophagus:0 | 17/138,393 | 10,174/26,262,527 | 0.32 | 1.31e-08 | 1.04e-07 |
| Anti-Bacterial Agents:0 | 16/138,393 | 16,489/26,262,527 | 0.18 | 2.22e-20 | 3.85e-19 |
| granulocyte:0 | 8/138,393 | 13,297/26,262,527 | 0.11 | 1.22e-20 | 2.15e-19 |
| Influenza:0 | 11/138,393 | 31,849/26,262,527 | 0.07 | 2.46e-56 | 1.21e-54 |
| Superoxides:0 | 42/138,393 | 33,584/26,262,527 | 0.24 | 7.15e-34 | 2.04e-32 |
| Electronic:0 | 30/138,393 | 17,937/26,262,527 | 0.32 | 1.78e-14 | 2.27e-13 |
| OBSTRUCTIVE SYMPTOM:0 | 73/138,393 | 883/26,262,527 | 15.70 | 1.68e-58 | 8.66e-57 |
| Purpose:0 | 165/138,393 | 12,262/26,262,527 | 2.56 | 2.87e-25 | 6.07e-24 |
| zoledronic acid:0 | 460/138,393 | 6,754/26,262,527 | 12.96 | 4.94e-324 | 1.47e-321 |
| Immunocompetent:0 | 7/138,393 | 9,469/26,262,527 | 0.14 | 8.22e-14 | 1.01e-12 |
| Myelin Basic Proteins:0 | 3/138,393 | 7,060/26,262,527 | 0.08 | 1.37e-12 | 1.53e-11 |
| Down Syndrome:0 | 8/138,393 | 29,640/26,262,527 | 0.05 | 3.76e-55 | 1.80e-53 |
| Ferritin:0 | 17/138,393 | 27,965/26,262,527 | 0.12 | 5.58e-42 | 2.03e-40 |
| Rubella:0 | 1/138,393 | 4,240/26,262,527 | 0.04 | 1.26e-08 | 1.00e-07 |
| BRF1 protein, human|ZFP36L1|BRF1|MST1L:0 | 7/138,393 | 83/26,262,527 | 16.01 | 5.55e-07 | 3.70e-06 |
| Candidate Disease Gene|AR:0 | 14/138,393 | 41/26,262,527 | 64.81 | 4.21e-20 | 7.18e-19 |
| receptor function:0 | 103/138,393 | 2,217/26,262,527 | 8.82 | 5.47e-59 | 2.84e-57 |
| Localized Carcinoma:0 | 194/138,393 | 875/26,262,527 | 42.13 | 8.44e-227 | 1.81e-224 |
| anemia; profound:0 | 6/138,393 | 8,260/26,262,527 | 0.14 | 2.85e-12 | 3.09e-11 |
| stage, prostate cancer:0 | 88/138,393 | 104/26,262,527 | 160.67 | 2.18e-145 | 2.86e-143 |
| Adrenergic alpha-Antagonists:0 | 97/138,393 | 6,118/26,262,527 | 3.01 | 4.42e-20 | 7.53e-19 |
| Glomerulonephritis, Membranous:0 | 6/138,393 | 5,515/26,262,527 | 0.21 | 5.35e-07 | 3.57e-06 |
| Tuberculosis, Pulmonary:0 | 7/138,393 | 24,017/26,262,527 | 0.06 | 2.72e-44 | 1.05e-42 |
| Protein-Energy Malnutrition:0 | 1/138,393 | 3,325/26,262,527 | 0.06 | 8.73e-07 | 5.71e-06 |
| Neural Crest Cell:0 | 1/138,393 | 3,662/26,262,527 | 0.05 | 2.25e-07 | 1.56e-06 |
| clinical aspects:0 | 73/138,393 | 5,781/26,262,527 | 2.40 | 7.58e-11 | 7.37e-10 |
| Thyroglobulin:0 | 2/138,393 | 4,191/26,262,527 | 0.09 | 1.50e-07 | 1.07e-06 |
| Bone Marrow Transplantation:0 | 2/138,393 | 15,796/26,262,527 | 0.02 | 6.46e-33 | 1.79e-31 |
| Common Terminology Criteria for Adverse Events:0 | 18/138,393 | 161/26,262,527 | 21.22 | 9.20e-18 | 1.41e-16 |
| Steroid biosynthesis:0 | 61/138,393 | 5,337/26,262,527 | 2.17 | 7.48e-08 | 5.47e-07 |
| Fanconi's Anemia:0 | 6/138,393 | 5,926/26,262,527 | 0.19 | 1.14e-07 | 8.15e-07 |
| Macaca fascicularis:0 | 9/138,393 | 8,211/26,262,527 | 0.21 | 5.81e-10 | 5.26e-09 |
| Prostatomegaly:0 | 9/138,393 | 26/26,262,527 | 65.69 | 1.87e-13 | 2.22e-12 |
| [X]Injury of blood vessel(s) of unspecified body region:0 | 2/138,393 | 5,348/26,262,527 | 0.07 | 5.30e-10 | 4.81e-09 |
| Alternative Therapies:0 | 66/138,393 | 4,334/26,262,527 | 2.89 | 1.95e-13 | 2.31e-12 |
| Prostate biopsy sample:0 | 26/138,393 | 28/26,262,527 | 176.25 | 8.28e-45 | 3.22e-43 |
| Cerebrovascular Disorders:0 | 10/138,393 | 10,771/26,262,527 | 0.18 | 5.33e-14 | 6.60e-13 |
| Bone structure of fibula:0 | 1/138,393 | 3,491/26,262,527 | 0.05 | 4.36e-07 | 2.94e-06 |
| MAPT:0 | 5/138,393 | 15,601/26,262,527 | 0.06 | 1.34e-28 | 3.20e-27 |
| Bronchoalveolar Lavage:0 | 5/138,393 | 7,477/26,262,527 | 0.13 | 1.30e-11 | 1.35e-10 |
| Aortic Aneurysm, Abdominal:0 | 14/138,393 | 13,741/26,262,527 | 0.19 | 1.26e-16 | 1.82e-15 |
| Amino Acids:0 | 225/138,393 | 113,658/26,262,527 | 0.37 | 1.72e-68 | 1.04e-66 |
| Anaphylaxis:0 | 7/138,393 | 12,567/26,262,527 | 0.11 | 5.40e-20 | 9.16e-19 |
| Seminal fluid:0 | 107/138,393 | 4,522/26,262,527 | 4.49 | 2.21e-35 | 6.64e-34 |
| CCND2 gene|CCND2:0 | 16/138,393 | 665/26,262,527 | 4.57 | 1.06e-06 | 6.84e-06 |
| Mucin-1 Staining Method:0 | 36/138,393 | 1,600/26,262,527 | 4.27 | 2.08e-12 | 2.28e-11 |
| Overtreated:0 | 6/138,393 | 48/26,262,527 | 23.72 | 4.32e-07 | 2.91e-06 |
| Brachytherapy:0 | 1,667/138,393 | 11,085/26,262,527 | 28.87 | 0.00e+00 | 0.00e+00 |
| Spinal Cord Injuries:0 | 22/138,393 | 31,318/26,262,527 | 0.13 | 4.04e-44 | 1.55e-42 |
| Toxic Epidermal Necrolysis:0 | 1/138,393 | 3,640/26,262,527 | 0.05 | 2.14e-07 | 1.49e-06 |
| Pregnancy, Ectopic:0 | 2/138,393 | 7,017/26,262,527 | 0.05 | 1.48e-13 | 1.77e-12 |
| ICI-118630:0 | 12/138,393 | 36/26,262,527 | 63.26 | 2.52e-17 | 3.78e-16 |
| IL2 gene|IL2:0 | 46/138,393 | 28,760/26,262,527 | 0.30 | 1.87e-23 | 3.67e-22 |
| Sensory nerve:0 | 2/138,393 | 3,872/26,262,527 | 0.10 | 5.94e-07 | 3.94e-06 |
| Pruritus:0 | 12/138,393 | 12,313/26,262,527 | 0.18 | 2.26e-15 | 3.05e-14 |
| Thapsigargin:0 | 67/138,393 | 5,803/26,262,527 | 2.19 | 1.14e-08 | 9.17e-08 |
| Fluconazole:0 | 4/138,393 | 11,389/26,262,527 | 0.07 | 1.16e-20 | 2.04e-19 |
| Human tissue:0 | 893/138,393 | 33,444/26,262,527 | 5.09 | 4.55e-318 | 1.33e-315 |
| CTRL gene|CTRL:0 | 32/138,393 | 563/26,262,527 | 10.79 | 5.94e-22 | 1.10e-20 |
| Devices:0 | 69/138,393 | 23,516/26,262,527 | 0.56 | 1.17e-07 | 8.42e-07 |
| cancer genetics:0 | 15/138,393 | 115/26,262,527 | 24.75 | 5.95e-16 | 8.26e-15 |
| Immunotherapy:0 | 560/138,393 | 27,020/26,262,527 | 3.94 | 6.24e-153 | 8.56e-151 |
| Testosterone:0 | 1,914/138,393 | 77,922/26,262,527 | 4.71 | 0.00e+00 | 0.00e+00 |
| Cytonal:0 | 6/138,393 | 13/26,262,527 | 87.59 | 5.31e-10 | 4.82e-09 |
| Diagnosis, Computer-Assisted:0 | 21/138,393 | 666/26,262,527 | 5.98 | 2.50e-10 | 2.33e-09 |
| Tumor stage:0 | 245/138,393 | 3,763/26,262,527 | 12.38 | 3.30e-169 | 5.15e-167 |
| Bombesin Receptor:0 | 128/138,393 | 1,264/26,262,527 | 19.23 | 2.47e-111 | 2.39e-109 |
| Adsorption:0 | 12/138,393 | 19,118/26,262,527 | 0.12 | 1.28e-28 | 3.07e-27 |
| Microbicides:0 | 56/138,393 | 48,730/26,262,527 | 0.22 | 1.24e-51 | 5.57e-50 |
| Simvastatin:0 | 31/138,393 | 21,163/26,262,527 | 0.28 | 3.69e-19 | 6.06e-18 |
| bicalutamide 50 MG:0 | 4/138,393 | 5/26,262,527 | 151.82 | 9.32e-08 | 6.77e-07 |
| inorganic phosphate:0 | 6/138,393 | 6,221/26,262,527 | 0.18 | 3.11e-08 | 2.37e-07 |
| immortalized cell:0 | 61/138,393 | 2,248/26,262,527 | 5.15 | 9.16e-24 | 1.83e-22 |
| Psychiatric symptom:0 | 1/138,393 | 3,878/26,262,527 | 0.05 | 7.61e-08 | 5.56e-07 |
| Thrombus:0 | 26/138,393 | 39,927/26,262,527 | 0.12 | 8.05e-58 | 4.09e-56 |
| San Francisco:0 | 27/138,393 | 1,143/26,262,527 | 4.48 | 3.92e-10 | 3.60e-09 |
| European Organization for Research and Treatment of Cancer:0 | 7/138,393 | 77/26,262,527 | 17.25 | 3.46e-07 | 2.36e-06 |
| dehydroepiandrosterone:0 | 140/138,393 | 14,695/26,262,527 | 1.81 | 1.91e-10 | 1.80e-09 |
| peroxisome:0 | 9/138,393 | 7,547/26,262,527 | 0.23 | 9.84e-09 | 7.94e-08 |
| Hypertrophic Cardiomyopathy:0 | 1/138,393 | 22,620/26,262,527 | 0.01 | 4.24e-50 | 1.86e-48 |
| Structure of capsule of prostate:0 | 38/138,393 | 86/26,262,527 | 83.87 | 1.67e-55 | 8.09e-54 |
| Bypass:0 | 8/138,393 | 15,328/26,262,527 | 0.10 | 8.11e-25 | 1.69e-23 |
| Ets Variant Protein 1|ETV1:0 | 14/138,393 | 107/26,262,527 | 24.83 | 5.30e-15 | 6.99e-14 |
| CDK4 gene|CDK4:0 | 28/138,393 | 1,719/26,262,527 | 3.09 | 3.86e-07 | 2.62e-06 |
| Calcineurin:0 | 7/138,393 | 9,681/26,262,527 | 0.14 | 2.98e-14 | 3.76e-13 |
| Recombinant Vaccinia-Prostate Specific Antigen:0 | 4/138,393 | 10/26,262,527 | 75.91 | 7.25e-07 | 4.78e-06 |
| Bone structure of ischium:0 | 104/138,393 | 44,575/26,262,527 | 0.44 | 1.54e-21 | 2.82e-20 |
| Urokinase|UCN2:0 | 9/138,393 | 9/26,262,527 | 189.78 | 1.39e-16 | 2.01e-15 |
| Recombinant Growth Hormone:0 | 2/138,393 | 15,277/26,262,527 | 0.02 | 8.03e-32 | 2.14e-30 |
| TP53 gene|TP53:0 | 1,032/138,393 | 108,855/26,262,527 | 1.81 | 3.13e-66 | 1.84e-64 |
| Lorazepam:0 | 1/138,393 | 3,545/26,262,527 | 0.05 | 2.97e-07 | 2.05e-06 |
| Muscle Fibers:0 | 5/138,393 | 23,782/26,262,527 | 0.04 | 2.41e-46 | 9.75e-45 |
| methaneselenol:0 | 13/138,393 | 79/26,262,527 | 31.23 | 3.43e-15 | 4.58e-14 |
| Tyrosine:0 | 41/138,393 | 19,411/26,262,527 | 0.40 | 1.03e-11 | 1.08e-10 |
| Entire renal artery:0 | 2/138,393 | 5,475/26,262,527 | 0.07 | 2.56e-10 | 2.39e-09 |
| Lupron:0 | 11/138,393 | 149/26,262,527 | 14.01 | 1.24e-09 | 1.09e-08 |
| Bystander Effect:0 | 24/138,393 | 1,167/26,262,527 | 3.90 | 4.49e-08 | 3.37e-07 |
| Xenotropic murine leukemia virus:0 | 7/138,393 | 65/26,262,527 | 20.44 | 1.19e-07 | 8.51e-07 |
| BIRC5 gene|BIRC5:0 | 122/138,393 | 7,616/26,262,527 | 3.04 | 3.60e-25 | 7.59e-24 |
| Radiotherapy, Targeted:0 | 14/138,393 | 280/26,262,527 | 9.49 | 9.08e-10 | 8.08e-09 |
| Radical prostatectomy:0 | 7,258/138,393 | 15,642/26,262,527 | 92.87 | 0.00e+00 | 0.00e+00 |
| Radiation Therapy Oncology Group:0 | 34/138,393 | 252/26,262,527 | 25.61 | 1.15e-34 | 3.38e-33 |
| Sleep Disorders:0 | 5/138,393 | 8,328/26,262,527 | 0.11 | 3.21e-13 | 3.75e-12 |
| Phosphorus:0 | 14/138,393 | 8,439/26,262,527 | 0.31 | 2.26e-07 | 1.57e-06 |
| Grains:0 | 245/138,393 | 4,992/26,262,527 | 9.33 | 9.47e-143 | 1.22e-140 |
| Prostatic pain:0 | 13/138,393 | 163/26,262,527 | 15.14 | 1.62e-11 | 1.66e-10 |
| monocyte:0 | 59/138,393 | 71,037/26,262,527 | 0.16 | 3.61e-91 | 2.85e-89 |
| LPXN gene|LPXN:0 | 6/138,393 | 25/26,262,527 | 45.55 | 1.36e-08 | 1.08e-07 |
| Minimum Inhibitory Concentration measurement:0 | 4/138,393 | 5,139/26,262,527 | 0.15 | 1.07e-07 | 7.67e-07 |
| Oral mucous membrane structure:0 | 9/138,393 | 12,071/26,262,527 | 0.14 | 2.50e-17 | 3.75e-16 |
| Tetrahydrocannabinol:0 | 8/138,393 | 10,189/26,262,527 | 0.15 | 2.56e-14 | 3.24e-13 |
| Subtotal prostatectomy:0 | 5/138,393 | 19/26,262,527 | 49.94 | 1.55e-07 | 1.09e-06 |
| student:0 | 9/138,393 | 50,357/26,262,527 | 0.03 | 2.93e-99 | 2.54e-97 |
| Alkaline Phosphatase:0 | 308/138,393 | 41,924/26,262,527 | 1.40 | 3.01e-08 | 2.30e-07 |
| Spastic syndrome:0 | 7/138,393 | 12,084/26,262,527 | 0.11 | 4.05e-19 | 6.65e-18 |
| CD79A:0 | 10/138,393 | 22,595/26,262,527 | 0.08 | 9.80e-38 | 3.18e-36 |
| Dislocations:0 | 3/138,393 | 18,600/26,262,527 | 0.03 | 1.07e-37 | 3.48e-36 |
| Leuprolide 7.5 MG:0 | 5/138,393 | 7/26,262,527 | 135.55 | 3.04e-09 | 2.58e-08 |
| Nose:0 | 27/138,393 | 52,329/26,262,527 | 0.10 | 4.90e-82 | 3.51e-80 |
| Benign neoplasm of prostate:0 | 5/138,393 | 10/26,262,527 | 94.89 | 1.14e-08 | 9.13e-08 |
| Muramidase|LYZ:0 | 2/138,393 | 8,525/26,262,527 | 0.04 | 7.82e-17 | 1.14e-15 |
| Casodex:0 | 212/138,393 | 709/26,262,527 | 56.83 | 1.38e-271 | 3.57e-269 |
| Prostate carcinoma:0 | 5,869/138,393 | 10,986/26,262,527 | 105.82 | 0.00e+00 | 0.00e+00 |
| Macaca:0 | 7/138,393 | 15,477/26,262,527 | 0.09 | 5.22e-26 | 1.13e-24 |
| Positive Finding:0 | 76/138,393 | 2,419/26,262,527 | 5.96 | 4.30e-33 | 1.20e-31 |
| Lymph Node Involvement:0 | 164/138,393 | 2,761/26,262,527 | 11.28 | 4.03e-108 | 3.77e-106 |
| Cytolysis:0 | 117/138,393 | 34,027/26,262,527 | 0.65 | 1.03e-06 | 6.66e-06 |
| Protein p53:0 | 31/138,393 | 2,056/26,262,527 | 2.86 | 4.79e-07 | 3.21e-06 |
| Urokinase Plasminogen Activator Receptor|PLAU|PRAP1:0 | 27/138,393 | 1,167/26,262,527 | 4.39 | 6.05e-10 | 5.47e-09 |
| 16s:0 | 13/138,393 | 25,719/26,262,527 | 0.10 | 3.77e-41 | 1.35e-39 |
| SCID Mice:0 | 283/138,393 | 9,013/26,262,527 | 5.97 | 4.04e-118 | 4.16e-116 |
| Health Personnel:0 | 103/138,393 | 34,329/26,262,527 | 0.57 | 4.96e-10 | 4.52e-09 |
| Autistic Disorder:0 | 5/138,393 | 29,901/26,262,527 | 0.03 | 7.29e-60 | 3.85e-58 |
| Diffusion weighted imaging:0 | 41/138,393 | 654/26,262,527 | 11.90 | 3.28e-29 | 8.00e-28 |
| Proto-Oncogene Proteins c-akt|AKT1:0 | 1,139/138,393 | 60,321/26,262,527 | 3.60 | 7.20e-276 | 1.89e-273 |
| Hypoprothrombinemias:0 | 20/138,393 | 464/26,262,527 | 8.18 | 3.32e-12 | 3.60e-11 |
| RNA, Messenger:0 | 628/138,393 | 80,755/26,262,527 | 1.48 | 4.91e-20 | 8.36e-19 |
| Plates:0 | 9/138,393 | 14,879/26,262,527 | 0.11 | 6.72e-23 | 1.30e-21 |
| hemolysis:0 | 2/138,393 | 9,371/26,262,527 | 0.04 | 1.01e-18 | 1.62e-17 |
| Entire ejaculatory duct:0 | 21/138,393 | 575/26,262,527 | 6.93 | 1.89e-11 | 1.93e-10 |
| MIR gene|MLXIP|MYLIP|MARCH8:0 | 14/138,393 | 341/26,262,527 | 7.79 | 9.98e-09 | 8.05e-08 |
| Ceftriaxone:0 | 3/138,393 | 7,789/26,262,527 | 0.07 | 4.07e-14 | 5.09e-13 |
| Flowers:0 | 1/138,393 | 4,195/26,262,527 | 0.05 | 1.15e-08 | 9.23e-08 |
| Chromogranin A|CHGA:0 | 50/138,393 | 32/26,262,527 | 296.62 | 4.71e-92 | 3.78e-90 |
| Hypertension, Portal:0 | 4/138,393 | 16,007/26,262,527 | 0.05 | 1.46e-30 | 3.75e-29 |
| Respiratory Burst:0 | 1/138,393 | 8,933/26,262,527 | 0.02 | 4.29e-19 | 7.03e-18 |
| Breeding:0 | 4/138,393 | 6,843/26,262,527 | 0.11 | 4.47e-11 | 4.45e-10 |
| Transfection:0 | 263/138,393 | 17,763/26,262,527 | 2.81 | 2.86e-46 | 1.15e-44 |
| Androgenetic Alopecia:0 | 37/138,393 | 2,458/26,262,527 | 2.86 | 4.21e-08 | 3.17e-07 |
| Colon and rectum:0 | 52/138,393 | 527/26,262,527 | 18.73 | 9.07e-46 | 3.61e-44 |
| Sample weight:0 | 8/138,393 | 87/26,262,527 | 17.45 | 4.62e-08 | 3.46e-07 |
| Congenital arteriovenous malformation:0 | 6/138,393 | 5,807/26,262,527 | 0.20 | 1.48e-07 | 1.05e-06 |
| prostate cancer screening:0 | 313/138,393 | 378/26,262,527 | 157.49 | 0.00e+00 | 0.00e+00 |
| Growth arrest:0 | 173/138,393 | 5,707/26,262,527 | 5.76 | 8.35e-71 | 5.17e-69 |
| Nerve Degeneration:0 | 11/138,393 | 17,269/26,262,527 | 0.12 | 6.04e-26 | 1.31e-24 |
| Vagina:0 | 46/138,393 | 25,993/26,262,527 | 0.34 | 4.40e-19 | 7.20e-18 |
| isoniazid:0 | 6/138,393 | 9,725/26,262,527 | 0.12 | 3.26e-15 | 4.36e-14 |
| Ventricular Fibrillation:0 | 5/138,393 | 13,499/26,262,527 | 0.07 | 6.02e-24 | 1.21e-22 |
| Chest Pain:0 | 3/138,393 | 15,084/26,262,527 | 0.04 | 5.40e-30 | 1.36e-28 |
| Amitriptyline:0 | 1/138,393 | 7,630/26,262,527 | 0.02 | 2.99e-16 | 4.22e-15 |
| Strontium-89 chloride:0 | 17/138,393 | 58/26,262,527 | 55.63 | 3.79e-23 | 7.37e-22 |
| Tongue:0 | 45/138,393 | 28,083/26,262,527 | 0.30 | 6.92e-23 | 1.34e-21 |
| Myoglobin:0 | 2/138,393 | 4,808/26,262,527 | 0.08 | 6.15e-09 | 5.08e-08 |
| Angiogenesis Factor:0 | 69/138,393 | 4,825/26,262,527 | 2.71 | 9.28e-13 | 1.05e-11 |
| Cruciferous Vegetable:0 | 24/138,393 | 160/26,262,527 | 28.47 | 6.29e-26 | 1.36e-24 |
| Clostridium difficile infection:0 | 1/138,393 | 4,270/26,262,527 | 0.04 | 8.05e-09 | 6.57e-08 |
| Sprain:0 | 1/138,393 | 6,307/26,262,527 | 0.03 | 3.26e-13 | 3.80e-12 |
| Mammalian Oviducts:0 | 24/138,393 | 17,249/26,262,527 | 0.26 | 1.45e-16 | 2.09e-15 |
| Toremifene:0 | 42/138,393 | 1,873/26,262,527 | 4.26 | 3.64e-14 | 4.57e-13 |
| Entire diaphragm:0 | 18/138,393 | 18,450/26,262,527 | 0.19 | 1.36e-22 | 2.58e-21 |
| Mesentery:0 | 14/138,393 | 11,713/26,262,527 | 0.23 | 6.11e-13 | 7.01e-12 |
| Papillary adenocarcinoma:0 | 23/138,393 | 1,030/26,262,527 | 4.24 | 2.02e-08 | 1.58e-07 |
| TMEFF2:0 | 13/138,393 | 118/26,262,527 | 20.91 | 3.69e-13 | 4.28e-12 |
| Trachea:0 | 21/138,393 | 33,555/26,262,527 | 0.12 | 1.72e-49 | 7.41e-48 |
| Viscosity:0 | 1/138,393 | 3,239/26,262,527 | 0.06 | 1.24e-06 | 7.97e-06 |
| Bone structure of pubis:0 | 20/138,393 | 1,024/26,262,527 | 3.71 | 1.22e-06 | 7.85e-06 |
| Platelet Activation:0 | 7/138,393 | 6,978/26,262,527 | 0.19 | 6.12e-09 | 5.05e-08 |
| TNFRSF5 gene|CD40:0 | 27/138,393 | 12,998/26,262,527 | 0.39 | 1.91e-08 | 1.50e-07 |
| Defibrillators, Implantable:0 | 1/138,393 | 21,781/26,262,527 | 0.01 | 3.55e-48 | 1.49e-46 |
| Aspergillosis:0 | 4/138,393 | 4,746/26,262,527 | 0.16 | 5.49e-07 | 3.66e-06 |
| Triticum aestivum:0 | 1/138,393 | 8,960/26,262,527 | 0.02 | 2.81e-19 | 4.64e-18 |
| Pathological Dilatation:0 | 38/138,393 | 36,205/26,262,527 | 0.20 | 4.78e-41 | 1.70e-39 |
| remifentanil:0 | 1/138,393 | 5,908/26,262,527 | 0.03 | 1.88e-12 | 2.07e-11 |
| Antitumor Response:0 | 59/138,393 | 1,852/26,262,527 | 6.05 | 2.27e-26 | 5.02e-25 |
| Prostate-Specific Antigen|KLK3:0 | 27/138,393 | 54/26,262,527 | 94.90 | 4.67e-41 | 1.67e-39 |
| Veins:0 | 88/138,393 | 36,057/26,262,527 | 0.46 | 2.26e-16 | 3.22e-15 |
| SHC4:0 | 8/138,393 | 64/26,262,527 | 23.72 | 5.06e-09 | 4.21e-08 |
| Blotting, Northern:0 | 56/138,393 | 4,450/26,262,527 | 2.39 | 1.06e-08 | 8.56e-08 |
| cell motility:0 | 636/138,393 | 30,404/26,262,527 | 3.98 | 2.52e-175 | 4.25e-173 |
| Steroid Metabolism:0 | 14/138,393 | 292/26,262,527 | 9.10 | 1.52e-09 | 1.32e-08 |
| Insecta:0 | 2/138,393 | 13,155/26,262,527 | 0.03 | 4.55e-27 | 1.03e-25 |
| Compartment syndromes:0 | 4/138,393 | 5,263/26,262,527 | 0.14 | 5.30e-08 | 3.93e-07 |
| Furosemide:0 | 6/138,393 | 12,124/26,262,527 | 0.09 | 3.78e-20 | 6.47e-19 |
| Somatotropin|TH:0 | 7/138,393 | 46/26,262,527 | 28.88 | 1.36e-08 | 1.08e-07 |
| thymocyte:0 | 3/138,393 | 18,181/26,262,527 | 0.03 | 9.61e-37 | 3.03e-35 |
| Paraurethral gland:0 | 11/138,393 | 90/26,262,527 | 23.20 | 8.46e-12 | 8.89e-11 |
| Carbon Dioxide:0 | 12/138,393 | 27,196/26,262,527 | 0.08 | 3.06e-45 | 1.20e-43 |
| 13q:0 | 26/138,393 | 631/26,262,527 | 7.82 | 5.70e-15 | 7.51e-14 |
| UGT2B15:0 | 10/138,393 | 129/26,262,527 | 14.71 | 4.51e-09 | 3.77e-08 |
| CD36 gene|CD36:0 | 6/138,393 | 5,849/26,262,527 | 0.19 | 1.56e-07 | 1.10e-06 |
| Haloperidol:0 | 5/138,393 | 20,279/26,262,527 | 0.05 | 1.10e-38 | 3.64e-37 |
| Malignant neoplasm of skin:0 | 168/138,393 | 9,025/26,262,527 | 3.54 | 1.54e-41 | 5.55e-40 |
| Archaea:0 | 2/138,393 | 13,635/26,262,527 | 0.03 | 3.48e-28 | 8.25e-27 |
| Gill structure:0 | 1/138,393 | 6,885/26,262,527 | 0.03 | 1.80e-14 | 2.29e-13 |
| Parasitic infection:0 | 2/138,393 | 4,572/26,262,527 | 0.08 | 2.68e-08 | 2.06e-07 |
| trastuzumab|EGFR:0 | 9/138,393 | 17/26,262,527 | 100.47 | 8.61e-15 | 1.12e-13 |
| Small RNA:0 | 113/138,393 | 9,008/26,262,527 | 2.38 | 9.96e-16 | 1.37e-14 |
| 16q:0 | 32/138,393 | 390/26,262,527 | 15.57 | 1.68e-26 | 3.74e-25 |
| Renal glomerular disease:0 | 2/138,393 | 10,672/26,262,527 | 0.04 | 1.54e-21 | 2.81e-20 |
| Digital palpation:0 | 42/138,393 | 526/26,262,527 | 15.16 | 8.03e-34 | 2.29e-32 |
| Tuber:0 | 1/138,393 | 4,352/26,262,527 | 0.04 | 5.68e-09 | 4.71e-08 |
| Salvage procedure:0 | 137/138,393 | 6,137/26,262,527 | 4.24 | 3.76e-42 | 1.38e-40 |
| hypercholesterolemia:0 | 37/138,393 | 19,273/26,262,527 | 0.36 | 3.23e-13 | 3.77e-12 |
| Hot flushes:0 | 46/138,393 | 1,253/26,262,527 | 6.97 | 2.72e-23 | 5.32e-22 |
| hydroxyurea:0 | 18/138,393 | 15,276/26,262,527 | 0.22 | 1.10e-16 | 1.60e-15 |
| GCK|KCNA2:0 | 9/138,393 | 56/26,262,527 | 30.50 | 7.33e-11 | 7.14e-10 |
| Cytochrome P450:0 | 86/138,393 | 35,805/26,262,527 | 0.46 | 9.52e-17 | 1.39e-15 |
| histological diagnosis:0 | 44/138,393 | 2,134/26,262,527 | 3.91 | 1.48e-13 | 1.77e-12 |
| PRCA1 gene|RNASEL:0 | 44/138,393 | 112/26,262,527 | 74.58 | 3.62e-62 | 2.00e-60 |
| Prostatic Secretory Proteins:0 | 7/138,393 | 35/26,262,527 | 37.96 | 2.50e-09 | 2.14e-08 |
| soy protein isolate:0 | 77/138,393 | 2,319/26,262,527 | 6.30 | 4.99e-35 | 1.48e-33 |
| Infarction:0 | 20/138,393 | 39,333/26,262,527 | 0.10 | 2.76e-62 | 1.53e-60 |
| alpha 1-Antichymotrypsin:0 | 33/138,393 | 1,270/26,262,527 | 4.93 | 4.12e-13 | 4.77e-12 |
| Tetracycline:0 | 16/138,393 | 10,002/26,262,527 | 0.30 | 6.55e-09 | 5.39e-08 |
| Aortic Valve Insufficiency:0 | 1/138,393 | 9,982/26,262,527 | 0.02 | 1.71e-21 | 3.12e-20 |
| Palliative Care:0 | 154/138,393 | 7,014/26,262,527 | 4.17 | 2.58e-46 | 1.04e-44 |
| Acinar Cell Carcinoma:0 | 60/138,393 | 1,453/26,262,527 | 7.84 | 1.83e-32 | 4.98e-31 |
| Respiratory physiology:0 | 4/138,393 | 13,048/26,262,527 | 0.06 | 3.29e-24 | 6.69e-23 |
| Mammaplasty:0 | 1/138,393 | 5,167/26,262,527 | 0.04 | 1.11e-10 | 1.07e-09 |
| Inactivation:0 | 236/138,393 | 30,483/26,262,527 | 1.47 | 2.83e-08 | 2.16e-07 |
| PROSTVAC:0 | 18/138,393 | 45/26,262,527 | 75.92 | 1.85e-26 | 4.09e-25 |
| Gastrin releasing peptide:0 | 70/138,393 | 2,963/26,262,527 | 4.48 | 1.02e-23 | 2.03e-22 |
| Cognitive Therapy:0 | 9/138,393 | 15,789/26,262,527 | 0.11 | 1.16e-24 | 2.40e-23 |
| Alcoholic Intoxication, Chronic:0 | 2/138,393 | 20,179/26,262,527 | 0.02 | 9.02e-43 | 3.36e-41 |
| Measles:0 | 6/138,393 | 8,796/26,262,527 | 0.13 | 2.77e-13 | 3.24e-12 |
| Cancer Registry:0 | 33/138,393 | 382/26,262,527 | 16.40 | 6.11e-28 | 1.43e-26 |
| TNFSF13B:0 | 2/138,393 | 3,878/26,262,527 | 0.10 | 5.96e-07 | 3.96e-06 |
| Capra hircus:0 | 3/138,393 | 13,290/26,262,527 | 0.04 | 4.46e-26 | 9.72e-25 |
| Amantadine:0 | 2/138,393 | 3,876/26,262,527 | 0.10 | 5.95e-07 | 3.95e-06 |
| Prostate:0 | 34,102/138,393 | 82,025/26,262,527 | 104.37 | 0.00e+00 | 0.00e+00 |
| Brush Border:0 | 4/138,393 | 5,812/26,262,527 | 0.13 | 5.24e-09 | 4.36e-08 |
| Tuberculosis, Meningeal:0 | 1/138,393 | 4,555/26,262,527 | 0.04 | 1.89e-09 | 1.63e-08 |
| saliva:0 | 7/138,393 | 11,347/26,262,527 | 0.12 | 1.24e-17 | 1.88e-16 |
| Hypercapnia:0 | 1/138,393 | 4,139/26,262,527 | 0.05 | 1.69e-08 | 1.33e-07 |
| Receptor Signaling:0 | 139/138,393 | 2,188/26,262,527 | 12.07 | 1.60e-95 | 1.33e-93 |
| Chlorophyll:0 | 1/138,393 | 8,722/26,262,527 | 0.02 | 1.29e-18 | 2.07e-17 |
| Hyperalgesia:0 | 6/138,393 | 6,852/26,262,527 | 0.17 | 1.57e-09 | 1.37e-08 |
| Helminths:0 | 3/138,393 | 7,955/26,262,527 | 0.07 | 2.09e-14 | 2.64e-13 |
| Urinary Retention:0 | 127/138,393 | 2,575/26,262,527 | 9.37 | 3.68e-75 | 2.42e-73 |
| alpha-Synuclein:0 | 2/138,393 | 10,033/26,262,527 | 0.04 | 4.03e-20 | 6.88e-19 |
| Conscious:0 | 1/138,393 | 21,359/26,262,527 | 0.01 | 3.24e-47 | 1.35e-45 |
| Metabolic Rates:0 | 5/138,393 | 8,636/26,262,527 | 0.11 | 8.40e-14 | 1.03e-12 |
| EIF3H:0 | 6/138,393 | 60/26,262,527 | 18.98 | 1.44e-06 | 9.13e-06 |
| leflunomide:0 | 2/138,393 | 4,316/26,262,527 | 0.09 | 7.29e-08 | 5.34e-07 |
| Felis catus:0 | 31/138,393 | 97,992/26,262,527 | 0.06 | 2.87e-174 | 4.71e-172 |
| Elbow:0 | 3/138,393 | 11,081/26,262,527 | 0.05 | 3.08e-21 | 5.55e-20 |
| Reproduction:0 | 32/138,393 | 17,601/26,262,527 | 0.34 | 5.70e-13 | 6.54e-12 |
| Stiffness:0 | 27/138,393 | 22,892/26,262,527 | 0.22 | 1.84e-24 | 3.77e-23 |
| Transurethral cystoscopy:0 | 15/138,393 | 211/26,262,527 | 13.49 | 2.14e-12 | 2.35e-11 |
| Sleeves:0 | 4/138,393 | 10,494/26,262,527 | 0.07 | 7.85e-19 | 1.27e-17 |
| mibolerone:0 | 35/138,393 | 259/26,262,527 | 25.65 | 1.17e-35 | 3.56e-34 |
| Secondary malignant neoplasm of bone:0 | 2,429/138,393 | 17,034/26,262,527 | 27.53 | 0.00e+00 | 0.00e+00 |
| Cystadenocarcinoma, Papillary:0 | 11/138,393 | 168/26,262,527 | 12.43 | 4.05e-09 | 3.41e-08 |
| Deoxycytidine:0 | 28/138,393 | 1,689/26,262,527 | 3.15 | 2.75e-07 | 1.90e-06 |
| Intima:0 | 1/138,393 | 7,517/26,262,527 | 0.03 | 6.56e-16 | 9.06e-15 |
| cabergoline:0 | 3/138,393 | 4,191/26,262,527 | 0.14 | 9.88e-07 | 6.40e-06 |
| PATHOLOGIC FINDINGS:0 | 130/138,393 | 4,874/26,262,527 | 5.07 | 7.13e-48 | 3.00e-46 |
| liarozole fumarate:0 | 5/138,393 | 19/26,262,527 | 49.94 | 1.55e-07 | 1.09e-06 |
| PSA Velocity:0 | 21/138,393 | 35/26,262,527 | 113.88 | 1.45e-33 | 4.10e-32 |
| Wing:0 | 10/138,393 | 9,698/26,262,527 | 0.20 | 7.01e-12 | 7.43e-11 |
| Neoplasms, Hormone-Dependent:0 | 5/138,393 | 29/26,262,527 | 32.72 | 9.70e-07 | 6.30e-06 |
| Malignant disease:0 | 312/138,393 | 12,923/26,262,527 | 4.59 | 1.12e-101 | 9.88e-100 |
| Metoclopramide:0 | 4/138,393 | 7,673/26,262,527 | 0.10 | 6.68e-13 | 7.61e-12 |
| Clusterin|CLU:0 | 100/138,393 | 3,932/26,262,527 | 4.83 | 1.28e-35 | 3.90e-34 |
| Convulsions:0 | 2/138,393 | 7,222/26,262,527 | 0.05 | 4.95e-14 | 6.15e-13 |
| Telencephalon:0 | 1/138,393 | 4,858/26,262,527 | 0.04 | 4.52e-10 | 4.13e-09 |
| Occult carcinoma:0 | 16/138,393 | 641/26,262,527 | 4.74 | 6.67e-07 | 4.40e-06 |
| Ovum:0 | 13/138,393 | 20,102/26,262,527 | 0.12 | 1.06e-29 | 2.65e-28 |
| Abdominal Pain:0 | 16/138,393 | 15,477/26,262,527 | 0.20 | 1.98e-18 | 3.14e-17 |
| N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid:0 | 6/138,393 | 12/26,262,527 | 94.89 | 3.65e-10 | 3.36e-09 |
| TNFSF11 gene|TNFSF11:0 | 33/138,393 | 861/26,262,527 | 7.27 | 1.08e-17 | 1.66e-16 |
| Decapeptyl:0 | 15/138,393 | 270/26,262,527 | 10.54 | 5.75e-11 | 5.66e-10 |
| TRYPTASE:0 | 1/138,393 | 5,141/26,262,527 | 0.04 | 1.05e-10 | 1.01e-09 |
| Adenocarcinoma Cell:0 | 188/138,393 | 2,697/26,262,527 | 13.24 | 2.93e-135 | 3.53e-133 |
| diindolylmethane:0 | 52/138,393 | 1,070/26,262,527 | 9.23 | 1.54e-31 | 4.08e-30 |
| MicroRNAs:0 | 697/138,393 | 76,708/26,262,527 | 1.73 | 1.28e-39 | 4.40e-38 |
| GSTT1 gene|GSTT1:0 | 37/138,393 | 2,016/26,262,527 | 3.48 | 2.74e-10 | 2.55e-09 |
| Hepatitis C virus:0 | 16/138,393 | 71,167/26,262,527 | 0.04 | 2.66e-135 | 3.22e-133 |
| Luciferases:0 | 282/138,393 | 15,682/26,262,527 | 3.42 | 1.86e-65 | 1.08e-63 |
| Aggressive cancer:0 | 320/138,393 | 1,584/26,262,527 | 38.42 | 0.00e+00 | 0.00e+00 |
| Degenerative abnormality:0 | 39/138,393 | 42,150/26,262,527 | 0.18 | 1.77e-51 | 7.93e-50 |
| Respiratory syncytial virus:0 | 2/138,393 | 7,501/26,262,527 | 0.05 | 1.17e-14 | 1.50e-13 |
| integrin-linked kinase:0 | 36/138,393 | 2,538/26,262,527 | 2.69 | 2.53e-07 | 1.76e-06 |
| Methylnitrosourea:0 | 46/138,393 | 2,813/26,262,527 | 3.10 | 8.40e-11 | 8.16e-10 |
| TUBULAR CELLS:0 | 15/138,393 | 8,635/26,262,527 | 0.33 | 3.18e-07 | 2.17e-06 |
| Annexins:0 | 55/138,393 | 4,684/26,262,527 | 2.23 | 1.57e-07 | 1.11e-06 |
| adrenomedullin|ADM:0 | 15/138,393 | 9,650/26,262,527 | 0.29 | 7.95e-09 | 6.49e-08 |
| methylene diphosphonate:0 | 15/138,393 | 307/26,262,527 | 9.27 | 3.13e-10 | 2.90e-09 |
| Male mammary gland:0 | 27/138,393 | 1,028/26,262,527 | 4.98 | 4.14e-11 | 4.13e-10 |
| Adenoma of large intestine:0 | 50/138,393 | 3,755/26,262,527 | 2.53 | 1.22e-08 | 9.76e-08 |
| White Matter:0 | 3/138,393 | 17,781/26,262,527 | 0.03 | 5.67e-36 | 1.74e-34 |
| Visual impairment:0 | 13/138,393 | 14,161/26,262,527 | 0.17 | 3.55e-18 | 5.56e-17 |
| Membrane Proteins:0 | 75/138,393 | 35,892/26,262,527 | 0.40 | 6.40e-21 | 1.14e-19 |
| Arthropathies NOS:0 | 8/138,393 | 17,947/26,262,527 | 0.08 | 3.02e-30 | 7.63e-29 |
| Granulocyte-Macrophage Colony-Stimulating Factor|CSF2:0 | 12/138,393 | 284/26,262,527 | 8.02 | 8.23e-08 | 5.99e-07 |
| Prostatism:0 | 41/138,393 | 337/26,262,527 | 23.09 | 8.35e-40 | 2.88e-38 |
| Acid phosphatase measurement:0 | 5/138,393 | 7/26,262,527 | 135.55 | 3.04e-09 | 2.58e-08 |
| Periodontal Ligament:0 | 2/138,393 | 13,783/26,262,527 | 0.03 | 1.69e-28 | 4.03e-27 |
| FRAP1 protein, human|MTOR:0 | 150/138,393 | 9,038/26,262,527 | 3.15 | 4.34e-32 | 1.17e-30 |
| rhenium-186 HEDP:0 | 27/138,393 | 97/26,262,527 | 52.83 | 2.34e-35 | 7.04e-34 |
| Low-Density Lipoproteins:0 | 27/138,393 | 30,185/26,262,527 | 0.17 | 8.00e-38 | 2.60e-36 |
| Prostate cancer stage C:0 | 70/138,393 | 130/26,262,527 | 102.23 | 1.18e-105 | 1.08e-103 |
| Malnutrition:0 | 21/138,393 | 36,361/26,262,527 | 0.11 | 2.75e-55 | 1.32e-53 |
| Receptor, EphA2:0 | 14/138,393 | 140/26,262,527 | 18.98 | 1.57e-13 | 1.87e-12 |
| Submandibular gland:0 | 7/138,393 | 13,984/26,262,527 | 0.09 | 5.20e-23 | 1.01e-21 |
| Atypia:0 | 40/138,393 | 1,292/26,262,527 | 5.88 | 5.24e-18 | 8.14e-17 |
| Receptors, Opioid, mu:0 | 2/138,393 | 9,301/26,262,527 | 0.04 | 1.45e-18 | 2.31e-17 |
| valylvaline:0 | 15/138,393 | 576/26,262,527 | 4.94 | 8.85e-07 | 5.78e-06 |
| infliximab:0 | 3/138,393 | 27,160/26,262,527 | 0.02 | 1.17e-56 | 5.81e-55 |
| KLK3 gene|KLK3:0 | 2,606/138,393 | 9,016/26,262,527 | 55.88 | 0.00e+00 | 0.00e+00 |
| Entire femoral artery:0 | 3/138,393 | 5,208/26,262,527 | 0.11 | 8.19e-09 | 6.67e-08 |
| Silicones:0 | 7/138,393 | 8,576/26,262,527 | 0.15 | 4.43e-12 | 4.77e-11 |
| Metronidazole:0 | 8/138,393 | 12,361/26,262,527 | 0.12 | 1.03e-18 | 1.66e-17 |
| Intracranial Hypertension:0 | 6/138,393 | 7,371/26,262,527 | 0.15 | 1.56e-10 | 1.49e-09 |
| silybin:0 | 72/138,393 | 3,579/26,262,527 | 3.82 | 1.44e-20 | 2.53e-19 |
| Primary carcinoma of the liver cells:0 | 250/138,393 | 149,029/26,262,527 | 0.32 | 4.82e-110 | 4.60e-108 |
| Respiratory Distress Syndrome, Adult:0 | 10/138,393 | 22,126/26,262,527 | 0.09 | 7.54e-37 | 2.39e-35 |
| Eulexin:0 | 20/138,393 | 41/26,262,527 | 92.58 | 1.25e-30 | 3.20e-29 |
| Genital infection:0 | 6/138,393 | 5,514/26,262,527 | 0.21 | 5.34e-07 | 3.57e-06 |
| Acute Erythroblastic Leukemia:0 | 10/138,393 | 7,204/26,262,527 | 0.26 | 1.94e-07 | 1.36e-06 |
| Lyase:0 | 40/138,393 | 2,033/26,262,527 | 3.73 | 7.18e-12 | 7.60e-11 |
| Lactose:0 | 3/138,393 | 5,571/26,262,527 | 0.10 | 2.23e-09 | 1.92e-08 |
| lymph nodes:0 | 684/138,393 | 62,543/26,262,527 | 2.08 | 8.41e-65 | 4.83e-63 |
| Intestinal Absorption:0 | 7/138,393 | 7,300/26,262,527 | 0.18 | 1.15e-09 | 1.01e-08 |
| Gastrointestinal toxicity:0 | 97/138,393 | 910/26,262,527 | 20.24 | 9.07e-87 | 6.88e-85 |
| Abscess:0 | 30/138,393 | 19,975/26,262,527 | 0.28 | 1.07e-17 | 1.64e-16 |
| androgen receptor signaling pathway:0 | 10/138,393 | 17/26,262,527 | 111.64 | 1.22e-16 | 1.76e-15 |
| cytotoxicity:0 | 415/138,393 | 37,559/26,262,527 | 2.10 | 4.75e-41 | 1.69e-39 |
| Septicemia:0 | 60/138,393 | 75,485/26,262,527 | 0.15 | 7.95e-99 | 6.86e-97 |
| Tacrine:0 | 1/138,393 | 4,240/26,262,527 | 0.04 | 1.26e-08 | 1.00e-07 |
| Equus caballus:0 | 10/138,393 | 55,761/26,262,527 | 0.03 | 1.10e-109 | 1.04e-107 |
| Apolipoprotein E|APOE:0 | 8/138,393 | 19,180/26,262,527 | 0.08 | 7.89e-33 | 2.17e-31 |
| Herbicides:0 | 9/138,393 | 9,611/26,262,527 | 0.18 | 1.93e-12 | 2.13e-11 |
| MCF7:0 | 221/138,393 | 18,383/26,262,527 | 2.28 | 4.45e-27 | 1.01e-25 |
| Ischemia:0 | 26/138,393 | 80,050/26,262,527 | 0.06 | 8.68e-142 | 1.11e-139 |
| Intellectual functioning disability:0 | 3/138,393 | 16,724/26,262,527 | 0.03 | 1.31e-33 | 3.70e-32 |
| Ligation:0 | 24/138,393 | 24,792/26,262,527 | 0.18 | 4.65e-30 | 1.17e-28 |
| Cell-Cell Adhesion:0 | 53/138,393 | 2,887/26,262,527 | 3.48 | 4.68e-14 | 5.83e-13 |
| Electromyography:0 | 8/138,393 | 17,349/26,262,527 | 0.09 | 7.45e-29 | 1.80e-27 |
| CYTOCHROME C OXIDASE:0 | 8/138,393 | 9,686/26,262,527 | 0.16 | 1.75e-13 | 2.09e-12 |
| Candida albicans:0 | 3/138,393 | 10,227/26,262,527 | 0.06 | 2.27e-19 | 3.76e-18 |
| Prazosin:0 | 20/138,393 | 10,792/26,262,527 | 0.35 | 3.57e-08 | 2.70e-07 |
| Antineoplastic Agents:0 | 631/138,393 | 26,836/26,262,527 | 4.48 | 4.24e-198 | 8.02e-196 |
| Urokinase:0 | 188/138,393 | 17,708/26,262,527 | 2.02 | 7.90e-18 | 1.22e-16 |
| anticoagulation:0 | 17/138,393 | 18,146/26,262,527 | 0.18 | 9.55e-23 | 1.83e-21 |
| Prostatic mass:0 | 14/138,393 | 21/26,262,527 | 126.52 | 2.47e-23 | 4.85e-22 |
| Plastids:0 | 1/138,393 | 5,505/26,262,527 | 0.03 | 1.73e-11 | 1.77e-10 |
| PIM1 gene|PIM1:0 | 45/138,393 | 838/26,262,527 | 10.19 | 3.17e-29 | 7.75e-28 |
| Autoimmune:0 | 12/138,393 | 9,127/26,262,527 | 0.25 | 1.15e-09 | 1.01e-08 |
| Genes, Immediate-Early:0 | 4/138,393 | 4,563/26,262,527 | 0.17 | 1.57e-06 | 9.89e-06 |
| Calmodulin:0 | 12/138,393 | 24,382/26,262,527 | 0.09 | 1.57e-39 | 5.37e-38 |
| Prostatic Intraepithelial Neoplasias:0 | 684/138,393 | 1,354/26,262,527 | 96.34 | 0.00e+00 | 0.00e+00 |
| Pancreatic Trypsin Secretory Inhibitor, Kazal|SPINK1:0 | 7/138,393 | 74/26,262,527 | 17.95 | 2.69e-07 | 1.86e-06 |
| Craniotomy:0 | 6/138,393 | 6,274/26,262,527 | 0.18 | 2.18e-08 | 1.69e-07 |
| Prostatectomy:0 | 1,251/138,393 | 3,080/26,262,527 | 77.77 | 0.00e+00 | 0.00e+00 |
| Epoprostenol:0 | 7/138,393 | 26,042/26,262,527 | 0.05 | 1.25e-48 | 5.34e-47 |
| Lipolysis:0 | 6/138,393 | 11,288/26,262,527 | 0.10 | 2.51e-18 | 3.96e-17 |
| Cyclin D1:0 | 31/138,393 | 1,424/26,262,527 | 4.13 | 1.45e-10 | 1.39e-09 |
| Hypertension, Renovascular:0 | 2/138,393 | 4,794/26,262,527 | 0.08 | 9.40e-09 | 7.60e-08 |
| ID-1:0 | 27/138,393 | 404/26,262,527 | 12.68 | 1.86e-20 | 3.25e-19 |
| Acetic Acid:0 | 10/138,393 | 11,333/26,262,527 | 0.17 | 5.73e-15 | 7.54e-14 |
| Pilum:0 | 1/138,393 | 6,516/26,262,527 | 0.03 | 1.08e-13 | 1.31e-12 |
| Magnetic resonance imaging guided biopsy:0 | 40/138,393 | 159/26,262,527 | 47.75 | 4.35e-50 | 1.90e-48 |
| 8p21:0 | 16/138,393 | 79/26,262,527 | 38.44 | 1.21e-19 | 2.03e-18 |
| Hela Cells:0 | 49/138,393 | 19,363/26,262,527 | 0.48 | 9.06e-09 | 7.34e-08 |
| [D]Musculoskeletal pain:0 | 1/138,393 | 3,575/26,262,527 | 0.05 | 3.11e-07 | 2.13e-06 |
| Stage:0 | 25/138,393 | 1,211/26,262,527 | 3.92 | 2.22e-08 | 1.73e-07 |
| Vascular Diseases:0 | 22/138,393 | 25,855/26,262,527 | 0.16 | 1.82e-33 | 5.11e-32 |
| Primordium:0 | 4/138,393 | 6,444/26,262,527 | 0.12 | 2.35e-10 | 2.20e-09 |
| hypothermia, natural:0 | 7/138,393 | 10,262/26,262,527 | 0.13 | 2.01e-15 | 2.72e-14 |
| Lisinopril:0 | 1/138,393 | 5,333/26,262,527 | 0.04 | 3.44e-11 | 3.45e-10 |
| CHEK2 gene|CHEK2:0 | 44/138,393 | 1,719/26,262,527 | 4.86 | 1.01e-16 | 1.47e-15 |
| Receptors, Steroid:0 | 109/138,393 | 2,993/26,262,527 | 6.92 | 1.75e-52 | 7.99e-51 |
| Somatropin:0 | 7/138,393 | 8,734/26,262,527 | 0.15 | 2.31e-12 | 2.53e-11 |
| Anoikis:0 | 44/138,393 | 1,668/26,262,527 | 5.01 | 3.55e-17 | 5.28e-16 |
| Motor Neuron Disease:0 | 4/138,393 | 4,835/26,262,527 | 0.16 | 4.00e-07 | 2.71e-06 |
| Mycoses:0 | 8/138,393 | 20,101/26,262,527 | 0.08 | 1.26e-34 | 3.68e-33 |
| Gastrin releasing peptide|GRP:0 | 39/138,393 | 730/26,262,527 | 10.14 | 1.79e-25 | 3.80e-24 |
| Vascular Cell Adhesion Molecule-1:0 | 14/138,393 | 9,899/26,262,527 | 0.27 | 9.00e-10 | 8.03e-09 |
| hepsin|HPN:0 | 45/138,393 | 410/26,262,527 | 20.83 | 1.03e-41 | 3.75e-40 |
| Placenta:0 | 46/138,393 | 41,745/26,262,527 | 0.21 | 8.69e-46 | 3.46e-44 |
| Malignant Bone Neoplasm:0 | 46/138,393 | 2,646/26,262,527 | 3.30 | 1.21e-11 | 1.25e-10 |
| Cancer-related morbidities:0 | 15/138,393 | 113/26,262,527 | 25.19 | 4.70e-16 | 6.55e-15 |
| Entire suprachiasmatic nucleus:0 | 1/138,393 | 3,914/26,262,527 | 0.05 | 4.94e-08 | 3.69e-07 |
| Knee joint:0 | 1/138,393 | 4,966/26,262,527 | 0.04 | 2.11e-10 | 1.99e-09 |
| Electricity:0 | 8/138,393 | 8,201/26,262,527 | 0.19 | 1.20e-10 | 1.16e-09 |
| CD4 Positive T Lymphocytes:0 | 6/138,393 | 7,855/26,262,527 | 0.14 | 2.24e-11 | 2.27e-10 |
| Secondary malignant neoplasm of bone marrow:0 | 25/138,393 | 457/26,262,527 | 10.38 | 3.95e-17 | 5.86e-16 |
| 17beta-hydroxysteroid dehydrogenase type 3:0 | 8/138,393 | 48/26,262,527 | 31.63 | 6.47e-10 | 5.83e-09 |
| Chemoprevention:0 | 303/138,393 | 4,192/26,262,527 | 13.74 | 4.75e-221 | 9.84e-219 |
| Ivermectin:0 | 2/138,393 | 6,509/26,262,527 | 0.06 | 1.79e-12 | 1.98e-11 |
| Excretory function:0 | 72/138,393 | 56,259/26,262,527 | 0.24 | 8.64e-55 | 4.09e-53 |
| PERINEURAL INVASION:0 | 134/138,393 | 1,360/26,262,527 | 18.71 | 5.00e-115 | 5.04e-113 |
| Coronary heart disease:0 | 49/138,393 | 55,695/26,262,527 | 0.17 | 1.61e-69 | 9.87e-68 |
| Tissue specimen:0 | 510/138,393 | 20,806/26,262,527 | 4.67 | 1.44e-167 | 2.22e-165 |
| BRCA1 Mutation:0 | 29/138,393 | 1,461/26,262,527 | 3.77 | 4.11e-09 | 3.45e-08 |
| Octreotide|CALCA|PCYT1A:0 | 5/138,393 | 15/26,262,527 | 63.26 | 5.75e-08 | 4.25e-07 |
| Cornea:0 | 4/138,393 | 39,321/26,262,527 | 0.02 | 2.33e-82 | 1.67e-80 |
| Androgen Receptor:0 | 282/138,393 | 2,781/26,262,527 | 19.28 | 4.30e-243 | 1.01e-240 |
| Metabolic Diseases:0 | 37/138,393 | 18,111/26,262,527 | 0.39 | 1.65e-11 | 1.69e-10 |
| Depressive disorder:0 | 108/138,393 | 109,945/26,262,527 | 0.19 | 1.67e-127 | 1.88e-125 |
| Sex Characteristics:0 | 9/138,393 | 8,399/26,262,527 | 0.20 | 3.18e-10 | 2.95e-09 |
| Sulpiride:0 | 2/138,393 | 5,048/26,262,527 | 0.08 | 2.16e-09 | 1.86e-08 |
| Myotonic Dystrophy:0 | 1/138,393 | 4,985/26,262,527 | 0.04 | 2.14e-10 | 2.01e-09 |
| Statistical Analysis:0 | 95/138,393 | 9,890/26,262,527 | 1.82 | 1.04e-07 | 7.52e-07 |
| Medication Management:0 | 82/138,393 | 6,852/26,262,527 | 2.27 | 5.96e-11 | 5.86e-10 |
| VN 85-1:0 | 4/138,393 | 6/26,262,527 | 126.52 | 1.55e-07 | 1.09e-06 |
| Triptorelin:0 | 59/138,393 | 924/26,262,527 | 12.12 | 1.05e-41 | 3.80e-40 |
| Retinal Vein Occlusion:0 | 1/138,393 | 4,163/26,262,527 | 0.05 | 1.78e-08 | 1.40e-07 |
| Ofloxacin:0 | 2/138,393 | 5,582/26,262,527 | 0.07 | 1.88e-10 | 1.78e-09 |
| Breast Cancer Cell:0 | 341/138,393 | 19,866/26,262,527 | 3.26 | 5.71e-74 | 3.68e-72 |
| Tumour flare:0 | 13/138,393 | 28/26,262,527 | 88.11 | 3.47e-20 | 5.94e-19 |
| Thiamine:0 | 2/138,393 | 6,241/26,262,527 | 0.06 | 7.79e-12 | 8.21e-11 |
| Sucrose:0 | 12/138,393 | 16,416/26,262,527 | 0.14 | 2.24e-23 | 4.40e-22 |
| Nicotiana:0 | 4/138,393 | 6,165/26,262,527 | 0.12 | 9.38e-10 | 8.33e-09 |
| RC 3940-II:0 | 8/138,393 | 87/26,262,527 | 17.45 | 4.62e-08 | 3.46e-07 |
| Neural Development:0 | 10/138,393 | 18,006/26,262,527 | 0.11 | 2.88e-28 | 6.82e-27 |
| Chromosome 8 Short Arm:0 | 38/138,393 | 253/26,262,527 | 28.51 | 3.88e-40 | 1.35e-38 |
| Lipopolysaccharides:0 | 41/138,393 | 111,592/26,262,527 | 0.07 | 1.39e-191 | 2.55e-189 |
| Hydroxyindoleacetic Acid:0 | 2/138,393 | 5,532/26,262,527 | 0.07 | 1.78e-10 | 1.69e-09 |
| Proto-Oncogene Proteins c-akt:0 | 48/138,393 | 4,092/26,262,527 | 2.23 | 7.92e-07 | 5.20e-06 |
| Vascular resistance:0 | 2/138,393 | 13,052/26,262,527 | 0.03 | 6.36e-27 | 1.43e-25 |
| Tetradecapeptide:0 | 10/138,393 | 247/26,262,527 | 7.68 | 1.40e-06 | 8.92e-06 |
| Carbapenems:0 | 1/138,393 | 4,179/26,262,527 | 0.05 | 1.14e-08 | 9.14e-08 |
| Regional Cancer:0 | 33/138,393 | 234/26,262,527 | 26.77 | 2.91e-34 | 8.39e-33 |
| Nephrons:0 | 3/138,393 | 6,141/26,262,527 | 0.09 | 1.35e-10 | 1.29e-09 |
| Chromaffin Cells:0 | 3/138,393 | 8,002/26,262,527 | 0.07 | 1.40e-14 | 1.80e-13 |
| Biological Assay:0 | 9/138,393 | 6,895/26,262,527 | 0.25 | 1.62e-07 | 1.14e-06 |
| Umbilical Cord Blood:0 | 5/138,393 | 7,296/26,262,527 | 0.13 | 3.72e-11 | 3.72e-10 |
| AIDS patient:0 | 3/138,393 | 9,823/26,262,527 | 0.06 | 2.01e-18 | 3.19e-17 |
| Lymphangiography:0 | 45/138,393 | 3,130/26,262,527 | 2.73 | 6.11e-09 | 5.05e-08 |
| Enterococcus:0 | 1/138,393 | 3,785/26,262,527 | 0.05 | 1.04e-07 | 7.50e-07 |
| Apoptosis Regulator:0 | 21/138,393 | 422/26,262,527 | 9.44 | 7.06e-14 | 8.68e-13 |
| Apigenin:0 | 60/138,393 | 3,918/26,262,527 | 2.91 | 1.85e-12 | 2.04e-11 |
| fatty-acid synthase activity:0 | 8/138,393 | 118/26,262,527 | 12.87 | 4.13e-07 | 2.80e-06 |
| Hemibody Irradiation:0 | 22/138,393 | 259/26,262,527 | 16.12 | 5.22e-19 | 8.51e-18 |
| Fecal analysis procedure:0 | 1/138,393 | 3,768/26,262,527 | 0.05 | 1.01e-07 | 7.33e-07 |
| Brackets:0 | 1/138,393 | 3,993/26,262,527 | 0.05 | 3.47e-08 | 2.63e-07 |
| Hepatitis, Chronic Active:0 | 2/138,393 | 4,916/26,262,527 | 0.08 | 4.44e-09 | 3.72e-08 |
| growth hormone secretion:0 | 3/138,393 | 4,880/26,262,527 | 0.12 | 4.69e-08 | 3.51e-07 |
| Syringomyelia:0 | 1/138,393 | 3,257/26,262,527 | 0.06 | 1.26e-06 | 8.04e-06 |
| SP1 gene|SP1:0 | 89/138,393 | 8,423/26,262,527 | 2.01 | 4.62e-09 | 3.86e-08 |
| Gentamicins:0 | 6/138,393 | 19,522/26,262,527 | 0.06 | 9.88e-36 | 3.01e-34 |
| E-Cadherin:0 | 336/138,393 | 16,321/26,262,527 | 3.91 | 8.26e-92 | 6.59e-90 |
| O-desmethylangolensin:0 | 8/138,393 | 74/26,262,527 | 20.52 | 1.44e-08 | 1.14e-07 |
| Triglycerides:0 | 41/138,393 | 49,742/26,262,527 | 0.16 | 1.91e-64 | 1.09e-62 |
| Prions:0 | 3/138,393 | 13,931/26,262,527 | 0.04 | 1.74e-27 | 4.00e-26 |
| Iressa:0 | 25/138,393 | 1,006/26,262,527 | 4.72 | 6.34e-10 | 5.72e-09 |
| GPI gene|GPI:0 | 23/138,393 | 14,881/26,262,527 | 0.29 | 3.43e-13 | 4.00e-12 |
| Macaca mulatta:0 | 13/138,393 | 23,673/26,262,527 | 0.10 | 5.76e-37 | 1.84e-35 |
| Coronary artery:0 | 6/138,393 | 42,726/26,262,527 | 0.03 | 1.08e-86 | 8.19e-85 |
| Lipase:0 | 5/138,393 | 18,932/26,262,527 | 0.05 | 1.02e-35 | 3.10e-34 |
| Toluene:0 | 1/138,393 | 6,029/26,262,527 | 0.03 | 1.43e-12 | 1.59e-11 |
| cetrorelix:0 | 24/138,393 | 891/26,262,527 | 5.11 | 2.97e-10 | 2.75e-09 |
| PPAR alpha:0 | 4/138,393 | 6,269/26,262,527 | 0.12 | 4.58e-10 | 4.19e-09 |
| Serum Albumin, Bovine:0 | 28/138,393 | 15,491/26,262,527 | 0.34 | 1.18e-11 | 1.23e-10 |
| Bladder stenosis:0 | 17/138,393 | 90/26,262,527 | 35.85 | 2.53e-20 | 4.37e-19 |
| APC8015:0 | 8/138,393 | 13/26,262,527 | 116.79 | 1.09e-13 | 1.32e-12 |
| Occipital lobe:0 | 4/138,393 | 4,737/26,262,527 | 0.16 | 5.45e-07 | 3.63e-06 |
| HK3:0 | 12/138,393 | 53/26,262,527 | 42.97 | 1.34e-15 | 1.83e-14 |
| Glutathione:0 | 93/138,393 | 43,134/26,262,527 | 0.41 | 1.07e-23 | 2.12e-22 |
| Entire radius:0 | 31/138,393 | 15,539/26,262,527 | 0.38 | 2.56e-10 | 2.39e-09 |
| Entire utricle:0 | 39/138,393 | 1,279/26,262,527 | 5.79 | 2.19e-17 | 3.29e-16 |
| Opioids:0 | 53/138,393 | 37,199/26,262,527 | 0.27 | 1.76e-33 | 4.96e-32 |
| TNF gene|TNF:0 | 50/138,393 | 18,811/26,262,527 | 0.50 | 7.86e-08 | 5.74e-07 |
| Employee:0 | 26/138,393 | 11,358/26,262,527 | 0.43 | 1.37e-06 | 8.68e-06 |
| Pokeweed Mitogens:0 | 1/138,393 | 3,463/26,262,527 | 0.05 | 4.23e-07 | 2.86e-06 |
| salicylate:0 | 2/138,393 | 4,170/26,262,527 | 0.09 | 1.47e-07 | 1.04e-06 |
| Receptors, Antigen, B-Cell:0 | 2/138,393 | 5,243/26,262,527 | 0.07 | 7.36e-10 | 6.61e-09 |
| human leukocyte interferon|IFNA1:0 | 42/138,393 | 24,848/26,262,527 | 0.32 | 2.36e-19 | 3.91e-18 |
| Prostate Rhabdomyosarcoma:0 | 33/138,393 | 63/26,262,527 | 99.43 | 2.30e-50 | 1.02e-48 |
| Balloon Dilatation:0 | 6/138,393 | 5,331/26,262,527 | 0.21 | 9.91e-07 | 6.42e-06 |
| 13q14:0 | 17/138,393 | 523/26,262,527 | 6.17 | 7.90e-09 | 6.47e-08 |
| Digital Rectal Examination:0 | 656/138,393 | 1,378/26,262,527 | 90.76 | 0.00e+00 | 0.00e+00 |
| Pervasive Development Disorders:0 | 2/138,393 | 4,166/26,262,527 | 0.09 | 1.47e-07 | 1.04e-06 |
| Coitus:0 | 58/138,393 | 3,907/26,262,527 | 2.82 | 1.38e-11 | 1.43e-10 |
| Cerebrovascular accident:0 | 62/138,393 | 145,345/26,262,527 | 0.08 | 1.09e-239 | 2.49e-237 |
| Nerve Tissue:0 | 9/138,393 | 6,432/26,262,527 | 0.27 | 9.86e-07 | 6.39e-06 |
| National Cancer Institute:0 | 33/138,393 | 627/26,262,527 | 9.99 | 1.28e-21 | 2.35e-20 |
| Tumor tissue sample:0 | 20/138,393 | 627/26,262,527 | 6.05 | 5.43e-10 | 4.93e-09 |
| Echinococcosis:0 | 1/138,393 | 17,952/26,262,527 | 0.01 | 2.49e-39 | 8.42e-38 |
| Bronchial:0 | 32/138,393 | 19,354/26,262,527 | 0.31 | 1.34e-15 | 1.82e-14 |
| Radiotherapy Research:0 | 76/138,393 | 3,335/26,262,527 | 4.33 | 1.08e-24 | 2.24e-23 |
| Residual Tissues:0 | 26/138,393 | 843/26,262,527 | 5.85 | 3.19e-12 | 3.46e-11 |
| alpha 1-Antichymotrypsin|ADRA1D:0 | 20/138,393 | 319/26,262,527 | 11.90 | 4.65e-15 | 6.15e-14 |
| High Density Lipoprotein Cholesterol:0 | 28/138,393 | 19,129/26,262,527 | 0.28 | 1.91e-17 | 2.88e-16 |
| Radioisotope scan of bone:0 | 63/138,393 | 1,077/26,262,527 | 11.11 | 2.72e-42 | 9.99e-41 |
| Conception:0 | 4/138,393 | 5,682/26,262,527 | 0.13 | 6.94e-09 | 5.70e-08 |
| Purpura, Thrombocytopenic, Idiopathic:0 | 2/138,393 | 8,743/26,262,527 | 0.04 | 2.67e-17 | 4.00e-16 |
| Transplantation of liver:0 | 1/138,393 | 3,461/26,262,527 | 0.05 | 4.23e-07 | 2.85e-06 |
| Chemotherapy-Oncologic Procedure:0 | 271/138,393 | 21,257/26,262,527 | 2.42 | 8.45e-37 | 2.68e-35 |
| Carnitine:0 | 3/138,393 | 11,536/26,262,527 | 0.05 | 3.69e-22 | 6.90e-21 |
| cyclin-dependent kinase inhibitor 1B|IFI27|PSMD9|SSSCA1|DCTN6|TMED7:0 | 19/138,393 | 454/26,262,527 | 7.94 | 1.85e-11 | 1.89e-10 |
| HPCX:0 | 5/138,393 | 11/26,262,527 | 86.26 | 1.65e-08 | 1.30e-07 |
| Genus Mycobacterium:0 | 1/138,393 | 7,574/26,262,527 | 0.03 | 4.41e-16 | 6.16e-15 |
| Dissection of aorta:0 | 3/138,393 | 8,332/26,262,527 | 0.07 | 2.35e-15 | 3.16e-14 |
| Urology department:0 | 18/138,393 | 115/26,262,527 | 29.71 | 4.00e-20 | 6.83e-19 |
| Atom:0 | 19/138,393 | 22,616/26,262,527 | 0.16 | 1.35e-29 | 3.34e-28 |
| Databases:0 | 174/138,393 | 9,383/26,262,527 | 3.52 | 9.43e-43 | 3.51e-41 |
| Ketamine:0 | 3/138,393 | 17,803/26,262,527 | 0.03 | 5.72e-36 | 1.76e-34 |
| Splenomegaly:0 | 2/138,393 | 5,031/26,262,527 | 0.08 | 2.13e-09 | 1.84e-08 |
| ARCH:0 | 2/138,393 | 6,284/26,262,527 | 0.06 | 5.17e-12 | 5.54e-11 |
| Transitional cell carcinoma in situ:0 | 10/138,393 | 97/26,262,527 | 19.57 | 3.47e-10 | 3.20e-09 |
| COGNITIVE DEFICIT:0 | 1/138,393 | 10,422/26,262,527 | 0.02 | 1.95e-22 | 3.67e-21 |
| Aminophylline:0 | 1/138,393 | 4,237/26,262,527 | 0.04 | 1.25e-08 | 9.94e-08 |
| Phosphatidylserines:0 | 21/138,393 | 11,355/26,262,527 | 0.35 | 1.24e-08 | 9.93e-08 |
| Acute Lung Injury:0 | 1/138,393 | 9,708/26,262,527 | 0.02 | 7.54e-21 | 1.34e-19 |
| Red blood cells, blood product:0 | 1/138,393 | 4,803/26,262,527 | 0.04 | 6.73e-10 | 6.05e-09 |
| ADENOSINE DEAMINASE|ADA:0 | 4/138,393 | 5,271/26,262,527 | 0.14 | 5.35e-08 | 3.96e-07 |
| Galactose:0 | 6/138,393 | 9,269/26,262,527 | 0.12 | 2.49e-14 | 3.16e-13 |
| melanocyte:0 | 17/138,393 | 11,327/26,262,527 | 0.28 | 1.76e-10 | 1.67e-09 |
| CYP24|CYP24A1:0 | 17/138,393 | 466/26,262,527 | 6.92 | 1.52e-09 | 1.33e-08 |
| Leishmaniasis:0 | 2/138,393 | 7,441/26,262,527 | 0.05 | 1.70e-14 | 2.16e-13 |
| High-Grade Prostatic Intraepithelial Neoplasia:0 | 623/138,393 | 1,431/26,262,527 | 82.99 | 0.00e+00 | 0.00e+00 |
| autologous dendritic cells:0 | 34/138,393 | 414/26,262,527 | 15.59 | 4.57e-28 | 1.08e-26 |
| Pancreatic Polypeptide:0 | 2/138,393 | 4,316/26,262,527 | 0.09 | 7.29e-08 | 5.34e-07 |
| MATCHING:0 | 50/138,393 | 4,216/26,262,527 | 2.25 | 3.57e-07 | 2.43e-06 |
| estramustine-binding protein:0 | 36/138,393 | 229/26,262,527 | 29.84 | 9.46e-39 | 3.14e-37 |
| Feeling suicidal:0 | 4/138,393 | 5,472/26,262,527 | 0.14 | 1.92e-08 | 1.50e-07 |
| Adenocarcinoma:0 | 4,556/138,393 | 90,559/26,262,527 | 9.84 | 0.00e+00 | 0.00e+00 |
| Bacteremia:0 | 19/138,393 | 29,307/26,262,527 | 0.12 | 8.73e-43 | 3.25e-41 |
| Adrenergic beta-Antagonists:0 | 24/138,393 | 33,465/26,262,527 | 0.14 | 9.47e-47 | 3.86e-45 |
| Streptococcus pneumoniae:0 | 2/138,393 | 24,454/26,262,527 | 0.02 | 2.64e-52 | 1.20e-50 |
| Malignant neoplasm of urinary bladder:0 | 1,133/138,393 | 29,148/26,262,527 | 7.43 | 0.00e+00 | 0.00e+00 |
| HSV-Tk Gene:0 | 39/138,393 | 1,439/26,262,527 | 5.14 | 8.97e-16 | 1.23e-14 |
| Recombinants:0 | 303/138,393 | 76,161/26,262,527 | 0.75 | 3.48e-07 | 2.38e-06 |
| Titration:0 | 5/138,393 | 6,499/26,262,527 | 0.15 | 1.53e-09 | 1.34e-08 |
| Inflammatory Response:0 | 83/138,393 | 44,093/26,262,527 | 0.36 | 2.70e-29 | 6.63e-28 |
| Antibiotics:0 | 163/138,393 | 125,747/26,262,527 | 0.25 | 1.73e-119 | 1.79e-117 |
| Stem Cell Factor:0 | 10/138,393 | 7,904/26,262,527 | 0.24 | 8.86e-09 | 7.19e-08 |
| Stem cell transplant:0 | 7/138,393 | 11,078/26,262,527 | 0.12 | 4.87e-17 | 7.21e-16 |
| Tumor Necrosis Factor Receptor Superfamily, Member 10B|TNFRSF10B:0 | 40/138,393 | 1,590/26,262,527 | 4.78 | 4.11e-15 | 5.45e-14 |
| Troponin T:0 | 1/138,393 | 3,410/26,262,527 | 0.06 | 6.17e-07 | 4.09e-06 |
| Tobramycin:0 | 2/138,393 | 5,244/26,262,527 | 0.07 | 7.36e-10 | 6.61e-09 |
| Pelvic Exenteration:0 | 57/138,393 | 1,324/26,262,527 | 8.17 | 8.23e-32 | 2.19e-30 |
| Large T-Antigen:0 | 56/138,393 | 4,723/26,262,527 | 2.25 | 1.01e-07 | 7.30e-07 |
| Evaluable Disease:0 | 350/138,393 | 11,731/26,262,527 | 5.67 | 2.68e-139 | 3.37e-137 |
| Transcriptional Activation:0 | 232/138,393 | 17,807/26,262,527 | 2.47 | 4.86e-33 | 1.35e-31 |
| Nodule:0 | 249/138,393 | 26,639/26,262,527 | 1.78 | 1.49e-16 | 2.14e-15 |
| Permeability:0 | 30/138,393 | 29,709/26,262,527 | 0.19 | 7.12e-35 | 2.10e-33 |
| Autoimmune Diseases:0 | 45/138,393 | 47,146/26,262,527 | 0.18 | 2.10e-56 | 1.04e-54 |
| Anorexia Nervosa:0 | 1/138,393 | 16,728/26,262,527 | 0.01 | 1.22e-36 | 3.85e-35 |
| Cholelithiasis:0 | 5/138,393 | 7,141/26,262,527 | 0.13 | 7.24e-11 | 7.06e-10 |
| R-1881:0 | 198/138,393 | 855/26,262,527 | 44.01 | 1.01e-234 | 2.25e-232 |
| Hyperparathyroidism, Primary:0 | 8/138,393 | 12,986/26,262,527 | 0.12 | 7.22e-20 | 1.22e-18 |
| EZH2 gene|EZH2:0 | 92/138,393 | 2,252/26,262,527 | 7.76 | 1.81e-48 | 7.69e-47 |
| Chitosan:0 | 11/138,393 | 10,488/26,262,527 | 0.20 | 9.66e-13 | 1.09e-11 |
| Vision:0 | 68/138,393 | 31,625/26,262,527 | 0.41 | 9.21e-18 | 1.41e-16 |
| irofulven:0 | 13/138,393 | 247/26,262,527 | 9.99 | 1.99e-09 | 1.72e-08 |
| Giant Cell Tumors:0 | 8/138,393 | 5,934/26,262,527 | 0.26 | 1.49e-06 | 9.42e-06 |
| Protein p53|TP53:0 | 122/138,393 | 10,111/26,262,527 | 2.29 | 8.72e-16 | 1.20e-14 |
| SLC5A5 protein, human|SLC5A5:0 | 36/138,393 | 2,684/26,262,527 | 2.55 | 8.97e-07 | 5.85e-06 |
| Carcinoma, urological:0 | 7/138,393 | 22/26,262,527 | 60.38 | 1.53e-10 | 1.46e-09 |
| Combined radiotherapy NOS:0 | 30/138,393 | 596/26,262,527 | 9.55 | 2.73e-19 | 4.51e-18 |
| Focal segmental glomerulosclerosis:0 | 1/138,393 | 4,997/26,262,527 | 0.04 | 2.17e-10 | 2.04e-09 |
| Animal Model:0 | 408/138,393 | 42,389/26,262,527 | 1.83 | 2.26e-28 | 5.38e-27 |
| Camptothecin:0 | 64/138,393 | 5,875/26,262,527 | 2.07 | 1.95e-07 | 1.37e-06 |
| MTSS1 gene|MTSS1:0 | 9/138,393 | 154/26,262,527 | 11.09 | 2.59e-07 | 1.79e-06 |
| Oils:0 | 34/138,393 | 29,698/26,262,527 | 0.22 | 5.00e-32 | 1.34e-30 |
| IgG4:0 | 7/138,393 | 6,304/26,262,527 | 0.21 | 1.08e-07 | 7.73e-07 |
| Farm Animals:0 | 1/138,393 | 4,651/26,262,527 | 0.04 | 1.36e-09 | 1.19e-08 |
| Generalized Anxiety Disorder:0 | 1/138,393 | 7,854/26,262,527 | 0.02 | 1.01e-16 | 1.47e-15 |
| Transrectal Ultrasound:0 | 640/138,393 | 1,339/26,262,527 | 91.12 | 0.00e+00 | 0.00e+00 |
| Singleton:0 | 2/138,393 | 6,282/26,262,527 | 0.06 | 5.16e-12 | 5.53e-11 |
| Entire iris:0 | 11/138,393 | 12,161/26,262,527 | 0.17 | 8.45e-16 | 1.16e-14 |
| Tyrosine 3-Monooxygenase|TH:0 | 1/138,393 | 16,191/26,262,527 | 0.01 | 1.53e-35 | 4.63e-34 |
| Ciprofloxacin:0 | 41/138,393 | 19,586/26,262,527 | 0.40 | 6.27e-12 | 6.66e-11 |
| ASPARAGINASE:0 | 1/138,393 | 4,883/26,262,527 | 0.04 | 4.78e-10 | 4.36e-09 |
| response to hormone stimulus:0 | 24/138,393 | 779/26,262,527 | 5.85 | 2.17e-11 | 2.20e-10 |
| BONE INVOLVEMENT:0 | 36/138,393 | 899/26,262,527 | 7.60 | 9.77e-20 | 1.64e-18 |
| Self Administration:0 | 3/138,393 | 10,664/26,262,527 | 0.05 | 2.68e-20 | 4.61e-19 |
| High dose brachytherapy:0 | 9/138,393 | 60/26,262,527 | 28.47 | 1.28e-10 | 1.22e-09 |
| Fluctuation:0 | 20/138,393 | 10,827/26,262,527 | 0.35 | 2.67e-08 | 2.05e-07 |
| Bacteriophages:0 | 33/138,393 | 18,110/26,262,527 | 0.35 | 2.67e-13 | 3.13e-12 |
| Stomach:0 | 243/138,393 | 81,540/26,262,527 | 0.56 | 1.71e-22 | 3.26e-21 |
| Hetastarch:0 | 1/138,393 | 3,683/26,262,527 | 0.05 | 1.44e-07 | 1.02e-06 |
| Amikacin:0 | 1/138,393 | 6,523/26,262,527 | 0.03 | 1.10e-13 | 1.33e-12 |
| Aggressive behavior:0 | 593/138,393 | 27,698/26,262,527 | 4.08 | 4.92e-168 | 7.66e-166 |
| radiotracer:0 | 27/138,393 | 1,692/26,262,527 | 3.03 | 8.99e-07 | 5.86e-06 |
| Ductal Carcinoma:0 | 44/138,393 | 1,969/26,262,527 | 4.24 | 1.03e-14 | 1.33e-13 |
| Violence:0 | 2/138,393 | 17,886/26,262,527 | 0.02 | 1.08e-37 | 3.48e-36 |
| Heart Diseases:0 | 66/138,393 | 34,418/26,262,527 | 0.36 | 1.36e-22 | 2.60e-21 |
| Ketoprofen:0 | 2/138,393 | 3,869/26,262,527 | 0.10 | 5.93e-07 | 3.94e-06 |
| Normal blood pressure:0 | 5/138,393 | 16,210/26,262,527 | 0.06 | 8.03e-30 | 2.01e-28 |
| Gleason pattern:0 | 29/138,393 | 39/26,262,527 | 141.14 | 8.25e-48 | 3.46e-46 |
| XRCC1 gene|XRCC1:0 | 48/138,393 | 3,893/26,262,527 | 2.34 | 2.00e-07 | 1.40e-06 |
| Carcinoma in Situ:0 | 160/138,393 | 7,386/26,262,527 | 4.11 | 2.41e-47 | 1.00e-45 |
| Cell Line, Tumor:0 | 567/138,393 | 15,602/26,262,527 | 6.92 | 1.56e-264 | 3.95e-262 |
| Monoclonal Antibodies:0 | 662/138,393 | 103,477/26,262,527 | 1.22 | 1.29e-06 | 8.26e-06 |
| fludarabine:0 | 6/138,393 | 5,844/26,262,527 | 0.19 | 1.55e-07 | 1.09e-06 |
| quetiapine:0 | 1/138,393 | 5,701/26,262,527 | 0.03 | 5.64e-12 | 6.02e-11 |
| Eye Movements:0 | 1/138,393 | 4,195/26,262,527 | 0.05 | 1.15e-08 | 9.23e-08 |
| Renal function:0 | 56/138,393 | 34,090/26,262,527 | 0.31 | 8.41e-27 | 1.88e-25 |
| MSMB gene|MSMB:0 | 83/138,393 | 1,733/26,262,527 | 9.09 | 7.73e-49 | 3.29e-47 |
| Phosphatidylinositols:0 | 17/138,393 | 14,277/26,262,527 | 0.23 | 1.37e-15 | 1.87e-14 |
| Thyroxine:0 | 16/138,393 | 24,296/26,262,527 | 0.12 | 1.93e-35 | 5.80e-34 |
| PDPN:0 | 22/138,393 | 1,069/26,262,527 | 3.91 | 1.58e-07 | 1.11e-06 |
| Premedication:0 | 11/138,393 | 7,133/26,262,527 | 0.29 | 6.87e-07 | 4.53e-06 |
| Curettage procedure:0 | 1/138,393 | 4,591/26,262,527 | 0.04 | 2.01e-09 | 1.74e-08 |
| Low Grade Prostatic Intraepithelial Neoplasia:0 | 53/138,393 | 87/26,262,527 | 115.65 | 1.28e-82 | 9.26e-81 |
| Deficiency of testosterone biosynthesis:0 | 35/138,393 | 903/26,262,527 | 7.36 | 8.22e-19 | 1.33e-17 |
| Prostate Stromal Sarcoma:0 | 9/138,393 | 23/26,262,527 | 74.26 | 7.52e-14 | 9.22e-13 |
| Endometriosis of uterus:0 | 1/138,393 | 3,665/26,262,527 | 0.05 | 1.43e-07 | 1.02e-06 |
| Crohn's disease:0 | 19/138,393 | 46,666/26,262,527 | 0.08 | 1.14e-78 | 7.92e-77 |
| Clamp:0 | 3/138,393 | 5,807/26,262,527 | 0.10 | 5.15e-10 | 4.69e-09 |
| Norepinephrine:0 | 25/138,393 | 89,081/26,262,527 | 0.05 | 1.49e-162 | 2.20e-160 |
| Mucocutaneous Lymph Node Syndrome:0 | 2/138,393 | 12,340/26,262,527 | 0.03 | 2.41e-25 | 5.10e-24 |
| nuclear receptor coactivator 1|SRC:0 | 17/138,393 | 404/26,262,527 | 7.99 | 1.92e-10 | 1.81e-09 |
| Hyperuricemia:0 | 3/138,393 | 6,892/26,262,527 | 0.08 | 2.72e-12 | 2.96e-11 |
| Rumen:0 | 2/138,393 | 8,987/26,262,527 | 0.04 | 5.99e-18 | 9.26e-17 |
| Ovarian Carcinoma:0 | 562/138,393 | 62,529/26,262,527 | 1.71 | 3.69e-31 | 9.67e-30 |
| Ceruloplasmin:0 | 5/138,393 | 6,329/26,262,527 | 0.15 | 2.89e-09 | 2.46e-08 |
| Age:0 | 558/138,393 | 54,184/26,262,527 | 1.96 | 6.22e-46 | 2.49e-44 |
| Creatine Kinase, BB Form:0 | 19/138,393 | 729/26,262,527 | 4.95 | 3.28e-08 | 2.50e-07 |
| Rectal hemorrhage:0 | 135/138,393 | 1,907/26,262,527 | 13.45 | 1.77e-98 | 1.52e-96 |
| Marihuana:0 | 9/138,393 | 6,973/26,262,527 | 0.24 | 1.20e-07 | 8.57e-07 |
| Monkeys:0 | 22/138,393 | 50,426/26,262,527 | 0.08 | 2.15e-83 | 1.56e-81 |
| Morphine:0 | 34/138,393 | 53,357/26,262,527 | 0.12 | 1.34e-77 | 9.18e-76 |
| Antiepileptic Agents:0 | 2/138,393 | 14,150/26,262,527 | 0.03 | 2.78e-29 | 6.81e-28 |
| equol:0 | 40/138,393 | 1,155/26,262,527 | 6.57 | 1.28e-19 | 2.14e-18 |
| Biopsy:0 | 5,998/138,393 | 137,987/26,262,527 | 8.58 | 0.00e+00 | 0.00e+00 |
| Lymph Node Dissection:0 | 491/138,393 | 7,473/26,262,527 | 12.51 | 0.00e+00 | 0.00e+00 |
| Deoxyribonuclease I:0 | 6/138,393 | 5,570/26,262,527 | 0.20 | 3.84e-07 | 2.61e-06 |
| Cholecystectomy, Laparoscopic:0 | 3/138,393 | 10,635/26,262,527 | 0.05 | 2.63e-20 | 4.53e-19 |
| Myoblasts:0 | 1/138,393 | 7,710/26,262,527 | 0.02 | 2.10e-16 | 3.00e-15 |
| Radionuclide Imaging:0 | 372/138,393 | 38,798/26,262,527 | 1.82 | 9.99e-26 | 2.15e-24 |
| IODINE,I-125:0 | 142/138,393 | 678/26,262,527 | 39.78 | 1.98e-163 | 2.95e-161 |
| Cellulose:0 | 2/138,393 | 8,456/26,262,527 | 0.04 | 1.13e-16 | 1.63e-15 |
| Vascular calcification:0 | 1/138,393 | 3,909/26,262,527 | 0.05 | 4.91e-08 | 3.67e-07 |
| Intussusception:0 | 7/138,393 | 9,055/26,262,527 | 0.15 | 6.34e-13 | 7.24e-12 |
| procaspase-9:0 | 14/138,393 | 314/26,262,527 | 8.46 | 3.68e-09 | 3.10e-08 |
| Propranolol:0 | 7/138,393 | 34,463/26,262,527 | 0.04 | 4.58e-67 | 2.72e-65 |
| Myeloproliferative disease:0 | 13/138,393 | 9,839/26,262,527 | 0.25 | 3.13e-10 | 2.90e-09 |
| Adipocytes:0 | 38/138,393 | 40,883/26,262,527 | 0.18 | 8.24e-50 | 3.57e-48 |
| Nuclear Translocation:0 | 92/138,393 | 3,640/26,262,527 | 4.80 | 1.02e-32 | 2.81e-31 |
| Mass Screening:0 | 56/138,393 | 1,361/26,262,527 | 7.81 | 2.43e-30 | 6.18e-29 |
| Hip Fractures:0 | 19/138,393 | 12,365/26,262,527 | 0.29 | 3.91e-11 | 3.91e-10 |
| Osteolytic lesion:0 | 32/138,393 | 1,495/26,262,527 | 4.06 | 1.12e-10 | 1.08e-09 |
| Bladder Adenocarcinoma:0 | 8/138,393 | 82/26,262,527 | 18.51 | 3.02e-08 | 2.31e-07 |
| Antihistamines:0 | 2/138,393 | 6,664/26,262,527 | 0.06 | 8.96e-13 | 1.01e-11 |
| Tumor destruction:0 | 15/138,393 | 297/26,262,527 | 9.59 | 2.02e-10 | 1.91e-09 |
| Ionizing radiation:0 | 64/138,393 | 3,253/26,262,527 | 3.73 | 5.13e-18 | 7.98e-17 |
| Fluorescent in Situ Hybridization:0 | 216/138,393 | 14,341/26,262,527 | 2.86 | 2.28e-39 | 7.74e-38 |
| Bone finding:0 | 16/138,393 | 135/26,262,527 | 22.49 | 2.55e-16 | 3.63e-15 |
| Transurethral Resection:0 | 479/138,393 | 4,657/26,262,527 | 19.58 | 0.00e+00 | 0.00e+00 |
| Oocytes:0 | 20/138,393 | 58,518/26,262,527 | 0.06 | 8.12e-103 | 7.26e-101 |
| Phosphatidic Acid:0 | 6/138,393 | 5,695/26,262,527 | 0.20 | 2.94e-07 | 2.03e-06 |
| Phytoestrogens:0 | 159/138,393 | 5,058/26,262,527 | 5.97 | 2.82e-67 | 1.68e-65 |
| Phosphoenolpyruvate Carboxylase:0 | 1/138,393 | 5,565/26,262,527 | 0.03 | 1.18e-11 | 1.23e-10 |
| Cilia:0 | 3/138,393 | 4,860/26,262,527 | 0.12 | 4.60e-08 | 3.45e-07 |
| Progressive Disease:0 | 193/138,393 | 8,361/26,262,527 | 4.39 | 9.56e-61 | 5.13e-59 |
| ileum:0 | 34/138,393 | 37,627/26,262,527 | 0.17 | 1.13e-46 | 4.60e-45 |
| Aorta:0 | 41/138,393 | 114,377/26,262,527 | 0.07 | 1.31e-197 | 2.46e-195 |
| brain development:0 | 3/138,393 | 5,694/26,262,527 | 0.10 | 1.07e-09 | 9.43e-09 |
| PCA3:0 | 90/138,393 | 189/26,262,527 | 90.42 | 1.64e-131 | 1.92e-129 |
| Ductal Mouse MIN:0 | 35/138,393 | 380/26,262,527 | 17.48 | 2.06e-30 | 5.26e-29 |
| Hypothyroidism:0 | 8/138,393 | 27,015/26,262,527 | 0.06 | 2.19e-49 | 9.45e-48 |
| Screening for cancer:0 | 24/138,393 | 134/26,262,527 | 33.99 | 1.41e-27 | 3.26e-26 |
| Adrenal Cortex Hormones:0 | 88/138,393 | 97,827/26,262,527 | 0.17 | 1.32e-119 | 1.37e-117 |
| alpha-methylacyl-CoA racemase:0 | 104/138,393 | 403/26,262,527 | 49.01 | 1.87e-128 | 2.12e-126 |
| Polycyclic Hydrocarbons, Aromatic:0 | 27/138,393 | 13,408/26,262,527 | 0.38 | 5.26e-09 | 4.37e-08 |
| Indomethacin:0 | 36/138,393 | 45,215/26,262,527 | 0.15 | 1.11e-59 | 5.83e-58 |
| Prostatic acid phosphatase measurement:0 | 16/138,393 | 20/26,262,527 | 151.83 | 2.15e-27 | 4.94e-26 |
| Vasectomy:0 | 44/138,393 | 1,623/26,262,527 | 5.15 | 1.36e-17 | 2.07e-16 |
| Synovitis:0 | 3/138,393 | 7,336/26,262,527 | 0.08 | 3.32e-13 | 3.87e-12 |
| alpha-Actin:0 | 43/138,393 | 21,531/26,262,527 | 0.38 | 8.39e-14 | 1.03e-12 |
| keratinocyte:0 | 30/138,393 | 40,966/26,262,527 | 0.14 | 2.75e-56 | 1.35e-54 |
| Prion Diseases:0 | 3/138,393 | 7,933/26,262,527 | 0.07 | 2.01e-14 | 2.55e-13 |
| Lung Diseases, Interstitial:0 | 3/138,393 | 8,762/26,262,527 | 0.06 | 4.38e-16 | 6.12e-15 |
| Hypernatremia:0 | 2/138,393 | 3,876/26,262,527 | 0.10 | 5.95e-07 | 3.95e-06 |
| Mesocricetus auratus:0 | 15/138,393 | 10,011/26,262,527 | 0.28 | 1.83e-09 | 1.59e-08 |
| Antithrombins:0 | 4/138,393 | 6,237/26,262,527 | 0.12 | 6.66e-10 | 5.99e-09 |
| MSR1:0 | 16/138,393 | 190/26,262,527 | 15.98 | 3.51e-14 | 4.41e-13 |
| Colorectal cancer metastatic:0 | 19/138,393 | 13,860/26,262,527 | 0.26 | 1.06e-13 | 1.29e-12 |
| Diet:0 | 194/138,393 | 18,955/26,262,527 | 1.94 | 1.01e-16 | 1.48e-15 |
| Monobactams:0 | 4/138,393 | 5,537/26,262,527 | 0.14 | 1.37e-08 | 1.08e-07 |
| Body mass index procedure:0 | 103/138,393 | 4,418/26,262,527 | 4.43 | 1.28e-33 | 3.63e-32 |
| Radical cystoprostatectomy:0 | 133/138,393 | 414/26,262,527 | 61.02 | 1.25e-174 | 2.07e-172 |
| Liver and Intrahepatic Biliary Tract Carcinoma:0 | 106/138,393 | 9,459/26,262,527 | 2.13 | 4.82e-12 | 5.18e-11 |
| Parkinson Disease:0 | 36/138,393 | 82,730/26,262,527 | 0.08 | 4.46e-136 | 5.45e-134 |
| Bulla:0 | 7/138,393 | 9,356/26,262,527 | 0.14 | 1.69e-13 | 2.01e-12 |
| Action Potentials:0 | 1/138,393 | 13,041/26,262,527 | 0.01 | 2.44e-28 | 5.79e-27 |
| Purpura, Thrombotic Thrombocytopenic:0 | 7/138,393 | 9,087/26,262,527 | 0.15 | 4.32e-13 | 5.00e-12 |
| Immune System Diseases:0 | 10/138,393 | 10,364/26,262,527 | 0.18 | 3.88e-13 | 4.49e-12 |
| Accessory Sex Organs:0 | 18/138,393 | 238/26,262,527 | 14.35 | 5.17e-15 | 6.83e-14 |
| Delirium:0 | 4/138,393 | 11,265/26,262,527 | 0.07 | 2.44e-20 | 4.23e-19 |
| TWIST1 gene|TWIST1:0 | 53/138,393 | 3,172/26,262,527 | 3.17 | 1.53e-12 | 1.70e-11 |
| chromosome 8p22:0 | 11/138,393 | 52/26,262,527 | 40.15 | 3.94e-14 | 4.92e-13 |
| brush border membrane:0 | 6/138,393 | 11,582/26,262,527 | 0.10 | 6.34e-19 | 1.03e-17 |
| Nuclear Receptor Coactivator 4|NCOA4:0 | 29/138,393 | 141/26,262,527 | 39.04 | 1.55e-34 | 4.49e-33 |
| Muscle, Striated:0 | 2/138,393 | 3,732/26,262,527 | 0.10 | 1.20e-06 | 7.69e-06 |
| Immunosuppressive Agents:0 | 18/138,393 | 15,821/26,262,527 | 0.22 | 1.28e-17 | 1.95e-16 |
| Injection site granuloma:0 | 6/138,393 | 17/26,262,527 | 66.98 | 1.94e-09 | 1.68e-08 |
| Signal Transduction:0 | 664/138,393 | 76,577/26,262,527 | 1.65 | 2.45e-32 | 6.62e-31 |
| Dextran:0 | 10/138,393 | 6,951/26,262,527 | 0.27 | 4.62e-07 | 3.10e-06 |
| atrial natriuretic factor prohormone (31-67):0 | 11/138,393 | 138/26,262,527 | 15.13 | 5.83e-10 | 5.28e-09 |
| ESR1 gene|ESR1:0 | 45/138,393 | 3,762/26,262,527 | 2.27 | 1.37e-06 | 8.73e-06 |
| Pancytopenia:0 | 12/138,393 | 7,292/26,262,527 | 0.31 | 1.37e-06 | 8.68e-06 |
| Loss of Heterozygosity:0 | 151/138,393 | 5,442/26,262,527 | 5.27 | 2.29e-57 | 1.16e-55 |
| Rectal ultrasound:0 | 15/138,393 | 39/26,262,527 | 73.00 | 4.43e-22 | 8.25e-21 |
| Stenosis:0 | 3/138,393 | 7,935/26,262,527 | 0.07 | 2.01e-14 | 2.55e-13 |
| Kidney Failure, Acute:0 | 36/138,393 | 23,981/26,262,527 | 0.28 | 5.38e-21 | 9.61e-20 |
| 17 alpha-ethinyl-3-isopropylsulfonyloxyestradiol:0 | 10/138,393 | 28/26,262,527 | 67.78 | 6.48e-15 | 8.49e-14 |
| Proto-Oncogene Proteins c-ets:0 | 71/138,393 | 672/26,262,527 | 20.06 | 9.44e-64 | 5.33e-62 |
| Black race:0 | 156/138,393 | 11,185/26,262,527 | 2.65 | 1.35e-25 | 2.88e-24 |
| Contusions:0 | 3/138,393 | 5,509/26,262,527 | 0.10 | 2.06e-09 | 1.78e-08 |
| Isoflavones:0 | 182/138,393 | 6,568/26,262,527 | 5.26 | 1.14e-68 | 6.93e-67 |
| androgen receptor binding:0 | 18/138,393 | 51/26,262,527 | 66.99 | 1.19e-25 | 2.56e-24 |
| molecular imaging:0 | 19/138,393 | 806/26,262,527 | 4.47 | 1.48e-07 | 1.05e-06 |
| Cysteine:0 | 35/138,393 | 25,836/26,262,527 | 0.26 | 1.21e-24 | 2.50e-23 |
| Trisomy 7:0 | 11/138,393 | 146/26,262,527 | 14.30 | 1.02e-09 | 9.02e-09 |
| CYP17A1 gene|CYP17A1:0 | 73/138,393 | 1,594/26,262,527 | 8.69 | 6.12e-42 | 2.23e-40 |
| Paracrine Communication:0 | 20/138,393 | 457/26,262,527 | 8.31 | 2.56e-12 | 2.79e-11 |
| Enlargement of lymph nodes:0 | 44/138,393 | 3,420/26,262,527 | 2.44 | 1.97e-07 | 1.38e-06 |
| Image Cytometry:0 | 15/138,393 | 401/26,262,527 | 7.10 | 9.93e-09 | 8.01e-08 |
| Myasthenia Gravis:0 | 2/138,393 | 17,936/26,262,527 | 0.02 | 1.15e-37 | 3.72e-36 |
| Rupture, Spontaneous:0 | 7/138,393 | 6,095/26,262,527 | 0.22 | 1.91e-07 | 1.34e-06 |
| NADH:0 | 9/138,393 | 8,815/26,262,527 | 0.19 | 4.57e-11 | 4.55e-10 |
| Histone Acetylation:0 | 35/138,393 | 1,342/26,262,527 | 4.95 | 7.44e-14 | 9.13e-13 |
| Phosphorylation:0 | 618/138,393 | 62,763/26,262,527 | 1.87 | 6.43e-45 | 2.52e-43 |
| erbB-2 Receptor|ERBB2:0 | 86/138,393 | 6,216/26,262,527 | 2.63 | 1.42e-14 | 1.82e-13 |
| TAP-144|SCTR|SNCG:0 | 4/138,393 | 1/26,262,527 | 759.09 | 3.76e-09 | 3.17e-08 |
| Sterols:0 | 16/138,393 | 11,018/26,262,527 | 0.28 | 1.51e-10 | 1.45e-09 |
| Epidermal Growth Factor:0 | 60/138,393 | 2,455/26,262,527 | 4.64 | 2.95e-21 | 5.33e-20 |
| abiraterone:0 | 287/138,393 | 590/26,262,527 | 92.50 | 0.00e+00 | 0.00e+00 |
| Electrocardiogram:0 | 7/138,393 | 18,423/26,262,527 | 0.07 | 2.89e-32 | 7.80e-31 |
| Headache:0 | 17/138,393 | 29,574/26,262,527 | 0.11 | 3.06e-45 | 1.20e-43 |
| Paroxysmal atrial fibrillation:0 | 2/138,393 | 6,229/26,262,527 | 0.06 | 7.59e-12 | 8.02e-11 |
| Catalysis:0 | 12/138,393 | 8,616/26,262,527 | 0.26 | 9.61e-09 | 7.77e-08 |
| Entire vas deferens:0 | 29/138,393 | 12,638/26,262,527 | 0.44 | 3.82e-07 | 2.60e-06 |
| Corticotropin-Releasing Hormone:0 | 8/138,393 | 22,269/26,262,527 | 0.07 | 3.27e-39 | 1.10e-37 |
| Neural Tube Defects:0 | 2/138,393 | 4,305/26,262,527 | 0.09 | 7.25e-08 | 5.32e-07 |
| RB1 gene|RB1:0 | 35/138,393 | 2,355/26,262,527 | 2.82 | 1.28e-07 | 9.15e-07 |
| Graft Survival:0 | 1/138,393 | 7,547/26,262,527 | 0.03 | 4.25e-16 | 5.96e-15 |
| Colon Carcinoma:0 | 111/138,393 | 10,214/26,262,527 | 2.06 | 1.21e-11 | 1.26e-10 |
| Hemangioma:0 | 18/138,393 | 16,746/26,262,527 | 0.20 | 2.06e-19 | 3.41e-18 |
| Lymphokines:0 | 7/138,393 | 7,007/26,262,527 | 0.19 | 4.21e-09 | 3.53e-08 |
| Entire ascending aorta:0 | 1/138,393 | 5,403/26,262,527 | 0.04 | 2.39e-11 | 2.42e-10 |
| Nitrogen:0 | 15/138,393 | 22,805/26,262,527 | 0.12 | 2.50e-33 | 6.98e-32 |
| Nucleoproteins:0 | 1/138,393 | 4,523/26,262,527 | 0.04 | 2.92e-09 | 2.48e-08 |
| Antineutrophil Cytoplasmic Antibodies:0 | 1/138,393 | 3,500/26,262,527 | 0.05 | 4.43e-07 | 2.98e-06 |
| Encephalitis:0 | 5/138,393 | 16,483/26,262,527 | 0.06 | 1.89e-30 | 4.84e-29 |
| VICTIM:0 | 7/138,393 | 21,487/26,262,527 | 0.06 | 6.97e-39 | 2.32e-37 |
| malignant state:0 | 9/138,393 | 139/26,262,527 | 12.29 | 1.14e-07 | 8.15e-07 |
| skills:0 | 21/138,393 | 16,422/26,262,527 | 0.24 | 8.74e-17 | 1.28e-15 |
| Retinoblastoma Genes:0 | 23/138,393 | 1,060/26,262,527 | 4.12 | 3.34e-08 | 2.54e-07 |
| Intensive Care Units, Neonatal:0 | 1/138,393 | 3,638/26,262,527 | 0.05 | 2.13e-07 | 1.48e-06 |
| At risk for suicide:0 | 1/138,393 | 5,364/26,262,527 | 0.04 | 3.59e-11 | 3.59e-10 |
| jejunum:0 | 14/138,393 | 24,480/26,262,527 | 0.11 | 9.57e-38 | 3.11e-36 |
| Intubation:0 | 1/138,393 | 10,918/26,262,527 | 0.02 | 1.49e-23 | 2.95e-22 |
| Carpal Tunnel Syndrome:0 | 1/138,393 | 10,205/26,262,527 | 0.02 | 5.79e-22 | 1.08e-20 |
| Glycogen (Starch) Synthase:0 | 2/138,393 | 4,845/26,262,527 | 0.08 | 6.34e-09 | 5.22e-08 |
| AOD use:0 | 1/138,393 | 8,954/26,262,527 | 0.02 | 2.81e-19 | 4.64e-18 |
| tamsulosin:0 | 51/138,393 | 3,152/26,262,527 | 3.07 | 1.21e-11 | 1.25e-10 |
| TRH gene|TRH:0 | 3/138,393 | 8,700/26,262,527 | 0.07 | 3.99e-16 | 5.60e-15 |
| Abscess of prostate:0 | 14/138,393 | 384/26,262,527 | 6.92 | 4.13e-08 | 3.11e-07 |
| Genes, cdc:0 | 61/138,393 | 1,853/26,262,527 | 6.25 | 6.35e-28 | 1.49e-26 |
| phenethyl isothiocyanate:0 | 47/138,393 | 1,577/26,262,527 | 5.66 | 3.09e-20 | 5.30e-19 |
| CDKN1A|TCEAL1|NSG1|H3F3AP6:0 | 433/138,393 | 21,430/26,262,527 | 3.84 | 3.58e-115 | 3.62e-113 |
| thrombocytosis:0 | 2/138,393 | 4,186/26,262,527 | 0.09 | 1.49e-07 | 1.06e-06 |
| Zinc measurement:0 | 22/138,393 | 797/26,262,527 | 5.24 | 1.03e-09 | 9.14e-09 |
| Dihydrotestosterone Assay:0 | 34/138,393 | 143/26,262,527 | 45.13 | 4.29e-42 | 1.57e-40 |
| Clinical Trials, Phase II:0 | 126/138,393 | 2,618/26,262,527 | 9.14 | 2.03e-73 | 1.30e-71 |
| Transition Zone PSA Density:0 | 6/138,393 | 14/26,262,527 | 81.33 | 7.55e-10 | 6.76e-09 |
| NADP:0 | 25/138,393 | 14,550/26,262,527 | 0.33 | 1.26e-11 | 1.31e-10 |
| Osteoclasts:0 | 151/138,393 | 15,216/26,262,527 | 1.88 | 1.78e-12 | 1.97e-11 |
| C-reactive protein:0 | 78/138,393 | 36,920/26,262,527 | 0.40 | 4.00e-21 | 7.17e-20 |
| Vomiting:0 | 29/138,393 | 21,150/26,262,527 | 0.26 | 3.46e-20 | 5.93e-19 |
| Pancreatitis, Chronic:0 | 19/138,393 | 19,284/26,262,527 | 0.19 | 2.02e-23 | 3.96e-22 |
| Antimalarials:0 | 2/138,393 | 8,591/26,262,527 | 0.04 | 5.40e-17 | 7.98e-16 |
| human CAP|CTAA1|LNPEP|SERPINB6|PTPLA|CAP1|SORBS1|BRD4:0 | 14/138,393 | 27/26,262,527 | 98.41 | 3.65e-22 | 6.82e-21 |
| Training:0 | 28/138,393 | 15,077/26,262,527 | 0.35 | 6.18e-11 | 6.06e-10 |
| Xenopus:0 | 9/138,393 | 11,600/26,262,527 | 0.15 | 2.67e-16 | 3.79e-15 |
| HIV Infections:0 | 33/138,393 | 63,295/26,262,527 | 0.10 | 1.15e-98 | 9.94e-97 |
| Bax protein|BAX:0 | 29/138,393 | 1,193/26,262,527 | 4.61 | 4.74e-11 | 4.70e-10 |
| Supernatant:0 | 82/138,393 | 31,224/26,262,527 | 0.50 | 1.88e-12 | 2.07e-11 |
| Wounds and Injuries:0 | 52/138,393 | 88,259/26,262,527 | 0.11 | 1.88e-131 | 2.19e-129 |
| Angiotensin-Converting Enzyme Inhibitors:0 | 20/138,393 | 35,503/26,262,527 | 0.11 | 1.59e-54 | 7.46e-53 |
| Exudate:0 | 1/138,393 | 3,381/26,262,527 | 0.06 | 6.04e-07 | 4.01e-06 |
| vitamin analog:0 | 15/138,393 | 432/26,262,527 | 6.59 | 2.55e-08 | 1.97e-07 |
| Microvilli:0 | 5/138,393 | 5,578/26,262,527 | 0.17 | 7.83e-08 | 5.72e-07 |
| Supraaortic valve area structure:0 | 1/138,393 | 3,742/26,262,527 | 0.05 | 9.96e-08 | 7.21e-07 |
| Racemases:0 | 56/138,393 | 337/26,262,527 | 31.55 | 1.51e-60 | 8.04e-59 |
| Infertility:0 | 69/138,393 | 41,348/26,262,527 | 0.32 | 9.75e-32 | 2.59e-30 |
| Heme:0 | 9/138,393 | 14,199/26,262,527 | 0.12 | 1.42e-21 | 2.61e-20 |
| Anticoagulants:0 | 42/138,393 | 18,990/26,262,527 | 0.42 | 9.81e-11 | 9.48e-10 |
| Infections, Hospital:0 | 2/138,393 | 11,298/26,262,527 | 0.03 | 5.72e-23 | 1.11e-21 |
| early detection of colorectal cancer:0 | 26/138,393 | 1,323/26,262,527 | 3.73 | 3.05e-08 | 2.33e-07 |
| Positron-Emission Tomography:0 | 345/138,393 | 24,142/26,262,527 | 2.72 | 9.69e-57 | 4.83e-55 |
| Hamman-Rich syndrome:0 | 4/138,393 | 14,347/26,262,527 | 0.05 | 5.40e-27 | 1.22e-25 |
| Axilla:0 | 12/138,393 | 9,492/26,262,527 | 0.24 | 2.48e-10 | 2.32e-09 |
| Bladder control:0 | 85/138,393 | 485/26,262,527 | 33.28 | 9.70e-93 | 7.87e-91 |
| Open approach:0 | 96/138,393 | 9,668/26,262,527 | 1.88 | 2.17e-08 | 1.69e-07 |
| Karnofsky Performance Status:0 | 13/138,393 | 307/26,262,527 | 8.04 | 2.35e-08 | 1.82e-07 |
| Dissection:0 | 175/138,393 | 22,460/26,262,527 | 1.48 | 1.22e-06 | 7.85e-06 |
| Right atrial structure:0 | 1/138,393 | 9,088/26,262,527 | 0.02 | 2.13e-19 | 3.53e-18 |
| Serotonin Uptake Inhibitors:0 | 9/138,393 | 15,966/26,262,527 | 0.11 | 3.95e-25 | 8.29e-24 |
| bevacizumab|COX5A:0 | 12/138,393 | 1/26,262,527 | 2277.41 | 5.57e-27 | 1.25e-25 |
| Cardiomyopathies:0 | 6/138,393 | 24,678/26,262,527 | 0.05 | 6.42e-47 | 2.64e-45 |
| EAF2:0 | 11/138,393 | 65/26,262,527 | 32.12 | 3.44e-13 | 4.00e-12 |
| CYTOCHROME C:0 | 102/138,393 | 10,006/26,262,527 | 1.94 | 2.02e-09 | 1.75e-08 |
| Seedling:0 | 1/138,393 | 6,636/26,262,527 | 0.03 | 4.98e-14 | 6.18e-13 |
| Hepatitis B virus DNA:0 | 1/138,393 | 3,546/26,262,527 | 0.05 | 2.97e-07 | 2.05e-06 |
| HOXB13 gene|HOXB13:0 | 9/138,393 | 14/26,262,527 | 122.00 | 2.29e-15 | 3.08e-14 |
| NOS2A protein, human|NOS2:0 | 57/138,393 | 46,952/26,262,527 | 0.23 | 9.37e-48 | 3.92e-46 |
| Meningomyelocele:0 | 1/138,393 | 4,271/26,262,527 | 0.04 | 8.06e-09 | 6.57e-08 |
| Intraocular pressure disorder:0 | 3/138,393 | 24,294/26,262,527 | 0.02 | 2.42e-50 | 1.07e-48 |
| SLC2A4:0 | 2/138,393 | 4,660/26,262,527 | 0.08 | 1.25e-08 | 9.94e-08 |
| Breast:0 | 3,608/138,393 | 108,991/26,262,527 | 6.42 | 0.00e+00 | 0.00e+00 |
| cDNA Microarray device:0 | 44/138,393 | 1,599/26,262,527 | 5.22 | 8.07e-18 | 1.24e-16 |
| PCSK6:0 | 12/138,393 | 311/26,262,527 | 7.32 | 2.10e-07 | 1.46e-06 |
| 1,2-diacylglycerol:0 | 17/138,393 | 9,942/26,262,527 | 0.32 | 3.04e-08 | 2.32e-07 |
| Protein C|SPANXC:0 | 5/138,393 | 11,999/26,262,527 | 0.08 | 6.33e-21 | 1.12e-19 |
| Genus Capra:0 | 11/138,393 | 8,037/26,262,527 | 0.26 | 1.95e-08 | 1.53e-07 |
| Urea:0 | 31/138,393 | 26,100/26,262,527 | 0.23 | 1.68e-27 | 3.87e-26 |
| Hepatitis A:0 | 2/138,393 | 5,178/26,262,527 | 0.07 | 1.05e-09 | 9.30e-09 |
| Low Density Lipoprotein Receptor:0 | 10/138,393 | 9,473/26,262,527 | 0.20 | 1.82e-11 | 1.86e-10 |
| Lymphography:0 | 65/138,393 | 1,559/26,262,527 | 7.92 | 2.95e-35 | 8.80e-34 |
| Cholecystectomy:0 | 8/138,393 | 9,340/26,262,527 | 0.16 | 9.22e-13 | 1.04e-11 |
| myopodin:0 | 8/138,393 | 90/26,262,527 | 16.87 | 5.90e-08 | 4.35e-07 |
| Suicide attempt:0 | 1/138,393 | 6,608/26,262,527 | 0.03 | 4.87e-14 | 6.05e-13 |
| Aredia:0 | 11/138,393 | 91/26,262,527 | 22.94 | 9.44e-12 | 9.89e-11 |
| Lactate:0 | 44/138,393 | 30,371/26,262,527 | 0.27 | 3.27e-27 | 7.47e-26 |
| Cytarabine:0 | 14/138,393 | 11,592/26,262,527 | 0.23 | 1.18e-12 | 1.32e-11 |
| Epidermal cell:0 | 2/138,393 | 3,991/26,262,527 | 0.10 | 4.44e-07 | 2.99e-06 |
| donepezil:0 | 1/138,393 | 4,718/26,262,527 | 0.04 | 9.40e-10 | 8.34e-09 |
| Psychotherapy, Multiple:0 | 159/138,393 | 11,764/26,262,527 | 2.57 | 9.53e-25 | 1.98e-23 |
| Homeostasis:0 | 194/138,393 | 51,612/26,262,527 | 0.71 | 7.84e-07 | 5.15e-06 |
| Thrombolytic Therapy:0 | 10/138,393 | 14,313/26,262,527 | 0.13 | 6.74e-21 | 1.20e-19 |
| Hormone preparation:0 | 6/138,393 | 51/26,262,527 | 22.33 | 5.99e-07 | 3.97e-06 |
| Embryonic Development:0 | 69/138,393 | 23,945/26,262,527 | 0.55 | 4.36e-08 | 3.27e-07 |
| NPSA:0 | 7/138,393 | 14/26,262,527 | 94.89 | 1.19e-11 | 1.23e-10 |
| Clomipramine:0 | 2/138,393 | 4,683/26,262,527 | 0.08 | 1.26e-08 | 1.00e-07 |
| Transfer RNA:0 | 9/138,393 | 13,831/26,262,527 | 0.12 | 7.76e-21 | 1.37e-19 |
| Pacemakers:0 | 2/138,393 | 4,041/26,262,527 | 0.09 | 3.01e-07 | 2.07e-06 |
| Soft tissue lesion:0 | 16/138,393 | 530/26,262,527 | 5.73 | 5.72e-08 | 4.23e-07 |
| Entire thigh:0 | 21/138,393 | 10,387/26,262,527 | 0.38 | 4.07e-07 | 2.76e-06 |
| Structure of venule:0 | 2/138,393 | 5,997/26,262,527 | 0.06 | 2.16e-11 | 2.19e-10 |
| Apoptosis Inhibitor:0 | 14/138,393 | 433/26,262,527 | 6.14 | 1.70e-07 | 1.19e-06 |
| Teens:0 | 2/138,393 | 10,597/26,262,527 | 0.04 | 2.19e-21 | 3.97e-20 |
| Valeriana jatamansi:0 | 5/138,393 | 26/26,262,527 | 36.50 | 6.00e-07 | 3.98e-06 |
| Pulmonary function tests:0 | 1/138,393 | 3,259/26,262,527 | 0.06 | 1.26e-06 | 8.06e-06 |
| CAROTID:0 | 4/138,393 | 19,664/26,262,527 | 0.04 | 1.00e-38 | 3.32e-37 |
| Carcinoma, Signet Ring Cell:0 | 49/138,393 | 2,180/26,262,527 | 4.27 | 2.71e-16 | 3.84e-15 |
| Colitis:0 | 11/138,393 | 17,745/26,262,527 | 0.12 | 8.07e-27 | 1.81e-25 |
| ITK gene|ITK:0 | 40/138,393 | 1,505/26,262,527 | 5.04 | 7.25e-16 | 1.00e-14 |
| Dilution:0 | 34/138,393 | 13,688/26,262,527 | 0.47 | 1.08e-06 | 6.95e-06 |
| ETS Family Protein:0 | 18/138,393 | 391/26,262,527 | 8.74 | 1.40e-11 | 1.45e-10 |
| Deep Vein Thrombosis:0 | 53/138,393 | 27,708/26,262,527 | 0.36 | 1.89e-18 | 3.01e-17 |
| HSD11B1:0 | 11/138,393 | 9,430/26,262,527 | 0.22 | 7.90e-11 | 7.68e-10 |
| PSAT1:0 | 6/138,393 | 49/26,262,527 | 23.24 | 4.83e-07 | 3.23e-06 |
| Pseudomonas aeruginosa:0 | 8/138,393 | 28,409/26,262,527 | 0.05 | 1.61e-52 | 7.37e-51 |
| Mice, Inbred NOD:0 | 9/138,393 | 8,069/26,262,527 | 0.21 | 1.10e-09 | 9.68e-09 |
| Ribosomes:0 | 4/138,393 | 13,082/26,262,527 | 0.06 | 2.23e-24 | 4.55e-23 |
| Finding / disorder:0 | 31/138,393 | 2,121/26,262,527 | 2.77 | 9.00e-07 | 5.87e-06 |
| Scanning/Transmission Electron Microscopes:0 | 1/138,393 | 4,559/26,262,527 | 0.04 | 1.89e-09 | 1.64e-08 |
| Prostatic acid phosphatase antigen:0 | 5/138,393 | 10/26,262,527 | 94.89 | 1.14e-08 | 9.13e-08 |
| Acetylcholine:0 | 9/138,393 | 46,175/26,262,527 | 0.04 | 5.77e-90 | 4.50e-88 |
| Nerve-Sparing Prostatectomy:0 | 93/138,393 | 233/26,262,527 | 75.79 | 5.12e-130 | 5.91e-128 |
| NG-Nitroarginine Methyl Ester:0 | 2/138,393 | 7,086/26,262,527 | 0.05 | 1.03e-13 | 1.25e-12 |
| invasive growth:0 | 22/138,393 | 1,149/26,262,527 | 3.63 | 5.10e-07 | 3.41e-06 |
| Hyponatremia:0 | 9/138,393 | 6,979/26,262,527 | 0.24 | 1.21e-07 | 8.64e-07 |
| Cell Cycle Checkpoint:0 | 24/138,393 | 1,086/26,262,527 | 4.19 | 1.22e-08 | 9.75e-08 |
| Nested Case-Control Studies:0 | 21/138,393 | 391/26,262,527 | 10.19 | 1.73e-14 | 2.21e-13 |
| Pentoxifylline:0 | 3/138,393 | 10,509/26,262,527 | 0.05 | 5.41e-20 | 9.18e-19 |
| Atrial Natriuretic Factor:0 | 17/138,393 | 32,015/26,262,527 | 0.10 | 3.89e-50 | 1.71e-48 |
| Atrophic:0 | 118/138,393 | 34,792/26,262,527 | 0.64 | 3.54e-07 | 2.41e-06 |
| Carbamazepine:0 | 2/138,393 | 15,123/26,262,527 | 0.03 | 1.65e-31 | 4.36e-30 |
| temozolomide:0 | 18/138,393 | 12,119/26,262,527 | 0.28 | 2.52e-11 | 2.55e-10 |
| Clinical Trials:0 | 967/138,393 | 74,283/26,262,527 | 2.48 | 9.39e-132 | 1.11e-129 |
| Boys:0 | 67/138,393 | 83,324/26,262,527 | 0.15 | 2.34e-108 | 2.20e-106 |
| Thickened:0 | 35/138,393 | 18,698/26,262,527 | 0.36 | 2.97e-13 | 3.48e-12 |
| Arthroplasty, Replacement, Knee:0 | 7/138,393 | 15,405/26,262,527 | 0.09 | 7.40e-26 | 1.60e-24 |
| 17q:0 | 17/138,393 | 370/26,262,527 | 8.72 | 5.26e-11 | 5.19e-10 |
| Neoplastic Cell:0 | 362/138,393 | 13,088/26,262,527 | 5.26 | 1.96e-134 | 2.36e-132 |
| Rest:0 | 6/138,393 | 6,697/26,262,527 | 0.17 | 3.01e-09 | 2.56e-08 |
| Lymphocyte antigen CD66A:0 | 12/138,393 | 145/26,262,527 | 15.71 | 6.49e-11 | 6.35e-10 |
| Liposomes:0 | 114/138,393 | 47,071/26,262,527 | 0.46 | 2.98e-21 | 5.37e-20 |
| Pelvic Neoplasms:0 | 50/138,393 | 832/26,262,527 | 11.41 | 1.94e-34 | 5.60e-33 |
| Antigens, Differentiation:0 | 44/138,393 | 3,590/26,262,527 | 2.33 | 7.53e-07 | 4.96e-06 |
| Leukotriene B4:0 | 5/138,393 | 8,582/26,262,527 | 0.11 | 7.83e-14 | 9.59e-13 |
| Interleukin-2|IL2:0 | 13/138,393 | 11,492/26,262,527 | 0.21 | 3.53e-13 | 4.10e-12 |
| Cerebellar Nuclei:0 | 1/138,393 | 6,920/26,262,527 | 0.03 | 1.16e-14 | 1.49e-13 |
| 5-Alpha reductase inhibitor:0 | 115/138,393 | 837/26,262,527 | 26.09 | 6.14e-114 | 6.13e-112 |
| Caerulein:0 | 1/138,393 | 3,741/26,262,527 | 0.05 | 9.96e-08 | 7.21e-07 |
| Hypercalcemia:0 | 136/138,393 | 15,116/26,262,527 | 1.71 | 8.75e-09 | 7.10e-08 |
| Disease Outcome:0 | 56/138,393 | 2,020/26,262,527 | 5.26 | 2.26e-22 | 4.26e-21 |
| Contraction:0 | 67/138,393 | 128,982/26,262,527 | 0.10 | 2.96e-200 | 5.63e-198 |
| Antigen assay:0 | 336/138,393 | 2,919/26,262,527 | 21.89 | 6.23e-306 | 1.76e-303 |
| Stage A2:0 | 5/138,393 | 5/26,262,527 | 189.77 | 9.76e-10 | 8.66e-09 |
| Mechanical ventilation:0 | 2/138,393 | 12,782/26,262,527 | 0.03 | 2.75e-26 | 6.06e-25 |
| MMP9 gene|MMP9:0 | 18/138,393 | 526/26,262,527 | 6.49 | 1.35e-09 | 1.18e-08 |
| CDC2 gene|CDK1|POLD1:0 | 41/138,393 | 2,874/26,262,527 | 2.71 | 3.41e-08 | 2.59e-07 |
| Cytotoxic Chemotherapy:0 | 114/138,393 | 3,047/26,262,527 | 7.10 | 6.26e-56 | 3.06e-54 |
| Ovalbumin:0 | 3/138,393 | 10,708/26,262,527 | 0.05 | 1.84e-20 | 3.21e-19 |
| MAPK8 gene|MAPK8:0 | 190/138,393 | 24,551/26,262,527 | 1.47 | 5.99e-07 | 3.97e-06 |
| EB 1089:0 | 22/138,393 | 492/26,262,527 | 8.49 | 1.41e-13 | 1.70e-12 |
| Cell division phases:0 | 105/138,393 | 3,200/26,262,527 | 6.23 | 1.15e-46 | 4.65e-45 |
| beta-microseminoprotein:0 | 9/138,393 | 52/26,262,527 | 32.85 | 4.05e-11 | 4.04e-10 |
| CDKN1B gene|CDKN1B:0 | 69/138,393 | 2,344/26,262,527 | 5.59 | 1.29e-28 | 3.09e-27 |
| inner membrane:0 | 3/138,393 | 5,225/26,262,527 | 0.11 | 8.23e-09 | 6.70e-08 |
| Estimated blood loss:0 | 26/138,393 | 432/26,262,527 | 11.42 | 1.05e-18 | 1.69e-17 |
| Urethra excision:0 | 30/138,393 | 178/26,262,527 | 31.99 | 2.26e-33 | 6.35e-32 |
| Cavia:0 | 20/138,393 | 91,408/26,262,527 | 0.04 | 4.51e-174 | 7.33e-172 |
| Structure of aggregated lymphoid follicle of small intestine:0 | 2/138,393 | 4,540/26,262,527 | 0.08 | 2.55e-08 | 1.97e-07 |
| Ring device:0 | 19/138,393 | 18,530/26,262,527 | 0.19 | 7.19e-22 | 1.33e-20 |
| Entire sympathetic nerve:0 | 3/138,393 | 17,878/26,262,527 | 0.03 | 4.00e-36 | 1.24e-34 |
| Gossypol:0 | 53/138,393 | 3,537/26,262,527 | 2.84 | 7.27e-11 | 7.08e-10 |
| Biopsy of rectum:0 | 30/138,393 | 696/26,262,527 | 8.18 | 1.55e-17 | 2.35e-16 |
| Pneumocyte:0 | 2/138,393 | 3,960/26,262,527 | 0.10 | 4.23e-07 | 2.86e-06 |
| Pancreatic carcinoma:0 | 374/138,393 | 47,753/26,262,527 | 1.49 | 6.32e-13 | 7.22e-12 |
| Esters:0 | 43/138,393 | 20,125/26,262,527 | 0.41 | 6.25e-12 | 6.64e-11 |
| Fluorodeoxyglucose F18:0 | 38/138,393 | 2,457/26,262,527 | 2.94 | 1.42e-08 | 1.12e-07 |
| Spinal Stenosis:0 | 1/138,393 | 4,480/26,262,527 | 0.04 | 2.70e-09 | 2.31e-08 |
| Adhesives:0 | 1/138,393 | 3,344/26,262,527 | 0.06 | 8.93e-07 | 5.83e-06 |
| Medical Castration:0 | 95/138,393 | 178/26,262,527 | 101.35 | 1.80e-142 | 2.30e-140 |
| Entire lower urinary tract:0 | 48/138,393 | 2,889/26,262,527 | 3.15 | 1.98e-11 | 2.02e-10 |
| Hydrogen Peroxide:0 | 100/138,393 | 58,759/26,262,527 | 0.32 | 1.41e-43 | 5.34e-42 |
| fungus:0 | 14/138,393 | 18,807/26,262,527 | 0.14 | 2.89e-26 | 6.36e-25 |
| CLOCK:0 | 2/138,393 | 5,524/26,262,527 | 0.07 | 2.77e-10 | 2.57e-09 |
| Hormone Receptor:0 | 45/138,393 | 2,658/26,262,527 | 3.21 | 4.57e-11 | 4.54e-10 |
| Cell Growth:0 | 1,354/138,393 | 44,816/26,262,527 | 5.78 | 0.00e+00 | 0.00e+00 |
| Monoclonal Antibodies|BGLAP:0 | 12/138,393 | 14/26,262,527 | 162.67 | 3.88e-21 | 6.97e-20 |
| myostatin|MSTN:0 | 1/138,393 | 3,365/26,262,527 | 0.06 | 9.29e-07 | 6.05e-06 |
| Empty rectum:0 | 5/138,393 | 15/26,262,527 | 63.26 | 5.75e-08 | 4.25e-07 |
| Carcinogenesis Mechanism:0 | 5/138,393 | 8/26,262,527 | 118.61 | 4.92e-09 | 4.09e-08 |
| Icterus:0 | 18/138,393 | 11,125/26,262,527 | 0.31 | 1.08e-09 | 9.57e-09 |
| Lecithin:0 | 16/138,393 | 25,302/26,262,527 | 0.12 | 1.64e-37 | 5.29e-36 |
| Well Differentiated Prostate Adenocarcinoma:0 | 5/138,393 | 8/26,262,527 | 118.61 | 4.92e-09 | 4.09e-08 |
| PTEN Phosphohydrolase|PTEN:0 | 24/138,393 | 441/26,262,527 | 10.33 | 1.85e-16 | 2.65e-15 |
| Division (procedure):0 | 449/138,393 | 36,693/26,262,527 | 2.33 | 3.89e-55 | 1.86e-53 |
| Kupffer Cells:0 | 2/138,393 | 7,235/26,262,527 | 0.05 | 5.06e-14 | 6.28e-13 |
| heart rate:0 | 3/138,393 | 17,291/26,262,527 | 0.03 | 7.19e-35 | 2.12e-33 |
| Stable Disease:0 | 198/138,393 | 9,400/26,262,527 | 4.00 | 2.40e-56 | 1.19e-54 |
| Forskolin:0 | 32/138,393 | 19,277/26,262,527 | 0.31 | 1.77e-15 | 2.40e-14 |
| Acute onset pain:0 | 3/138,393 | 4,564/26,262,527 | 0.12 | 1.81e-07 | 1.27e-06 |
| Urogenital sinus:0 | 51/138,393 | 421/26,262,527 | 23.00 | 5.15e-49 | 2.20e-47 |
| Exanthema:0 | 41/138,393 | 28,632/26,262,527 | 0.27 | 7.30e-26 | 1.58e-24 |
| PRUNE2:0 | 7/138,393 | 68/26,262,527 | 19.54 | 1.58e-07 | 1.11e-06 |
| Fibrinolytic Agents:0 | 2/138,393 | 9,502/26,262,527 | 0.04 | 4.82e-19 | 7.88e-18 |
| racial differences:0 | 63/138,393 | 1,455/26,262,527 | 8.22 | 4.11e-35 | 1.22e-33 |
| Carcinogens:0 | 520/138,393 | 29,931/26,262,527 | 3.31 | 1.15e-113 | 1.15e-111 |
| Citalopram:0 | 1/138,393 | 6,879/26,262,527 | 0.03 | 1.77e-14 | 2.25e-13 |
| lycopene:0 | 239/138,393 | 5,675/26,262,527 | 8.00 | 1.35e-125 | 1.49e-123 |
| Autologous Stem Cell Transplantation:0 | 3/138,393 | 5,699/26,262,527 | 0.10 | 1.08e-09 | 9.51e-09 |
| Potassium Channel:0 | 9/138,393 | 8,693/26,262,527 | 0.20 | 8.86e-11 | 8.59e-10 |
| End stage renal failure:0 | 42/138,393 | 47,038/26,262,527 | 0.17 | 1.96e-58 | 1.01e-56 |
| Peripheral blood mononuclear cell:0 | 126/138,393 | 47,207/26,262,527 | 0.51 | 1.31e-17 | 1.99e-16 |
| Macrophages, Peritoneal:0 | 7/138,393 | 19,042/26,262,527 | 0.07 | 1.18e-33 | 3.35e-32 |
| Insulin:0 | 112/138,393 | 109,430/26,262,527 | 0.19 | 9.49e-124 | 1.04e-121 |
| Tumor Cell Invasion:0 | 161/138,393 | 4,558/26,262,527 | 6.71 | 7.69e-75 | 5.02e-73 |
| Ventricular Premature Complexes:0 | 1/138,393 | 6,102/26,262,527 | 0.03 | 9.97e-13 | 1.12e-11 |
| Sterility:0 | 5/138,393 | 6,642/26,262,527 | 0.14 | 7.80e-10 | 6.98e-09 |
| Hepatitis:0 | 20/138,393 | 16,775/26,262,527 | 0.23 | 4.30e-18 | 6.71e-17 |
| Acclimatization:0 | 23/138,393 | 13,400/26,262,527 | 0.33 | 1.04e-10 | 1.01e-09 |
| Interleukin-1 beta:0 | 83/138,393 | 96,977/26,262,527 | 0.16 | 6.45e-122 | 6.90e-120 |
| Alloys:0 | 4/138,393 | 5,287/26,262,527 | 0.14 | 5.46e-08 | 4.04e-07 |
| Functional RNA:0 | 136/138,393 | 9,580/26,262,527 | 2.70 | 3.12e-23 | 6.09e-22 |
| Epithelial Cell Proliferation:0 | 38/138,393 | 1,730/26,262,527 | 4.17 | 1.04e-12 | 1.17e-11 |
| FADD gene|FADD:0 | 29/138,393 | 1,334/26,262,527 | 4.13 | 5.73e-10 | 5.19e-09 |
| Intervertebral disc structure:0 | 1/138,393 | 6,239/26,262,527 | 0.03 | 4.73e-13 | 5.45e-12 |
| Epidermal Growth Factor Receptor:0 | 84/138,393 | 7,705/26,262,527 | 2.07 | 2.38e-09 | 2.04e-08 |
| Meiosis:0 | 2/138,393 | 6,763/26,262,527 | 0.06 | 4.15e-13 | 4.80e-12 |
| Anemia:0 | 128/138,393 | 50,156/26,262,527 | 0.48 | 2.11e-20 | 3.67e-19 |
| Emission:0 | 24/138,393 | 21,549/26,262,527 | 0.21 | 5.56e-24 | 1.12e-22 |
| Extent:0 | 95/138,393 | 7,729/26,262,527 | 2.33 | 5.43e-13 | 6.23e-12 |
| Gastrointestinal Diseases:0 | 7/138,393 | 8,324/26,262,527 | 0.16 | 1.77e-11 | 1.81e-10 |
| Urinary Sphincter, Artificial:0 | 60/138,393 | 1,836/26,262,527 | 6.20 | 2.46e-27 | 5.63e-26 |
| Brain Stem:0 | 9/138,393 | 35,259/26,262,527 | 0.05 | 5.17e-66 | 3.03e-64 |
| Cytoplasmic:0 | 171/138,393 | 21,988/26,262,527 | 1.48 | 1.55e-06 | 9.77e-06 |
| 7q31.1:0 | 8/138,393 | 29/26,262,527 | 52.35 | 1.92e-11 | 1.96e-10 |
| Respiration:0 | 18/138,393 | 53,579/26,262,527 | 0.06 | 1.50e-94 | 1.24e-92 |
| Renal Cell:0 | 48/138,393 | 20,439/26,262,527 | 0.45 | 1.81e-10 | 1.72e-09 |
| matrigel:0 | 87/138,393 | 3,052/26,262,527 | 5.41 | 1.21e-34 | 3.55e-33 |
| Infraclass Eutheria:0 | 38/138,393 | 29,696/26,262,527 | 0.24 | 1.74e-29 | 4.29e-28 |
| Eye diseases:0 | 3/138,393 | 6,613/26,262,527 | 0.09 | 1.11e-11 | 1.16e-10 |
| Deep Brain Stimulation:0 | 1/138,393 | 11,458/26,262,527 | 0.02 | 7.60e-25 | 1.58e-23 |
| Tryptophan:0 | 15/138,393 | 22,300/26,262,527 | 0.13 | 2.69e-32 | 7.29e-31 |
| WDR77:0 | 9/138,393 | 49/26,262,527 | 34.86 | 2.52e-11 | 2.55e-10 |
| Organoselenium Compounds:0 | 10/138,393 | 218/26,262,527 | 8.71 | 4.76e-07 | 3.19e-06 |
| Seeks information:0 | 10/138,393 | 250/26,262,527 | 7.59 | 1.56e-06 | 9.85e-06 |
| Residual Tumor:0 | 118/138,393 | 8,307/26,262,527 | 2.70 | 2.08e-20 | 3.62e-19 |
| Urinary Fistula:0 | 14/138,393 | 434/26,262,527 | 6.12 | 1.74e-07 | 1.23e-06 |
| Eyelash:0 | 1/138,393 | 5,901/26,262,527 | 0.03 | 1.87e-12 | 2.06e-11 |
| Histamine Release:0 | 1/138,393 | 10,377/26,262,527 | 0.02 | 1.85e-22 | 3.49e-21 |
| Intermittent Claudication:0 | 1/138,393 | 6,039/26,262,527 | 0.03 | 9.00e-13 | 1.02e-11 |
| Acetaminophen:0 | 20/138,393 | 20,926/26,262,527 | 0.18 | 1.29e-25 | 2.75e-24 |
| [X]Painful micturition, unspecified:0 | 80/138,393 | 1,245/26,262,527 | 12.20 | 4.09e-56 | 2.00e-54 |
| androgen receptor activity:0 | 259/138,393 | 494/26,262,527 | 99.68 | 0.00e+00 | 0.00e+00 |
| albino rat:0 | 9/138,393 | 8,139/26,262,527 | 0.21 | 7.98e-10 | 7.13e-09 |
| Fatty Acids, Nonesterified:0 | 10/138,393 | 20,621/26,262,527 | 0.09 | 1.14e-33 | 3.25e-32 |
| Catalepsy:0 | 1/138,393 | 3,410/26,262,527 | 0.06 | 6.17e-07 | 4.09e-06 |
| Blades:0 | 2/138,393 | 3,937/26,262,527 | 0.10 | 4.17e-07 | 2.82e-06 |
| atrial natriuretic factor precursor (79-98):0 | 11/138,393 | 118/26,262,527 | 17.69 | 1.24e-10 | 1.19e-09 |
| Radioactive implant:0 | 18/138,393 | 81/26,262,527 | 42.18 | 1.50e-22 | 2.85e-21 |
| Immunohistochemistry:0 | 856/138,393 | 40,249/26,262,527 | 4.05 | 6.11e-240 | 1.41e-237 |
| Entire interstitial tissue of prostate:0 | 121/138,393 | 347/26,262,527 | 66.23 | 1.09e-162 | 1.63e-160 |
| Atrophy of prostate:0 | 17/138,393 | 79/26,262,527 | 40.84 | 3.59e-21 | 6.44e-20 |
| Common Carcinoma:0 | 14/138,393 | 205/26,262,527 | 12.96 | 1.90e-11 | 1.94e-10 |
| 2-aminodiphenyl:0 | 17/138,393 | 72/26,262,527 | 44.81 | 9.03e-22 | 1.67e-20 |
| Dinoprost:0 | 8/138,393 | 18,230/26,262,527 | 0.08 | 7.45e-31 | 1.93e-29 |
| Free prostate-specific antigen:0 | 176/138,393 | 244/26,262,527 | 137.05 | 4.54e-280 | 1.20e-277 |
| Blastocyst structure:0 | 1/138,393 | 10,456/26,262,527 | 0.02 | 1.28e-22 | 2.45e-21 |
| Signal Pathways:0 | 524/138,393 | 44,299/26,262,527 | 2.25 | 1.46e-59 | 7.64e-58 |
| Disorder characterized by fever:0 | 1/138,393 | 3,687/26,262,527 | 0.05 | 1.44e-07 | 1.03e-06 |
| Fluorouracil:0 | 185/138,393 | 49,996/26,262,527 | 0.70 | 4.39e-07 | 2.96e-06 |
| Bone marrow biopsy:0 | 32/138,393 | 1,697/26,262,527 | 3.58 | 2.23e-09 | 1.92e-08 |
| Copper:0 | 50/138,393 | 37,378/26,262,527 | 0.25 | 1.63e-35 | 4.93e-34 |
| Internal carotid artery structure:0 | 1/138,393 | 9,499/26,262,527 | 0.02 | 2.28e-20 | 3.96e-19 |
| Photon radiation therapy:0 | 8/138,393 | 81/26,262,527 | 18.74 | 2.76e-08 | 2.12e-07 |
| Tonics:0 | 2/138,393 | 4,370/26,262,527 | 0.09 | 5.09e-08 | 3.79e-07 |
| Microtus:0 | 1/138,393 | 3,975/26,262,527 | 0.05 | 3.40e-08 | 2.58e-07 |
| Interleukin-4:0 | 53/138,393 | 48,859/26,262,527 | 0.21 | 6.73e-54 | 3.14e-52 |
| Cell Cycle Arrest:0 | 478/138,393 | 14,182/26,262,527 | 6.41 | 2.83e-210 | 5.59e-208 |
| Encounter due to In vitro fertilization:0 | 9/138,393 | 9,996/26,262,527 | 0.17 | 2.59e-13 | 3.05e-12 |
| Bands:0 | 45/138,393 | 28,626/26,262,527 | 0.30 | 9.44e-24 | 1.89e-22 |
| Taxanes:0 | 92/138,393 | 1,843/26,262,527 | 9.48 | 2.24e-55 | 1.08e-53 |
| Neuropil:0 | 1/138,393 | 3,480/26,262,527 | 0.05 | 4.29e-07 | 2.90e-06 |
| Hip Replacement, Total:0 | 5/138,393 | 13,757/26,262,527 | 0.07 | 1.38e-24 | 2.84e-23 |
| Techniques:0 | 837/138,393 | 133,240/26,262,527 | 1.19 | 7.40e-07 | 4.87e-06 |
| Penicillins:0 | 6/138,393 | 16,359/26,262,527 | 0.07 | 5.94e-29 | 1.44e-27 |
| Anemic:0 | 5/138,393 | 5,053/26,262,527 | 0.19 | 7.65e-07 | 5.03e-06 |
| myelination:0 | 1/138,393 | 4,102/26,262,527 | 0.05 | 1.63e-08 | 1.29e-07 |
| Extravasation:0 | 105/138,393 | 32,803/26,262,527 | 0.61 | 3.53e-08 | 2.67e-07 |
| Clinicians:0 | 206/138,393 | 20,142/26,262,527 | 1.94 | 1.29e-17 | 1.96e-16 |
| Polymerase:0 | 58/138,393 | 5,194/26,262,527 | 2.12 | 4.25e-07 | 2.87e-06 |
| Inferior vena cava structure:0 | 8/138,393 | 8,445/26,262,527 | 0.18 | 4.61e-11 | 4.58e-10 |
| Radiation-Sensitizing Agents:0 | 50/138,393 | 1,463/26,262,527 | 6.49 | 7.19e-24 | 1.44e-22 |
| Matrix:0 | 32/138,393 | 14,074/26,262,527 | 0.43 | 6.63e-08 | 4.88e-07 |
| Tachykinin:0 | 1/138,393 | 4,407/26,262,527 | 0.04 | 3.88e-09 | 3.27e-08 |
| Parasites:0 | 8/138,393 | 30,835/26,262,527 | 0.05 | 8.31e-58 | 4.20e-56 |
| Malondialdehyde:0 | 12/138,393 | 19,359/26,262,527 | 0.12 | 3.10e-29 | 7.59e-28 |
| DNMT1:0 | 34/138,393 | 1,702/26,262,527 | 3.79 | 1.73e-10 | 1.64e-09 |
| Corticotropin:0 | 33/138,393 | 16,771/26,262,527 | 0.37 | 2.50e-11 | 2.53e-10 |
| Protein-Serine-Threonine Kinases:0 | 114/138,393 | 7,263/26,262,527 | 2.98 | 5.78e-23 | 1.12e-21 |
| Mitogen-Activated Protein Kinases:0 | 316/138,393 | 43,130/26,262,527 | 1.39 | 2.64e-08 | 2.03e-07 |
| Degenerative polyarthritis:0 | 24/138,393 | 72,359/26,262,527 | 0.06 | 1.18e-127 | 1.33e-125 |
| Microsomes, Liver:0 | 33/138,393 | 30,850/26,262,527 | 0.20 | 7.02e-35 | 2.08e-33 |
| Swab:0 | 5/138,393 | 4,978/26,262,527 | 0.19 | 1.06e-06 | 6.82e-06 |
| Pharyngeal structure:0 | 102/138,393 | 7,801/26,262,527 | 2.48 | 1.31e-15 | 1.79e-14 |
| Plasmacytoma:0 | 8/138,393 | 6,072/26,262,527 | 0.25 | 1.16e-06 | 7.45e-06 |
| Bone structure of cranium:0 | 49/138,393 | 21,756/26,262,527 | 0.43 | 7.74e-12 | 8.17e-11 |
| 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine:0 | 45/138,393 | 1,450/26,262,527 | 5.89 | 4.31e-20 | 7.35e-19 |
| Synovial:0 | 2/138,393 | 12,257/26,262,527 | 0.03 | 5.46e-25 | 1.14e-23 |
| Rhabdomyosarcoma, Embryonal:0 | 46/138,393 | 1,505/26,262,527 | 5.80 | 2.98e-20 | 5.12e-19 |
| Taste Buds:0 | 1/138,393 | 3,470/26,262,527 | 0.05 | 4.25e-07 | 2.87e-06 |
| Somatotropin deficiency:0 | 6/138,393 | 8,798/26,262,527 | 0.13 | 2.77e-13 | 3.25e-12 |
| pM category:0 | 102/138,393 | 2,231/26,262,527 | 8.68 | 8.08e-58 | 4.09e-56 |
| Aberrant DNA Methylation:0 | 23/138,393 | 585/26,262,527 | 7.46 | 5.08e-13 | 5.85e-12 |
| ARNT protein, human|ARNT:0 | 11/138,393 | 225/26,262,527 | 9.28 | 6.98e-08 | 5.13e-07 |
| urology:0 | 212/138,393 | 1,547/26,262,527 | 26.04 | 3.29e-208 | 6.41e-206 |
| rhenium-188 HEDP:0 | 6/138,393 | 32/26,262,527 | 35.58 | 4.96e-08 | 3.70e-07 |
| Entire bony skeleton:0 | 16/138,393 | 682/26,262,527 | 4.45 | 1.45e-06 | 9.21e-06 |
| Stimulant:0 | 4/138,393 | 12,887/26,262,527 | 0.06 | 6.56e-24 | 1.32e-22 |
| Operation on prostate:0 | 103/138,393 | 333/26,262,527 | 58.74 | 3.25e-134 | 3.89e-132 |
| Radioimmunoassay:0 | 145/138,393 | 14,040/26,262,527 | 1.96 | 2.99e-13 | 3.51e-12 |
| Frank hematuria:0 | 48/138,393 | 1,368/26,262,527 | 6.66 | 1.94e-23 | 3.80e-22 |
| Teratogenesis:0 | 3/138,393 | 4,936/26,262,527 | 0.12 | 3.27e-08 | 2.49e-07 |
| Adhesions:0 | 323/138,393 | 89,809/26,262,527 | 0.68 | 3.10e-13 | 3.63e-12 |
| Selenomethionine:0 | 33/138,393 | 1,487/26,262,527 | 4.21 | 2.35e-11 | 2.38e-10 |
| Entire acetabulum:0 | 6/138,393 | 5,305/26,262,527 | 0.21 | 1.41e-06 | 8.93e-06 |
| Electric Stimulation:0 | 22/138,393 | 30,604/26,262,527 | 0.14 | 7.77e-43 | 2.91e-41 |
| Silk:0 | 3/138,393 | 5,002/26,262,527 | 0.11 | 2.31e-08 | 1.79e-07 |
| sodium-iodide symporter:0 | 35/138,393 | 1,350/26,262,527 | 4.92 | 8.77e-14 | 1.07e-12 |
| ST segment elevation:0 | 3/138,393 | 4,762/26,262,527 | 0.12 | 9.77e-08 | 7.08e-07 |
| Chloroplasts:0 | 3/138,393 | 16,041/26,262,527 | 0.04 | 5.06e-32 | 1.36e-30 |
| Male gender:0 | 675/138,393 | 45,860/26,262,527 | 2.80 | 1.13e-114 | 1.13e-112 |
| Chlamydia Infections:0 | 1/138,393 | 3,960/26,262,527 | 0.05 | 3.37e-08 | 2.56e-07 |
| Gleason Pattern 5:0 | 14/138,393 | 24/26,262,527 | 110.71 | 1.02e-22 | 1.95e-21 |
| tacrolimus binding protein 4|FKBP4:0 | 17/138,393 | 586/26,262,527 | 5.51 | 3.89e-08 | 2.93e-07 |
| Leprosy:0 | 3/138,393 | 11,171/26,262,527 | 0.05 | 2.20e-21 | 3.98e-20 |
| PC12 Cells:0 | 7/138,393 | 14,343/26,262,527 | 0.09 | 9.17e-24 | 1.83e-22 |
| Thyrotropin-Releasing Hormone|TRH:0 | 5/138,393 | 6,118/26,262,527 | 0.16 | 7.96e-09 | 6.50e-08 |
| Case-Control Studies:0 | 74/138,393 | 5,857/26,262,527 | 2.40 | 5.41e-11 | 5.33e-10 |
| Hormonal resistance:0 | 40/138,393 | 467/26,262,527 | 16.26 | 2.19e-33 | 6.16e-32 |
| Amyloidosis:0 | 19/138,393 | 12,796/26,262,527 | 0.28 | 6.70e-12 | 7.11e-11 |
| Structure of beta Cell of islet:0 | 3/138,393 | 11,615/26,262,527 | 0.05 | 2.61e-22 | 4.91e-21 |
| Adrenal Cortex:0 | 17/138,393 | 9,762/26,262,527 | 0.33 | 5.19e-08 | 3.86e-07 |
| Hydralazine:0 | 3/138,393 | 5,227/26,262,527 | 0.11 | 8.24e-09 | 6.71e-08 |
| oxidized low density lipoprotein:0 | 4/138,393 | 13,161/26,262,527 | 0.06 | 1.56e-24 | 3.21e-23 |
| MYH14:0 | 6/138,393 | 10,182/26,262,527 | 0.11 | 4.28e-16 | 5.99e-15 |
| Programmed Cell Death, Type II:0 | 24/138,393 | 1,119/26,262,527 | 4.07 | 2.11e-08 | 1.64e-07 |
| Cretinism:0 | 1/138,393 | 4,464/26,262,527 | 0.04 | 2.67e-09 | 2.29e-08 |
| Schwann Cells:0 | 9/138,393 | 10,071/26,262,527 | 0.17 | 1.87e-13 | 2.22e-12 |
| Down-Regulation:0 | 685/138,393 | 35,195/26,262,527 | 3.71 | 5.17e-173 | 8.28e-171 |
| Mare:0 | 2/138,393 | 7,775/26,262,527 | 0.05 | 2.74e-15 | 3.68e-14 |
| NODE:0 | 306/138,393 | 20,800/26,262,527 | 2.80 | 5.55e-53 | 2.55e-51 |
| MG 132|PRB3:0 | 8/138,393 | 24/26,262,527 | 63.26 | 5.36e-12 | 5.74e-11 |
| Need for immunization against unspecified infectious disease:0 | 17/138,393 | 9,251/26,262,527 | 0.35 | 2.67e-07 | 1.85e-06 |
| PDLIM4:0 | 5/138,393 | 15/26,262,527 | 63.26 | 5.75e-08 | 4.25e-07 |
| Immunotherapeutic agent:0 | 20/138,393 | 583/26,262,527 | 6.51 | 1.62e-10 | 1.54e-09 |
| anti-IgG:0 | 21/138,393 | 9,958/26,262,527 | 0.40 | 1.45e-06 | 9.18e-06 |
| Stereotyped Behavior:0 | 1/138,393 | 3,472/26,262,527 | 0.05 | 4.26e-07 | 2.87e-06 |
| STAT3 gene|STAT3:0 | 250/138,393 | 21,298/26,262,527 | 2.23 | 6.80e-29 | 1.64e-27 |
| Recovery of Function:0 | 7/138,393 | 6,948/26,262,527 | 0.19 | 5.87e-09 | 4.86e-08 |
| Lights, manufactured:0 | 1/138,393 | 5,515/26,262,527 | 0.03 | 1.76e-11 | 1.80e-10 |
| RNASEL gene|RNASEL:0 | 11/138,393 | 17/26,262,527 | 122.80 | 1.62e-18 | 2.59e-17 |
| AR gene|AR:0 | 1,184/138,393 | 4,311/26,262,527 | 52.56 | 0.00e+00 | 0.00e+00 |
| TNM category pT:0 | 23/138,393 | 107/26,262,527 | 40.80 | 4.20e-28 | 9.91e-27 |
| Acyclovir:0 | 6/138,393 | 12,139/26,262,527 | 0.09 | 3.83e-20 | 6.55e-19 |
| vascular bed:0 | 6/138,393 | 10,564/26,262,527 | 0.11 | 7.92e-17 | 1.16e-15 |
| gabapentin:0 | 12/138,393 | 7,818/26,262,527 | 0.29 | 1.80e-07 | 1.26e-06 |
| Insulin-Like Growth Factor I:0 | 542/138,393 | 73,504/26,262,527 | 1.40 | 1.30e-13 | 1.57e-12 |
| Angiogenesis:0 | 710/138,393 | 41,445/26,262,527 | 3.26 | 1.54e-151 | 2.10e-149 |
| Apoptosis Inhibiting Proteins:0 | 50/138,393 | 1,855/26,262,527 | 5.12 | 1.15e-19 | 1.93e-18 |
| Ganglia, Spinal:0 | 14/138,393 | 28,145/26,262,527 | 0.09 | 3.26e-45 | 1.28e-43 |
| GLI1 gene|GLI1:0 | 42/138,393 | 2,402/26,262,527 | 3.32 | 7.64e-11 | 7.44e-10 |
| Alanine Transaminase:0 | 14/138,393 | 12,636/26,262,527 | 0.21 | 1.49e-14 | 1.90e-13 |
| MAP Kinase Kinase 4:0 | 8/138,393 | 105/26,262,527 | 14.46 | 1.79e-07 | 1.26e-06 |
| Antioxidants:0 | 352/138,393 | 91,598/26,262,527 | 0.73 | 5.40e-10 | 4.90e-09 |
| Hepatolenticular Degeneration:0 | 5/138,393 | 5,972/26,262,527 | 0.16 | 1.55e-08 | 1.22e-07 |
| Megakaryocytes:0 | 3/138,393 | 5,683/26,262,527 | 0.10 | 1.05e-09 | 9.30e-09 |
| Clodronate:0 | 49/138,393 | 2,493/26,262,527 | 3.73 | 3.64e-14 | 4.57e-13 |
| Prostascint:0 | 53/138,393 | 113/26,262,527 | 89.04 | 7.09e-78 | 4.87e-76 |
| sperm cell:0 | 14/138,393 | 33,859/26,262,527 | 0.08 | 3.55e-57 | 1.78e-55 |
| Histiocytosis, Langerhans-Cell:0 | 2/138,393 | 5,134/26,262,527 | 0.07 | 1.54e-09 | 1.34e-08 |
| Cell Cycle Regulation:0 | 110/138,393 | 5,772/26,262,527 | 3.62 | 1.26e-28 | 3.02e-27 |
| filtration:0 | 3/138,393 | 6,230/26,262,527 | 0.09 | 6.35e-11 | 6.22e-10 |
| BRCA2 Mutation:0 | 49/138,393 | 866/26,262,527 | 10.74 | 1.19e-32 | 3.25e-31 |
| multicatalytic endopeptidase complex:0 | 176/138,393 | 20,158/26,262,527 | 1.66 | 5.66e-10 | 5.12e-09 |
| Oils, Volatile:0 | 18/138,393 | 15,299/26,262,527 | 0.22 | 7.80e-17 | 1.14e-15 |
| Multiple Trauma:0 | 2/138,393 | 6,040/26,262,527 | 0.06 | 1.48e-11 | 1.52e-10 |
| Amphotericin B:0 | 4/138,393 | 16,214/26,262,527 | 0.05 | 4.90e-31 | 1.28e-29 |
| Entire cerebellar cortex:0 | 1/138,393 | 5,475/26,262,527 | 0.03 | 1.66e-11 | 1.71e-10 |
| Heat Shock Protein 27:0 | 36/138,393 | 2,037/26,262,527 | 3.35 | 1.24e-09 | 1.09e-08 |
| fluvastatin:0 | 4/138,393 | 4,934/26,262,527 | 0.15 | 2.99e-07 | 2.06e-06 |
| VEGF gene|VEGFA:0 | 78/138,393 | 6,193/26,262,527 | 2.39 | 1.66e-11 | 1.71e-10 |
| Androgens:0 | 4,106/138,393 | 38,318/26,262,527 | 20.93 | 0.00e+00 | 0.00e+00 |
| Subcapsular orchidectomy:0 | 28/138,393 | 68/26,262,527 | 78.16 | 1.30e-40 | 4.57e-39 |
| Urinary tract obstruction:0 | 118/138,393 | 3,002/26,262,527 | 7.46 | 5.76e-60 | 3.06e-58 |
| Human Glandular Kallikrein 2|HK2:0 | 100/138,393 | 525/26,262,527 | 36.17 | 5.35e-112 | 5.24e-110 |
| Tumor Cells, Cultured:0 | 24/138,393 | 928/26,262,527 | 4.91 | 6.46e-10 | 5.83e-09 |
| Breast fluid:0 | 7/138,393 | 77/26,262,527 | 17.25 | 3.46e-07 | 2.36e-06 |
| Equipment and supply inventories:0 | 6/138,393 | 5,259/26,262,527 | 0.22 | 1.36e-06 | 8.65e-06 |
| Diabetic Neuropathies:0 | 3/138,393 | 5,049/26,262,527 | 0.11 | 2.45e-08 | 1.89e-07 |
| Endometrial Stromal Cell:0 | 1/138,393 | 3,786/26,262,527 | 0.05 | 1.04e-07 | 7.51e-07 |
| Mycobacterium Infections:0 | 1/138,393 | 5,781/26,262,527 | 0.03 | 3.96e-12 | 4.27e-11 |
| Spheroids, Cellular:0 | 37/138,393 | 1,955/26,262,527 | 3.59 | 1.21e-10 | 1.16e-09 |
| nornitrogen mustard:0 | 4/138,393 | 10/26,262,527 | 75.91 | 7.25e-07 | 4.78e-06 |
| Diagnostic:0 | 118/138,393 | 10,130/26,262,527 | 2.21 | 2.93e-14 | 3.69e-13 |
| Constipation:0 | 13/138,393 | 12,387/26,262,527 | 0.20 | 7.99e-15 | 1.04e-13 |
| PCNA gene|PCNA:0 | 36/138,393 | 2,664/26,262,527 | 2.56 | 7.59e-07 | 4.99e-06 |
| Beagle:0 | 29/138,393 | 14,859/26,262,527 | 0.37 | 3.10e-10 | 2.88e-09 |
| Traumatic Brain Injury:0 | 3/138,393 | 32,268/26,262,527 | 0.02 | 4.24e-68 | 2.55e-66 |
| Snoring:0 | 1/138,393 | 4,237/26,262,527 | 0.04 | 1.25e-08 | 9.94e-08 |
| Composition:0 | 56/138,393 | 19,776/26,262,527 | 0.54 | 3.64e-07 | 2.47e-06 |
| Blast Cell:0 | 17/138,393 | 9,332/26,262,527 | 0.35 | 2.03e-07 | 1.42e-06 |
| Amylases:0 | 8/138,393 | 12,306/26,262,527 | 0.12 | 1.48e-18 | 2.36e-17 |
| Polychlorinated Biphenyls:0 | 25/138,393 | 12,489/26,262,527 | 0.38 | 1.92e-08 | 1.50e-07 |
| Chronic schizophrenia:0 | 3/138,393 | 5,419/26,262,527 | 0.11 | 4.40e-09 | 3.68e-08 |
| Trans-Activation (Genetics):0 | 206/138,393 | 7,069/26,262,527 | 5.54 | 4.36e-81 | 3.10e-79 |
| Recurrence:0 | 96/138,393 | 4,587/26,262,527 | 3.97 | 4.63e-28 | 1.09e-26 |
| Caenorhabditis elegans:0 | 2/138,393 | 10,949/26,262,527 | 0.03 | 3.55e-22 | 6.63e-21 |
| CDKN1A:0 | 20/138,393 | 849/26,262,527 | 4.47 | 7.13e-08 | 5.23e-07 |
| retinamide:0 | 24/138,393 | 418/26,262,527 | 10.90 | 5.95e-17 | 8.79e-16 |
| Phosphocreatine:0 | 2/138,393 | 4,718/26,262,527 | 0.08 | 1.33e-08 | 1.05e-07 |
| Urologic:0 | 13/138,393 | 185/26,262,527 | 13.34 | 7.07e-11 | 6.90e-10 |
| Validation:0 | 253/138,393 | 13,925/26,262,527 | 3.45 | 1.02e-59 | 5.34e-58 |
| Perineal approach:0 | 13/138,393 | 31/26,262,527 | 79.59 | 1.01e-19 | 1.69e-18 |
| Pelvic lymphadenectomy:0 | 340/138,393 | 1,935/26,262,527 | 33.42 | 0.00e+00 | 0.00e+00 |
| Coronary Artery Vasospasm:0 | 2/138,393 | 4,106/26,262,527 | 0.09 | 2.10e-07 | 1.47e-06 |
| Trigeminal Neuralgia:0 | 3/138,393 | 6,454/26,262,527 | 0.09 | 2.23e-11 | 2.26e-10 |
| Perceived quality of life:0 | 43/138,393 | 2,057/26,262,527 | 3.97 | 1.78e-13 | 2.11e-12 |
| promatrilysin:0 | 8/138,393 | 106/26,262,527 | 14.32 | 1.92e-07 | 1.34e-06 |
| Bleomycin:0 | 37/138,393 | 16,674/26,262,527 | 0.42 | 1.54e-09 | 1.34e-08 |
| Somatostatin analog|TAT:0 | 7/138,393 | 1/26,262,527 | 1328.44 | 8.66e-16 | 1.19e-14 |
| Toll-Like Receptor 2|TLR2:0 | 4/138,393 | 5,614/26,262,527 | 0.14 | 9.75e-09 | 7.87e-08 |
| Sperm Injections, Intracytoplasmic:0 | 3/138,393 | 4,938/26,262,527 | 0.12 | 3.28e-08 | 2.49e-07 |
| Urinary Diversion:0 | 137/138,393 | 3,551/26,262,527 | 7.33 | 2.22e-68 | 1.34e-66 |
| Phenytoin:0 | 5/138,393 | 14,284/26,262,527 | 0.07 | 1.21e-25 | 2.59e-24 |
| Ganglia:0 | 13/138,393 | 22,470/26,262,527 | 0.11 | 1.34e-34 | 3.90e-33 |
| Clonidine:0 | 9/138,393 | 20,330/26,262,527 | 0.08 | 3.73e-34 | 1.07e-32 |
| Plants:0 | 177/138,393 | 108,775/26,262,527 | 0.31 | 2.20e-83 | 1.59e-81 |
| Substance P Receptor:0 | 1/138,393 | 4,067/26,262,527 | 0.05 | 2.43e-08 | 1.88e-07 |
| Arteries:0 | 47/138,393 | 76,487/26,262,527 | 0.12 | 3.68e-112 | 3.64e-110 |
| Growth Cones:0 | 1/138,393 | 4,578/26,262,527 | 0.04 | 1.95e-09 | 1.69e-08 |
| Therapeutic Intervention:0 | 99/138,393 | 6,756/26,262,527 | 2.78 | 3.01e-18 | 4.73e-17 |
| Microbial Biofilms:0 | 1/138,393 | 8,859/26,262,527 | 0.02 | 6.15e-19 | 1.00e-17 |
| Fibrin Tissue Adhesive:0 | 5/138,393 | 6,166/26,262,527 | 0.15 | 5.55e-09 | 4.60e-08 |
| Hemoglobin A|SCN2A|KRT90P:0 | 1/138,393 | 3,942/26,262,527 | 0.05 | 5.20e-08 | 3.86e-07 |
| Nitrate:0 | 2/138,393 | 14,037/26,262,527 | 0.03 | 6.14e-29 | 1.49e-27 |
| Lipoproteins:0 | 38/138,393 | 42,716/26,262,527 | 0.17 | 2.44e-53 | 1.13e-51 |
| Ankylosing spondylitis:0 | 6/138,393 | 21,286/26,262,527 | 0.05 | 1.27e-39 | 4.38e-38 |
| MSMB protein, human|MSMB:0 | 32/138,393 | 156/26,262,527 | 38.94 | 6.52e-38 | 2.13e-36 |
| Spontaneous pneumothorax NOS:0 | 1/138,393 | 3,960/26,262,527 | 0.05 | 3.37e-08 | 2.56e-07 |
| Corticotropin|POMC:0 | 37/138,393 | 25,898/26,262,527 | 0.27 | 1.36e-23 | 2.70e-22 |
| Chronic pelvic pain syndrome:0 | 28/138,393 | 1,514/26,262,527 | 3.51 | 3.18e-08 | 2.42e-07 |
| phosphoric diester hydrolase:0 | 8/138,393 | 13,772/26,262,527 | 0.11 | 1.63e-21 | 2.98e-20 |
| Dinoprostone:0 | 77/138,393 | 47,360/26,262,527 | 0.31 | 4.08e-37 | 1.30e-35 |
| Immunoglobulins, E:0 | 3/138,393 | 4,371/26,262,527 | 0.13 | 5.16e-07 | 3.45e-06 |
| Methylene blue:0 | 7/138,393 | 8,418/26,262,527 | 0.16 | 8.53e-12 | 8.96e-11 |
| GLUTATHIONE PEROXIDASE:0 | 29/138,393 | 14,838/26,262,527 | 0.37 | 3.09e-10 | 2.86e-09 |
| Neurons, Afferent:0 | 12/138,393 | 13,094/26,262,527 | 0.17 | 6.28e-17 | 9.27e-16 |
| Early Detection Research Network:0 | 4/138,393 | 7/26,262,527 | 108.44 | 2.42e-07 | 1.68e-06 |
| Malignant neoplasm of kidney:0 | 271/138,393 | 6,073/26,262,527 | 8.48 | 5.37e-148 | 7.15e-146 |
| Caffeine:0 | 20/138,393 | 24,588/26,262,527 | 0.15 | 1.02e-32 | 2.81e-31 |
| Amputation:0 | 9/138,393 | 11,461/26,262,527 | 0.15 | 5.26e-16 | 7.33e-15 |
| Insulin-Like Growth Factor Receptor:0 | 45/138,393 | 2,246/26,262,527 | 3.80 | 2.05e-13 | 2.43e-12 |
| Dental Cementum:0 | 3/138,393 | 8,359/26,262,527 | 0.07 | 2.38e-15 | 3.21e-14 |
| soft tissue:0 | 202/138,393 | 20,368/26,262,527 | 1.88 | 3.94e-16 | 5.53e-15 |
| Losartan:0 | 7/138,393 | 17,302/26,262,527 | 0.08 | 8.58e-30 | 2.14e-28 |
| Demyelinating Diseases:0 | 1/138,393 | 3,907/26,262,527 | 0.05 | 4.90e-08 | 3.66e-07 |
| Mannitol:0 | 3/138,393 | 9,095/26,262,527 | 0.06 | 6.98e-17 | 1.03e-15 |
| Musculoskeletal Diseases:0 | 1/138,393 | 5,706/26,262,527 | 0.03 | 5.67e-12 | 6.05e-11 |
| Peritoneal Fluid:0 | 17/138,393 | 12,132/26,262,527 | 0.27 | 6.69e-12 | 7.10e-11 |
| macrophage:0 | 160/138,393 | 139,690/26,262,527 | 0.22 | 5.76e-146 | 7.59e-144 |
| electrode:0 | 23/138,393 | 21,123/26,262,527 | 0.21 | 5.52e-24 | 1.11e-22 |
| Yeasts:0 | 3/138,393 | 7,402/26,262,527 | 0.08 | 2.32e-13 | 2.74e-12 |
| Seasons:0 | 6/138,393 | 5,644/26,262,527 | 0.20 | 2.79e-07 | 1.93e-06 |
| Systemic Scleroderma:0 | 9/138,393 | 29,948/26,262,527 | 0.06 | 1.56e-54 | 7.36e-53 |
| imiquimod:0 | 2/138,393 | 4,055/26,262,527 | 0.09 | 3.08e-07 | 2.11e-06 |
| Fibroblasts:0 | 450/138,393 | 149,590/26,262,527 | 0.57 | 3.64e-39 | 1.23e-37 |
| BID gene|BID:0 | 34/138,393 | 1,949/26,262,527 | 3.31 | 4.76e-09 | 3.97e-08 |
| Tumor Necrosis Factor-alpha:0 | 133/138,393 | 99,753/26,262,527 | 0.25 | 9.50e-93 | 7.73e-91 |
| treatment method:0 | 74/138,393 | 7,505/26,262,527 | 1.87 | 9.41e-07 | 6.12e-06 |
| Mood Disorders:0 | 6/138,393 | 15,037/26,262,527 | 0.08 | 3.26e-26 | 7.14e-25 |
| SPOP gene|SPOP:0 | 8/138,393 | 49/26,262,527 | 30.98 | 7.49e-10 | 6.72e-09 |
| Vitamin D3 Receptor|VDR:0 | 37/138,393 | 1,779/26,262,527 | 3.95 | 9.32e-12 | 9.77e-11 |
| Mental health problem:0 | 1/138,393 | 5,683/26,262,527 | 0.03 | 5.56e-12 | 5.95e-11 |
| pregabalin:0 | 1/138,393 | 4,776/26,262,527 | 0.04 | 6.40e-10 | 5.77e-09 |
| Graves' Disease:0 | 4/138,393 | 20,112/26,262,527 | 0.04 | 1.16e-39 | 3.98e-38 |
| Honvan:0 | 16/138,393 | 35/26,262,527 | 86.76 | 1.96e-24 | 4.02e-23 |
| TNF protein, human|TNF:0 | 177/138,393 | 71,207/26,262,527 | 0.47 | 5.75e-30 | 1.44e-28 |
| Cholinesterases:0 | 3/138,393 | 4,612/26,262,527 | 0.12 | 1.92e-07 | 1.35e-06 |
| Irritable Bowel Syndrome:0 | 1/138,393 | 22,761/26,262,527 | 0.01 | 2.03e-50 | 9.00e-49 |
| Dopamine:0 | 26/138,393 | 98,385/26,262,527 | 0.05 | 2.26e-181 | 3.97e-179 |
| Cyclosporine:0 | 37/138,393 | 79,771/26,262,527 | 0.09 | 6.37e-129 | 7.25e-127 |
| JAZF1:0 | 10/138,393 | 131/26,262,527 | 14.49 | 5.18e-09 | 4.31e-08 |
| Heparin, Low-Molecular-Weight:0 | 18/138,393 | 25,463/26,262,527 | 0.13 | 5.35e-36 | 1.65e-34 |
| Erythropoiesis:0 | 8/138,393 | 6,024/26,262,527 | 0.25 | 1.10e-06 | 7.12e-06 |
| Pain relief:0 | 111/138,393 | 12,843/26,262,527 | 1.64 | 1.34e-06 | 8.50e-06 |
| Prostate mass:0 | 6/138,393 | 14/26,262,527 | 81.33 | 7.55e-10 | 6.76e-09 |
| Globulins:0 | 6/138,393 | 5,295/26,262,527 | 0.22 | 1.39e-06 | 8.83e-06 |
| Interstitial brachytherapy:0 | 154/138,393 | 1,094/26,262,527 | 26.74 | 2.17e-153 | 3.00e-151 |
| Pheochromocytoma:0 | 37/138,393 | 17,720/26,262,527 | 0.40 | 5.94e-11 | 5.85e-10 |
| advanced disease:0 | 677/138,393 | 17,023/26,262,527 | 7.58 | 0.00e+00 | 0.00e+00 |
| Pituitary Gland:0 | 35/138,393 | 14,450/26,262,527 | 0.46 | 2.56e-07 | 1.78e-06 |
| Interleukin-10:0 | 51/138,393 | 40,504/26,262,527 | 0.24 | 2.86e-40 | 9.99e-39 |
| Leukoencephalopathy, Progressive Multifocal:0 | 2/138,393 | 4,343/26,262,527 | 0.09 | 7.54e-08 | 5.51e-07 |
| Radioimmunoconjugates:0 | 23/138,393 | 961/26,262,527 | 4.54 | 5.89e-09 | 4.87e-08 |
| Hormonal:0 | 32/138,393 | 883/26,262,527 | 6.88 | 1.51e-16 | 2.18e-15 |
| Microarray Analysis:0 | 153/138,393 | 6,031/26,262,527 | 4.82 | 2.15e-53 | 9.95e-52 |
| Fetal Liver:0 | 4/138,393 | 5,096/26,262,527 | 0.15 | 1.02e-07 | 7.40e-07 |
| Conjunctivitis:0 | 1/138,393 | 3,795/26,262,527 | 0.05 | 1.06e-07 | 7.64e-07 |
| selenomethylselenocysteine:0 | 18/138,393 | 366/26,262,527 | 9.33 | 4.98e-12 | 5.35e-11 |
| Seizures, Focal:0 | 1/138,393 | 6,153/26,262,527 | 0.03 | 6.58e-13 | 7.50e-12 |
| kahalalide F:0 | 7/138,393 | 85/26,262,527 | 15.63 | 6.45e-07 | 4.27e-06 |
| Aspirin:0 | 142/138,393 | 69,399/26,262,527 | 0.39 | 2.39e-40 | 8.36e-39 |
| Compete:0 | 55/138,393 | 4,036/26,262,527 | 2.59 | 1.35e-09 | 1.18e-08 |
| Antidepressive Agents, Tricyclic:0 | 9/138,393 | 9,473/26,262,527 | 0.18 | 2.52e-12 | 2.75e-11 |
| Metribolone:0 | 41/138,393 | 344/26,262,527 | 22.62 | 1.78e-39 | 6.09e-38 |
| venlafaxine:0 | 2/138,393 | 4,941/26,262,527 | 0.08 | 4.66e-09 | 3.89e-08 |
| Streptozocin:0 | 6/138,393 | 21,207/26,262,527 | 0.05 | 1.81e-39 | 6.18e-38 |
| partial response:0 | 212/138,393 | 8,543/26,262,527 | 4.71 | 1.14e-71 | 7.13e-70 |
| Recanalization:0 | 1/138,393 | 4,666/26,262,527 | 0.04 | 1.41e-09 | 1.23e-08 |
| Epidermal Growth Factor Receptor|EGF:0 | 73/138,393 | 5,503/26,262,527 | 2.52 | 6.48e-12 | 6.88e-11 |
| Anxiety Disorders:0 | 3/138,393 | 14,864/26,262,527 | 0.04 | 1.59e-29 | 3.93e-28 |
| Adrenergic alpha-Agonists:0 | 1/138,393 | 3,731/26,262,527 | 0.05 | 1.55e-07 | 1.10e-06 |
| Lower urinary tract symptoms:0 | 418/138,393 | 7,699/26,262,527 | 10.33 | 3.58e-258 | 8.88e-256 |
| Autoimmune hemolytic anemia:0 | 1/138,393 | 3,575/26,262,527 | 0.05 | 3.11e-07 | 2.13e-06 |
| Hypoxemia:0 | 4/138,393 | 7,626/26,262,527 | 0.10 | 9.71e-13 | 1.09e-11 |
| Primary Gleason pattern:0 | 12/138,393 | 16/26,262,527 | 142.34 | 1.21e-20 | 2.13e-19 |
| 11p11.2:0 | 5/138,393 | 25/26,262,527 | 37.95 | 5.06e-07 | 3.38e-06 |
| Abdominal Cavity:0 | 8/138,393 | 6,803/26,262,527 | 0.22 | 5.13e-08 | 3.82e-07 |
| Cancer Intervention:0 | 7/138,393 | 31/26,262,527 | 42.85 | 1.19e-09 | 1.05e-08 |
| Extrinsic asthma NOS:0 | 4/138,393 | 7,007/26,262,527 | 0.11 | 1.49e-11 | 1.54e-10 |
| Brain tissue:0 | 17/138,393 | 22,468/26,262,527 | 0.14 | 5.25e-31 | 1.36e-29 |
| WDTC1:0 | 6/138,393 | 15,796/26,262,527 | 0.07 | 1.03e-27 | 2.39e-26 |
| Genomic Instability:0 | 55/138,393 | 3,926/26,262,527 | 2.66 | 3.47e-10 | 3.20e-09 |
| Entire retroperitoneal lymph node:0 | 13/138,393 | 396/26,262,527 | 6.23 | 3.92e-07 | 2.66e-06 |
| DAB2IP:0 | 17/138,393 | 167/26,262,527 | 19.32 | 3.10e-16 | 4.38e-15 |
| Cardiovascular Diseases:0 | 275/138,393 | 79,484/26,262,527 | 0.66 | 8.98e-14 | 1.10e-12 |
| Actins:0 | 79/138,393 | 33,661/26,262,527 | 0.45 | 1.84e-16 | 2.64e-15 |
| Disorder of artery:0 | 1/138,393 | 7,932/26,262,527 | 0.02 | 7.12e-17 | 1.05e-15 |
| Adventitia:0 | 3/138,393 | 4,443/26,262,527 | 0.13 | 3.66e-07 | 2.49e-06 |
| Cleft Lip:0 | 2/138,393 | 5,393/26,262,527 | 0.07 | 3.63e-10 | 3.34e-09 |
| Treadmill:0 | 2/138,393 | 5,092/26,262,527 | 0.07 | 2.33e-09 | 2.00e-08 |
| offender:0 | 1/138,393 | 6,822/26,262,527 | 0.03 | 1.63e-14 | 2.08e-13 |
| Cardiopulmonary Resuscitation:0 | 3/138,393 | 7,255/26,262,527 | 0.08 | 4.70e-13 | 5.41e-12 |
| Craniopharyngioma:0 | 1/138,393 | 3,708/26,262,527 | 0.05 | 1.48e-07 | 1.05e-06 |
| WWOX:0 | 24/138,393 | 870/26,262,527 | 5.24 | 1.87e-10 | 1.78e-09 |
| Hypoxia-Inducible Factor 1:0 | 75/138,393 | 4,011/26,262,527 | 3.55 | 1.26e-19 | 2.10e-18 |
| Fentanyl:0 | 12/138,393 | 15,583/26,262,527 | 0.15 | 1.28e-21 | 2.34e-20 |
| Guanosine Triphosphate:0 | 24/138,393 | 12,643/26,262,527 | 0.36 | 3.73e-09 | 3.15e-08 |
| Bombesin Receptor|GRPR:0 | 7/138,393 | 56/26,262,527 | 23.72 | 4.65e-08 | 3.48e-07 |
| Synovial Fluid:0 | 1/138,393 | 8,250/26,262,527 | 0.02 | 1.09e-17 | 1.67e-16 |
| Carbachol:0 | 6/138,393 | 15,909/26,262,527 | 0.07 | 4.79e-28 | 1.13e-26 |
| Genetic Markers:0 | 45/138,393 | 2,333/26,262,527 | 3.66 | 7.15e-13 | 8.11e-12 |
| atorvastatin:0 | 19/138,393 | 19,900/26,262,527 | 0.18 | 1.55e-24 | 3.20e-23 |
| Red meat:0 | 22/138,393 | 372/26,262,527 | 11.22 | 6.43e-16 | 8.90e-15 |
| radiosensitization:0 | 25/138,393 | 953/26,262,527 | 4.98 | 2.17e-10 | 2.04e-09 |
| Seed Implantation:0 | 187/138,393 | 579/26,262,527 | 61.37 | 3.96e-245 | 9.34e-243 |
| Pre-Eclampsia:0 | 7/138,393 | 39,960/26,262,527 | 0.03 | 3.65e-79 | 2.55e-77 |
| Cleft Palate:0 | 1/138,393 | 9,607/26,262,527 | 0.02 | 1.05e-20 | 1.85e-19 |
| 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene:0 | 4/138,393 | 9/26,262,527 | 84.34 | 5.20e-07 | 3.48e-06 |
| Atrial Fibrillation:0 | 7/138,393 | 74,235/26,262,527 | 0.02 | 1.40e-155 | 1.96e-153 |
| Vasoactive Intestinal Peptide:0 | 43/138,393 | 20,524/26,262,527 | 0.40 | 1.77e-12 | 1.96e-11 |
| Temporal Lobe:0 | 4/138,393 | 14,755/26,262,527 | 0.05 | 6.10e-28 | 1.43e-26 |
| Transient Ischemic Attack:0 | 6/138,393 | 13,164/26,262,527 | 0.09 | 2.97e-22 | 5.56e-21 |
| leiomyosarcoma:0 | 89/138,393 | 7,886/26,262,527 | 2.14 | 1.66e-10 | 1.58e-09 |
| Disinfection:0 | 2/138,393 | 4,092/26,262,527 | 0.09 | 2.08e-07 | 1.45e-06 |
| Goserelin Acetate|EREG|ESR1:0 | 7/138,393 | 8/26,262,527 | 166.06 | 6.74e-13 | 7.67e-12 |
| TPD52 gene|TPD52:0 | 12/138,393 | 134/26,262,527 | 17.00 | 2.77e-11 | 2.79e-10 |
| Hydrocarbons:0 | 12/138,393 | 9,881/26,262,527 | 0.23 | 5.35e-11 | 5.28e-10 |
| Signs and Symptoms, Respiratory:0 | 6/138,393 | 7,312/26,262,527 | 0.16 | 2.20e-10 | 2.07e-09 |
| Iodine 125 brachytherapy:0 | 71/138,393 | 253/26,262,527 | 53.28 | 1.67e-90 | 1.32e-88 |
| CyberKnife:0 | 69/138,393 | 1,255/26,262,527 | 10.44 | 1.63e-44 | 6.29e-43 |
| Renal impairment:0 | 17/138,393 | 11,584/26,262,527 | 0.28 | 5.28e-11 | 5.21e-10 |
| EGFR gene|EGFR:0 | 102/138,393 | 8,606/26,262,527 | 2.25 | 6.13e-13 | 7.02e-12 |
| Capsaicin:0 | 22/138,393 | 22,496/26,262,527 | 0.19 | 3.84e-27 | 8.73e-26 |
| membrane attack complex location:0 | 29/138,393 | 837/26,262,527 | 6.58 | 1.14e-14 | 1.47e-13 |
| Mitoxantrone:0 | 221/138,393 | 7,341/26,262,527 | 5.72 | 2.24e-89 | 1.73e-87 |
| Nephrotic Syndrome:0 | 8/138,393 | 16,074/26,262,527 | 0.09 | 2.57e-26 | 5.68e-25 |
| KCNH2:0 | 1/138,393 | 3,789/26,262,527 | 0.05 | 1.05e-07 | 7.55e-07 |
| Urethral catheter:0 | 34/138,393 | 505/26,262,527 | 12.78 | 1.93e-25 | 4.09e-24 |
| Chromosomal Instability:0 | 39/138,393 | 2,610/26,262,527 | 2.84 | 2.24e-08 | 1.74e-07 |
| Microglia:0 | 4/138,393 | 22,855/26,262,527 | 0.03 | 1.30e-45 | 5.15e-44 |
| AKT Signaling Pathway:0 | 38/138,393 | 1,023/26,262,527 | 7.05 | 1.09e-19 | 1.82e-18 |
| [D]Slowing of urinary stream:0 | 6/138,393 | 43/26,262,527 | 26.48 | 2.39e-07 | 1.66e-06 |
| Latent Infection:0 | 3/138,393 | 4,677/26,262,527 | 0.12 | 1.34e-07 | 9.60e-07 |
| Nociception:0 | 6/138,393 | 7,696/26,262,527 | 0.15 | 4.27e-11 | 4.26e-10 |
| Control Groups:0 | 395/138,393 | 107,052/26,262,527 | 0.70 | 7.23e-14 | 8.88e-13 |
| skin disorder:0 | 30/138,393 | 24,450/26,262,527 | 0.23 | 2.31e-25 | 4.90e-24 |
| Biopsy needle:0 | 23/138,393 | 368/26,262,527 | 11.86 | 4.63e-17 | 6.87e-16 |
| Radiotherapy, Adjuvant:0 | 224/138,393 | 4,265/26,262,527 | 9.98 | 1.95e-136 | 2.41e-134 |
| Gonadorelin|PLOD1:0 | 97/138,393 | 39/26,262,527 | 472.32 | 9.10e-188 | 1.65e-185 |
| Genes, Suppressor:0 | 21/138,393 | 964/26,262,527 | 4.13 | 1.21e-07 | 8.64e-07 |
| Alleles:0 | 163/138,393 | 19,033/26,262,527 | 1.63 | 9.97e-09 | 8.04e-08 |
| Prostatic cyst:0 | 9/138,393 | 157/26,262,527 | 10.88 | 3.02e-07 | 2.07e-06 |
| Impaired cognition:0 | 20/138,393 | 43,849/26,262,527 | 0.09 | 1.29e-71 | 8.02e-70 |
| Entire subthalamic nucleus:0 | 1/138,393 | 3,529/26,262,527 | 0.05 | 2.94e-07 | 2.03e-06 |
| Experimental Design:0 | 45/138,393 | 2,919/26,262,527 | 2.93 | 7.92e-10 | 7.08e-09 |
| Malignant neoplasm of pancreas:0 | 56/138,393 | 1,446/26,262,527 | 7.35 | 4.37e-29 | 1.06e-27 |
| SLC5A5 gene|SLC5A5:0 | 18/138,393 | 429/26,262,527 | 7.96 | 5.95e-11 | 5.85e-10 |
| docetaxel:0 | 1,579/138,393 | 22,855/26,262,527 | 13.25 | 0.00e+00 | 0.00e+00 |
| High pressure liquid chromatography procedure:0 | 70/138,393 | 28,243/26,262,527 | 0.47 | 1.07e-12 | 1.21e-11 |
| Hemoptysis:0 | 4/138,393 | 5,439/26,262,527 | 0.14 | 2.81e-08 | 2.15e-07 |
| Influenza A virus:0 | 2/138,393 | 4,737/26,262,527 | 0.08 | 8.76e-09 | 7.11e-08 |
| Recurrent Carcinoma:0 | 167/138,393 | 7,864/26,262,527 | 4.03 | 2.94e-48 | 1.24e-46 |
| SPATA7|HSD11B1L:0 | 7/138,393 | 46/26,262,527 | 28.88 | 1.36e-08 | 1.08e-07 |
| PAGE4:0 | 12/138,393 | 32/26,262,527 | 71.17 | 7.77e-18 | 1.20e-16 |
| Western society:0 | 35/138,393 | 1,521/26,262,527 | 4.37 | 2.27e-12 | 2.49e-11 |
| Walking:0 | 6/138,393 | 6,543/26,262,527 | 0.17 | 5.78e-09 | 4.78e-08 |
| beta-Lactamase:0 | 3/138,393 | 9,488/26,262,527 | 0.06 | 7.96e-18 | 1.23e-16 |
| Flexible fiberoptic sigmoidoscopy:0 | 23/138,393 | 687/26,262,527 | 6.35 | 1.15e-11 | 1.20e-10 |
| palladium-bacteriopheophorbide:0 | 6/138,393 | 23/26,262,527 | 49.51 | 8.89e-09 | 7.20e-08 |
| Hemiparesis:0 | 2/138,393 | 5,610/26,262,527 | 0.07 | 1.25e-10 | 1.20e-09 |
| gene therapy:0 | 289/138,393 | 17,854/26,262,527 | 3.08 | 5.49e-58 | 2.80e-56 |
| Syncope:0 | 4/138,393 | 11,073/26,262,527 | 0.07 | 4.65e-20 | 7.92e-19 |
| CAMP:0 | 12/138,393 | 7,579/26,262,527 | 0.30 | 4.29e-07 | 2.89e-06 |
| Reticular Formation:0 | 2/138,393 | 4,947/26,262,527 | 0.08 | 4.73e-09 | 3.94e-08 |
| Myocardium:0 | 12/138,393 | 51,212/26,262,527 | 0.04 | 5.27e-97 | 4.47e-95 |
| Puboprostatic ligament:0 | 13/138,393 | 25/26,262,527 | 98.69 | 1.08e-20 | 1.91e-19 |
| Relaxation:0 | 11/138,393 | 18,549/26,262,527 | 0.11 | 1.90e-28 | 4.53e-27 |
| Patient observation:0 | 279/138,393 | 1,373/26,262,527 | 38.64 | 5.33e-316 | 1.55e-313 |
| Pathological accumulation of air in tissues:0 | 7/138,393 | 10,373/26,262,527 | 0.13 | 1.49e-15 | 2.03e-14 |
| [D]Urinary system symptoms NOS:0 | 13/138,393 | 183/26,262,527 | 13.48 | 6.23e-11 | 6.11e-10 |
| ZEB1:0 | 32/138,393 | 1,544/26,262,527 | 3.93 | 2.42e-10 | 2.27e-09 |
| kinase activity:0 | 66/138,393 | 6,238/26,262,527 | 2.01 | 3.11e-07 | 2.13e-06 |
| Memory:0 | 8/138,393 | 13,655/26,262,527 | 0.11 | 2.21e-21 | 3.99e-20 |
| ACPP gene|ACPP:0 | 74/138,393 | 158/26,262,527 | 88.93 | 5.13e-108 | 4.77e-106 |
| Glial Fibrillary Acidic Protein:0 | 2/138,393 | 9,543/26,262,527 | 0.04 | 5.19e-19 | 8.46e-18 |
| Materials:0 | 55/138,393 | 28,268/26,262,527 | 0.37 | 2.01e-18 | 3.19e-17 |
| Dopamine Antagonists:0 | 3/138,393 | 4,945/26,262,527 | 0.12 | 3.30e-08 | 2.51e-07 |
| Birth Weight:0 | 9/138,393 | 13,104/26,262,527 | 0.13 | 2.28e-19 | 3.77e-18 |
| Gelatinase B:0 | 219/138,393 | 21,600/26,262,527 | 1.93 | 2.71e-18 | 4.26e-17 |
| Serum acid phosphatase measurement:0 | 17/138,393 | 27/26,262,527 | 119.50 | 1.02e-27 | 2.37e-26 |
| fluorodeoxyglucose positron emission tomography:0 | 62/138,393 | 5,933/26,262,527 | 1.98 | 1.04e-06 | 6.74e-06 |
| Magnetic Resonance Angiography:0 | 5/138,393 | 7,679/26,262,527 | 0.12 | 7.03e-12 | 7.45e-11 |
| Biopsy of prostate:0 | 198/138,393 | 316/26,262,527 | 119.07 | 1.08e-305 | 3.04e-303 |
| Lymph:0 | 2/138,393 | 3,856/26,262,527 | 0.10 | 5.91e-07 | 3.93e-06 |
| HYPERTHYROID:0 | 3/138,393 | 6,452/26,262,527 | 0.09 | 2.23e-11 | 2.26e-10 |
| Prostatic Neoplasms:0 | 2,156/138,393 | 3,143/26,262,527 | 132.22 | 0.00e+00 | 0.00e+00 |
| Capsid Proteins:0 | 10/138,393 | 16,125/26,262,527 | 0.12 | 2.15e-24 | 4.39e-23 |
| Samarium SM 153 lexidronam:0 | 28/138,393 | 228/26,262,527 | 23.31 | 8.39e-28 | 1.96e-26 |
| Irrigation:0 | 23/138,393 | 16,339/26,262,527 | 0.27 | 1.32e-15 | 1.80e-14 |
| Tumor Suppressor Proteins:0 | 49/138,393 | 2,295/26,262,527 | 4.05 | 1.81e-15 | 2.46e-14 |
| bicalutamide:0 | 588/138,393 | 1,877/26,262,527 | 59.70 | 0.00e+00 | 0.00e+00 |
| Laser vaporization:0 | 29/138,393 | 1,650/26,262,527 | 3.34 | 5.24e-08 | 3.89e-07 |
| Nicardipine:0 | 3/138,393 | 5,813/26,262,527 | 0.10 | 5.17e-10 | 4.70e-09 |
| beta-adrenergic receptor:0 | 2/138,393 | 5,576/26,262,527 | 0.07 | 1.86e-10 | 1.76e-09 |
| Cyanobacterium:0 | 2/138,393 | 14,949/26,262,527 | 0.03 | 5.21e-31 | 1.35e-29 |
| Urogenital organ:0 | 15/138,393 | 203/26,262,527 | 14.02 | 1.27e-12 | 1.43e-11 |
| conjunctiva:0 | 11/138,393 | 16,281/26,262,527 | 0.13 | 7.06e-24 | 1.42e-22 |
| Somatotropin|ELANE:0 | 7/138,393 | 34/26,262,527 | 39.07 | 2.09e-09 | 1.80e-08 |
| Neurotoxins:0 | 1/138,393 | 4,919/26,262,527 | 0.04 | 3.09e-10 | 2.87e-09 |
| Lipodystrophy:0 | 1/138,393 | 3,369/26,262,527 | 0.06 | 9.38e-07 | 6.10e-06 |
| Androgens, Synthetic:0 | 57/138,393 | 319/26,262,527 | 33.92 | 3.36e-63 | 1.88e-61 |
| Huntington Disease:0 | 3/138,393 | 13,382/26,262,527 | 0.04 | 3.15e-26 | 6.92e-25 |
| Cell Aging:0 | 61/138,393 | 4,977/26,262,527 | 2.33 | 6.65e-09 | 5.46e-08 |
| galiellalactone:0 | 6/138,393 | 43/26,262,527 | 26.48 | 2.39e-07 | 1.66e-06 |
| Monoamine Oxidase:0 | 6/138,393 | 11,257/26,262,527 | 0.10 | 2.42e-18 | 3.82e-17 |
| Biological function, NOS:0 | 163/138,393 | 15,496/26,262,527 | 2.00 | 2.68e-15 | 3.60e-14 |
| Caseins:0 | 8/138,393 | 8,560/26,262,527 | 0.18 | 3.53e-11 | 3.53e-10 |
| hair:0 | 17/138,393 | 23,415/26,262,527 | 0.14 | 6.82e-33 | 1.88e-31 |
| Interleukin-18:0 | 15/138,393 | 9,395/26,262,527 | 0.30 | 1.86e-08 | 1.45e-07 |
| K ATPase:0 | 4/138,393 | 5,277/26,262,527 | 0.14 | 5.38e-08 | 3.99e-07 |
| Birth:0 | 46/138,393 | 44,134/26,262,527 | 0.20 | 3.64e-50 | 1.60e-48 |
| Liver Regeneration:0 | 2/138,393 | 3,764/26,262,527 | 0.10 | 1.25e-06 | 7.98e-06 |
| Large prostate:0 | 258/138,393 | 1,200/26,262,527 | 40.87 | 6.07e-298 | 1.67e-295 |
| PLAU gene|PLAU:0 | 57/138,393 | 1,158/26,262,527 | 9.34 | 1.11e-34 | 3.26e-33 |
| M Phase Arrest:0 | 15/138,393 | 570/26,262,527 | 4.99 | 7.80e-07 | 5.13e-06 |
| protein C activator peptide|PCAP:0 | 5/138,393 | 22/26,262,527 | 43.13 | 2.90e-07 | 2.00e-06 |
| AKT1 gene|AKT1:0 | 21/138,393 | 774/26,262,527 | 5.15 | 3.27e-09 | 2.76e-08 |
| Somatostatin analog|SST:0 | 67/138,393 | 4,095/26,262,527 | 3.11 | 5.24e-15 | 6.93e-14 |
| Glucagon:0 | 7/138,393 | 14,558/26,262,527 | 0.09 | 3.23e-24 | 6.58e-23 |
| Naproxen:0 | 6/138,393 | 5,886/26,262,527 | 0.19 | 1.08e-07 | 7.74e-07 |
| Water consumption:0 | 17/138,393 | 8,929/26,262,527 | 0.36 | 1.07e-06 | 6.94e-06 |
| Arachidonic Acid:0 | 93/138,393 | 29,281/26,262,527 | 0.60 | 1.38e-07 | 9.82e-07 |
| Surgical sutures:0 | 31/138,393 | 13,027/26,262,527 | 0.45 | 5.83e-07 | 3.88e-06 |
| Ibandronate:0 | 35/138,393 | 1,862/26,262,527 | 3.57 | 4.46e-10 | 4.08e-09 |
| orexin:0 | 5/138,393 | 6,115/26,262,527 | 0.16 | 7.92e-09 | 6.48e-08 |
| Atopic:0 | 1/138,393 | 9,030/26,262,527 | 0.02 | 1.95e-19 | 3.25e-18 |
| Lymphocele:0 | 66/138,393 | 1,485/26,262,527 | 8.44 | 2.40e-37 | 7.71e-36 |
| Esophagitis:0 | 2/138,393 | 5,006/26,262,527 | 0.08 | 3.22e-09 | 2.73e-08 |
| Hashimoto Disease:0 | 2/138,393 | 5,723/26,262,527 | 0.07 | 9.17e-11 | 8.88e-10 |
| Pathological aspects:0 | 23/138,393 | 848/26,262,527 | 5.15 | 6.05e-10 | 5.47e-09 |
| Lipid Peroxides:0 | 9/138,393 | 7,784/26,262,527 | 0.22 | 3.90e-09 | 3.28e-08 |
| Soldiers:0 | 2/138,393 | 4,972/26,262,527 | 0.08 | 3.06e-09 | 2.60e-08 |
| Epilepsy:0 | 18/138,393 | 98,304/26,262,527 | 0.03 | 3.25e-192 | 6.05e-190 |
| Adolescents, Male:0 | 1/138,393 | 3,267/26,262,527 | 0.06 | 1.27e-06 | 8.12e-06 |
| Prostatic plexus:0 | 6/138,393 | 19/26,262,527 | 59.93 | 3.37e-09 | 2.85e-08 |
| Base Sequence:0 | 18/138,393 | 12,546/26,262,527 | 0.27 | 6.01e-12 | 6.40e-11 |
| Methotrexate:0 | 97/138,393 | 55,579/26,262,527 | 0.33 | 4.39e-40 | 1.52e-38 |
| TMPRSS2 gene|TMPRSS2:0 | 164/138,393 | 267/26,262,527 | 116.70 | 1.97e-252 | 4.82e-250 |
| Hernia:0 | 28/138,393 | 32,741/26,262,527 | 0.16 | 4.55e-42 | 1.66e-40 |
| pomegranate juice:0 | 7/138,393 | 74/26,262,527 | 17.95 | 2.69e-07 | 1.86e-06 |
| Allografting:0 | 13/138,393 | 16,059/26,262,527 | 0.15 | 1.05e-21 | 1.93e-20 |
| SRC gene|SRC:0 | 31/138,393 | 923/26,262,527 | 6.37 | 3.20e-15 | 4.28e-14 |
| Micrometastasis:0 | 106/138,393 | 5,758/26,262,527 | 3.50 | 1.63e-26 | 3.63e-25 |
| Lead measurement:0 | 6/138,393 | 8,162/26,262,527 | 0.14 | 3.94e-12 | 4.25e-11 |
| Electroencephalography:0 | 3/138,393 | 12,215/26,262,527 | 0.05 | 9.85e-24 | 1.96e-22 |
| Platelet aggregation:0 | 9/138,393 | 21,541/26,262,527 | 0.08 | 9.67e-37 | 3.05e-35 |
| Ventral Tegmental Area:0 | 1/138,393 | 9,654/26,262,527 | 0.02 | 1.13e-20 | 2.00e-19 |
| Pilocarpine:0 | 1/138,393 | 5,813/26,262,527 | 0.03 | 4.24e-12 | 4.57e-11 |
| Nonsteroidal antiandrogen:0 | 114/138,393 | 247/26,262,527 | 87.66 | 7.50e-165 | 1.14e-162 |
| Forecast of outcome:0 | 14/138,393 | 515/26,262,527 | 5.16 | 1.25e-06 | 7.98e-06 |
| Peripheral Neuropathy:0 | 16/138,393 | 11,821/26,262,527 | 0.26 | 5.62e-12 | 6.01e-11 |
| Tretinoin:0 | 139/138,393 | 52,149/26,262,527 | 0.51 | 2.06e-19 | 3.42e-18 |
| Erinaceidae:0 | 59/138,393 | 5,173/26,262,527 | 2.16 | 1.36e-07 | 9.68e-07 |
| Social stigmata:0 | 3/138,393 | 4,181/26,262,527 | 0.14 | 9.85e-07 | 6.39e-06 |
| Refractory Disease:0 | 57/138,393 | 2,639/26,262,527 | 4.10 | 6.13e-18 | 9.48e-17 |
| Urologic Diseases:0 | 124/138,393 | 2,323/26,262,527 | 10.14 | 3.77e-77 | 2.56e-75 |
| Genome:0 | 101/138,393 | 38,319/26,262,527 | 0.50 | 5.71e-15 | 7.52e-14 |
| Hemolytic-Uremic Syndrome:0 | 13/138,393 | 9,531/26,262,527 | 0.26 | 1.04e-09 | 9.20e-09 |
| NCOR2 gene|NCOR2:0 | 20/138,393 | 671/26,262,527 | 5.66 | 1.66e-09 | 1.44e-08 |
| Globin:0 | 1/138,393 | 5,831/26,262,527 | 0.03 | 2.69e-12 | 2.93e-11 |
| Hemin:0 | 5/138,393 | 5,568/26,262,527 | 0.17 | 7.77e-08 | 5.68e-07 |
| Cholera Toxin:0 | 9/138,393 | 8,543/26,262,527 | 0.20 | 1.68e-10 | 1.59e-09 |
| Gastric acid secretion:0 | 1/138,393 | 7,084/26,262,527 | 0.03 | 5.79e-15 | 7.62e-14 |
| Head of femur:0 | 12/138,393 | 11,408/26,262,527 | 0.20 | 1.04e-13 | 1.26e-12 |
| Radiotherapy Systems, Linear Accelerator:0 | 85/138,393 | 1,574/26,262,527 | 10.25 | 7.68e-54 | 3.59e-52 |
| CASP8 and FADD-like apoptosis regulating protein:0 | 35/138,393 | 1,659/26,262,527 | 4.00 | 2.28e-11 | 2.31e-10 |
| Urologic Surgical Procedures:0 | 26/138,393 | 466/26,262,527 | 10.59 | 5.99e-18 | 9.26e-17 |
| Intracavernous injection:0 | 18/138,393 | 399/26,262,527 | 8.56 | 1.93e-11 | 1.96e-10 |
| Dental Implants:0 | 2/138,393 | 6,678/26,262,527 | 0.06 | 9.26e-13 | 1.04e-11 |
| valsartan:0 | 2/138,393 | 5,218/26,262,527 | 0.07 | 1.10e-09 | 9.72e-09 |
| Stratum germinativum:0 | 62/138,393 | 4,136/26,262,527 | 2.85 | 1.92e-12 | 2.11e-11 |
| exenatide:0 | 2/138,393 | 5,140/26,262,527 | 0.07 | 1.55e-09 | 1.35e-08 |
| T-Lymphocyte:0 | 290/138,393 | 147,455/26,262,527 | 0.37 | 3.09e-89 | 2.38e-87 |
| Glutaral:0 | 3/138,393 | 5,519/26,262,527 | 0.10 | 2.07e-09 | 1.78e-08 |
| Spondylarthropathies:0 | 1/138,393 | 3,827/26,262,527 | 0.05 | 6.98e-08 | 5.13e-07 |
| NF-kappa B:0 | 445/138,393 | 61,562/26,262,527 | 1.37 | 2.42e-10 | 2.26e-09 |
| CD34 gene|CD34:0 | 31/138,393 | 13,264/26,262,527 | 0.44 | 2.84e-07 | 1.96e-06 |
| Ulcerative Colitis:0 | 29/138,393 | 49,700/26,262,527 | 0.11 | 9.29e-75 | 6.06e-73 |
| Cephalosporins:0 | 3/138,393 | 8,335/26,262,527 | 0.07 | 2.35e-15 | 3.16e-14 |
| Primates:0 | 40/138,393 | 33,961/26,262,527 | 0.22 | 8.25e-36 | 2.52e-34 |
| ELAC2 gene|ELAC2:0 | 8/138,393 | 11/26,262,527 | 138.02 | 4.09e-14 | 5.11e-13 |
| Prostatic fluid sample:0 | 5/138,393 | 14/26,262,527 | 67.78 | 4.33e-08 | 3.25e-07 |
| Stress Disorders, Post-Traumatic:0 | 5/138,393 | 38,052/26,262,527 | 0.02 | 7.58e-78 | 5.19e-76 |
| APEX1 protein, human|APEX1:0 | 213/138,393 | 15,580/26,262,527 | 2.60 | 3.38e-33 | 9.43e-32 |
| Anatomic structures:0 | 227/138,393 | 28,966/26,262,527 | 1.49 | 1.98e-08 | 1.54e-07 |
| Cadherins:0 | 137/138,393 | 8,715/26,262,527 | 2.99 | 2.66e-27 | 6.10e-26 |
| Cobalt:0 | 5/138,393 | 5,425/26,262,527 | 0.17 | 1.50e-07 | 1.06e-06 |
| Local:0 | 46/138,393 | 511/26,262,527 | 17.09 | 4.92e-39 | 1.65e-37 |
| Structure of cortex of kidney:0 | 3/138,393 | 5,735/26,262,527 | 0.10 | 7.30e-10 | 6.56e-09 |
| Buccal mucosa:0 | 1/138,393 | 3,694/26,262,527 | 0.05 | 1.45e-07 | 1.03e-06 |
| Relationships:0 | 255/138,393 | 23,029/26,262,527 | 2.10 | 5.13e-26 | 1.11e-24 |
| AKR1C3:0 | 43/138,393 | 389/26,262,527 | 20.98 | 4.72e-40 | 1.64e-38 |
| inpatient:0 | 51/138,393 | 26,102/26,262,527 | 0.37 | 5.37e-17 | 7.95e-16 |
| Dutasteride 0.5 MG:0 | 5/138,393 | 10/26,262,527 | 94.89 | 1.14e-08 | 9.13e-08 |
| plant growth/development:0 | 1/138,393 | 5,024/26,262,527 | 0.04 | 2.30e-10 | 2.16e-09 |
| Ataxia:0 | 3/138,393 | 6,704/26,262,527 | 0.08 | 7.99e-12 | 8.41e-11 |
| cyclin B1|CCNB1:0 | 40/138,393 | 1,487/26,262,527 | 5.11 | 4.94e-16 | 6.88e-15 |
| Lymph node of mesentery:0 | 5/138,393 | 6,066/26,262,527 | 0.16 | 1.15e-08 | 9.23e-08 |
| Monocyte Chemoattractant Protein-1:0 | 19/138,393 | 11,657/26,262,527 | 0.31 | 5.12e-10 | 4.65e-09 |
| Fatty degeneration:0 | 4/138,393 | 8,633/26,262,527 | 0.09 | 7.36e-15 | 9.61e-14 |
| Antigens, Nuclear:0 | 26/138,393 | 1,592/26,262,527 | 3.10 | 9.36e-07 | 6.09e-06 |
| Ventricular Septal Defects:0 | 1/138,393 | 7,930/26,262,527 | 0.02 | 7.09e-17 | 1.04e-15 |
| Prostate cancer recurrent:0 | 713/138,393 | 1,240/26,262,527 | 109.68 | 0.00e+00 | 0.00e+00 |
| Mitral Valve Stenosis:0 | 1/138,393 | 7,687/26,262,527 | 0.02 | 2.04e-16 | 2.92e-15 |
| Cell membrane:0 | 335/138,393 | 112,376/26,262,527 | 0.56 | 1.53e-30 | 3.92e-29 |
| CANCER OCCULT:0 | 12/138,393 | 348/26,262,527 | 6.54 | 6.60e-07 | 4.36e-06 |
| LARP6:0 | 14/138,393 | 225/26,262,527 | 11.81 | 6.07e-11 | 5.97e-10 |
| Ventricular Dysfunction, Left:0 | 2/138,393 | 12,554/26,262,527 | 0.03 | 8.11e-26 | 1.75e-24 |
| Prostate cancer stage III:0 | 10/138,393 | 14/26,262,527 | 135.56 | 2.87e-17 | 4.29e-16 |
| Hyperthyroidism:0 | 6/138,393 | 17,484/26,262,527 | 0.07 | 1.99e-31 | 5.24e-30 |
| Mean blood pressure:0 | 1/138,393 | 12,748/26,262,527 | 0.01 | 1.04e-27 | 2.41e-26 |
| Trimethoprim-Sulfamethoxazole Combination:0 | 7/138,393 | 11,794/26,262,527 | 0.11 | 1.59e-18 | 2.54e-17 |
| Bypass surgery:0 | 1/138,393 | 4,710/26,262,527 | 0.04 | 9.27e-10 | 8.24e-09 |
| ascorbate:0 | 13/138,393 | 9,826/26,262,527 | 0.25 | 3.08e-10 | 2.86e-09 |
| Adenylate Cyclase:0 | 26/138,393 | 31,469/26,262,527 | 0.16 | 3.80e-41 | 1.36e-39 |
| Cardiac Catheterization Procedures:0 | 3/138,393 | 4,578/26,262,527 | 0.12 | 1.83e-07 | 1.28e-06 |
| Pituitary Gland, Posterior:0 | 2/138,393 | 5,124/26,262,527 | 0.07 | 1.52e-09 | 1.33e-08 |
| Anticonvulsants:0 | 8/138,393 | 15,380/26,262,527 | 0.10 | 8.53e-25 | 1.77e-23 |
| Hepatoblastoma:0 | 2/138,393 | 4,024/26,262,527 | 0.09 | 2.96e-07 | 2.04e-06 |
| Cardiolipins:0 | 3/138,393 | 5,064/26,262,527 | 0.11 | 1.63e-08 | 1.29e-07 |
| Atopy:0 | 4/138,393 | 8,581/26,262,527 | 0.09 | 1.08e-14 | 1.39e-13 |
| Amylin:0 | 1/138,393 | 6,743/26,262,527 | 0.03 | 3.74e-14 | 4.68e-13 |
| conserved helix-loop-helix ubiquitous kinase:0 | 16/138,393 | 580/26,262,527 | 5.24 | 1.85e-07 | 1.30e-06 |
| Systolic blood pressure:0 | 7/138,393 | 19,939/26,262,527 | 0.07 | 1.74e-35 | 5.26e-34 |
| negative regulation of cyclin dependent protein kinase activity:0 | 35/138,393 | 1,221/26,262,527 | 5.44 | 5.27e-15 | 6.96e-14 |
| Albumins|ALB:0 | 11/138,393 | 17,266/26,262,527 | 0.12 | 6.04e-26 | 1.31e-24 |
| Common carotid artery:0 | 1/138,393 | 4,519/26,262,527 | 0.04 | 2.89e-09 | 2.46e-08 |
| Methimazole:0 | 1/138,393 | 4,833/26,262,527 | 0.04 | 4.38e-10 | 4.01e-09 |
| Myocardial Infarction:0 | 74/138,393 | 101,061/26,262,527 | 0.14 | 3.10e-137 | 3.87e-135 |
| Brown Fat:0 | 1/138,393 | 9,266/26,262,527 | 0.02 | 6.62e-20 | 1.12e-18 |
| Phacoemulsification:0 | 1/138,393 | 6,231/26,262,527 | 0.03 | 4.64e-13 | 5.35e-12 |
| Muscle - Striated (Skeletal) (MMHCC):0 | 22/138,393 | 30,400/26,262,527 | 0.14 | 2.14e-42 | 7.88e-41 |
| SRD5A2 gene|SRD5A2:0 | 42/138,393 | 176/26,262,527 | 45.30 | 1.14e-51 | 5.13e-50 |
| Cholecystokinin|CCK:0 | 3/138,393 | 9,616/26,262,527 | 0.06 | 5.98e-18 | 9.26e-17 |
| N-Cadherins:0 | 66/138,393 | 3,639/26,262,527 | 3.44 | 7.48e-17 | 1.10e-15 |
| Neuronal Plasticity:0 | 1/138,393 | 4,861/26,262,527 | 0.04 | 4.54e-10 | 4.15e-09 |
| Interleukin-3:0 | 6/138,393 | 8,012/26,262,527 | 0.14 | 7.70e-12 | 8.13e-11 |
| 1,4,7-triazacyclononane-N,N',N''-triacetic acid:0 | 12/138,393 | 148/26,262,527 | 15.39 | 8.09e-11 | 7.87e-10 |
| human leukocyte interferon|DNAJC5:0 | 7/138,393 | 31/26,262,527 | 42.85 | 1.19e-09 | 1.05e-08 |
| Homelessness:0 | 1/138,393 | 7,632/26,262,527 | 0.02 | 2.99e-16 | 4.23e-15 |
| Bladder cancer recurrent:0 | 20/138,393 | 354/26,262,527 | 10.72 | 2.94e-14 | 3.71e-13 |
| Dynorphins:0 | 1/138,393 | 3,537/26,262,527 | 0.05 | 2.95e-07 | 2.04e-06 |
| Biopsy finding:0 | 12/138,393 | 377/26,262,527 | 6.04 | 1.48e-06 | 9.34e-06 |
| Allergens:0 | 3/138,393 | 16,957/26,262,527 | 0.03 | 4.49e-34 | 1.29e-32 |
| Physical and emotional exhaustion state:0 | 1/138,393 | 4,552/26,262,527 | 0.04 | 1.88e-09 | 1.63e-08 |
| granulosa cell:0 | 8/138,393 | 18,285/26,262,527 | 0.08 | 7.89e-31 | 2.04e-29 |
| Coronary Stenosis:0 | 2/138,393 | 7,107/26,262,527 | 0.05 | 1.07e-13 | 1.30e-12 |
| diagnostic use:0 | 15/138,393 | 439/26,262,527 | 6.48 | 3.13e-08 | 2.39e-07 |
| Spleen:0 | 180/138,393 | 137,561/26,262,527 | 0.25 | 1.57e-129 | 1.79e-127 |
| Entire brachial plexus:0 | 3/138,393 | 5,446/26,262,527 | 0.10 | 2.92e-09 | 2.49e-08 |
| Acoustics:0 | 9/138,393 | 6,408/26,262,527 | 0.27 | 9.64e-07 | 6.26e-06 |
| Cancer Diagnosis:0 | 1,083/138,393 | 3,927/26,262,527 | 52.74 | 0.00e+00 | 0.00e+00 |
| Injury to kidney NOS:0 | 2/138,393 | 5,761/26,262,527 | 0.07 | 6.16e-11 | 6.05e-10 |
| Recombinant human granulocyte colony stimulating factor:0 | 1/138,393 | 3,274/26,262,527 | 0.06 | 1.28e-06 | 8.20e-06 |
| radiation toxicity:0 | 36/138,393 | 721/26,262,527 | 9.48 | 1.03e-22 | 1.96e-21 |
| Toes:0 | 1/138,393 | 6,088/26,262,527 | 0.03 | 9.61e-13 | 1.08e-11 |
| Amygdaloid structure:0 | 2/138,393 | 24,001/26,262,527 | 0.02 | 2.28e-51 | 1.02e-49 |
| Host-Tumor Interaction:0 | 7/138,393 | 93/26,262,527 | 14.28 | 1.14e-06 | 7.32e-06 |
| Nematoda:0 | 1/138,393 | 15,896/26,262,527 | 0.01 | 1.06e-34 | 3.11e-33 |
| Tension:0 | 13/138,393 | 26,487/26,262,527 | 0.09 | 7.98e-43 | 2.99e-41 |
| Essential Hypertension:0 | 3/138,393 | 32,632/26,262,527 | 0.02 | 4.22e-69 | 2.57e-67 |
| Androgens measurement:0 | 53/138,393 | 357/26,262,527 | 28.18 | 4.47e-55 | 2.13e-53 |
| Depressed mood:0 | 97/138,393 | 38,138/26,262,527 | 0.48 | 6.22e-16 | 8.63e-15 |
| Macule:0 | 1/138,393 | 3,719/26,262,527 | 0.05 | 1.51e-07 | 1.07e-06 |
| 2-methoxyestradiol:0 | 35/138,393 | 1,557/26,262,527 | 4.27 | 4.26e-12 | 4.58e-11 |
| Neuroglia:0 | 10/138,393 | 21,448/26,262,527 | 0.09 | 2.66e-35 | 7.98e-34 |
| Sexual Dysfunction:0 | 113/138,393 | 4,011/26,262,527 | 5.35 | 5.41e-44 | 2.07e-42 |
| Signet ring cell:0 | 27/138,393 | 893/26,262,527 | 5.74 | 1.93e-12 | 2.12e-11 |
| proto-oncogene proteins pim|PIM1:0 | 11/138,393 | 166/26,262,527 | 12.58 | 3.60e-09 | 3.04e-08 |
| Supernumerary mandibular left first primary molar:0 | 15/138,393 | 333/26,262,527 | 8.55 | 9.05e-10 | 8.06e-09 |
| Metalloproteases:0 | 111/138,393 | 12,450/26,262,527 | 1.69 | 3.36e-07 | 2.29e-06 |
| interferon therapy:0 | 1/138,393 | 4,447/26,262,527 | 0.04 | 4.15e-09 | 3.48e-08 |
| Guillain-Barre Syndrome:0 | 3/138,393 | 9,932/26,262,527 | 0.06 | 9.42e-19 | 1.52e-17 |
| Disabled Homolog 2 Protein|DAB2:0 | 11/138,393 | 199/26,262,527 | 10.49 | 2.12e-08 | 1.65e-07 |
| Xylocaine gel:0 | 14/138,393 | 207/26,262,527 | 12.84 | 2.14e-11 | 2.18e-10 |
| Magnetic resonance imaging guidance:0 | 5/138,393 | 29/26,262,527 | 32.72 | 9.70e-07 | 6.30e-06 |
| Ito cell:0 | 2/138,393 | 8,238/26,262,527 | 0.05 | 3.30e-16 | 4.65e-15 |
| beta-Galactosidase|GLA:0 | 4/138,393 | 4/26,262,527 | 189.77 | 5.20e-08 | 3.86e-07 |
| Carotid Stenosis:0 | 1/138,393 | 8,274/26,262,527 | 0.02 | 1.12e-17 | 1.71e-16 |
| Diabetic Nephropathy:0 | 2/138,393 | 18,684/26,262,527 | 0.02 | 1.95e-39 | 6.65e-38 |
| nervous system disorder:0 | 28/138,393 | 28,697/26,262,527 | 0.18 | 2.60e-34 | 7.49e-33 |
| Mastication:0 | 4/138,393 | 7,781/26,262,527 | 0.10 | 4.93e-13 | 5.68e-12 |
| Fusion Gene:0 | 77/138,393 | 3,748/26,262,527 | 3.90 | 2.16e-22 | 4.06e-21 |
| dihydropyridine:0 | 2/138,393 | 4,969/26,262,527 | 0.08 | 3.06e-09 | 2.59e-08 |
| Melatonin:0 | 84/138,393 | 49,828/26,262,527 | 0.32 | 1.48e-37 | 4.77e-36 |
| CDK5RAP1:0 | 72/138,393 | 165/26,262,527 | 82.85 | 2.38e-103 | 2.16e-101 |
| Severe pre-eclampsia unspecified:0 | 3/138,393 | 5,231/26,262,527 | 0.11 | 8.27e-09 | 6.72e-08 |
| Protein Expression:0 | 122/138,393 | 8,415/26,262,527 | 2.75 | 1.00e-21 | 1.85e-20 |
| Ion Transport:0 | 6/138,393 | 7,154/26,262,527 | 0.16 | 4.22e-10 | 3.87e-09 |
| Focal Adhesion Kinase 1|PTK2:0 | 43/138,393 | 2,331/26,262,527 | 3.50 | 9.02e-12 | 9.46e-11 |
| atrial natriuretic factor prohormone (1-30), human:0 | 9/138,393 | 124/26,262,527 | 13.77 | 4.53e-08 | 3.40e-07 |
| Gonadorelin|TRH:0 | 5/138,393 | 6/26,262,527 | 158.15 | 1.78e-09 | 1.55e-08 |
| Coronary Occlusion:0 | 3/138,393 | 5,881/26,262,527 | 0.10 | 3.64e-10 | 3.35e-09 |
| OR51E2:0 | 13/138,393 | 65/26,262,527 | 37.96 | 3.62e-16 | 5.10e-15 |
| Hypercholesterolemia, Familial:0 | 2/138,393 | 8,544/26,262,527 | 0.04 | 8.17e-17 | 1.19e-15 |
| Cataract Extraction:0 | 1/138,393 | 9,076/26,262,527 | 0.02 | 2.07e-19 | 3.43e-18 |
| Entire nerve:0 | 141/138,393 | 45,393/26,262,527 | 0.59 | 9.84e-12 | 1.03e-10 |
| Memory impairment:0 | 2/138,393 | 13,896/26,262,527 | 0.03 | 1.28e-28 | 3.06e-27 |
| Physical shape:0 | 7/138,393 | 7,852/26,262,527 | 0.17 | 1.21e-10 | 1.17e-09 |
| prostatein:0 | 7/138,393 | 76/26,262,527 | 17.48 | 3.19e-07 | 2.18e-06 |
| Toxin:0 | 48/138,393 | 40,594/26,262,527 | 0.22 | 2.69e-42 | 9.87e-41 |
| Photosensitizing Agents:0 | 59/138,393 | 4,931/26,262,527 | 2.27 | 2.30e-08 | 1.79e-07 |
| network:0 | 281/138,393 | 76,430/26,262,527 | 0.70 | 1.90e-10 | 1.80e-09 |
| Xenopus laevis:0 | 11/138,393 | 11,627/26,262,527 | 0.18 | 8.03e-15 | 1.05e-13 |
| Pelvic lymph node group:0 | 135/138,393 | 621/26,262,527 | 41.29 | 2.16e-157 | 3.08e-155 |
| Medicare:0 | 69/138,393 | 3,813/26,262,527 | 3.44 | 1.70e-17 | 2.57e-16 |
| 3 (or 17)-beta-hydroxysteroid dehydrogenase:0 | 38/138,393 | 1,840/26,262,527 | 3.92 | 6.04e-12 | 6.42e-11 |
| Arteriovenous fistula:0 | 1/138,393 | 8,738/26,262,527 | 0.02 | 1.35e-18 | 2.16e-17 |
| Carotenoids:0 | 132/138,393 | 13,825/26,262,527 | 1.81 | 5.25e-10 | 4.77e-09 |
| Mechanics:0 | 1/138,393 | 3,249/26,262,527 | 0.06 | 1.25e-06 | 8.00e-06 |
| Urine:0 | 281/138,393 | 29,355/26,262,527 | 1.82 | 9.77e-20 | 1.64e-18 |
| univariate analysis:0 | 22/138,393 | 1,204/26,262,527 | 3.47 | 1.08e-06 | 6.94e-06 |
| Islets of Langerhans:0 | 9/138,393 | 18,654/26,262,527 | 0.09 | 1.12e-30 | 2.87e-29 |
| Turtles:0 | 1/138,393 | 6,862/26,262,527 | 0.03 | 1.70e-14 | 2.17e-13 |
| Cerebral Infarction:0 | 4/138,393 | 13,474/26,262,527 | 0.06 | 3.85e-25 | 8.08e-24 |
| ewes:0 | 1/138,393 | 11,754/26,262,527 | 0.02 | 1.78e-25 | 3.78e-24 |
| Arginine:0 | 43/138,393 | 43,072/26,262,527 | 0.19 | 2.60e-50 | 1.15e-48 |
| Alteplase:0 | 22/138,393 | 31,590/26,262,527 | 0.13 | 1.02e-44 | 3.97e-43 |
| Tacrolimus:0 | 9/138,393 | 18,513/26,262,527 | 0.09 | 2.24e-30 | 5.69e-29 |
| Bone Marrow Cells:0 | 82/138,393 | 30,792/26,262,527 | 0.51 | 5.50e-12 | 5.89e-11 |
| Malignant neoplasm of endocrine gland:0 | 23/138,393 | 485/26,262,527 | 9.00 | 1.24e-14 | 1.59e-13 |
| Spasm:0 | 8/138,393 | 7,166/26,262,527 | 0.21 | 1.06e-08 | 8.51e-08 |
| High Resolution Computed Tomography:0 | 1/138,393 | 3,569/26,262,527 | 0.05 | 3.07e-07 | 2.11e-06 |
| cancer angiogenesis:0 | 27/138,393 | 389/26,262,527 | 13.17 | 7.49e-21 | 1.33e-19 |
| hepcidin:0 | 2/138,393 | 7,146/26,262,527 | 0.05 | 7.05e-14 | 8.68e-13 |
| Lung diseases:0 | 19/138,393 | 28,836/26,262,527 | 0.12 | 6.39e-42 | 2.33e-40 |
| pT3 stage:0 | 8/138,393 | 15/26,262,527 | 101.22 | 2.61e-13 | 3.06e-12 |
| EPHA2 gene|EPHA2:0 | 32/138,393 | 1,275/26,262,527 | 4.76 | 2.21e-12 | 2.43e-11 |
| Hydrocephalus:0 | 2/138,393 | 15,505/26,262,527 | 0.02 | 2.75e-32 | 7.43e-31 |
| LDL Cholesterol Lipoproteins:0 | 17/138,393 | 12,142/26,262,527 | 0.27 | 6.72e-12 | 7.13e-11 |
| Scleroderma:0 | 6/138,393 | 8,732/26,262,527 | 0.13 | 3.94e-13 | 4.56e-12 |
| Cyclic AMP:0 | 39/138,393 | 37,786/26,262,527 | 0.20 | 3.00e-43 | 1.14e-41 |
| Cartilage:0 | 16/138,393 | 39,892/26,262,527 | 0.08 | 9.88e-68 | 5.90e-66 |
| eosinophil:0 | 8/138,393 | 20,090/26,262,527 | 0.08 | 1.23e-34 | 3.59e-33 |
| Erythromycin:0 | 3/138,393 | 13,774/26,262,527 | 0.04 | 5.52e-27 | 1.24e-25 |
| destruction; bone:0 | 57/138,393 | 2,980/26,262,527 | 3.63 | 1.01e-15 | 1.38e-14 |
| Cessation of life:0 | 1,243/138,393 | 124,741/26,262,527 | 1.90 | 9.43e-92 | 7.50e-90 |
| Prostate cancer stage II:0 | 8/138,393 | 12/26,262,527 | 126.52 | 6.79e-14 | 8.37e-13 |
| Necrotizing fasciitis:0 | 1/138,393 | 5,285/26,262,527 | 0.04 | 5.09e-11 | 5.03e-10 |
| Testosterone 5-alpha-Reductase:0 | 117/138,393 | 1,652/26,262,527 | 13.45 | 1.28e-85 | 9.56e-84 |
| HSPB1 gene|HSPB1:0 | 52/138,393 | 4,096/26,262,527 | 2.41 | 3.11e-08 | 2.37e-07 |
| Basal Cell:0 | 250/138,393 | 5,052/26,262,527 | 9.41 | 2.11e-146 | 2.78e-144 |
| Los Angeles:0 | 31/138,393 | 816/26,262,527 | 7.21 | 1.29e-16 | 1.87e-15 |
| Nephrostomy:0 | 18/138,393 | 400/26,262,527 | 8.54 | 2.00e-11 | 2.04e-10 |
| Cochlear structure:0 | 1/138,393 | 22,375/26,262,527 | 0.01 | 1.92e-49 | 8.27e-48 |
| Prostate implant brachytherapy:0 | 5/138,393 | 8/26,262,527 | 118.61 | 4.92e-09 | 4.09e-08 |
| Tumor-Associated Vasculature:0 | 82/138,393 | 778/26,262,527 | 20.01 | 2.85e-73 | 1.82e-71 |
| Atherogenesis:0 | 4/138,393 | 7,828/26,262,527 | 0.10 | 3.37e-13 | 3.92e-12 |
| Plant Roots:0 | 26/138,393 | 15,185/26,262,527 | 0.32 | 4.57e-12 | 4.92e-11 |
| Manganese:0 | 8/138,393 | 11,093/26,262,527 | 0.14 | 3.14e-16 | 4.44e-15 |
| Radiotherapy, Interstitial:0 | 19/138,393 | 196/26,262,527 | 18.40 | 1.32e-17 | 2.01e-16 |
| Muscarinic Antagonists:0 | 3/138,393 | 5,205/26,262,527 | 0.11 | 1.25e-08 | 1.00e-07 |
| Learning:0 | 9/138,393 | 14,207/26,262,527 | 0.12 | 1.43e-21 | 2.61e-20 |
| JNK Mitogen-Activated Protein Kinases|JUN:0 | 49/138,393 | 4,157/26,262,527 | 2.24 | 5.40e-07 | 3.61e-06 |
| Lipoid nephrosis:0 | 1/138,393 | 5,515/26,262,527 | 0.03 | 1.76e-11 | 1.80e-10 |
| Nucleolar Organizer Region:0 | 25/138,393 | 1,491/26,262,527 | 3.18 | 9.49e-07 | 6.17e-06 |
| Cadaver:0 | 9/138,393 | 6,974/26,262,527 | 0.24 | 1.20e-07 | 8.58e-07 |
| Multiple Organ Failure:0 | 4/138,393 | 8,746/26,262,527 | 0.09 | 3.59e-15 | 4.79e-14 |
| Prostate finding:0 | 23/138,393 | 31/26,262,527 | 140.82 | 3.28e-38 | 1.07e-36 |
| Estrogen Receptor beta:0 | 135/138,393 | 3,835/26,262,527 | 6.69 | 6.82e-63 | 3.80e-61 |
| Audiological observations:0 | 3/138,393 | 9,152/26,262,527 | 0.06 | 4.79e-17 | 7.10e-16 |
| Serotonin:0 | 55/138,393 | 85,111/26,262,527 | 0.12 | 3.19e-122 | 3.44e-120 |
| Ions:0 | 91/138,393 | 93,385/26,262,527 | 0.18 | 4.98e-109 | 4.69e-107 |
| ATP phosphohydrolase|DNAH8:0 | 11/138,393 | 11,279/26,262,527 | 0.19 | 4.18e-14 | 5.21e-13 |
| Megavoltage radiation therapy:0 | 7/138,393 | 81/26,262,527 | 16.40 | 4.76e-07 | 3.19e-06 |
| Sclerotherapy:0 | 5/138,393 | 8,655/26,262,527 | 0.11 | 5.55e-14 | 6.87e-13 |
| Radiotherapy, Conformal:0 | 610/138,393 | 3,376/26,262,527 | 34.44 | 0.00e+00 | 0.00e+00 |
| Temporal Arteritis:0 | 4/138,393 | 7,457/26,262,527 | 0.10 | 1.89e-12 | 2.09e-11 |
| RU 23908:0 | 8/138,393 | 17/26,262,527 | 89.31 | 5.69e-13 | 6.53e-12 |
| Fluorescein Angiography:0 | 4/138,393 | 4,644/26,262,527 | 0.16 | 7.53e-07 | 4.96e-06 |
| Entire humerus:0 | 10/138,393 | 7,796/26,262,527 | 0.24 | 1.69e-08 | 1.33e-07 |
| Paw:0 | 5/138,393 | 8,222/26,262,527 | 0.12 | 4.35e-13 | 5.03e-12 |
| Amino Acids, Branched-Chain:0 | 2/138,393 | 4,696/26,262,527 | 0.08 | 1.28e-08 | 1.02e-07 |
| Right eye:0 | 11/138,393 | 8,210/26,262,527 | 0.25 | 1.07e-08 | 8.64e-08 |
| MG 132:0 | 44/138,393 | 3,393/26,262,527 | 2.46 | 1.64e-07 | 1.15e-06 |
| Anaplasia:0 | 65/138,393 | 3,922/26,262,527 | 3.15 | 7.44e-15 | 9.71e-14 |
| S-allylmercaptocysteine:0 | 7/138,393 | 95/26,262,527 | 13.98 | 1.30e-06 | 8.29e-06 |
| Tumor Immunity:0 | 57/138,393 | 2,629/26,262,527 | 4.12 | 5.21e-18 | 8.10e-17 |
| RNA-Directed DNA Polymerase:0 | 16/138,393 | 10,742/26,262,527 | 0.28 | 3.58e-10 | 3.30e-09 |
| Receptors, Purinergic P1:0 | 9/138,393 | 7,894/26,262,527 | 0.22 | 2.04e-09 | 1.76e-08 |
| Plasmids:0 | 253/138,393 | 74,834/26,262,527 | 0.64 | 3.41e-14 | 4.28e-13 |
| Autologous bone marrow transplant:0 | 1/138,393 | 4,786/26,262,527 | 0.04 | 6.49e-10 | 5.85e-09 |
| Support, device:0 | 75/138,393 | 30,333/26,262,527 | 0.47 | 1.11e-13 | 1.35e-12 |
| Mesangial Cells:0 | 5/138,393 | 11,555/26,262,527 | 0.08 | 5.17e-20 | 8.78e-19 |
| Neuropathy:0 | 34/138,393 | 25,696/26,262,527 | 0.25 | 5.56e-25 | 1.16e-23 |
| A-23187:0 | 8/138,393 | 11,786/26,262,527 | 0.13 | 1.56e-17 | 2.36e-16 |
| Vocal cord structure:0 | 3/138,393 | 6,276/26,262,527 | 0.09 | 6.59e-11 | 6.45e-10 |
| Vulva:0 | 25/138,393 | 11,573/26,262,527 | 0.41 | 3.14e-07 | 2.15e-06 |
| Congenital Abnormality:0 | 52/138,393 | 94,082/26,262,527 | 0.10 | 2.23e-143 | 2.89e-141 |
| Executives:0 | 1/138,393 | 5,138/26,262,527 | 0.04 | 1.05e-10 | 1.01e-09 |
| Musculoskeletal torsion, function:0 | 1/138,393 | 6,265/26,262,527 | 0.03 | 3.04e-13 | 3.56e-12 |
| Acinar Pattern:0 | 5/138,393 | 14/26,262,527 | 67.78 | 4.33e-08 | 3.25e-07 |
| Scanning:0 | 623/138,393 | 64,067/26,262,527 | 1.85 | 1.12e-43 | 4.25e-42 |
| ETV1 gene|ETV1:0 | 37/138,393 | 379/26,262,527 | 18.53 | 6.74e-33 | 1.86e-31 |
| Synoviocytes:0 | 3/138,393 | 7,324/26,262,527 | 0.08 | 3.30e-13 | 3.85e-12 |
| Total excision of stomach NOS:0 | 3/138,393 | 4,188/26,262,527 | 0.14 | 9.87e-07 | 6.40e-06 |
| Pedicles:0 | 40/138,393 | 17,144/26,262,527 | 0.44 | 4.96e-09 | 4.13e-08 |
| Entire tibialis anterior:0 | 1/138,393 | 6,105/26,262,527 | 0.03 | 6.25e-13 | 7.15e-12 |
| Oligonucleotides, Antisense:0 | 158/138,393 | 8,265/26,262,527 | 3.63 | 1.76e-40 | 6.20e-39 |
| Sedatives:0 | 7/138,393 | 7,924/26,262,527 | 0.17 | 8.71e-11 | 8.45e-10 |
| Photoreceptors:0 | 1/138,393 | 11,423/26,262,527 | 0.02 | 1.17e-24 | 2.41e-23 |
| Lymphatic Metastasis:0 | 37/138,393 | 1,534/26,262,527 | 4.58 | 1.43e-13 | 1.72e-12 |
| Hepatic Encephalopathy:0 | 2/138,393 | 8,909/26,262,527 | 0.04 | 8.58e-18 | 1.32e-16 |
| Nitric Oxide Synthase:0 | 27/138,393 | 27,141/26,262,527 | 0.19 | 2.95e-32 | 7.96e-31 |
| Chlormadinone Acetate:0 | 55/138,393 | 842/26,262,527 | 12.40 | 1.77e-39 | 6.06e-38 |
| Urinary symptoms:0 | 145/138,393 | 1,682/26,262,527 | 16.38 | 9.61e-117 | 9.80e-115 |
| Entire eyelid:0 | 3/138,393 | 6,785/26,262,527 | 0.08 | 5.70e-12 | 6.08e-11 |
| Entire face:0 | 3/138,393 | 7,429/26,262,527 | 0.08 | 2.38e-13 | 2.81e-12 |
| Structure of blastomere:0 | 1/138,393 | 4,465/26,262,527 | 0.04 | 2.67e-09 | 2.29e-08 |
| Psychotropic Drugs:0 | 2/138,393 | 5,007/26,262,527 | 0.08 | 3.23e-09 | 2.73e-08 |
| Somatostatin analog:0 | 62/138,393 | 2,244/26,262,527 | 5.25 | 1.63e-24 | 3.35e-23 |
| C11 Chalcone:0 | 7/138,393 | 94/26,262,527 | 14.13 | 1.22e-06 | 7.81e-06 |
| Eclampsia:0 | 1/138,393 | 3,518/26,262,527 | 0.05 | 4.62e-07 | 3.10e-06 |
| LOX gene|LOX:0 | 18/138,393 | 422/26,262,527 | 8.10 | 4.61e-11 | 4.58e-10 |
| Taurine:0 | 7/138,393 | 17,855/26,262,527 | 0.07 | 4.89e-31 | 1.28e-29 |
| Interleukin-5:0 | 6/138,393 | 12,834/26,262,527 | 0.09 | 1.81e-21 | 3.29e-20 |
| Hip Prosthesis:0 | 30/138,393 | 1,408/26,262,527 | 4.04 | 4.62e-10 | 4.22e-09 |
| Metastasis Suppressor Proteins:0 | 6/138,393 | 31/26,262,527 | 36.73 | 4.20e-08 | 3.16e-07 |
| Free Radicals:0 | 50/138,393 | 20,506/26,262,527 | 0.46 | 6.95e-10 | 6.25e-09 |
| Fever:0 | 167/138,393 | 49,128/26,262,527 | 0.64 | 1.55e-09 | 1.35e-08 |
| Oxides:0 | 11/138,393 | 9,016/26,262,527 | 0.23 | 5.28e-10 | 4.80e-09 |
| Physical object:0 | 1/138,393 | 4,616/26,262,527 | 0.04 | 1.30e-09 | 1.14e-08 |
| Hemolysin:0 | 2/138,393 | 4,314/26,262,527 | 0.09 | 7.28e-08 | 5.34e-07 |
| Mandible:0 | 41/138,393 | 39,102/26,262,527 | 0.20 | 2.23e-44 | 8.60e-43 |
| TAP-144:0 | 5/138,393 | 14/26,262,527 | 67.78 | 4.33e-08 | 3.25e-07 |
| Histamine H2 Receptors:0 | 2/138,393 | 4,154/26,262,527 | 0.09 | 1.46e-07 | 1.04e-06 |
| Bronchoalveolar Lavage Fluid:0 | 1/138,393 | 11,220/26,262,527 | 0.02 | 3.60e-24 | 7.29e-23 |
| Mesenchyma:0 | 64/138,393 | 5,515/26,262,527 | 2.20 | 2.35e-08 | 1.82e-07 |
| Hamsters, Chinese:0 | 8/138,393 | 6,961/26,262,527 | 0.22 | 2.76e-08 | 2.12e-07 |
| Fetus:0 | 5/138,393 | 22,753/26,262,527 | 0.04 | 5.85e-44 | 2.24e-42 |
| TRYPSIN:0 | 54/138,393 | 34,580/26,262,527 | 0.30 | 1.26e-28 | 3.03e-27 |
| mycophenolate mofetil:0 | 4/138,393 | 13,174/26,262,527 | 0.06 | 1.58e-24 | 3.24e-23 |
| Silicon:0 | 3/138,393 | 5,133/26,262,527 | 0.11 | 1.77e-08 | 1.39e-07 |
| Disseminated Malignant Neoplasm:0 | 45/138,393 | 1,421/26,262,527 | 6.01 | 2.04e-20 | 3.56e-19 |
| Liver Failure, Acute:0 | 12/138,393 | 13,490/26,262,527 | 0.17 | 1.25e-17 | 1.91e-16 |
| Pathogenesis:0 | 554/138,393 | 139,660/26,262,527 | 0.75 | 2.63e-12 | 2.86e-11 |
| Antiplatelet Agents:0 | 3/138,393 | 5,144/26,262,527 | 0.11 | 1.16e-08 | 9.28e-08 |
| Plasma Cells:0 | 7/138,393 | 7,894/26,262,527 | 0.17 | 8.51e-11 | 8.26e-10 |
| Myoclonus:0 | 1/138,393 | 4,080/26,262,527 | 0.05 | 2.49e-08 | 1.92e-07 |
| sulforafan:0 | 78/138,393 | 3,867/26,262,527 | 3.83 | 3.33e-22 | 6.23e-21 |
| Transaminases:0 | 12/138,393 | 9,219/26,262,527 | 0.25 | 8.57e-10 | 7.65e-09 |
| Tremor:0 | 2/138,393 | 10,634/26,262,527 | 0.04 | 1.46e-21 | 2.68e-20 |
| Fluorescence:0 | 56/138,393 | 21,002/26,262,527 | 0.51 | 1.53e-08 | 1.21e-07 |
| Hemoperfusion:0 | 1/138,393 | 3,636/26,262,527 | 0.05 | 2.12e-07 | 1.48e-06 |
| Septic Shock:0 | 7/138,393 | 18,488/26,262,527 | 0.07 | 2.01e-32 | 5.45e-31 |
| Thermogenesis:0 | 1/138,393 | 6,106/26,262,527 | 0.03 | 6.25e-13 | 7.15e-12 |
| Elevation procedure:0 | 105/138,393 | 1,993/26,262,527 | 10.00 | 4.32e-65 | 2.49e-63 |
| Acromegaly:0 | 23/138,393 | 11,240/26,262,527 | 0.39 | 1.45e-07 | 1.03e-06 |
| sarcoma:0 | 305/138,393 | 41,508/26,262,527 | 1.40 | 3.74e-08 | 2.83e-07 |
| Logistic Regression:0 | 135/138,393 | 7,898/26,262,527 | 3.25 | 3.06e-30 | 7.74e-29 |
| Hypotension:0 | 12/138,393 | 16,287/26,262,527 | 0.14 | 4.40e-23 | 8.55e-22 |
| Recombinant DNA:0 | 12/138,393 | 11,217/26,262,527 | 0.20 | 1.91e-13 | 2.26e-12 |
| Entire atrium:0 | 3/138,393 | 14,916/26,262,527 | 0.04 | 1.71e-29 | 4.21e-28 |
| Prostate Brachytherapy Needles:0 | 4/138,393 | 4/26,262,527 | 189.77 | 5.20e-08 | 3.86e-07 |
| Human herpesvirus 3:0 | 3/138,393 | 8,097/26,262,527 | 0.07 | 1.02e-14 | 1.32e-13 |
| Interleukin-8:0 | 101/138,393 | 30,800/26,262,527 | 0.62 | 3.44e-07 | 2.35e-06 |
| High Grade Intraepithelial Neoplasia:0 | 23/138,393 | 810/26,262,527 | 5.39 | 2.59e-10 | 2.41e-09 |
| Emulsions:0 | 2/138,393 | 3,913/26,262,527 | 0.10 | 6.24e-07 | 4.13e-06 |
| gamma-Tocopherol:0 | 30/138,393 | 1,526/26,262,527 | 3.73 | 2.78e-09 | 2.37e-08 |
| serotonin transporter:0 | 1/138,393 | 5,737/26,262,527 | 0.03 | 6.03e-12 | 6.41e-11 |
| Antiandrogen therapy:0 | 185/138,393 | 531/26,262,527 | 66.20 | 1.12e-247 | 2.69e-245 |
| ethinyl estradiol sulfonate:0 | 7/138,393 | 24/26,262,527 | 55.35 | 2.56e-10 | 2.39e-09 |
| Diptera:0 | 2/138,393 | 12,310/26,262,527 | 0.03 | 3.63e-25 | 7.65e-24 |
| Otitis Media:0 | 3/138,393 | 8,839/26,262,527 | 0.06 | 1.96e-16 | 2.80e-15 |
| BAD gene|BAD:0 | 53/138,393 | 2,510/26,262,527 | 4.01 | 2.09e-16 | 2.99e-15 |
| Cancer-Predisposing Gene:0 | 142/138,393 | 4,315/26,262,527 | 6.25 | 1.32e-62 | 7.31e-61 |
| Hematological Disease:0 | 10/138,393 | 11,355/26,262,527 | 0.17 | 3.92e-15 | 5.21e-14 |
| bevacizumab:0 | 74/138,393 | 28,455/26,262,527 | 0.49 | 1.04e-11 | 1.09e-10 |
| Coffee intake:0 | 10/138,393 | 193/26,262,527 | 9.83 | 1.63e-07 | 1.15e-06 |
| Transplanted tissue:0 | 49/138,393 | 51,196/26,262,527 | 0.18 | 4.28e-61 | 2.32e-59 |
| Gigantism:0 | 2/138,393 | 4,055/26,262,527 | 0.09 | 3.08e-07 | 2.11e-06 |
| Inflammatory Bowel Diseases:0 | 36/138,393 | 53,108/26,262,527 | 0.13 | 3.53e-75 | 2.33e-73 |
| Lipid Peroxidation:0 | 9/138,393 | 11,517/26,262,527 | 0.15 | 3.68e-16 | 5.18e-15 |
| TERT gene|TERT:0 | 71/138,393 | 5,086/26,262,527 | 2.65 | 1.30e-12 | 1.45e-11 |
| Muromonab-CD3:0 | 5/138,393 | 11,575/26,262,527 | 0.08 | 5.22e-20 | 8.86e-19 |
| Factor VIII:0 | 8/138,393 | 9,823/26,262,527 | 0.15 | 1.35e-13 | 1.63e-12 |
| Hypnotics:0 | 2/138,393 | 5,611/26,262,527 | 0.07 | 1.25e-10 | 1.20e-09 |
| Angioplasty:0 | 1/138,393 | 15,057/26,262,527 | 0.01 | 5.49e-33 | 1.52e-31 |
| Pylorus:0 | 1/138,393 | 5,281/26,262,527 | 0.04 | 5.06e-11 | 5.00e-10 |
| Hypermethylation:0 | 89/138,393 | 2,597/26,262,527 | 6.51 | 3.18e-41 | 1.14e-39 |
| Supernumerary mandibular left second molar:0 | 4/138,393 | 6,356/26,262,527 | 0.12 | 3.27e-10 | 3.03e-09 |
| Central venous catheter:0 | 3/138,393 | 4,691/26,262,527 | 0.12 | 1.38e-07 | 9.85e-07 |
| coenzyme Q10:0 | 2/138,393 | 6,217/26,262,527 | 0.06 | 7.44e-12 | 7.87e-11 |
| Acute radiation proctitis:0 | 11/138,393 | 33/26,262,527 | 63.26 | 5.37e-16 | 7.47e-15 |
| Interleukin-4|IL4:0 | 3/138,393 | 4,536/26,262,527 | 0.13 | 2.69e-07 | 1.86e-06 |
| Minerals:0 | 5/138,393 | 11,725/26,262,527 | 0.08 | 2.60e-20 | 4.50e-19 |
| Ancestors:0 | 4/138,393 | 4,836/26,262,527 | 0.16 | 4.01e-07 | 2.72e-06 |
| Concanavalin A:0 | 16/138,393 | 15,325/26,262,527 | 0.20 | 3.72e-18 | 5.83e-17 |
| ERBB2|NEU1|NEURL1:0 | 104/138,393 | 4,784/26,262,527 | 4.13 | 1.57e-31 | 4.14e-30 |
| Acute infectious disease:0 | 4/138,393 | 9,556/26,262,527 | 0.08 | 7.64e-17 | 1.12e-15 |
| Skin lesion:0 | 11/138,393 | 10,334/26,262,527 | 0.20 | 1.82e-12 | 2.01e-11 |
| Poisoning:0 | 3/138,393 | 11,433/26,262,527 | 0.05 | 5.12e-22 | 9.52e-21 |
| Caco-2 Cells:0 | 8/138,393 | 7,001/26,262,527 | 0.22 | 1.97e-08 | 1.54e-07 |
| neoplasm/cancer invasiveness:0 | 24/138,393 | 181/26,262,527 | 25.17 | 8.95e-25 | 1.86e-23 |
| KLK14:0 | 8/138,393 | 70/26,262,527 | 21.69 | 9.64e-09 | 7.79e-08 |
| Na(+)-K(+)-Exchanging ATPase:0 | 9/138,393 | 9,668/26,262,527 | 0.18 | 1.36e-12 | 1.52e-11 |
| Liver Cirrhosis:0 | 22/138,393 | 26,587/26,262,527 | 0.16 | 6.76e-35 | 2.00e-33 |
| nilutamide:0 | 79/138,393 | 289/26,262,527 | 51.90 | 1.01e-99 | 8.77e-98 |
| Duodenum:0 | 28/138,393 | 33,644/26,262,527 | 0.16 | 8.98e-44 | 3.42e-42 |
| Iodine:0 | 38/138,393 | 15,074/26,262,527 | 0.48 | 3.52e-07 | 2.40e-06 |
| cetuximab|EGFR:0 | 15/138,393 | 381/26,262,527 | 7.47 | 5.16e-09 | 4.29e-08 |
| Shell:0 | 9/138,393 | 15,293/26,262,527 | 0.11 | 8.58e-24 | 1.72e-22 |
| Chronic prostatitis:0 | 93/138,393 | 2,750/26,262,527 | 6.42 | 1.50e-42 | 5.55e-41 |
| Ara-C:0 | 5/138,393 | 5,910/26,262,527 | 0.16 | 2.20e-08 | 1.71e-07 |
| Viremia:0 | 5/138,393 | 12,925/26,262,527 | 0.07 | 1.02e-22 | 1.95e-21 |
| Locomotion:0 | 9/138,393 | 9,664/26,262,527 | 0.18 | 1.35e-12 | 1.51e-11 |
| Verbal:0 | 10/138,393 | 8,522/26,262,527 | 0.22 | 7.51e-10 | 6.73e-09 |
| Guanylate Cyclase:0 | 2/138,393 | 6,970/26,262,527 | 0.05 | 1.41e-13 | 1.70e-12 |
| Youth:0 | 7/138,393 | 39,079/26,262,527 | 0.03 | 2.78e-77 | 1.90e-75 |
| Naltrexone:0 | 1/138,393 | 11,123/26,262,527 | 0.02 | 4.88e-24 | 9.86e-23 |
| Sperm Motility:0 | 3/138,393 | 4,779/26,262,527 | 0.12 | 6.46e-08 | 4.76e-07 |
| Fluorides:0 | 18/138,393 | 19,834/26,262,527 | 0.17 | 4.17e-25 | 8.75e-24 |
| Basal cell hyperplasia:0 | 26/138,393 | 180/26,262,527 | 27.42 | 1.41e-27 | 3.26e-26 |
| AR protein, human|AR:0 | 113/138,393 | 652/26,262,527 | 32.92 | 3.40e-122 | 3.65e-120 |
| Cryopreservation:0 | 4/138,393 | 6,118/26,262,527 | 0.12 | 9.06e-10 | 8.07e-09 |
| Superficial Bladder Cancer:0 | 90/138,393 | 2,708/26,262,527 | 6.31 | 1.13e-40 | 4.00e-39 |
| Blood capillaries:0 | 50/138,393 | 35,266/26,262,527 | 0.27 | 6.86e-32 | 1.83e-30 |
| Sodium Dodecyl Sulfate:0 | 7/138,393 | 10,706/26,262,527 | 0.12 | 2.65e-16 | 3.76e-15 |
| Botulinum Toxin Type A:0 | 1/138,393 | 4,576/26,262,527 | 0.04 | 1.95e-09 | 1.68e-08 |
| Entire coronary sinus:0 | 1/138,393 | 5,283/26,262,527 | 0.04 | 5.07e-11 | 5.02e-10 |
| Epigenetic Process:0 | 63/138,393 | 3,895/26,262,527 | 3.07 | 5.37e-14 | 6.64e-13 |
| Estrogens:0 | 1,215/138,393 | 98,867/26,262,527 | 2.34 | 2.02e-147 | 2.68e-145 |
| Slide:0 | 101/138,393 | 10,864/26,262,527 | 1.76 | 1.96e-07 | 1.37e-06 |
| Adverse effects:0 | 970/138,393 | 80,172/26,262,527 | 2.31 | 2.40e-114 | 2.40e-112 |
| Sickle Cell Anemia:0 | 6/138,393 | 33,065/26,262,527 | 0.03 | 2.00e-65 | 1.16e-63 |
| Erectile dysfunction:0 | 549/138,393 | 22,316/26,262,527 | 4.68 | 6.57e-181 | 1.14e-178 |
| Perineal prostatectomy:0 | 23/138,393 | 48/26,262,527 | 90.95 | 7.34e-35 | 2.16e-33 |
| Fungi, Filamentous:0 | 6/138,393 | 5,897/26,262,527 | 0.19 | 1.09e-07 | 7.82e-07 |
| Students, Medical:0 | 3/138,393 | 7,181/26,262,527 | 0.08 | 6.68e-13 | 7.60e-12 |
| Entire prostatic fascia:0 | 11/138,393 | 32/26,262,527 | 65.24 | 4.05e-16 | 5.68e-15 |
| HIGH SENSITIVITY:0 | 76/138,393 | 6,654/26,262,527 | 2.17 | 1.89e-09 | 1.64e-08 |
| Prostate Lymphoma:0 | 10/138,393 | 13/26,262,527 | 145.99 | 1.68e-17 | 2.54e-16 |
| cell stroma:0 | 11/138,393 | 199/26,262,527 | 10.49 | 2.12e-08 | 1.65e-07 |
| Bradykinin:0 | 20/138,393 | 20,704/26,262,527 | 0.18 | 3.38e-25 | 7.13e-24 |
| BCL-2 Protein:0 | 139/138,393 | 7,357/26,262,527 | 3.59 | 2.52e-35 | 7.56e-34 |
| Hepatitis B Vaccines:0 | 1/138,393 | 3,915/26,262,527 | 0.05 | 4.94e-08 | 3.69e-07 |
| AKAP12:0 | 9/138,393 | 187/26,262,527 | 9.13 | 1.21e-06 | 7.77e-06 |
| Vimentin:0 | 52/138,393 | 4,262/26,262,527 | 2.32 | 1.18e-07 | 8.46e-07 |
| Cancer Cell Growth:0 | 757/138,393 | 6,349/26,262,527 | 22.75 | 0.00e+00 | 0.00e+00 |
| Oncology Group:0 | 21/138,393 | 255/26,262,527 | 15.63 | 5.83e-18 | 9.04e-17 |
| FOS gene|FOS:0 | 31/138,393 | 15,994/26,262,527 | 0.37 | 5.24e-11 | 5.17e-10 |
| CARDIAC EVENT:0 | 8/138,393 | 8,080/26,262,527 | 0.19 | 2.34e-10 | 2.19e-09 |
| Ursodeoxycholic Acid:0 | 3/138,393 | 7,661/26,262,527 | 0.07 | 8.48e-14 | 1.04e-12 |
| Nuclear Proteins|AR:0 | 9/138,393 | 21/26,262,527 | 81.33 | 3.87e-14 | 4.85e-13 |
| Orgasm:0 | 21/138,393 | 811/26,262,527 | 4.91 | 7.15e-09 | 5.86e-08 |
| Splenocyte:0 | 17/138,393 | 12,182/26,262,527 | 0.26 | 7.00e-12 | 7.43e-11 |
| Chronic inflammation:0 | 161/138,393 | 15,739/26,262,527 | 1.94 | 4.13e-14 | 5.16e-13 |
| Retinal Diseases:0 | 8/138,393 | 17,498/26,262,527 | 0.09 | 3.74e-29 | 9.11e-28 |
| Neuroblast:0 | 1/138,393 | 3,712/26,262,527 | 0.05 | 1.49e-07 | 1.06e-06 |
| Stereotactic radiotherapy:0 | 108/138,393 | 4,918/26,262,527 | 4.17 | 4.94e-33 | 1.37e-31 |
| Adipose tissue:0 | 50/138,393 | 43,666/26,262,527 | 0.22 | 1.60e-46 | 6.47e-45 |
| Systemic infection:0 | 1/138,393 | 6,228/26,262,527 | 0.03 | 4.61e-13 | 5.32e-12 |
| penis:0 | 252/138,393 | 15,693/26,262,527 | 3.05 | 3.19e-50 | 1.41e-48 |
| Transmission Electron Microscopy:0 | 8/138,393 | 7,710/26,262,527 | 0.20 | 1.16e-09 | 1.02e-08 |
| athymia:0 | 17/138,393 | 753/26,262,527 | 4.28 | 1.15e-06 | 7.40e-06 |
| oncoprotein p21:0 | 15/138,393 | 249/26,262,527 | 11.43 | 1.96e-11 | 2.00e-10 |
| arterial stiffness:0 | 6/138,393 | 5,315/26,262,527 | 0.21 | 1.43e-06 | 9.05e-06 |
| Calcium ion:0 | 7/138,393 | 7,514/26,262,527 | 0.18 | 4.34e-10 | 3.98e-09 |
| Normal cell:0 | 444/138,393 | 15,779/26,262,527 | 5.35 | 4.30e-167 | 6.62e-165 |
| Urokinase|PLG:0 | 15/138,393 | 344/26,262,527 | 8.28 | 1.38e-09 | 1.21e-08 |
| 23s:0 | 2/138,393 | 4,369/26,262,527 | 0.09 | 5.09e-08 | 3.79e-07 |
| Acinar cell of pancreas:0 | 1/138,393 | 3,369/26,262,527 | 0.06 | 9.38e-07 | 6.10e-06 |
| Hereditary Diseases:0 | 32/138,393 | 25,666/26,262,527 | 0.24 | 3.16e-26 | 6.93e-25 |
| Rectal pain:0 | 10/138,393 | 141/26,262,527 | 13.46 | 1.00e-08 | 8.08e-08 |
| Hypoplasia:0 | 6/138,393 | 16,242/26,262,527 | 0.07 | 8.03e-29 | 1.94e-27 |
| Lymphoid Cells:0 | 7/138,393 | 8,145/26,262,527 | 0.16 | 3.25e-11 | 3.27e-10 |
| Transitional epithelium:0 | 19/138,393 | 588/26,262,527 | 6.13 | 1.18e-09 | 1.04e-08 |
| Tomography, Optical Coherence:0 | 16/138,393 | 12,770/26,262,527 | 0.24 | 1.51e-13 | 1.81e-12 |
| Steroid 17-alpha-monooxygenase|CYP17A1:0 | 123/138,393 | 1,391/26,262,527 | 16.79 | 1.54e-100 | 1.34e-98 |
| Ablation:0 | 1,158/138,393 | 35,852/26,262,527 | 6.17 | 0.00e+00 | 0.00e+00 |
| Diastasis:0 | 49/138,393 | 36,223/26,262,527 | 0.26 | 3.59e-34 | 1.03e-32 |
| Ammonium:0 | 4/138,393 | 4,607/26,262,527 | 0.16 | 1.07e-06 | 6.94e-06 |
| Avodart:0 | 7/138,393 | 32/26,262,527 | 41.51 | 1.44e-09 | 1.26e-08 |
| Androgen Suppression:0 | 376/138,393 | 1,047/26,262,527 | 68.33 | 0.00e+00 | 0.00e+00 |
| Acute myocardial infarction:0 | 25/138,393 | 70,477/26,262,527 | 0.07 | 1.80e-122 | 1.96e-120 |
| Gerbils:0 | 8/138,393 | 7,048/26,262,527 | 0.22 | 2.05e-08 | 1.60e-07 |
| Tissue factor pathway inhibitor:0 | 1/138,393 | 4,406/26,262,527 | 0.04 | 3.87e-09 | 3.26e-08 |
| Matrigel Invasion Assay:0 | 10/138,393 | 80/26,262,527 | 23.72 | 6.12e-11 | 6.01e-10 |
| Rectourinary fistula:0 | 9/138,393 | 24/26,262,527 | 71.17 | 1.03e-13 | 1.25e-12 |
| Immunoassay:0 | 96/138,393 | 10,682/26,262,527 | 1.71 | 1.35e-06 | 8.57e-06 |
| Atresia:0 | 4/138,393 | 12,187/26,262,527 | 0.06 | 2.36e-22 | 4.44e-21 |
| L12ADT:0 | 4/138,393 | 8/26,262,527 | 94.89 | 3.61e-07 | 2.46e-06 |
| GGCT:0 | 9/138,393 | 158/26,262,527 | 10.81 | 3.17e-07 | 2.17e-06 |
| Mass Fragmentography:0 | 11/138,393 | 7,186/26,262,527 | 0.29 | 7.17e-07 | 4.73e-06 |
| Age related macular degeneration:0 | 10/138,393 | 23,211/26,262,527 | 0.08 | 4.00e-39 | 1.35e-37 |
| VEGFA:0 | 176/138,393 | 18,757/26,262,527 | 1.78 | 2.60e-12 | 2.83e-11 |
| Radioimmunotherapy:0 | 41/138,393 | 2,624/26,262,527 | 2.97 | 2.98e-09 | 2.54e-08 |
| Androgen Receptor|AR:0 | 2,483/138,393 | 13,713/26,262,527 | 34.97 | 0.00e+00 | 0.00e+00 |
| androgen binding:0 | 7/138,393 | 43/26,262,527 | 30.89 | 8.92e-09 | 7.22e-08 |
| Bone Diseases:0 | 139/138,393 | 7,501/26,262,527 | 3.52 | 1.72e-34 | 4.98e-33 |
| Cerebrovascular Circulation:0 | 1/138,393 | 17,649/26,262,527 | 0.01 | 1.03e-38 | 3.40e-37 |
| Staphylococcus aureus:0 | 7/138,393 | 31,303/26,262,527 | 0.04 | 3.53e-60 | 1.88e-58 |
| high-dose chemotherapy:0 | 11/138,393 | 7,461/26,262,527 | 0.28 | 2.15e-07 | 1.50e-06 |
| Warfarin:0 | 34/138,393 | 34,912/26,262,527 | 0.18 | 1.21e-41 | 4.38e-40 |
| Selective Estrogen Receptor Modulators:0 | 62/138,393 | 4,129/26,262,527 | 2.85 | 1.79e-12 | 1.98e-11 |
| caveolin 1:0 | 106/138,393 | 7,004/26,262,527 | 2.87 | 2.25e-20 | 3.90e-19 |
| PTGS2 gene|PTGS2:0 | 43/138,393 | 2,038/26,262,527 | 4.00 | 1.32e-13 | 1.59e-12 |
| Malignant neoplasm of gastrointestinal tract:0 | 57/138,393 | 5,283/26,262,527 | 2.05 | 1.47e-06 | 9.33e-06 |
| BCL1 Oncogene:0 | 47/138,393 | 2,305/26,262,527 | 3.87 | 3.33e-14 | 4.19e-13 |
| Dyspnea:0 | 22/138,393 | 17,378/26,262,527 | 0.24 | 6.75e-18 | 1.04e-16 |
| trafficking:0 | 123/138,393 | 35,325/26,262,527 | 0.66 | 1.13e-06 | 7.27e-06 |
| Bullous pemphigoid:0 | 3/138,393 | 4,312/26,262,527 | 0.13 | 7.41e-07 | 4.88e-06 |
| zinc transporter:0 | 25/138,393 | 668/26,262,527 | 7.10 | 1.45e-13 | 1.74e-12 |
| Leukemic Cell:0 | 29/138,393 | 12,312/26,262,527 | 0.45 | 1.00e-06 | 6.48e-06 |
| CD40 Ligand|CD40LG:0 | 9/138,393 | 8,136/26,262,527 | 0.21 | 7.97e-10 | 7.13e-09 |
| Rat Cell Line:0 | 91/138,393 | 5,998/26,262,527 | 2.88 | 8.48e-18 | 1.30e-16 |
| Burn injury:0 | 5/138,393 | 22,243/26,262,527 | 0.04 | 7.09e-43 | 2.66e-41 |
| Natriuresis:0 | 1/138,393 | 4,081/26,262,527 | 0.05 | 2.49e-08 | 1.92e-07 |
| hepatic arterial infusion:0 | 2/138,393 | 4,244/26,262,527 | 0.09 | 1.04e-07 | 7.47e-07 |
| Lactoferrin:0 | 14/138,393 | 15,063/26,262,527 | 0.18 | 3.82e-19 | 6.27e-18 |
| Provenge:0 | 18/138,393 | 28/26,262,527 | 122.01 | 2.19e-29 | 5.38e-28 |
| Chondrocytes:0 | 6/138,393 | 28,053/26,262,527 | 0.04 | 3.00e-54 | 1.41e-52 |
| Total Peripheral Resistance:0 | 1/138,393 | 4,941/26,262,527 | 0.04 | 3.22e-10 | 2.97e-09 |
| AMACR gene|AMACR:0 | 24/138,393 | 66/26,262,527 | 69.02 | 5.83e-34 | 1.67e-32 |
| Dorsal grey horn:0 | 3/138,393 | 12,578/26,262,527 | 0.05 | 1.63e-24 | 3.35e-23 |
| Proteoglycan:0 | 36/138,393 | 22,352/26,262,527 | 0.31 | 2.22e-18 | 3.50e-17 |
| Pericardial effusion:0 | 5/138,393 | 5,394/26,262,527 | 0.18 | 2.21e-07 | 1.53e-06 |
| Triptorelin|TYRP1:0 | 31/138,393 | 61/26,262,527 | 96.46 | 4.39e-47 | 1.81e-45 |
| Antipsychotic Agents:0 | 8/138,393 | 43,217/26,262,527 | 0.04 | 7.15e-85 | 5.29e-83 |
| Glutamine:0 | 40/138,393 | 22,670/26,262,527 | 0.33 | 6.81e-17 | 1.00e-15 |
| Influenza virus vaccine:0 | 5/138,393 | 5,384/26,262,527 | 0.18 | 2.17e-07 | 1.51e-06 |
| Adrenergic Receptor:0 | 47/138,393 | 34,819/26,262,527 | 0.26 | 6.76e-33 | 1.87e-31 |
| Prostate infection:0 | 13/138,393 | 84/26,262,527 | 29.37 | 6.98e-15 | 9.13e-14 |
| Thymoma:0 | 7/138,393 | 6,741/26,262,527 | 0.20 | 1.57e-08 | 1.24e-07 |
| c-myc Genes|MYC:0 | 239/138,393 | 18,126/26,262,527 | 2.50 | 9.62e-35 | 2.83e-33 |
| Periodontitis:0 | 6/138,393 | 25,059/26,262,527 | 0.05 | 1.12e-47 | 4.70e-46 |
| SOD2 gene|SOD2:0 | 26/138,393 | 1,206/26,262,527 | 4.09 | 5.05e-09 | 4.20e-08 |
| Needle device:0 | 88/138,393 | 4,224/26,262,527 | 3.96 | 9.71e-26 | 2.09e-24 |
| Cancer of Rectum:0 | 205/138,393 | 23,945/26,262,527 | 1.63 | 1.47e-10 | 1.40e-09 |
| Virion:0 | 6/138,393 | 17,570/26,262,527 | 0.06 | 1.42e-31 | 3.76e-30 |
| Dihydrofolate Reductase|DHFR:0 | 5/138,393 | 6,923/26,262,527 | 0.14 | 2.00e-10 | 1.88e-09 |
| peptide hormone:0 | 62/138,393 | 4,578/26,262,527 | 2.57 | 1.29e-10 | 1.23e-09 |
| Lymphocyte antigen CD82|CD82:0 | 20/138,393 | 181/26,262,527 | 20.97 | 1.78e-19 | 2.96e-18 |
| Dendrites:0 | 5/138,393 | 19,037/26,262,527 | 0.05 | 4.83e-36 | 1.49e-34 |
| Uterine Cancer:0 | 34/138,393 | 1,725/26,262,527 | 3.74 | 2.42e-10 | 2.26e-09 |
| RASSF1:0 | 10/138,393 | 182/26,262,527 | 10.43 | 9.74e-08 | 7.06e-07 |
| 1-Phosphatidylinositol 3-Kinase:0 | 183/138,393 | 17,867/26,262,527 | 1.94 | 6.29e-16 | 8.72e-15 |
| Granulocyte Colony-Stimulating Factor:0 | 23/138,393 | 15,790/26,262,527 | 0.28 | 1.46e-14 | 1.87e-13 |
| Sodium Chloride:0 | 102/138,393 | 131,341/26,262,527 | 0.15 | 3.38e-173 | 5.45e-171 |
| SMUG1:0 | 29/138,393 | 1,835/26,262,527 | 3.00 | 4.40e-07 | 2.96e-06 |
| Hepatitis B:0 | 9/138,393 | 15,017/26,262,527 | 0.11 | 3.38e-23 | 6.58e-22 |
| PCA3 gene|PCA3:0 | 54/138,393 | 100/26,262,527 | 102.51 | 6.04e-82 | 4.32e-80 |
| Hypertensive:0 | 23/138,393 | 68,876/26,262,527 | 0.06 | 1.89e-121 | 2.01e-119 |
| Phase I/II Trial:0 | 14/138,393 | 148/26,262,527 | 17.95 | 3.16e-13 | 3.69e-12 |
| HK2 gene|HK2:0 | 47/138,393 | 411/26,262,527 | 21.71 | 3.03e-44 | 1.17e-42 |
| Rheumatic Heart Disease:0 | 2/138,393 | 4,186/26,262,527 | 0.09 | 1.49e-07 | 1.06e-06 |
| Alpha tocopheryl succinate:0 | 16/138,393 | 519/26,262,527 | 5.85 | 4.34e-08 | 3.26e-07 |
| Glass:0 | 36/138,393 | 15,578/26,262,527 | 0.44 | 1.79e-08 | 1.40e-07 |
| Multiple malignancy:0 | 191/138,393 | 3,248/26,262,527 | 11.17 | 7.25e-125 | 7.99e-123 |
| Entire ear:0 | 7/138,393 | 21,238/26,262,527 | 0.06 | 2.98e-38 | 9.75e-37 |
| Ricin:0 | 1/138,393 | 3,234/26,262,527 | 0.06 | 1.24e-06 | 7.96e-06 |
| Vesico-Ureteral Reflux:0 | 8/138,393 | 8,822/26,262,527 | 0.17 | 9.13e-12 | 9.57e-11 |
| Carcinosarcoma:0 | 52/138,393 | 4,105/26,262,527 | 2.40 | 3.24e-08 | 2.47e-07 |
| VAV3 gene|VAV3:0 | 17/138,393 | 319/26,262,527 | 10.11 | 5.80e-12 | 6.18e-11 |
| Physical therapy:0 | 16/138,393 | 11,805/26,262,527 | 0.26 | 7.95e-12 | 8.36e-11 |
| Memorial Sloan-Kettering Cancer Center:0 | 23/138,393 | 191/26,262,527 | 22.86 | 6.09e-23 | 1.18e-21 |
| Weighing patient:0 | 71/138,393 | 2,364/26,262,527 | 5.70 | 6.75e-30 | 1.69e-28 |
| Neuromyelitis Optica:0 | 2/138,393 | 4,820/26,262,527 | 0.08 | 6.18e-09 | 5.10e-08 |
| AR:0 | 77/138,393 | 315/26,262,527 | 46.41 | 5.34e-94 | 4.40e-92 |
| Dermatitis, Atopic:0 | 4/138,393 | 35,920/26,262,527 | 0.02 | 9.91e-75 | 6.45e-73 |
| Prior Hormone Therapy:0 | 18/138,393 | 39/26,262,527 | 87.60 | 2.28e-27 | 5.23e-26 |
| Households:0 | 7/138,393 | 11,485/26,262,527 | 0.12 | 9.42e-18 | 1.45e-16 |
| Triamcinolone:0 | 2/138,393 | 4,031/26,262,527 | 0.09 | 2.98e-07 | 2.05e-06 |
| Multiparity:0 | 1/138,393 | 5,025/26,262,527 | 0.04 | 2.31e-10 | 2.16e-09 |
| Gastritis:0 | 3/138,393 | 9,942/26,262,527 | 0.06 | 9.50e-19 | 1.53e-17 |
| Radiation-Induced Change:0 | 77/138,393 | 2,853/26,262,527 | 5.12 | 2.11e-29 | 5.20e-28 |
| Ceramics:0 | 2/138,393 | 9,239/26,262,527 | 0.04 | 2.11e-18 | 3.35e-17 |
| Cuff:0 | 9/138,393 | 7,070/26,262,527 | 0.24 | 6.22e-08 | 4.58e-07 |
| Incontinence:0 | 332/138,393 | 9,316/26,262,527 | 6.78 | 2.47e-153 | 3.40e-151 |
| Transcription, Genetic:0 | 864/138,393 | 90,323/26,262,527 | 1.82 | 3.75e-57 | 1.88e-55 |
| Peptidyl-Dipeptidase A:0 | 13/138,393 | 22,478/26,262,527 | 0.11 | 1.34e-34 | 3.91e-33 |
| Myosin Heavy Chains:0 | 7/138,393 | 8,891/26,262,527 | 0.15 | 1.20e-12 | 1.35e-11 |
| Surface Enhanced Laser Desorption Ionization Mass Spectrometry:0 | 14/138,393 | 309/26,262,527 | 8.60 | 3.03e-09 | 2.57e-08 |
| Calcium Channel:0 | 20/138,393 | 12,832/26,262,527 | 0.30 | 2.52e-11 | 2.55e-10 |
| Nurses:0 | 58/138,393 | 32,452/26,262,527 | 0.34 | 3.15e-23 | 6.14e-22 |
| Urologic Neoplasms:0 | 35/138,393 | 359/26,262,527 | 18.51 | 3.44e-31 | 9.04e-30 |
| Aminoglutethimide:0 | 46/138,393 | 2,301/26,262,527 | 3.79 | 1.21e-13 | 1.46e-12 |
| Tumor Markers:0 | 361/138,393 | 5,491/26,262,527 | 12.51 | 9.62e-250 | 2.34e-247 |
| Performance Status:0 | 120/138,393 | 5,009/26,262,527 | 4.55 | 5.87e-40 | 2.03e-38 |
| Agent Orange:0 | 12/138,393 | 161/26,262,527 | 14.15 | 2.01e-10 | 1.89e-09 |
| Entire portal vein:0 | 2/138,393 | 11,822/26,262,527 | 0.03 | 4.73e-24 | 9.57e-23 |
| Adenocarcinoma of the prostate metastatic:0 | 79/138,393 | 107/26,262,527 | 140.19 | 2.72e-127 | 3.04e-125 |
| Sterile coverings:0 | 3/138,393 | 7,396/26,262,527 | 0.08 | 2.32e-13 | 2.74e-12 |
| insulinoma:0 | 5/138,393 | 6,517/26,262,527 | 0.15 | 1.04e-09 | 9.20e-09 |
| Palate:0 | 3/138,393 | 14,988/26,262,527 | 0.04 | 1.19e-29 | 2.97e-28 |
| Tuberculosis:0 | 31/138,393 | 90,519/26,262,527 | 0.06 | 3.47e-158 | 5.00e-156 |
| Holmium:YAG laser device:0 | 31/138,393 | 1,019/26,262,527 | 5.77 | 4.02e-14 | 5.03e-13 |
| Screening procedure:0 | 789/138,393 | 59,844/26,262,527 | 2.51 | 2.28e-110 | 2.18e-108 |
| Gait:0 | 3/138,393 | 6,524/26,262,527 | 0.09 | 1.57e-11 | 1.62e-10 |
| SUBCUTANEOUS TUMOR:0 | 29/138,393 | 610/26,262,527 | 9.02 | 4.51e-18 | 7.03e-17 |
| Fluoxetine:0 | 2/138,393 | 17,857/26,262,527 | 0.02 | 1.63e-37 | 5.25e-36 |
| Intrauterine Devices:0 | 1/138,393 | 3,732/26,262,527 | 0.05 | 1.56e-07 | 1.10e-06 |
| AMACR protein, human|AMACR:0 | 58/138,393 | 140/26,262,527 | 78.65 | 1.62e-82 | 1.16e-80 |
| Osteomyelitis:0 | 20/138,393 | 20,402/26,262,527 | 0.19 | 1.21e-24 | 2.50e-23 |
| Ultrasonic guidance procedure:0 | 38/138,393 | 849/26,262,527 | 8.50 | 2.55e-22 | 4.80e-21 |
| Prostate Urothelial Carcinoma:0 | 19/138,393 | 45/26,262,527 | 80.14 | 3.26e-28 | 7.72e-27 |
| Estracyt:0 | 102/138,393 | 287/26,262,527 | 67.49 | 3.87e-138 | 4.84e-136 |
| Entire facial nerve:0 | 2/138,393 | 5,977/26,262,527 | 0.06 | 2.11e-11 | 2.15e-10 |
| Goserelin:0 | 129/138,393 | 1,311/26,262,527 | 18.69 | 9.72e-111 | 9.38e-109 |
| Selenium:0 | 304/138,393 | 23,060/26,262,527 | 2.51 | 1.30e-43 | 4.92e-42 |
| Sleep Apnea Syndromes:0 | 6/138,393 | 10,816/26,262,527 | 0.11 | 1.90e-17 | 2.87e-16 |
| Hypertriglyceridemia:0 | 13/138,393 | 7,770/26,262,527 | 0.32 | 8.66e-07 | 5.66e-06 |
| Dithiothreitol:0 | 9/138,393 | 6,297/26,262,527 | 0.27 | 1.28e-06 | 8.20e-06 |
| Bladder outflow obstruction:0 | 11/138,393 | 245/26,262,527 | 8.52 | 1.58e-07 | 1.11e-06 |
| pioglitazone:0 | 16/138,393 | 9,937/26,262,527 | 0.31 | 8.80e-09 | 7.14e-08 |
| epigallocatechin gallate:0 | 157/138,393 | 15,409/26,262,527 | 1.93 | 8.69e-14 | 1.06e-12 |
| Skin Transplantation:0 | 1/138,393 | 3,730/26,262,527 | 0.05 | 1.55e-07 | 1.09e-06 |
| Plasminogen Activator Inhibitor 1:0 | 27/138,393 | 15,149/26,262,527 | 0.34 | 1.47e-11 | 1.52e-10 |
| Entire prostate:0 | 61/138,393 | 109/26,262,527 | 106.25 | 4.31e-93 | 3.52e-91 |
| Acute suppurative arthritis due to bacteria:0 | 4/138,393 | 7,302/26,262,527 | 0.10 | 3.76e-12 | 4.06e-11 |
| AZGP1:0 | 8/138,393 | 105/26,262,527 | 14.46 | 1.79e-07 | 1.26e-06 |
| NCOA4 gene|NCOA4:0 | 5/138,393 | 21/26,262,527 | 45.18 | 2.37e-07 | 1.65e-06 |
| Methylation:0 | 118/138,393 | 5,655/26,262,527 | 3.96 | 5.72e-34 | 1.64e-32 |
| Thyroid dysfunction:0 | 1/138,393 | 3,326/26,262,527 | 0.06 | 8.74e-07 | 5.71e-06 |
| Epithelial Mesenchymal Transition Tumor of the Mouse Mammary Gland:0 | 22/138,393 | 378/26,262,527 | 11.05 | 8.79e-16 | 1.21e-14 |
| Skin fibroblast:0 | 35/138,393 | 15,758/26,262,527 | 0.42 | 4.19e-09 | 3.52e-08 |
| ITGB2 gene|ITGB2:0 | 2/138,393 | 5,248/26,262,527 | 0.07 | 7.37e-10 | 6.61e-09 |
| Angiotensins:0 | 12/138,393 | 9,424/26,262,527 | 0.24 | 3.38e-10 | 3.12e-09 |
| polyphenols:0 | 91/138,393 | 9,715/26,262,527 | 1.78 | 5.45e-07 | 3.63e-06 |
| Brain Diseases:0 | 2/138,393 | 4,413/26,262,527 | 0.09 | 5.28e-08 | 3.92e-07 |
| Gases:0 | 15/138,393 | 10,909/26,262,527 | 0.26 | 5.20e-11 | 5.14e-10 |
| Listeria monocytogenes:0 | 1/138,393 | 5,333/26,262,527 | 0.04 | 3.44e-11 | 3.45e-10 |
| Residual function:0 | 1/138,393 | 4,610/26,262,527 | 0.04 | 1.30e-09 | 1.14e-08 |
| Myoglobin|MB:0 | 1/138,393 | 4,328/26,262,527 | 0.04 | 5.54e-09 | 4.59e-08 |
| Channel Blockers:0 | 4/138,393 | 4,555/26,262,527 | 0.17 | 1.54e-06 | 9.75e-06 |
| kinase inhibitor:0 | 77/138,393 | 6,724/26,262,527 | 2.17 | 1.34e-09 | 1.17e-08 |
| Infestation:0 | 7/138,393 | 9,567/26,262,527 | 0.14 | 6.08e-14 | 7.50e-13 |
| Total urinary incontinence:0 | 11/138,393 | 131/26,262,527 | 15.94 | 3.49e-10 | 3.22e-09 |
| Bacterial Endocarditis:0 | 3/138,393 | 12,510/26,262,527 | 0.05 | 2.34e-24 | 4.78e-23 |
| Steroid hormone:0 | 201/138,393 | 9,653/26,262,527 | 3.96 | 1.99e-56 | 9.89e-55 |
| abarelix:0 | 28/138,393 | 102/26,262,527 | 52.10 | 1.84e-36 | 5.76e-35 |
| Chronic liver disease NOS:0 | 4/138,393 | 18,493/26,262,527 | 0.04 | 4.80e-36 | 1.48e-34 |
| Ovary:0 | 445/138,393 | 63,209/26,262,527 | 1.34 | 5.40e-09 | 4.48e-08 |
| Reverse Transcriptase Polymerase Chain Reaction:0 | 333/138,393 | 19,373/26,262,527 | 3.27 | 2.04e-72 | 1.29e-70 |
| Antitubercular Agents:0 | 4/138,393 | 6,221/26,262,527 | 0.12 | 6.53e-10 | 5.88e-09 |
| RNase L|RNASEL:0 | 25/138,393 | 850/26,262,527 | 5.58 | 2.17e-11 | 2.21e-10 |
| NKX3-1 gene|NKX3-1:0 | 100/138,393 | 278/26,262,527 | 68.31 | 6.62e-136 | 8.04e-134 |
| Arthritis, Psoriatic:0 | 1/138,393 | 11,231/26,262,527 | 0.02 | 2.27e-24 | 4.63e-23 |
| TACSTD2 protein, human|TACSTD2:0 | 54/138,393 | 1,802/26,262,527 | 5.69 | 4.17e-23 | 8.11e-22 |
| Myeloid Leukemia, Chronic:0 | 50/138,393 | 33,835/26,262,527 | 0.28 | 1.30e-29 | 3.22e-28 |
| Hormone-refractory prostate cancer:0 | 1,488/138,393 | 3,646/26,262,527 | 78.28 | 0.00e+00 | 0.00e+00 |
| General Anesthesia:0 | 37/138,393 | 17,394/26,262,527 | 0.40 | 1.63e-10 | 1.55e-09 |
| Hypoglycemic Agents:0 | 5/138,393 | 8,449/26,262,527 | 0.11 | 1.57e-13 | 1.87e-12 |
| DN-101:0 | 7/138,393 | 10/26,262,527 | 132.84 | 2.02e-12 | 2.22e-11 |
| Genitourinary symptoms NOS:0 | 8/138,393 | 138/26,262,527 | 11.00 | 1.26e-06 | 8.08e-06 |
| Anandron:0 | 35/138,393 | 134/26,262,527 | 49.58 | 1.58e-44 | 6.14e-43 |
| lissamine rhodamine B:0 | 46/138,393 | 675/26,262,527 | 12.94 | 4.73e-34 | 1.36e-32 |
| Retinal Degeneration:0 | 2/138,393 | 4,440/26,262,527 | 0.09 | 3.58e-08 | 2.71e-07 |
| Jaw:0 | 159/138,393 | 16,387/26,262,527 | 1.84 | 2.48e-12 | 2.71e-11 |
| Avulsed wound:0 | 3/138,393 | 6,821/26,262,527 | 0.08 | 3.87e-12 | 4.18e-11 |
| Glucagon-Like Peptide 1:0 | 1/138,393 | 6,583/26,262,527 | 0.03 | 7.41e-14 | 9.11e-13 |
| Starch:0 | 8/138,393 | 14,654/26,262,527 | 0.10 | 2.69e-23 | 5.26e-22 |
| Interleukin 2 Receptor:0 | 6/138,393 | 7,575/26,262,527 | 0.15 | 5.71e-11 | 5.62e-10 |
| Dipyridamole:0 | 8/138,393 | 8,580/26,262,527 | 0.18 | 2.39e-11 | 2.42e-10 |
| Narcotic Antagonists:0 | 4/138,393 | 6,419/26,262,527 | 0.12 | 2.32e-10 | 2.17e-09 |
| divalent metal:0 | 2/138,393 | 4,465/26,262,527 | 0.08 | 3.62e-08 | 2.74e-07 |
| Animal fat:0 | 16/138,393 | 404/26,262,527 | 7.52 | 1.49e-09 | 1.30e-08 |
| School child:0 | 1/138,393 | 15,822/26,262,527 | 0.01 | 1.52e-34 | 4.40e-33 |
| Sedation:0 | 5/138,393 | 11,355/26,262,527 | 0.08 | 1.49e-19 | 2.48e-18 |
| Dietary Supplements:0 | 24/138,393 | 1,025/26,262,527 | 4.44 | 4.20e-09 | 3.52e-08 |
| Cancer Treatment:0 | 929/138,393 | 14,359/26,262,527 | 12.35 | 0.00e+00 | 0.00e+00 |
| Protein Overexpression:0 | 48/138,393 | 2,895/26,262,527 | 3.15 | 2.12e-11 | 2.16e-10 |
| Meperidine:0 | 1/138,393 | 4,464/26,262,527 | 0.04 | 2.67e-09 | 2.29e-08 |
| Interferon-alpha:0 | 42/138,393 | 31,276/26,262,527 | 0.25 | 8.58e-30 | 2.14e-28 |
| Brain Edema:0 | 1/138,393 | 6,056/26,262,527 | 0.03 | 9.10e-13 | 1.03e-11 |
| Gelatin:0 | 3/138,393 | 5,156/26,262,527 | 0.11 | 1.17e-08 | 9.33e-08 |
| Carrageenan:0 | 3/138,393 | 4,881/26,262,527 | 0.12 | 4.69e-08 | 3.51e-07 |
| Erythrocytes:0 | 82/138,393 | 129,624/26,262,527 | 0.12 | 2.75e-187 | 4.98e-185 |
| Aplastic Anemia:0 | 4/138,393 | 9,396/26,262,527 | 0.08 | 2.38e-16 | 3.40e-15 |
| Craniocerebral Trauma:0 | 2/138,393 | 15,264/26,262,527 | 0.02 | 7.95e-32 | 2.12e-30 |
| Specific antigen:0 | 61/138,393 | 4,234/26,262,527 | 2.73 | 1.36e-11 | 1.41e-10 |
| Liver damage:0 | 14/138,393 | 11,372/26,262,527 | 0.23 | 2.06e-12 | 2.26e-11 |
| caspase-7:0 | 21/138,393 | 618/26,262,527 | 6.45 | 6.76e-11 | 6.61e-10 |
| CXCL12 gene|CXCL12:0 | 23/138,393 | 915/26,262,527 | 4.77 | 2.43e-09 | 2.09e-08 |
| Blotting, Western:0 | 181/138,393 | 12,727/26,262,527 | 2.70 | 2.05e-30 | 5.22e-29 |
| Vibration - physical agent:0 | 8/138,393 | 6,128/26,262,527 | 0.25 | 8.31e-07 | 5.45e-06 |
| Autism spectrum disorder:0 | 3/138,393 | 23,464/26,262,527 | 0.02 | 2.03e-48 | 8.62e-47 |
| Sertraline:0 | 3/138,393 | 5,786/26,262,527 | 0.10 | 7.83e-10 | 7.01e-09 |
| Entire right coronary artery:0 | 1/138,393 | 4,056/26,262,527 | 0.05 | 2.39e-08 | 1.85e-07 |
| Mycotoxins:0 | 4/138,393 | 8,150/26,262,527 | 0.09 | 8.78e-14 | 1.07e-12 |
| Prednisone 5 MG:0 | 9/138,393 | 15/26,262,527 | 113.87 | 3.64e-15 | 4.85e-14 |
| PTEN gene|PTEN:0 | 603/138,393 | 16,075/26,262,527 | 7.15 | 3.45e-288 | 9.19e-286 |
| Cystectomy:0 | 165/138,393 | 4,129/26,262,527 | 7.59 | 4.20e-84 | 3.09e-82 |
| Syphilis:0 | 4/138,393 | 9,037/26,262,527 | 0.08 | 8.87e-16 | 1.22e-14 |
| Growth delay:0 | 43/138,393 | 1,496/26,262,527 | 5.46 | 4.17e-18 | 6.51e-17 |
| Stenosis, unspecified:0 | 38/138,393 | 48,746/26,262,527 | 0.15 | 7.12e-65 | 4.10e-63 |
| Cholestasis:0 | 5/138,393 | 11,909/26,262,527 | 0.08 | 1.38e-20 | 2.42e-19 |
| African Trypanosomiasis:0 | 2/138,393 | 4,897/26,262,527 | 0.08 | 4.35e-09 | 3.64e-08 |
| Early Diagnosis:0 | 504/138,393 | 18,626/26,262,527 | 5.15 | 1.37e-182 | 2.45e-180 |
| Glomerulosclerosis:0 | 1/138,393 | 3,543/26,262,527 | 0.05 | 2.97e-07 | 2.04e-06 |
| Axon:0 | 11/138,393 | 44,507/26,262,527 | 0.05 | 1.36e-83 | 9.90e-82 |
| ATP phosphohydrolase:0 | 21/138,393 | 21,057/26,262,527 | 0.19 | 3.30e-25 | 6.95e-24 |
| Layer (organ part):0 | 2/138,393 | 3,726/26,262,527 | 0.10 | 1.19e-06 | 7.66e-06 |
| Entire lumbar disc:0 | 1/138,393 | 7,267/26,262,527 | 0.03 | 1.84e-15 | 2.49e-14 |
| Cavitation:0 | 32/138,393 | 14,924/26,262,527 | 0.41 | 4.28e-09 | 3.58e-08 |
| Doxorubicin:0 | 361/138,393 | 45,594/26,262,527 | 1.50 | 4.68e-13 | 5.40e-12 |
| agonists:0 | 764/138,393 | 90,321/26,262,527 | 1.61 | 8.08e-34 | 2.31e-32 |
| Oxygen uptake:0 | 1/138,393 | 3,297/26,262,527 | 0.06 | 1.34e-06 | 8.56e-06 |
| IMMUNOHISTOCHEMICAL:0 | 142/138,393 | 6,908/26,262,527 | 3.90 | 7.98e-40 | 2.76e-38 |
| Psychotic Disorders:0 | 2/138,393 | 33,047/26,262,527 | 0.01 | 8.48e-72 | 5.30e-70 |
| Osteosclerosis:0 | 20/138,393 | 999/26,262,527 | 3.80 | 8.48e-07 | 5.55e-06 |
| Herpesviridae:0 | 17/138,393 | 9,646/26,262,527 | 0.33 | 6.75e-08 | 4.97e-07 |
| Tissue fiber:0 | 35/138,393 | 44,822/26,262,527 | 0.15 | 9.76e-60 | 5.13e-58 |
| Allelic Imbalance:0 | 23/138,393 | 579/26,262,527 | 7.54 | 4.15e-13 | 4.81e-12 |
| Misoprostol:0 | 3/138,393 | 9,987/26,262,527 | 0.06 | 6.56e-19 | 1.06e-17 |
| Niacinamide:0 | 5/138,393 | 6,106/26,262,527 | 0.16 | 7.83e-09 | 6.41e-08 |
| Culture Media, Conditioned:0 | 44/138,393 | 2,677/26,262,527 | 3.12 | 1.82e-10 | 1.72e-09 |
| monooxyethylene trimethylolpropane tristearate:0 | 50/138,393 | 2,185/26,262,527 | 4.34 | 6.86e-17 | 1.01e-15 |
| Alopecia Areata:0 | 1/138,393 | 4,438/26,262,527 | 0.04 | 4.06e-09 | 3.41e-08 |
| Hereditary Malignant Neoplasm:0 | 71/138,393 | 4,972/26,262,527 | 2.71 | 4.71e-13 | 5.43e-12 |
| Pregnant Women:0 | 10/138,393 | 65,502/26,262,527 | 0.03 | 2.56e-131 | 2.98e-129 |
| Aldehyde Reductase:0 | 1/138,393 | 4,242/26,262,527 | 0.04 | 7.92e-09 | 6.47e-08 |
| Fibril:0 | 1/138,393 | 7,362/26,262,527 | 0.03 | 1.32e-15 | 1.81e-14 |
| Appendicitis:0 | 4/138,393 | 7,607/26,262,527 | 0.10 | 9.50e-13 | 1.07e-11 |
| Bladder neck sclerosis:0 | 7/138,393 | 51/26,262,527 | 26.05 | 2.59e-08 | 1.99e-07 |
| Interferon Alfa-2a:0 | 1/138,393 | 3,365/26,262,527 | 0.06 | 9.29e-07 | 6.05e-06 |
| Corpus Callosum:0 | 5/138,393 | 7,711/26,262,527 | 0.12 | 4.74e-12 | 5.10e-11 |
| Nystagmus:0 | 1/138,393 | 4,504/26,262,527 | 0.04 | 2.79e-09 | 2.38e-08 |
| SDS-PAGE:0 | 28/138,393 | 13,315/26,262,527 | 0.40 | 1.95e-08 | 1.52e-07 |
| Synovial Membrane:0 | 2/138,393 | 16,277/26,262,527 | 0.02 | 4.89e-34 | 1.40e-32 |
| HIV:0 | 22/138,393 | 45,079/26,262,527 | 0.09 | 3.39e-72 | 2.13e-70 |
| Head and neck structure:0 | 306/138,393 | 25,931/26,262,527 | 2.24 | 2.04e-35 | 6.15e-34 |
| Histone H3:0 | 63/138,393 | 4,130/26,262,527 | 2.90 | 6.25e-13 | 7.15e-12 |
| Anti-Anxiety Agents:0 | 33/138,393 | 14,991/26,262,527 | 0.42 | 9.10e-09 | 7.37e-08 |
| Gastric ulcer:0 | 9/138,393 | 12,559/26,262,527 | 0.14 | 3.49e-18 | 5.47e-17 |
| L-Selenomethionine:0 | 10/138,393 | 81/26,262,527 | 23.43 | 6.84e-11 | 6.68e-10 |
| bone morphogenetic protein 6:0 | 13/138,393 | 388/26,262,527 | 6.36 | 3.14e-07 | 2.15e-06 |
| Tissue Microarray:0 | 267/138,393 | 2,648/26,262,527 | 19.17 | 1.12e-229 | 2.43e-227 |
| Amphetamine:0 | 51/138,393 | 44,263/26,262,527 | 0.22 | 5.97e-47 | 2.46e-45 |
| Parasitic Diseases:0 | 5/138,393 | 5,914/26,262,527 | 0.16 | 2.22e-08 | 1.72e-07 |
| TRPM2:0 | 8/138,393 | 79/26,262,527 | 19.22 | 2.31e-08 | 1.79e-07 |
| Entire lacrimal gland:0 | 2/138,393 | 4,049/26,262,527 | 0.09 | 3.05e-07 | 2.09e-06 |
| APP protein, human|APP:0 | 2/138,393 | 4,741/26,262,527 | 0.08 | 8.77e-09 | 7.12e-08 |
| Signal Transduction Pathways:0 | 409/138,393 | 35,895/26,262,527 | 2.17 | 2.96e-43 | 1.12e-41 |
| Hyperlipidemia:0 | 376/138,393 | 17,455/26,262,527 | 4.10 | 5.42e-108 | 5.02e-106 |
| Prostatic nodule:0 | 32/138,393 | 43/26,262,527 | 141.25 | 1.32e-52 | 6.06e-51 |
| Helminthiasis:0 | 2/138,393 | 7,033/26,262,527 | 0.05 | 1.53e-13 | 1.83e-12 |
| Ionophores:0 | 11/138,393 | 10,445/26,262,527 | 0.20 | 1.38e-12 | 1.53e-11 |
| Body of uterus:0 | 88/138,393 | 7,923/26,262,527 | 2.11 | 5.10e-10 | 4.64e-09 |
| Crosstalk:0 | 91/138,393 | 5,877/26,262,527 | 2.94 | 2.52e-18 | 3.97e-17 |
| Driving While Intoxicated:0 | 19/138,393 | 766/26,262,527 | 4.71 | 6.92e-08 | 5.10e-07 |
| TXNL4B:0 | 9/138,393 | 113/26,262,527 | 15.12 | 2.14e-08 | 1.67e-07 |
| Intestinal Diseases:0 | 6/138,393 | 7,493/26,262,527 | 0.15 | 7.95e-11 | 7.73e-10 |
| Radioimmunodetection:0 | 46/138,393 | 1,079/26,262,527 | 8.09 | 7.85e-26 | 1.69e-24 |
| oncoprotein p21|CDKN1A|SLC12A9:0 | 19/138,393 | 763/26,262,527 | 4.73 | 6.53e-08 | 4.81e-07 |
| Absence of pain sensation:0 | 9/138,393 | 16,178/26,262,527 | 0.11 | 1.41e-25 | 3.00e-24 |
| Biopsy gun:0 | 20/138,393 | 186/26,262,527 | 20.41 | 2.90e-19 | 4.79e-18 |
| Prostatic acinus:0 | 43/138,393 | 84/26,262,527 | 97.17 | 8.43e-65 | 4.83e-63 |
| Operon:0 | 2/138,393 | 15,621/26,262,527 | 0.02 | 1.28e-32 | 3.51e-31 |
| ERG gene|ERG:0 | 249/138,393 | 1,893/26,262,527 | 25.00 | 3.22e-240 | 7.47e-238 |
| 8q24:0 | 105/138,393 | 542/26,262,527 | 36.79 | 3.44e-118 | 3.55e-116 |
| Peritonitis:0 | 7/138,393 | 17,909/26,262,527 | 0.07 | 3.36e-31 | 8.83e-30 |
| Sildenafil citrate:0 | 28/138,393 | 1,601/26,262,527 | 3.32 | 9.69e-08 | 7.03e-07 |
| Paraneoplastic Syndromes:0 | 35/138,393 | 2,478/26,262,527 | 2.68 | 4.04e-07 | 2.74e-06 |
| Vasculitis:0 | 8/138,393 | 20,241/26,262,527 | 0.07 | 6.18e-35 | 1.83e-33 |
| Hypertension, Pulmonary:0 | 3/138,393 | 32,936/26,262,527 | 0.02 | 9.91e-70 | 6.09e-68 |
| EAF2 gene|EAF2:0 | 5/138,393 | 23/26,262,527 | 41.26 | 3.52e-07 | 2.40e-06 |
| Quinine:0 | 2/138,393 | 4,986/26,262,527 | 0.08 | 3.11e-09 | 2.64e-08 |
| Acidosis:0 | 9/138,393 | 7,796/26,262,527 | 0.22 | 3.95e-09 | 3.32e-08 |
| Prostate cancer stage B:0 | 35/138,393 | 42/26,262,527 | 158.18 | 1.22e-58 | 6.29e-57 |
| Autoimmune thyroiditis:0 | 2/138,393 | 3,977/26,262,527 | 0.10 | 4.33e-07 | 2.92e-06 |
| B-Lymphocytes:0 | 65/138,393 | 72,947/26,262,527 | 0.17 | 4.39e-90 | 3.43e-88 |
| Maximal urinary flow rate:0 | 8/138,393 | 97/26,262,527 | 15.65 | 1.01e-07 | 7.31e-07 |
| Meningitis:0 | 11/138,393 | 22,154/26,262,527 | 0.09 | 6.27e-36 | 1.92e-34 |
| Prepulse Inhibition:0 | 1/138,393 | 3,770/26,262,527 | 0.05 | 1.02e-07 | 7.35e-07 |
| White American:0 | 26/138,393 | 500/26,262,527 | 9.87 | 3.00e-17 | 4.47e-16 |
| histrelin:0 | 10/138,393 | 71/26,262,527 | 26.73 | 2.10e-11 | 2.13e-10 |
| Acquired Immunodeficiency Syndrome:0 | 86/138,393 | 95,671/26,262,527 | 0.17 | 3.80e-117 | 3.89e-115 |
| Immunoglobulins:0 | 47/138,393 | 46,117/26,262,527 | 0.19 | 4.70e-53 | 2.16e-51 |
| T-Cell Receptor:0 | 18/138,393 | 19,039/26,262,527 | 0.18 | 1.52e-23 | 2.99e-22 |
| Acetazolamide:0 | 1/138,393 | 6,316/26,262,527 | 0.03 | 3.34e-13 | 3.89e-12 |
| Ingestion:0 | 9/138,393 | 11,900/26,262,527 | 0.14 | 7.12e-17 | 1.05e-15 |
| Entrapment:0 | 5/138,393 | 5,213/26,262,527 | 0.18 | 4.04e-07 | 2.73e-06 |
| QUANTUM:0 | 2/138,393 | 5,557/26,262,527 | 0.07 | 1.81e-10 | 1.72e-09 |
| Transjugular intrahepatic portosystemic shunt procedure:0 | 28/138,393 | 13,954/26,262,527 | 0.38 | 2.48e-09 | 2.13e-08 |
| Gleason Pattern 4:0 | 11/138,393 | 17/26,262,527 | 122.80 | 1.62e-18 | 2.59e-17 |
| Scotoma:0 | 1/138,393 | 3,574/26,262,527 | 0.05 | 3.10e-07 | 2.13e-06 |
| Anions:0 | 27/138,393 | 29,624/26,262,527 | 0.17 | 7.30e-37 | 2.32e-35 |
| Metaphysis:0 | 6/138,393 | 5,323/26,262,527 | 0.21 | 1.44e-06 | 9.15e-06 |
| Vasodilation:0 | 5/138,393 | 21,463/26,262,527 | 0.04 | 3.77e-41 | 1.35e-39 |
| glial cell-line derived neurotrophic factor|GDNF:0 | 4/138,393 | 5,352/26,262,527 | 0.14 | 3.85e-08 | 2.91e-07 |
| Antithyroid Agents:0 | 1/138,393 | 4,092/26,262,527 | 0.05 | 2.56e-08 | 1.97e-07 |
| Arylesterase:0 | 2/138,393 | 4,164/26,262,527 | 0.09 | 1.46e-07 | 1.04e-06 |
| RNASEL:0 | 41/138,393 | 99/26,262,527 | 78.61 | 8.15e-59 | 4.21e-57 |
| serine repeat antigen, Plasmodium:0 | 22/138,393 | 550/26,262,527 | 7.59 | 1.16e-12 | 1.30e-11 |
| Bipolar Disorder:0 | 7/138,393 | 34,877/26,262,527 | 0.04 | 5.20e-68 | 3.11e-66 |
| Prognostic Factor:0 | 576/138,393 | 20,896/26,262,527 | 5.25 | 4.32e-212 | 8.57e-210 |
| BAX gene|BAX:0 | 313/138,393 | 19,223/26,262,527 | 3.09 | 3.51e-63 | 1.97e-61 |
| Stratum corneum:0 | 3/138,393 | 6,500/26,262,527 | 0.09 | 2.34e-11 | 2.36e-10 |
| DELIVER:0 | 77/138,393 | 4,901/26,262,527 | 2.98 | 4.35e-16 | 6.09e-15 |
| PubMed:0 | 135/138,393 | 6,212/26,262,527 | 4.13 | 2.23e-40 | 7.83e-39 |
| RHOC gene|RHOC:0 | 19/138,393 | 672/26,262,527 | 5.37 | 9.47e-09 | 7.66e-08 |
| pT2 stage:0 | 6/138,393 | 15/26,262,527 | 75.91 | 1.05e-09 | 9.30e-09 |
| Therapeutic radioisotope:0 | 6/138,393 | 49/26,262,527 | 23.24 | 4.83e-07 | 3.23e-06 |
| ID1:0 | 25/138,393 | 1,505/26,262,527 | 3.15 | 1.12e-06 | 7.20e-06 |
| Bromocriptine:0 | 25/138,393 | 16,163/26,262,527 | 0.29 | 3.27e-14 | 4.11e-13 |
| Retinoblastoma Protein:0 | 58/138,393 | 2,684/26,262,527 | 4.10 | 3.11e-18 | 4.89e-17 |
| Suramin:0 | 137/138,393 | 5,616/26,262,527 | 4.63 | 3.43e-46 | 1.38e-44 |
| Impotence:0 | 133/138,393 | 4,113/26,262,527 | 6.14 | 6.36e-58 | 3.23e-56 |
| Hypogonadism:0 | 184/138,393 | 4,420/26,262,527 | 7.91 | 2.38e-96 | 2.00e-94 |
| Oestrogen therapy:0 | 142/138,393 | 2,250/26,262,527 | 11.99 | 3.49e-97 | 2.97e-95 |
| Colchicine:0 | 14/138,393 | 13,619/26,262,527 | 0.19 | 2.47e-16 | 3.52e-15 |
| Cytotoxic agent:0 | 160/138,393 | 6,824/26,262,527 | 4.45 | 1.64e-51 | 7.36e-50 |
| Sodium Nitroprusside:0 | 9/138,393 | 13,185/26,262,527 | 0.13 | 1.63e-19 | 2.72e-18 |
| Opioid Peptide:0 | 5/138,393 | 5,394/26,262,527 | 0.18 | 2.21e-07 | 1.53e-06 |
| I Kappa B-Alpha:0 | 102/138,393 | 9,353/26,262,527 | 2.07 | 4.93e-11 | 4.88e-10 |
| mevalonate pathway:0 | 18/138,393 | 345/26,262,527 | 9.90 | 1.96e-12 | 2.16e-11 |
| Diabetic:0 | 132/138,393 | 148,453/26,262,527 | 0.17 | 2.58e-182 | 4.58e-180 |
| Liver tissue:0 | 18/138,393 | 18,941/26,262,527 | 0.18 | 2.02e-23 | 3.96e-22 |
| Plasticity:0 | 26/138,393 | 34,522/26,262,527 | 0.14 | 5.13e-47 | 2.12e-45 |
| BCL-2 Protein|BCL2:0 | 37/138,393 | 1,872/26,262,527 | 3.75 | 3.76e-11 | 3.76e-10 |
| androstan-3-one:0 | 11/138,393 | 153/26,262,527 | 13.64 | 1.62e-09 | 1.40e-08 |
| Entire paraventricular nucleus:0 | 1/138,393 | 5,996/26,262,527 | 0.03 | 1.33e-12 | 1.49e-11 |
| Nodular hyperplasia:0 | 39/138,393 | 2,401/26,262,527 | 3.08 | 2.56e-09 | 2.19e-08 |
| Polyp of urethra:0 | 21/138,393 | 126/26,262,527 | 31.63 | 9.73e-24 | 1.94e-22 |
| Temporomandibular Joint Disorders:0 | 2/138,393 | 6,459/26,262,527 | 0.06 | 2.68e-12 | 2.92e-11 |
| GLIPR1:0 | 13/138,393 | 100/26,262,527 | 24.67 | 5.32e-14 | 6.59e-13 |
| 6-Mercaptopurine:0 | 3/138,393 | 5,010/26,262,527 | 0.11 | 2.32e-08 | 1.80e-07 |
| Low Back Pain:0 | 13/138,393 | 18,774/26,262,527 | 0.13 | 4.55e-27 | 1.03e-25 |
| Cancer Vaccines:0 | 186/138,393 | 2,979/26,262,527 | 11.86 | 6.25e-126 | 6.94e-124 |
| Primary infection NOS:0 | 4/138,393 | 7,934/26,262,527 | 0.10 | 2.50e-13 | 2.94e-12 |
| Estramustine:0 | 327/138,393 | 1,158/26,262,527 | 53.71 | 0.00e+00 | 0.00e+00 |
| S100P gene|S100P:0 | 18/138,393 | 627/26,262,527 | 5.45 | 1.83e-08 | 1.44e-07 |
| Alprostadil:0 | 20/138,393 | 13,971/26,262,527 | 0.27 | 3.13e-13 | 3.67e-12 |
| Leukotrienes:0 | 12/138,393 | 7,278/26,262,527 | 0.31 | 1.36e-06 | 8.62e-06 |
| PROSTATE CALCIFICATION:0 | 11/138,393 | 45/26,262,527 | 46.39 | 9.84e-15 | 1.27e-13 |
| Fetal Growth Retardation:0 | 1/138,393 | 10,582/26,262,527 | 0.02 | 9.79e-23 | 1.88e-21 |
| beta-lapachone:0 | 22/138,393 | 942/26,262,527 | 4.43 | 1.89e-08 | 1.48e-07 |
| Angina Pectoris:0 | 6/138,393 | 10,871/26,262,527 | 0.10 | 1.34e-17 | 2.04e-16 |
| uptake:0 | 126/138,393 | 53,645/26,262,527 | 0.45 | 2.39e-25 | 5.06e-24 |
| Feathers:0 | 1/138,393 | 3,301/26,262,527 | 0.06 | 1.36e-06 | 8.64e-06 |
| Leptin|HSD3B1:0 | 9/138,393 | 17/26,262,527 | 100.47 | 8.61e-15 | 1.12e-13 |
| Penile Prosthesis:0 | 36/138,393 | 981/26,262,527 | 6.97 | 1.40e-18 | 2.25e-17 |
| Chromosome Pairing:0 | 5/138,393 | 37,079/26,262,527 | 0.03 | 8.08e-76 | 5.38e-74 |
| Hypophysectomy, Chemical:0 | 4/138,393 | 12/26,262,527 | 63.26 | 1.31e-06 | 8.33e-06 |
| Pelvic lymphadenopathy:0 | 8/138,393 | 27/26,262,527 | 56.23 | 1.18e-11 | 1.23e-10 |
| PIK3CA|PIK3CB|PIK3CD|PIK3CG:0 | 137/138,393 | 6,650/26,262,527 | 3.91 | 1.39e-38 | 4.59e-37 |
| Sjogren's Syndrome:0 | 3/138,393 | 11,129/26,262,527 | 0.05 | 3.33e-21 | 6.00e-20 |
| Collagen:0 | 107/138,393 | 70,942/26,262,527 | 0.29 | 2.20e-59 | 1.15e-57 |
| Inflammatory disorder:0 | 52/138,393 | 26,207/26,262,527 | 0.38 | 9.18e-17 | 1.34e-15 |
| Human Papillomavirus:0 | 67/138,393 | 27,273/26,262,527 | 0.47 | 1.49e-12 | 1.65e-11 |
| Need for isolation:0 | 47/138,393 | 24,893/26,262,527 | 0.36 | 4.47e-17 | 6.64e-16 |
| Entire pelvic lymph node:0 | 33/138,393 | 144/26,262,527 | 43.50 | 1.92e-40 | 6.77e-39 |
| Suppression treatment:0 | 12/138,393 | 81/26,262,527 | 28.12 | 1.21e-13 | 1.46e-12 |
| Ossification, Heterotopic:0 | 1/138,393 | 3,367/26,262,527 | 0.06 | 9.34e-07 | 6.07e-06 |
| Hyperplasia:0 | 452/138,393 | 28,023/26,262,527 | 3.07 | 3.81e-89 | 2.93e-87 |
| Antiplatelet therapy:0 | 3/138,393 | 6,138/26,262,527 | 0.09 | 1.34e-10 | 1.28e-09 |
| tadalafil:0 | 39/138,393 | 2,920/26,262,527 | 2.54 | 5.37e-07 | 3.58e-06 |
| Interleukin 2 Receptor, Alpha|IL2RA|ISG20:0 | 12/138,393 | 8,769/26,262,527 | 0.26 | 5.28e-09 | 4.39e-08 |
| Racial group:0 | 291/138,393 | 14,629/26,262,527 | 3.78 | 1.35e-76 | 9.04e-75 |
| Guanosine Diphosphate:0 | 1/138,393 | 3,419/26,262,527 | 0.06 | 6.26e-07 | 4.14e-06 |
| phenoxodiol:0 | 9/138,393 | 161/26,262,527 | 10.61 | 3.69e-07 | 2.51e-06 |
| Levodopa:0 | 8/138,393 | 35,782/26,262,527 | 0.04 | 1.44e-68 | 8.72e-67 |
| Apolipoproteins B|APOB:0 | 2/138,393 | 10,176/26,262,527 | 0.04 | 1.95e-20 | 3.41e-19 |
| HOXB13:0 | 44/138,393 | 205/26,262,527 | 40.74 | 2.82e-52 | 1.28e-50 |
| Troponin:0 | 1/138,393 | 5,858/26,262,527 | 0.03 | 2.78e-12 | 3.02e-11 |
| beta-2 Adrenergic Receptors:0 | 4/138,393 | 7,174/26,262,527 | 0.11 | 7.58e-12 | 8.02e-11 |
| Epithelium:0 | 788/138,393 | 84,968/26,262,527 | 1.76 | 1.20e-47 | 5.00e-46 |
| Apolipoproteins:0 | 4/138,393 | 6,217/26,262,527 | 0.12 | 6.51e-10 | 5.86e-09 |
| Cryoablation of prostate:0 | 7/138,393 | 43/26,262,527 | 30.89 | 8.92e-09 | 7.22e-08 |
| Dialysis Solutions:0 | 1/138,393 | 7,094/26,262,527 | 0.03 | 5.94e-15 | 7.80e-14 |
| Leg:0 | 11/138,393 | 10,740/26,262,527 | 0.19 | 3.83e-13 | 4.44e-12 |
| Fishes:0 | 39/138,393 | 47,006/26,262,527 | 0.16 | 1.17e-60 | 6.27e-59 |
| Young adult:0 | 59/138,393 | 46,051/26,262,527 | 0.24 | 4.55e-45 | 1.78e-43 |
| cancer regression:0 | 11/138,393 | 127/26,262,527 | 16.44 | 2.56e-10 | 2.39e-09 |
| Pelvic organ:0 | 23/138,393 | 1,187/26,262,527 | 3.68 | 2.33e-07 | 1.62e-06 |
| Mice, Inbred DBA:0 | 1/138,393 | 3,828/26,262,527 | 0.05 | 6.98e-08 | 5.13e-07 |
| Generalized illness:0 | 54/138,393 | 4,079/26,262,527 | 2.51 | 3.65e-09 | 3.08e-08 |
| Thromboplastin:0 | 48/138,393 | 20,241/26,262,527 | 0.45 | 3.78e-10 | 3.47e-09 |
| Tetanus:0 | 2/138,393 | 5,368/26,262,527 | 0.07 | 5.48e-10 | 4.97e-09 |
| Edetic Acid:0 | 11/138,393 | 17,584/26,262,527 | 0.12 | 1.57e-26 | 3.49e-25 |
| Thalamic structure:0 | 1/138,393 | 15,961/26,262,527 | 0.01 | 7.21e-35 | 2.13e-33 |
| Right ventricular failure:0 | 1/138,393 | 3,759/26,262,527 | 0.05 | 1.00e-07 | 7.27e-07 |
| Carotid Body:0 | 1/138,393 | 5,714/26,262,527 | 0.03 | 5.74e-12 | 6.12e-11 |
| Chronic Obstructive Airway Disease:0 | 29/138,393 | 92,185/26,262,527 | 0.06 | 2.53e-164 | 3.81e-162 |
| Sarcoidosis:0 | 11/138,393 | 26,298/26,262,527 | 0.08 | 1.49e-44 | 5.78e-43 |
| Gastric mucosa:0 | 14/138,393 | 20,792/26,262,527 | 0.13 | 3.39e-30 | 8.55e-29 |
| Polymers:0 | 38/138,393 | 25,862/26,262,527 | 0.28 | 5.02e-23 | 9.74e-22 |
| Iron:0 | 61/138,393 | 86,457/26,262,527 | 0.13 | 1.25e-119 | 1.30e-117 |
| Cytomegalovirus Infections:0 | 7/138,393 | 17,799/26,262,527 | 0.07 | 7.18e-31 | 1.86e-29 |
| Nephrolithotomy, Percutaneous:0 | 1/138,393 | 3,483/26,262,527 | 0.05 | 4.31e-07 | 2.91e-06 |
| prostate gland development:0 | 5/138,393 | 17/26,262,527 | 55.82 | 9.68e-08 | 7.02e-07 |
| Chickens:0 | 1/138,393 | 8,393/26,262,527 | 0.02 | 5.26e-18 | 8.18e-17 |
| Epithelial proliferation:0 | 41/138,393 | 1,812/26,262,527 | 4.29 | 5.47e-14 | 6.76e-13 |
| receptor expression:0 | 289/138,393 | 8,538/26,262,527 | 6.43 | 2.39e-128 | 2.70e-126 |
| Lobectomy:0 | 10/138,393 | 11,415/26,262,527 | 0.17 | 4.19e-15 | 5.55e-14 |
| Neurilemmoma:0 | 19/138,393 | 12,463/26,262,527 | 0.29 | 3.00e-11 | 3.02e-10 |
| Fatty-acid synthase:0 | 97/138,393 | 5,011/26,262,527 | 3.68 | 6.31e-26 | 1.37e-24 |
| Paclitaxel:0 | 410/138,393 | 38,401/26,262,527 | 2.03 | 1.97e-37 | 6.31e-36 |
| Resins, Plant:0 | 14/138,393 | 10,987/26,262,527 | 0.24 | 1.37e-11 | 1.42e-10 |
| PTPRC gene|PTPRC:0 | 5/138,393 | 6,016/26,262,527 | 0.16 | 1.08e-08 | 8.66e-08 |
| Intravenous pyelogram:0 | 37/138,393 | 2,431/26,262,527 | 2.89 | 3.22e-08 | 2.45e-07 |
| Human Glandular Kallikrein 2|KLK2:0 | 20/138,393 | 61/26,262,527 | 62.23 | 8.48e-28 | 1.98e-26 |
| prenatal:0 | 5/138,393 | 11,422/26,262,527 | 0.08 | 1.05e-19 | 1.76e-18 |
| Muscle function:0 | 12/138,393 | 14,779/26,262,527 | 0.15 | 4.94e-20 | 8.40e-19 |
| peer:0 | 6/138,393 | 8,117/26,262,527 | 0.14 | 5.60e-12 | 5.98e-11 |
| Caudal:0 | 18/138,393 | 14,282/26,262,527 | 0.24 | 5.91e-15 | 7.76e-14 |
| Recombinant Interferon-gamma|CALR:0 | 9/138,393 | 20/26,262,527 | 85.40 | 2.72e-14 | 3.44e-13 |
| DNA Repair Gene:0 | 55/138,393 | 2,976/26,262,527 | 3.51 | 1.22e-14 | 1.57e-13 |
| metaplastic cell transformation:0 | 44/138,393 | 1,506/26,262,527 | 5.55 | 9.65e-19 | 1.56e-17 |
| Somatomedins|BP3:0 | 10/138,393 | 51/26,262,527 | 37.21 | 1.11e-12 | 1.24e-11 |
| Acinar Prostate Adenocarcinoma:0 | 11/138,393 | 16/26,262,527 | 130.48 | 9.91e-19 | 1.60e-17 |
| Pro-Opiomelanocortin:0 | 2/138,393 | 4,330/26,262,527 | 0.09 | 7.39e-08 | 5.41e-07 |
| Calcitonin Gene-Related Peptide:0 | 15/138,393 | 18,800/26,262,527 | 0.15 | 1.67e-25 | 3.55e-24 |
| Up-Regulation (Physiology):0 | 302/138,393 | 22,987/26,262,527 | 2.50 | 4.07e-43 | 1.53e-41 |
| Carbon Monoxide:0 | 4/138,393 | 5,450/26,262,527 | 0.14 | 2.87e-08 | 2.20e-07 |
| Autoimmunity:0 | 23/138,393 | 14,850/26,262,527 | 0.29 | 4.68e-13 | 5.40e-12 |
| matriptase:0 | 33/138,393 | 1,088/26,262,527 | 5.76 | 6.76e-15 | 8.86e-14 |
| Secondary malignant neoplasm of lung:0 | 201/138,393 | 13,625/26,262,527 | 2.80 | 1.34e-35 | 4.07e-34 |
| Ischemic stroke:0 | 10/138,393 | 44,460/26,262,527 | 0.04 | 6.73e-85 | 5.00e-83 |
| Rating:0 | 11/138,393 | 7,072/26,262,527 | 0.30 | 9.26e-07 | 6.03e-06 |
| Anticoagulant therapy:0 | 8/138,393 | 6,927/26,262,527 | 0.22 | 2.69e-08 | 2.07e-07 |
| Coronary Artery Bypass Surgery:0 | 2/138,393 | 36,304/26,262,527 | 0.01 | 3.76e-79 | 2.62e-77 |
| Stimulation procedure:0 | 487/138,393 | 131,618/26,262,527 | 0.70 | 1.43e-16 | 2.06e-15 |
| Cystoprostatectomy:0 | 129/138,393 | 354/26,262,527 | 69.22 | 2.16e-175 | 3.66e-173 |
| Betamethasone:0 | 2/138,393 | 4,855/26,262,527 | 0.08 | 6.45e-09 | 5.31e-08 |
| Phosphoric Monoester Hydrolases:0 | 225/138,393 | 17,361/26,262,527 | 2.46 | 8.24e-32 | 2.20e-30 |
| Addictive Behavior:0 | 5/138,393 | 9,713/26,262,527 | 0.10 | 4.62e-16 | 6.45e-15 |
| Epinephrine:0 | 15/138,393 | 45,013/26,262,527 | 0.06 | 8.85e-80 | 6.22e-78 |
| Parasitemia:0 | 1/138,393 | 6,777/26,262,527 | 0.03 | 2.40e-14 | 3.04e-13 |
| Fibroblast Growth Factor Receptors:0 | 56/138,393 | 4,214/26,262,527 | 2.52 | 1.68e-09 | 1.46e-08 |
| Replicon:0 | 1/138,393 | 3,779/26,262,527 | 0.05 | 1.03e-07 | 7.43e-07 |
| Frozen Sections:0 | 98/138,393 | 8,271/26,262,527 | 2.25 | 1.31e-12 | 1.47e-11 |
| Attention deficit hyperactivity disorder:0 | 2/138,393 | 58,657/26,262,527 | 0.01 | 8.94e-130 | 1.02e-127 |
| Fascia of individual pelvic organ:0 | 8/138,393 | 32/26,262,527 | 47.44 | 3.78e-11 | 3.77e-10 |
| Conservative therapy:0 | 99/138,393 | 7,174/26,262,527 | 2.62 | 1.52e-16 | 2.18e-15 |
| Vertigo:0 | 4/138,393 | 6,279/26,262,527 | 0.12 | 4.60e-10 | 4.20e-09 |
| Risk Reduction:0 | 85/138,393 | 4,050/26,262,527 | 3.98 | 4.01e-25 | 8.41e-24 |
| Injury wounds:0 | 13/138,393 | 11,938/26,262,527 | 0.21 | 5.33e-14 | 6.60e-13 |
| Etanercept:0 | 2/138,393 | 13,242/26,262,527 | 0.03 | 3.26e-27 | 7.45e-26 |
| G1 Arrest:0 | 51/138,393 | 1,073/26,262,527 | 9.02 | 1.55e-30 | 3.97e-29 |
| Appendix:0 | 10/138,393 | 7,492/26,262,527 | 0.25 | 5.70e-08 | 4.21e-07 |
| Receptors, Metabotropic Glutamate:0 | 3/138,393 | 6,268/26,262,527 | 0.09 | 6.52e-11 | 6.37e-10 |
| HISTORY OF SYMPTOMS & DISEASES:FINDING:POINT IN TIME:HEREDITARY:NOMINAL:0 | 25/138,393 | 1,182/26,262,527 | 4.01 | 1.41e-08 | 1.12e-07 |
| Cerebral hemisphere hemorrhage:0 | 6/138,393 | 15,342/26,262,527 | 0.07 | 8.16e-27 | 1.82e-25 |
| Physiologic Organization:0 | 15/138,393 | 17,641/26,262,527 | 0.16 | 3.32e-23 | 6.47e-22 |
| Lung Transplantation:0 | 1/138,393 | 5,836/26,262,527 | 0.03 | 2.70e-12 | 2.94e-11 |
| Total thyroidectomy:0 | 2/138,393 | 5,449/26,262,527 | 0.07 | 3.92e-10 | 3.60e-09 |
| UVRAG|TP63|CKAP4:0 | 102/138,393 | 4,488/26,262,527 | 4.32 | 1.90e-32 | 5.16e-31 |
| Empirical therapy:0 | 3/138,393 | 4,832/26,262,527 | 0.12 | 6.89e-08 | 5.07e-07 |
| KLK3|PLAG1|PROS1|NPEPPS|PSAT1:0 | 137/138,393 | 363/26,262,527 | 71.69 | 6.76e-188 | 1.24e-185 |
| Stroma:0 | 988/138,393 | 54,679/26,262,527 | 3.45 | 4.24e-226 | 9.01e-224 |
| ABT 627:0 | 8/138,393 | 125/26,262,527 | 12.15 | 6.24e-07 | 4.13e-06 |
| Mouse Intraepithelial Neoplasia:0 | 4/138,393 | 11/26,262,527 | 69.01 | 9.84e-07 | 6.38e-06 |
| Defecation:0 | 47/138,393 | 3,786/26,262,527 | 2.36 | 2.34e-07 | 1.63e-06 |
| Menstruation:0 | 3/138,393 | 4,242/26,262,527 | 0.13 | 1.05e-06 | 6.78e-06 |
| Moving:0 | 3/138,393 | 8,308/26,262,527 | 0.07 | 3.50e-15 | 4.67e-14 |
| Retinal Detachment:0 | 1/138,393 | 9,387/26,262,527 | 0.02 | 3.13e-20 | 5.36e-19 |
| Color:0 | 14/138,393 | 9,872/26,262,527 | 0.27 | 8.81e-10 | 7.86e-09 |
| Bulbar urethra:0 | 14/138,393 | 428/26,262,527 | 6.21 | 1.48e-07 | 1.05e-06 |
| Growth Factor Receptors:0 | 64/138,393 | 3,070/26,262,527 | 3.96 | 3.36e-19 | 5.52e-18 |
| Tissue membrane:0 | 87/138,393 | 79,269/26,262,527 | 0.21 | 7.26e-86 | 5.45e-84 |
| CANCER WORKUP:0 | 7/138,393 | 41/26,262,527 | 32.40 | 6.63e-09 | 5.45e-08 |
| Malignant neoplasm of brain:0 | 64/138,393 | 3,745/26,262,527 | 3.24 | 3.09e-15 | 4.13e-14 |
| cDNA Microarray procedure:0 | 12/138,393 | 332/26,262,527 | 6.86 | 4.09e-07 | 2.77e-06 |
| Octreotide|PLXNA2:0 | 9/138,393 | 36/26,262,527 | 47.44 | 2.23e-12 | 2.45e-11 |
| Thioctic Acid:0 | 6/138,393 | 8,508/26,262,527 | 0.13 | 1.08e-12 | 1.21e-11 |
| kallikrein 10:0 | 6/138,393 | 55/26,262,527 | 20.70 | 9.00e-07 | 5.87e-06 |
| Combined Modality Therapy:0 | 633/138,393 | 57,532/26,262,527 | 2.09 | 5.68e-61 | 3.08e-59 |
| monoamine:0 | 4/138,393 | 5,439/26,262,527 | 0.14 | 2.81e-08 | 2.15e-07 |
| African race:0 | 166/138,393 | 18,751/26,262,527 | 1.68 | 8.63e-10 | 7.70e-09 |
| antisense therapy:0 | 10/138,393 | 173/26,262,527 | 10.97 | 6.21e-08 | 4.58e-07 |
| Recipient, Transplant:0 | 92/138,393 | 54,994/26,262,527 | 0.32 | 1.37e-41 | 4.96e-40 |
| Danazol:0 | 4/138,393 | 6,043/26,262,527 | 0.13 | 1.94e-09 | 1.68e-08 |
| Albumins:0 | 36/138,393 | 25,581/26,262,527 | 0.27 | 1.14e-23 | 2.26e-22 |
| CATALASE:0 | 27/138,393 | 17,074/26,262,527 | 0.30 | 1.32e-14 | 1.69e-13 |
| Aspartate Transaminase:0 | 11/138,393 | 10,748/26,262,527 | 0.19 | 3.88e-13 | 4.49e-12 |
| Prostatic Intraepithelial Neoplasia of the Mouse Prostate Gland:0 | 60/138,393 | 106/26,262,527 | 107.46 | 7.97e-92 | 6.38e-90 |
| Whole Body Imaging:0 | 32/138,393 | 1,291/26,262,527 | 4.70 | 3.03e-12 | 3.28e-11 |
| Entire left seminal vesicle:0 | 5/138,393 | 32/26,262,527 | 29.65 | 1.50e-06 | 9.49e-06 |
| Rats, Inbred ACI:0 | 18/138,393 | 397/26,262,527 | 8.61 | 1.78e-11 | 1.82e-10 |
| steroid hormone receptor:0 | 75/138,393 | 1,392/26,262,527 | 10.23 | 1.18e-47 | 4.95e-46 |
| Pollutant:0 | 2/138,393 | 6,946/26,262,527 | 0.05 | 2.12e-13 | 2.50e-12 |
| Histologic:0 | 27/138,393 | 442/26,262,527 | 11.59 | 1.61e-19 | 2.69e-18 |
| Heterocyclic Amines:0 | 19/138,393 | 880/26,262,527 | 4.10 | 5.34e-07 | 3.57e-06 |
| Pulmonary artery structure:0 | 3/138,393 | 8,547/26,262,527 | 0.07 | 8.10e-16 | 1.12e-14 |
| Vaccines:0 | 339/138,393 | 85,027/26,262,527 | 0.76 | 8.99e-08 | 6.54e-07 |
| Angioneurotic Edema:0 | 2/138,393 | 3,954/26,262,527 | 0.10 | 4.21e-07 | 2.85e-06 |
| Connective Tissue Diseases:0 | 2/138,393 | 8,855/26,262,527 | 0.04 | 1.24e-17 | 1.89e-16 |
| Parotid Gland:0 | 19/138,393 | 11,617/26,262,527 | 0.31 | 7.04e-10 | 6.33e-09 |
| Fertilization:0 | 5/138,393 | 8,941/26,262,527 | 0.11 | 1.40e-14 | 1.80e-13 |
| Stratification:0 | 81/138,393 | 3,430/26,262,527 | 4.48 | 3.67e-27 | 8.35e-26 |
| Binding Sites:0 | 220/138,393 | 59,087/26,262,527 | 0.71 | 6.09e-08 | 4.49e-07 |
| BRCA2 Protein|BRCA2:0 | 12/138,393 | 147/26,262,527 | 15.49 | 7.52e-11 | 7.33e-10 |
| caspase-3:0 | 343/138,393 | 20,964/26,262,527 | 3.11 | 1.55e-69 | 9.50e-68 |
| Pancreaticoduodenectomy:0 | 4/138,393 | 8,301/26,262,527 | 0.09 | 4.43e-14 | 5.52e-13 |
| Mycobacterium tuberculosis:0 | 5/138,393 | 19,195/26,262,527 | 0.05 | 2.37e-36 | 7.39e-35 |
| SKP2 gene|SKP2:0 | 21/138,393 | 919/26,262,527 | 4.34 | 5.59e-08 | 4.14e-07 |
| EP300 gene|EP300:0 | 18/138,393 | 777/26,262,527 | 4.40 | 3.95e-07 | 2.68e-06 |
| Phagocytes:0 | 8/138,393 | 10,762/26,262,527 | 0.14 | 1.73e-15 | 2.35e-14 |
| terminal deoxynucleotidyl transferase nick end labeling:0 | 22/138,393 | 698/26,262,527 | 5.98 | 9.55e-11 | 9.24e-10 |
| Androstenediols:0 | 10/138,393 | 228/26,262,527 | 8.32 | 7.03e-07 | 4.64e-06 |
| Dysmyelopoietic Syndromes:0 | 35/138,393 | 27,883/26,262,527 | 0.24 | 3.50e-28 | 8.29e-27 |
| Cerebral Vasospasm:0 | 1/138,393 | 4,664/26,262,527 | 0.04 | 1.40e-09 | 1.23e-08 |
| Peroxidase|MPO:0 | 1/138,393 | 3,682/26,262,527 | 0.05 | 1.44e-07 | 1.02e-06 |
| Thalassemia:0 | 1/138,393 | 6,434/26,262,527 | 0.03 | 1.52e-13 | 1.82e-12 |
| RANTES:0 | 2/138,393 | 4,705/26,262,527 | 0.08 | 1.29e-08 | 1.03e-07 |
| Obstetric Labor, Premature:0 | 2/138,393 | 7,598/26,262,527 | 0.05 | 8.48e-15 | 1.10e-13 |
| Neutrophil Infiltration:0 | 1/138,393 | 3,974/26,262,527 | 0.05 | 3.40e-08 | 2.58e-07 |
| Mitosis:0 | 156/138,393 | 17,328/26,262,527 | 1.71 | 7.09e-10 | 6.38e-09 |
| Polysaccharides:0 | 90/138,393 | 51,669/26,262,527 | 0.33 | 1.87e-37 | 5.99e-36 |
| Cancer of Pelvis:0 | 39/138,393 | 346/26,262,527 | 21.40 | 8.85e-37 | 2.79e-35 |
| Renal tubular disorder:0 | 40/138,393 | 20,480/26,262,527 | 0.37 | 1.27e-13 | 1.53e-12 |
| Hyperparathyroidism, Secondary:0 | 10/138,393 | 7,429/26,262,527 | 0.26 | 7.85e-08 | 5.73e-07 |
| Entire axial skeleton:0 | 27/138,393 | 1,077/26,262,527 | 4.76 | 1.12e-10 | 1.08e-09 |
| N-Myc Downstream Regulated Protein 1|NDRG1:0 | 22/138,393 | 566/26,262,527 | 7.38 | 1.99e-12 | 2.19e-11 |
| Neoadjuvant Therapy:0 | 441/138,393 | 10,341/26,262,527 | 8.12 | 3.81e-232 | 8.37e-230 |
| Benzene:0 | 6/138,393 | 7,194/26,262,527 | 0.16 | 4.48e-10 | 4.09e-09 |
| Glucosephosphate Dehydrogenase:0 | 1/138,393 | 4,739/26,262,527 | 0.04 | 9.86e-10 | 8.74e-09 |
| Osteoporosis:0 | 392/138,393 | 51,099/26,262,527 | 1.46 | 2.86e-12 | 3.10e-11 |
| Cell physiology:0 | 361/138,393 | 46,073/26,262,527 | 1.49 | 1.59e-12 | 1.77e-11 |
| Mycosis Fungoides:0 | 5/138,393 | 6,221/26,262,527 | 0.15 | 3.95e-09 | 3.32e-08 |
| K562 Cells:0 | 9/138,393 | 7,782/26,262,527 | 0.22 | 3.89e-09 | 3.27e-08 |
| androgen biosynthesis:0 | 42/138,393 | 194/26,262,527 | 41.10 | 4.09e-50 | 1.79e-48 |
| Saccades:0 | 1/138,393 | 4,535/26,262,527 | 0.04 | 1.86e-09 | 1.61e-08 |
| Dactinomycin|MYC:0 | 5/138,393 | 6/26,262,527 | 158.15 | 1.78e-09 | 1.55e-08 |
| glandular epithelium:0 | 80/138,393 | 2,051/26,262,527 | 7.41 | 5.16e-41 | 1.84e-39 |
| Hemophiliacs:0 | 1/138,393 | 3,303/26,262,527 | 0.06 | 1.37e-06 | 8.68e-06 |
| American:0 | 138/138,393 | 11,187/26,262,527 | 2.34 | 2.70e-18 | 4.25e-17 |
| mutation analysis:0 | 46/138,393 | 3,884/26,262,527 | 2.25 | 1.17e-06 | 7.49e-06 |
| Thrombectomy:0 | 1/138,393 | 4,755/26,262,527 | 0.04 | 6.28e-10 | 5.67e-09 |
| Mesenteric Arteries:0 | 1/138,393 | 8,887/26,262,527 | 0.02 | 4.06e-19 | 6.65e-18 |
| Nerve injury NOS:0 | 11/138,393 | 7,112/26,262,527 | 0.29 | 9.63e-07 | 6.25e-06 |
| Castration:0 | 766/138,393 | 4,619/26,262,527 | 31.64 | 0.00e+00 | 0.00e+00 |
| PECAM1 gene|PECAM1:0 | 35/138,393 | 2,487/26,262,527 | 2.67 | 4.38e-07 | 2.95e-06 |
| Labyrinth:0 | 6/138,393 | 15,615/26,262,527 | 0.07 | 1.95e-27 | 4.49e-26 |
| PROSTATE SPECIFIC:0 | 135/138,393 | 196/26,262,527 | 130.83 | 3.13e-213 | 6.28e-211 |
| Protein S|CDSN:0 | 1/138,393 | 3,236/26,262,527 | 0.06 | 1.24e-06 | 7.96e-06 |
| Prostatic Glandular Cell:0 | 11/138,393 | 38/26,262,527 | 54.94 | 1.99e-15 | 2.69e-14 |
| Phosphodiesterase 5 inhibitor:0 | 72/138,393 | 3,804/26,262,527 | 3.59 | 3.50e-19 | 5.75e-18 |
| 1-amino-3-fluorocyclobutane-1-carboxylic acid:0 | 6/138,393 | 10/26,262,527 | 113.87 | 1.59e-10 | 1.51e-09 |
| Thrombomodulin|THBD:0 | 1/138,393 | 4,604/26,262,527 | 0.04 | 1.29e-09 | 1.14e-08 |
| Ureterostomy procedure:0 | 13/138,393 | 306/26,262,527 | 8.06 | 2.26e-08 | 1.76e-07 |
| Medical center:0 | 79/138,393 | 7,680/26,262,527 | 1.95 | 9.50e-08 | 6.89e-07 |
| Membrane Transport Proteins:0 | 105/138,393 | 42,033/26,262,527 | 0.47 | 4.98e-18 | 7.76e-17 |
| beta-Lactams:0 | 2/138,393 | 5,655/26,262,527 | 0.07 | 1.32e-10 | 1.26e-09 |
| samarium ethylenediaminetetramethylenephosphonate:0 | 9/138,393 | 68/26,262,527 | 25.12 | 3.50e-10 | 3.22e-09 |
| Prodrugs:0 | 28/138,393 | 1,010/26,262,527 | 5.26 | 5.46e-12 | 5.84e-11 |
| Deferoxamine:0 | 12/138,393 | 8,914/26,262,527 | 0.26 | 2.87e-09 | 2.45e-08 |
| VIABLE CELLS:0 | 66/138,393 | 4,542/26,262,527 | 2.76 | 1.44e-12 | 1.61e-11 |
| Experimental Autoimmune Encephalomyelitis:0 | 1/138,393 | 8,356/26,262,527 | 0.02 | 7.89e-18 | 1.22e-16 |
| Titanium:0 | 3/138,393 | 4,558/26,262,527 | 0.12 | 1.80e-07 | 1.27e-06 |
| Imaging Device:0 | 55/138,393 | 1,386/26,262,527 | 7.53 | 4.32e-29 | 1.05e-27 |
| Histone Deacetylase Inhibitor:0 | 73/138,393 | 2,304/26,262,527 | 6.02 | 4.47e-32 | 1.20e-30 |
| Genetic Predisposition to Disease:0 | 37/138,393 | 2,750/26,262,527 | 2.55 | 5.96e-07 | 3.96e-06 |
| Death (finding):0 | 446/138,393 | 31,124/26,262,527 | 2.72 | 3.98e-73 | 2.53e-71 |
| [M]Unspecified tumor cell NOS:0 | 2,310/138,393 | 75,073/26,262,527 | 5.92 | 0.00e+00 | 0.00e+00 |
| OCM:0 | 8/138,393 | 93/26,262,527 | 16.32 | 7.47e-08 | 5.47e-07 |
| Promoter Regions (Genetics):0 | 114/138,393 | 6,625/26,262,527 | 3.27 | 4.83e-26 | 1.05e-24 |
| Wolff-Parkinson-White Syndrome:0 | 1/138,393 | 3,995/26,262,527 | 0.05 | 3.48e-08 | 2.64e-07 |
| Neurovascular bundle:0 | 157/138,393 | 843/26,262,527 | 35.38 | 2.11e-173 | 3.41e-171 |
| Albuminuria:0 | 3/138,393 | 5,215/26,262,527 | 0.11 | 8.20e-09 | 6.68e-08 |
| DNA, Complementary:0 | 234/138,393 | 22,436/26,262,527 | 1.98 | 7.96e-21 | 1.41e-19 |
| Entire olfactory bulb:0 | 1/138,393 | 9,936/26,262,527 | 0.02 | 2.60e-21 | 4.70e-20 |
| Orthomyxoviridae:0 | 4/138,393 | 11,219/26,262,527 | 0.07 | 2.29e-20 | 3.98e-19 |
| Thyrotropin:0 | 16/138,393 | 13,729/26,262,527 | 0.22 | 2.70e-15 | 3.63e-14 |
| Overweight:0 | 85/138,393 | 36,917/26,262,527 | 0.44 | 1.78e-18 | 2.82e-17 |
| leukemia:0 | 441/138,393 | 53,501/26,262,527 | 1.57 | 2.16e-18 | 3.42e-17 |
| Prolactin|PGR|PR@|PRH2|TMEM37|ERVK-10:0 | 8/138,393 | 107/26,262,527 | 14.19 | 2.05e-07 | 1.43e-06 |
| THIN FILM:0 | 2/138,393 | 6,081/26,262,527 | 0.06 | 1.54e-11 | 1.59e-10 |
| Prosencephalon:0 | 1/138,393 | 22,614/26,262,527 | 0.01 | 6.78e-50 | 2.94e-48 |
| Suicide Gene Therapy:0 | 40/138,393 | 474/26,262,527 | 16.02 | 3.74e-33 | 1.04e-31 |
| Stroke, Acute:0 | 2/138,393 | 11,484/26,262,527 | 0.03 | 1.88e-23 | 3.70e-22 |
| Entire common bile duct:0 | 3/138,393 | 6,365/26,262,527 | 0.09 | 4.80e-11 | 4.75e-10 |
| dihydroxy-vitamin D3:0 | 102/138,393 | 4,786/26,262,527 | 4.05 | 2.66e-30 | 6.74e-29 |
| Substance P:0 | 12/138,393 | 34,092/26,262,527 | 0.07 | 6.35e-60 | 3.36e-58 |
| Mutagens:0 | 43/138,393 | 16,676/26,262,527 | 0.49 | 1.78e-07 | 1.25e-06 |
| Lithium:0 | 5/138,393 | 24,098/26,262,527 | 0.04 | 6.00e-47 | 2.47e-45 |
| Cancer Prognosis:0 | 22/138,393 | 208/26,262,527 | 20.07 | 6.78e-21 | 1.20e-19 |
| Xerostomia:0 | 4/138,393 | 4,914/26,262,527 | 0.15 | 2.89e-07 | 1.99e-06 |
| Pneumothorax:0 | 2/138,393 | 7,607/26,262,527 | 0.05 | 8.66e-15 | 1.12e-13 |
| Coronary Arteriosclerosis:0 | 36/138,393 | 101,100/26,262,527 | 0.07 | 6.09e-175 | 1.02e-172 |
| CDK2 gene|CDK2:0 | 86/138,393 | 4,776/26,262,527 | 3.42 | 2.95e-21 | 5.33e-20 |
| Tuberculosis, active:0 | 2/138,393 | 3,930/26,262,527 | 0.10 | 4.17e-07 | 2.82e-06 |
| Mineralocorticoid Receptor:0 | 7/138,393 | 5,670/26,262,527 | 0.23 | 1.26e-06 | 8.08e-06 |
| Glucocorticoids:0 | 101/138,393 | 49,055/26,262,527 | 0.39 | 1.05e-28 | 2.53e-27 |
| caspase:0 | 183/138,393 | 12,222/26,262,527 | 2.84 | 2.48e-33 | 6.94e-32 |
| Entire gastrocnemius:0 | 1/138,393 | 13,338/26,262,527 | 0.01 | 5.78e-29 | 1.40e-27 |
| Destructive procedure on pituitary gland:0 | 6/138,393 | 53/26,262,527 | 21.48 | 7.37e-07 | 4.85e-06 |
| Excitation:0 | 5/138,393 | 8,513/26,262,527 | 0.11 | 1.11e-13 | 1.34e-12 |
| Revascularization - action:0 | 5/138,393 | 24,538/26,262,527 | 0.04 | 7.10e-48 | 2.99e-46 |
| DNA Fragmentation:0 | 51/138,393 | 3,362/26,262,527 | 2.88 | 1.08e-10 | 1.04e-09 |
| DNA, Mitochondrial:0 | 36/138,393 | 15,528/26,262,527 | 0.44 | 2.31e-08 | 1.79e-07 |
| Child Development Disorders:0 | 1/138,393 | 8,686/26,262,527 | 0.02 | 1.22e-18 | 1.96e-17 |
| Bulimia:0 | 1/138,393 | 7,635/26,262,527 | 0.02 | 3.01e-16 | 4.25e-15 |
| Short stature:0 | 3/138,393 | 6,540/26,262,527 | 0.09 | 1.58e-11 | 1.63e-10 |
| Goserelin|EREG|ESR1:0 | 31/138,393 | 57/26,262,527 | 103.23 | 8.36e-48 | 3.51e-46 |
| New Zealand white rabbit:0 | 1/138,393 | 4,168/26,262,527 | 0.05 | 1.80e-08 | 1.41e-07 |
| Author:0 | 442/138,393 | 57,164/26,262,527 | 1.47 | 3.28e-14 | 4.12e-13 |
| Virus Diseases:0 | 84/138,393 | 71,852/26,262,527 | 0.22 | 1.37e-74 | 8.87e-73 |
| Ciliary Body:0 | 2/138,393 | 4,899/26,262,527 | 0.08 | 4.36e-09 | 3.65e-08 |
| Taxotere:0 | 107/138,393 | 1,690/26,262,527 | 12.02 | 7.95e-74 | 5.11e-72 |
| growth hormone-releasing hormone receptor:0 | 15/138,393 | 487/26,262,527 | 5.85 | 1.14e-07 | 8.19e-07 |
| Radical hysterectomy:0 | 1/138,393 | 4,080/26,262,527 | 0.05 | 2.49e-08 | 1.92e-07 |
| Dialysis procedure:0 | 14/138,393 | 21,075/26,262,527 | 0.13 | 8.64e-31 | 2.23e-29 |
| Respiratory Failure:0 | 7/138,393 | 12,928/26,262,527 | 0.10 | 9.62e-21 | 1.70e-19 |
| Antiretroviral Therapy, Highly Active:0 | 5/138,393 | 8,395/26,262,527 | 0.11 | 2.26e-13 | 2.66e-12 |
| Nifedipine:0 | 7/138,393 | 24,785/26,262,527 | 0.05 | 8.39e-46 | 3.35e-44 |
| Cell Nucleus:0 | 95/138,393 | 8,243/26,262,527 | 2.19 | 1.79e-11 | 1.83e-10 |
| Cyclosporine|RIT2:0 | 4/138,393 | 5/26,262,527 | 151.82 | 9.32e-08 | 6.77e-07 |
| Skin Diseases, Infectious:0 | 1/138,393 | 4,324/26,262,527 | 0.04 | 5.53e-09 | 4.58e-08 |
| wave:0 | 27/138,393 | 23,746/26,262,527 | 0.22 | 6.24e-26 | 1.35e-24 |
| Fibronectins:0 | 123/138,393 | 41,633/26,262,527 | 0.56 | 1.89e-12 | 2.08e-11 |
| Uveitis:0 | 1/138,393 | 15,813/26,262,527 | 0.01 | 1.48e-34 | 4.30e-33 |
| Flare:0 | 81/138,393 | 4,483/26,262,527 | 3.43 | 3.32e-20 | 5.70e-19 |
| Interferon Type II:0 | 2/138,393 | 4,065/26,262,527 | 0.09 | 3.14e-07 | 2.15e-06 |
| Paraffin:0 | 149/138,393 | 11,560/26,262,527 | 2.45 | 1.85e-21 | 3.37e-20 |
| KLK10 gene|KLK10:0 | 6/138,393 | 56/26,262,527 | 20.33 | 9.92e-07 | 6.42e-06 |
| Primary Carcinoma:0 | 178/138,393 | 15,209/26,262,527 | 2.22 | 6.12e-21 | 1.09e-19 |
| Mitochondria:0 | 230/138,393 | 66,534/26,262,527 | 0.66 | 8.57e-12 | 8.99e-11 |
| Urine specimen:0 | 70/138,393 | 2,827/26,262,527 | 4.70 | 7.98e-25 | 1.66e-23 |
| Growth acceleration:0 | 26/138,393 | 1,546/26,262,527 | 3.19 | 5.53e-07 | 3.69e-06 |
| Folic Acid:0 | 23/138,393 | 11,855/26,262,527 | 0.37 | 1.76e-08 | 1.39e-07 |
| Polysomnography:0 | 1/138,393 | 5,289/26,262,527 | 0.04 | 5.13e-11 | 5.06e-10 |
| Gonadotropin releasing hormone antagonist:0 | 64/138,393 | 1,354/26,262,527 | 8.97 | 9.54e-38 | 3.10e-36 |
| Glioma:0 | 199/138,393 | 63,251/26,262,527 | 0.60 | 2.92e-15 | 3.91e-14 |
| Thoracotomy:0 | 2/138,393 | 9,289/26,262,527 | 0.04 | 1.43e-18 | 2.28e-17 |
| OGX-011:0 | 14/138,393 | 59/26,262,527 | 45.03 | 3.27e-18 | 5.14e-17 |
| Multiple System Atrophy:0 | 1/138,393 | 5,614/26,262,527 | 0.03 | 8.01e-12 | 8.43e-11 |
| Urethral Diseases:0 | 16/138,393 | 543/26,262,527 | 5.59 | 7.86e-08 | 5.74e-07 |
| Defibrillators:0 | 1/138,393 | 5,368/26,262,527 | 0.04 | 3.62e-11 | 3.62e-10 |
| Gastrin|GAST:0 | 4/138,393 | 9,718/26,262,527 | 0.08 | 3.83e-17 | 5.70e-16 |
| Blood flow:0 | 46/138,393 | 56,850/26,262,527 | 0.15 | 4.90e-74 | 3.16e-72 |
| Forearm:0 | 11/138,393 | 12,495/26,262,527 | 0.17 | 1.59e-16 | 2.29e-15 |
| Advanced cancer:0 | 1,013/138,393 | 28,658/26,262,527 | 6.75 | 0.00e+00 | 0.00e+00 |
| Congestive heart failure:0 | 26/138,393 | 43,135/26,262,527 | 0.11 | 2.59e-64 | 1.47e-62 |
| Urination:0 | 143/138,393 | 4,559/26,262,527 | 5.96 | 1.39e-60 | 7.42e-59 |
| Spinal Dysraphism:0 | 1/138,393 | 5,403/26,262,527 | 0.04 | 2.39e-11 | 2.42e-10 |
| effusion:0 | 14/138,393 | 9,202/26,262,527 | 0.29 | 1.26e-08 | 1.01e-07 |
| Retinol Binding Proteins:0 | 1/138,393 | 3,778/26,262,527 | 0.05 | 1.03e-07 | 7.42e-07 |
| Fibrosis, Liver:0 | 2/138,393 | 17,065/26,262,527 | 0.02 | 8.89e-36 | 2.71e-34 |
| Imaging Techniques:0 | 104/138,393 | 5,126/26,262,527 | 3.85 | 3.24e-29 | 7.91e-28 |
| PSCA:0 | 20/138,393 | 84/26,262,527 | 45.19 | 2.06e-25 | 4.36e-24 |
| Respiration Disorders:0 | 7/138,393 | 18,555/26,262,527 | 0.07 | 1.41e-32 | 3.84e-31 |
| Preoptic Areas:0 | 1/138,393 | 5,387/26,262,527 | 0.04 | 3.79e-11 | 3.79e-10 |
| Radiofrequency ablation:0 | 26/138,393 | 16,915/26,262,527 | 0.29 | 9.22e-15 | 1.20e-13 |
| Organic Chemicals:0 | 10/138,393 | 7,880/26,262,527 | 0.24 | 1.26e-08 | 1.00e-07 |
| Infectious disease of lung:0 | 5/138,393 | 8,789/26,262,527 | 0.11 | 2.79e-14 | 3.52e-13 |
| External iliac lymph node group:0 | 5/138,393 | 22/26,262,527 | 43.13 | 2.90e-07 | 2.00e-06 |
| Organ:0 | 1,173/138,393 | 129,821/26,262,527 | 1.72 | 2.04e-64 | 1.16e-62 |
| Gallbladder:0 | 71/138,393 | 23,982/26,262,527 | 0.56 | 1.23e-07 | 8.78e-07 |
| Mail:0 | 55/138,393 | 4,698/26,262,527 | 2.22 | 1.65e-07 | 1.16e-06 |
| free radical oxygen:0 | 2/138,393 | 4,315/26,262,527 | 0.09 | 7.29e-08 | 5.34e-07 |
| Adenovirus Vector:0 | 66/138,393 | 2,652/26,262,527 | 4.72 | 1.29e-23 | 2.55e-22 |
| Polyneuropathy:0 | 1/138,393 | 5,576/26,262,527 | 0.03 | 1.20e-11 | 1.25e-10 |
| Sudden infant death syndrome:0 | 1/138,393 | 4,985/26,262,527 | 0.04 | 2.14e-10 | 2.01e-09 |
| MYC gene|MYC:0 | 151/138,393 | 8,634/26,262,527 | 3.32 | 1.20e-34 | 3.51e-33 |
| Octreotide|OXT:0 | 4/138,393 | 6/26,262,527 | 126.52 | 1.55e-07 | 1.09e-06 |
| Azithromycin:0 | 1/138,393 | 10,563/26,262,527 | 0.02 | 9.32e-23 | 1.79e-21 |
| disorder control:0 | 77/138,393 | 4,228/26,262,527 | 3.46 | 1.77e-19 | 2.95e-18 |
| Second Primary Cancers:0 | 274/138,393 | 6,073/26,262,527 | 8.58 | 9.64e-151 | 1.31e-148 |
| Sun Exposure:0 | 20/138,393 | 1,023/26,262,527 | 3.71 | 1.21e-06 | 7.74e-06 |
| Female breast:0 | 69/138,393 | 1,023/26,262,527 | 12.81 | 6.16e-50 | 2.68e-48 |
| voriconazole:0 | 1/138,393 | 5,275/26,262,527 | 0.04 | 5.02e-11 | 4.96e-10 |
| Cicatrix:0 | 14/138,393 | 16,629/26,262,527 | 0.16 | 4.07e-22 | 7.60e-21 |
| Elements:0 | 74/138,393 | 31,020/26,262,527 | 0.45 | 7.16e-15 | 9.35e-14 |
| Polycystic Ovary Syndrome:0 | 19/138,393 | 40,526/26,262,527 | 0.09 | 9.28e-66 | 5.42e-64 |
| Lens, Crystalline:0 | 6/138,393 | 33,999/26,262,527 | 0.03 | 1.80e-67 | 1.08e-65 |
| modafinil:0 | 1/138,393 | 3,335/26,262,527 | 0.06 | 8.82e-07 | 5.76e-06 |
| Trehalose:0 | 1/138,393 | 4,473/26,262,527 | 0.04 | 2.69e-09 | 2.29e-08 |
| Flow:0 | 19/138,393 | 16,174/26,262,527 | 0.22 | 1.17e-17 | 1.78e-16 |
| Megestrol Acetate:0 | 36/138,393 | 2,501/26,262,527 | 2.73 | 1.81e-07 | 1.27e-06 |
| Prostate Embryonal Rhabdomyosarcoma:0 | 5/138,393 | 18/26,262,527 | 52.72 | 1.23e-07 | 8.80e-07 |
| Diarrhea:0 | 87/138,393 | 33,922/26,262,527 | 0.49 | 4.31e-14 | 5.36e-13 |
| Midazolam:0 | 10/138,393 | 15,325/26,262,527 | 0.12 | 9.06e-23 | 1.74e-21 |
| myometrium:0 | 7/138,393 | 11,935/26,262,527 | 0.11 | 8.03e-19 | 1.30e-17 |
| Ritonavir:0 | 3/138,393 | 4,736/26,262,527 | 0.12 | 9.34e-08 | 6.78e-07 |
| Vascular anomaly:0 | 4/138,393 | 6,866/26,262,527 | 0.11 | 2.97e-11 | 2.99e-10 |
| Androsterone:0 | 18/138,393 | 588/26,262,527 | 5.81 | 7.12e-09 | 5.84e-08 |
| Serine Protease:0 | 250/138,393 | 13,678/26,262,527 | 3.47 | 1.72e-59 | 9.01e-58 |
| Leuprolide Acetate:0 | 130/138,393 | 1,845/26,262,527 | 13.38 | 1.15e-94 | 9.56e-93 |
| Verapamil:0 | 15/138,393 | 26,283/26,262,527 | 0.11 | 1.93e-40 | 6.79e-39 |
| XPR1:0 | 7/138,393 | 58/26,262,527 | 22.90 | 5.80e-08 | 4.28e-07 |
| Hard prostate:0 | 9/138,393 | 10/26,262,527 | 170.80 | 2.63e-16 | 3.74e-15 |
| Enkephalins:0 | 3/138,393 | 9,157/26,262,527 | 0.06 | 4.82e-17 | 7.14e-16 |
| Early gastric cancer:0 | 6/138,393 | 6,027/26,262,527 | 0.19 | 5.62e-08 | 4.16e-07 |
| Cell Adhesion:0 | 228/138,393 | 15,305/26,262,527 | 2.83 | 9.45e-41 | 3.35e-39 |
| ESR1 protein, human|ESR1:0 | 190/138,393 | 20,573/26,262,527 | 1.75 | 1.54e-12 | 1.71e-11 |
| Deglutition Disorders:0 | 5/138,393 | 17,665/26,262,527 | 0.05 | 6.68e-33 | 1.85e-31 |
| Bone structure of carpus:0 | 1/138,393 | 3,920/26,262,527 | 0.05 | 4.98e-08 | 3.71e-07 |
| Apomorphine:0 | 2/138,393 | 9,867/26,262,527 | 0.04 | 7.98e-20 | 1.35e-18 |
| Cyclin D1|LMOD1|BBS9:0 | 50/138,393 | 3,310/26,262,527 | 2.87 | 1.87e-10 | 1.77e-09 |
| Benign prostatic hypertrophy:0 | 3,638/138,393 | 23,882/26,262,527 | 29.66 | 0.00e+00 | 0.00e+00 |
| Iron deficiency:0 | 2/138,393 | 9,269/26,262,527 | 0.04 | 1.41e-18 | 2.26e-17 |
| Domestic Sheep:0 | 6/138,393 | 30,073/26,262,527 | 0.04 | 7.93e-59 | 4.11e-57 |
| Rectal Fistula:0 | 16/138,393 | 142/26,262,527 | 21.38 | 5.29e-16 | 7.36e-15 |
| Microinjections:0 | 1/138,393 | 4,486/26,262,527 | 0.04 | 2.72e-09 | 2.32e-08 |
| Acetate:0 | 333/138,393 | 18,826/26,262,527 | 3.36 | 2.78e-75 | 1.84e-73 |
| fosfestrol:0 | 85/138,393 | 224/26,262,527 | 72.05 | 1.94e-117 | 1.99e-115 |
| COLLAGENASE:0 | 21/138,393 | 14,543/26,262,527 | 0.27 | 1.10e-13 | 1.33e-12 |
| Cholinergic Receptors:0 | 3/138,393 | 10,158/26,262,527 | 0.06 | 3.26e-19 | 5.36e-18 |
| Carcinoembryonic Antigen:0 | 118/138,393 | 12,639/26,262,527 | 1.77 | 1.30e-08 | 1.03e-07 |
| Leukocytes:0 | 143/138,393 | 61,338/26,262,527 | 0.44 | 3.23e-29 | 7.90e-28 |
| antiangiogenesis therapy:0 | 26/138,393 | 895/26,262,527 | 5.51 | 1.14e-11 | 1.19e-10 |
| Partial excision of bladder NOS:0 | 22/138,393 | 862/26,262,527 | 4.84 | 4.09e-09 | 3.44e-08 |
| Pertussis Toxin:0 | 16/138,393 | 10,876/26,262,527 | 0.28 | 2.76e-10 | 2.56e-09 |
| Helicobacter pylori:0 | 10/138,393 | 21,931/26,262,527 | 0.09 | 2.21e-36 | 6.91e-35 |
| Gene Expression Profiling:0 | 50/138,393 | 2,732/26,262,527 | 3.47 | 2.64e-13 | 3.11e-12 |
| Disorder of soft tissue:0 | 35/138,393 | 432/26,262,527 | 15.38 | 1.17e-28 | 2.81e-27 |
| Necrosis:0 | 153/138,393 | 43,217/26,262,527 | 0.67 | 1.98e-07 | 1.38e-06 |
| Longitudinal Studies:0 | 766/138,393 | 50,484/26,262,527 | 2.89 | 2.16e-136 | 2.65e-134 |
| Neurostimulation procedures of spinal cord tissue:0 | 1/138,393 | 3,804/26,262,527 | 0.05 | 1.09e-07 | 7.79e-07 |
| adalimumab:0 | 1/138,393 | 9,514/26,262,527 | 0.02 | 2.37e-20 | 4.10e-19 |
| Doxazosin:0 | 58/138,393 | 4,209/26,262,527 | 2.62 | 2.14e-10 | 2.01e-09 |
| 10q:0 | 29/138,393 | 426/26,262,527 | 12.92 | 4.63e-22 | 8.62e-21 |
| Proprotein Convertase 1|KRT6A|PCSK1|BTG2|ACTR1B|CBX8:0 | 468/138,393 | 1,009/26,262,527 | 88.31 | 0.00e+00 | 0.00e+00 |
| oblimersen:0 | 16/138,393 | 255/26,262,527 | 11.91 | 2.38e-12 | 2.60e-11 |
| Hydrogen, Homeopathic preparation:0 | 2/138,393 | 5,836/26,262,527 | 0.07 | 4.32e-11 | 4.31e-10 |
| Muscle Contraction:0 | 4/138,393 | 5,320/26,262,527 | 0.14 | 3.75e-08 | 2.83e-07 |
| Claudication:0 | 1/138,393 | 4,172/26,262,527 | 0.05 | 1.14e-08 | 9.13e-08 |
| Follicular Fluid:0 | 5/138,393 | 5,209/26,262,527 | 0.18 | 4.02e-07 | 2.72e-06 |
| topiramate:0 | 1/138,393 | 9,134/26,262,527 | 0.02 | 1.40e-19 | 2.34e-18 |
| Urologist:0 | 390/138,393 | 2,124/26,262,527 | 34.94 | 0.00e+00 | 0.00e+00 |
| Cancer Prevention Trial:0 | 7/138,393 | 35/26,262,527 | 37.96 | 2.50e-09 | 2.14e-08 |
| Fenretinide:0 | 45/138,393 | 2,080/26,262,527 | 4.11 | 1.57e-14 | 2.00e-13 |
| Frequency of micturition:0 | 18/138,393 | 731/26,262,527 | 4.67 | 1.68e-07 | 1.18e-06 |
| ADAM9:0 | 11/138,393 | 297/26,262,527 | 7.03 | 9.79e-07 | 6.35e-06 |
| Rats, Sprague-Dawley:0 | 40/138,393 | 25,325/26,262,527 | 0.30 | 5.07e-21 | 9.06e-20 |
| Growth stimulant:0 | 28/138,393 | 822/26,262,527 | 6.47 | 4.82e-14 | 5.99e-13 |
| Replacement blood transfusion:0 | 9/138,393 | 25/26,262,527 | 68.32 | 1.39e-13 | 1.68e-12 |
| Estrogen Receptor alpha:0 | 187/138,393 | 17,690/26,262,527 | 2.01 | 1.31e-17 | 1.99e-16 |
| Histamine:0 | 15/138,393 | 39,491/26,262,527 | 0.07 | 6.09e-68 | 3.64e-66 |
| REG3A|ASAP2|MRPS30|PAPOLA|PDAP1|TUSC2|ASAP1:0 | 38/138,393 | 1,005/26,262,527 | 7.18 | 6.14e-20 | 1.04e-18 |
| Magnetic resonance imaging unit:0 | 22/138,393 | 918/26,262,527 | 4.55 | 1.22e-08 | 9.72e-08 |
| 2,3-bis(3'-hydroxybenzyl)butyrolactone:0 | 32/138,393 | 737/26,262,527 | 8.24 | 1.10e-18 | 1.76e-17 |
| glutathione S-transferase pi:0 | 33/138,393 | 1,341/26,262,527 | 4.67 | 1.69e-12 | 1.88e-11 |
| Traumatic Rupture:0 | 2/138,393 | 10,573/26,262,527 | 0.04 | 2.12e-21 | 3.84e-20 |
| HSP90 Heat-Shock Proteins|HSP90AA1:0 | 86/138,393 | 8,829/26,262,527 | 1.85 | 2.15e-07 | 1.50e-06 |
| Heart Ventricle:0 | 1/138,393 | 11,109/26,262,527 | 0.02 | 4.78e-24 | 9.67e-23 |
| Inositol Phosphates:0 | 8/138,393 | 6,319/26,262,527 | 0.24 | 3.23e-07 | 2.21e-06 |
| Vertebrates:0 | 46/138,393 | 46,550/26,262,527 | 0.19 | 1.38e-54 | 6.55e-53 |
| Cyclin-Dependent Kinase Inhibitor Proteins:0 | 61/138,393 | 2,206/26,262,527 | 5.25 | 3.66e-24 | 7.41e-23 |
| Splenectomy:0 | 8/138,393 | 13,191/26,262,527 | 0.12 | 2.53e-20 | 4.37e-19 |
| Condoms, Male:0 | 18/138,393 | 14,953/26,262,527 | 0.23 | 3.70e-16 | 5.21e-15 |
| Helicobacter Infections:0 | 3/138,393 | 12,472/26,262,527 | 0.05 | 3.49e-24 | 7.09e-23 |
| Papillomavirus Infections:0 | 47/138,393 | 17,843/26,262,527 | 0.50 | 1.46e-07 | 1.04e-06 |
| Muscle, Smooth, Vascular:0 | 6/138,393 | 12,385/26,262,527 | 0.09 | 1.41e-20 | 2.47e-19 |
| Entire fetus:0 | 3/138,393 | 11,682/26,262,527 | 0.05 | 1.81e-22 | 3.43e-21 |
| Pulmonary arterial hypertension:0 | 1/138,393 | 15,930/26,262,527 | 0.01 | 6.77e-35 | 2.01e-33 |
| Central gray substance of midbrain:0 | 1/138,393 | 6,291/26,262,527 | 0.03 | 3.14e-13 | 3.68e-12 |
| mesalamine:0 | 5/138,393 | 6,884/26,262,527 | 0.14 | 1.94e-10 | 1.84e-09 |
| Nitric Oxide:0 | 84/138,393 | 147,628/26,262,527 | 0.11 | 5.28e-222 | 1.11e-219 |
| Mutant:0 | 18/138,393 | 21,170/26,262,527 | 0.16 | 1.18e-27 | 2.73e-26 |
| Retro-pubic prostatectomy:0 | 5/138,393 | 8/26,262,527 | 118.61 | 4.92e-09 | 4.09e-08 |
| Therapies, Investigational:0 | 26/138,393 | 1,105/26,262,527 | 4.47 | 8.85e-10 | 7.90e-09 |
| Brachytherapy Systems:0 | 10/138,393 | 75/26,262,527 | 25.30 | 3.43e-11 | 3.44e-10 |
| Urogenital Diseases:0 | 34/138,393 | 451/26,262,527 | 14.31 | 6.21e-27 | 1.40e-25 |
| Areae:0 | 482/138,393 | 68,353/26,262,527 | 1.34 | 9.79e-10 | 8.68e-09 |
| Chromogranin A|CGA:0 | 62/138,393 | 353/26,262,527 | 33.34 | 3.52e-68 | 2.12e-66 |
| Antibody Formation:0 | 41/138,393 | 22,333/26,262,527 | 0.35 | 6.39e-16 | 8.84e-15 |
| Chlorpromazine:0 | 2/138,393 | 8,523/26,262,527 | 0.04 | 7.79e-17 | 1.14e-15 |
| Dementia:0 | 23/138,393 | 70,232/26,262,527 | 0.06 | 3.45e-124 | 3.79e-122 |
| HLA-DR Antigens:0 | 1/138,393 | 3,427/26,262,527 | 0.06 | 6.35e-07 | 4.20e-06 |
| Immunoconjugates:0 | 25/138,393 | 960/26,262,527 | 4.94 | 2.51e-10 | 2.35e-09 |
| Gonadorelin|GNRH1:0 | 443/138,393 | 18,242/26,262,527 | 4.62 | 2.03e-144 | 2.65e-142 |
| Genes, rRNA:0 | 6/138,393 | 21,335/26,262,527 | 0.05 | 1.39e-39 | 4.76e-38 |
| Tendon structure:0 | 3/138,393 | 7,180/26,262,527 | 0.08 | 6.67e-13 | 7.60e-12 |
| Entire membranous urethra:0 | 13/138,393 | 141/26,262,527 | 17.50 | 2.97e-12 | 3.22e-11 |
| Nuclear Receptor Coactivator 4|AR:0 | 6/138,393 | 19/26,262,527 | 59.93 | 3.37e-09 | 2.85e-08 |
| Cyclin-Dependent Kinase 4|CDK4:0 | 45/138,393 | 1,947/26,262,527 | 4.39 | 1.63e-15 | 2.22e-14 |
| CHKA gene|CHKA:0 | 23/138,393 | 536/26,262,527 | 8.14 | 9.06e-14 | 1.11e-12 |
| Schools, Medical:0 | 7/138,393 | 8,600/26,262,527 | 0.15 | 4.56e-12 | 4.90e-11 |
| cancer radiation therapy:0 | 7/138,393 | 49/26,262,527 | 27.11 | 2.01e-08 | 1.57e-07 |
| Saphenous Vein:0 | 1/138,393 | 5,794/26,262,527 | 0.03 | 4.05e-12 | 4.37e-11 |
| Oxidoreductase:0 | 330/138,393 | 36,175/26,262,527 | 1.73 | 6.97e-20 | 1.18e-18 |
| college student:0 | 2/138,393 | 10,231/26,262,527 | 0.04 | 1.32e-20 | 2.31e-19 |
| Prenatal Diagnosis:0 | 2/138,393 | 5,195/26,262,527 | 0.07 | 1.07e-09 | 9.41e-09 |
| Radioisotopes:0 | 111/138,393 | 8,895/26,262,527 | 2.37 | 2.22e-15 | 2.99e-14 |
| Cervical spine:0 | 12/138,393 | 15,690/26,262,527 | 0.15 | 6.31e-22 | 1.17e-20 |
| Gliosis:0 | 1/138,393 | 3,440/26,262,527 | 0.06 | 6.53e-07 | 4.31e-06 |
| Hypersensitivity:0 | 43/138,393 | 46,309/26,262,527 | 0.18 | 2.68e-56 | 1.32e-54 |
| Dopamine Receptor:0 | 3/138,393 | 12,517/26,262,527 | 0.05 | 2.35e-24 | 4.80e-23 |
| Somatomedins:0 | 354/138,393 | 19,992/26,262,527 | 3.37 | 5.06e-80 | 3.57e-78 |
| Problem drinker:0 | 3/138,393 | 17,564/26,262,527 | 0.03 | 2.67e-35 | 7.99e-34 |
| catheter device:0 | 34/138,393 | 14,019/26,262,527 | 0.46 | 3.28e-07 | 2.24e-06 |
| Bombesin Antagonist:0 | 17/138,393 | 127/26,262,527 | 25.40 | 4.70e-18 | 7.32e-17 |
| Interstitial fibrosis:0 | 1/138,393 | 3,782/26,262,527 | 0.05 | 1.04e-07 | 7.47e-07 |
| Ultraviolet B Radiation:0 | 8/138,393 | 10,970/26,262,527 | 0.14 | 6.25e-16 | 8.66e-15 |
| Adenosis:0 | 11/138,393 | 291/26,262,527 | 7.17 | 8.08e-07 | 5.31e-06 |
| Glutamate-Ammonia Ligase:0 | 3/138,393 | 6,488/26,262,527 | 0.09 | 2.29e-11 | 2.32e-10 |
| Prostatectomy, Retropubic:0 | 271/138,393 | 610/26,262,527 | 84.47 | 0.00e+00 | 0.00e+00 |
| ETS1 gene|ETS1:0 | 109/138,393 | 3,178/26,262,527 | 6.51 | 4.12e-50 | 1.80e-48 |
| Hyperactive behavior:0 | 13/138,393 | 10,180/26,262,527 | 0.24 | 6.62e-11 | 6.46e-10 |
| Myocytes, Smooth Muscle:0 | 111/138,393 | 97,507/26,262,527 | 0.22 | 1.19e-102 | 1.06e-100 |
| Mastodynia:0 | 31/138,393 | 829/26,262,527 | 7.10 | 1.96e-16 | 2.80e-15 |
| Anti-Arrhythmia Agents:0 | 5/138,393 | 17,292/26,262,527 | 0.05 | 3.86e-32 | 1.04e-30 |
| Voice:0 | 3/138,393 | 5,011/26,262,527 | 0.11 | 2.32e-08 | 1.80e-07 |
| Callithrix:0 | 2/138,393 | 4,862/26,262,527 | 0.08 | 6.54e-09 | 5.38e-08 |
| Leak NOS:0 | 28/138,393 | 11,996/26,262,527 | 0.44 | 1.02e-06 | 6.61e-06 |
| Hemodynamics:0 | 8/138,393 | 37,608/26,262,527 | 0.04 | 1.92e-72 | 1.22e-70 |
| Goserelin Acetate:0 | 68/138,393 | 308/26,262,527 | 41.92 | 1.38e-80 | 9.76e-79 |
| Fertility:0 | 67/138,393 | 28,282/26,262,527 | 0.45 | 9.29e-14 | 1.13e-12 |
| Candidiasis:0 | 2/138,393 | 8,780/26,262,527 | 0.04 | 1.77e-17 | 2.67e-16 |
| Lobe:0 | 483/138,393 | 41,342/26,262,527 | 2.22 | 1.18e-53 | 5.47e-52 |
| Neural Cell Adhesion Molecules:0 | 5/138,393 | 5,170/26,262,527 | 0.18 | 5.85e-07 | 3.89e-06 |
| ELL:0 | 9/138,393 | 191/26,262,527 | 8.94 | 1.43e-06 | 9.07e-06 |
| CYP19A1 gene|CYP19A1:0 | 23/138,393 | 1,117/26,262,527 | 3.91 | 8.28e-08 | 6.03e-07 |
| Oligosaccharides:0 | 11/138,393 | 14,713/26,262,527 | 0.14 | 7.92e-21 | 1.40e-19 |
| Endorectal:0 | 286/138,393 | 1,305/26,262,527 | 41.67 | 0.00e+00 | 0.00e+00 |
| Solid tumor:0 | 1,007/138,393 | 33,165/26,262,527 | 5.80 | 0.00e+00 | 0.00e+00 |
| Voluntary Workers:0 | 103/138,393 | 52,274/26,262,527 | 0.37 | 1.69e-32 | 4.62e-31 |
| phosphoprotein 32|ANP32A:0 | 10/138,393 | 147/26,262,527 | 12.91 | 1.46e-08 | 1.15e-07 |
| Hormone manipulation:0 | 154/138,393 | 531/26,262,527 | 55.10 | 4.67e-196 | 8.74e-194 |
| Isoflurane:0 | 5/138,393 | 14,813/26,262,527 | 0.06 | 6.65e-27 | 1.49e-25 |
| Simian B disease:0 | 2/138,393 | 11,138/26,262,527 | 0.03 | 1.16e-22 | 2.22e-21 |
| Implants:0 | 332/138,393 | 44,210/26,262,527 | 1.43 | 1.13e-09 | 9.91e-09 |
| Tumorigenicity:0 | 330/138,393 | 8,583/26,262,527 | 7.31 | 1.44e-161 | 2.11e-159 |
| CYP24A1:0 | 24/138,393 | 696/26,262,527 | 6.54 | 2.30e-12 | 2.52e-11 |
| Extraction:0 | 76/138,393 | 45,536/26,262,527 | 0.32 | 1.03e-34 | 3.03e-33 |
| Prostatic obstruction:0 | 44/138,393 | 721/26,262,527 | 11.58 | 9.05e-31 | 2.34e-29 |
| Ankylosis:0 | 2/138,393 | 13,559/26,262,527 | 0.03 | 5.00e-28 | 1.17e-26 |
| telomerase activity:0 | 56/138,393 | 3,842/26,262,527 | 2.77 | 5.91e-11 | 5.81e-10 |
| Hepatitis B Virus:0 | 3/138,393 | 17,893/26,262,527 | 0.03 | 4.08e-36 | 1.26e-34 |
| ADRBK1 gene|ADRBK1:0 | 47/138,393 | 22,256/26,262,527 | 0.40 | 3.14e-13 | 3.67e-12 |
| Interleukin-2:0 | 108/138,393 | 40,038/26,262,527 | 0.51 | 9.39e-15 | 1.22e-13 |
| Nutraceuticals:0 | 16/138,393 | 555/26,262,527 | 5.47 | 1.05e-07 | 7.53e-07 |
| Hyperparathyroidism:0 | 10/138,393 | 7,952/26,262,527 | 0.24 | 9.21e-09 | 7.45e-08 |
| Vital capacity:0 | 2/138,393 | 5,196/26,262,527 | 0.07 | 1.07e-09 | 9.42e-09 |
| Chiroptera:0 | 6/138,393 | 5,924/26,262,527 | 0.19 | 1.13e-07 | 8.12e-07 |
| Numerical Chromosomal Abnormality:0 | 12/138,393 | 363/26,262,527 | 6.27 | 1.01e-06 | 6.54e-06 |
| Specimen:0 | 100/138,393 | 6,593/26,262,527 | 2.88 | 2.21e-19 | 3.67e-18 |
| Hip region structure:0 | 4/138,393 | 4,705/26,262,527 | 0.16 | 7.99e-07 | 5.25e-06 |
| Lateral Geniculate Body:0 | 1/138,393 | 6,492/26,262,527 | 0.03 | 1.03e-13 | 1.25e-12 |
| Alveolar ventilation function:0 | 21/138,393 | 14,343/26,262,527 | 0.28 | 2.71e-13 | 3.17e-12 |
| homocysteine:0 | 17/138,393 | 25,184/26,262,527 | 0.13 | 2.17e-36 | 6.81e-35 |
| Drug eluting stent:0 | 2/138,393 | 11,120/26,262,527 | 0.03 | 1.84e-22 | 3.47e-21 |
| Carcinoma, Ehrlich Tumor:0 | 5/138,393 | 5,207/26,262,527 | 0.18 | 4.01e-07 | 2.72e-06 |
| Cancer Survivor:0 | 181/138,393 | 3,396/26,262,527 | 10.13 | 1.24e-111 | 1.21e-109 |
| Vascular constriction (function):0 | 2/138,393 | 21,099/26,262,527 | 0.02 | 7.70e-45 | 3.01e-43 |
| Matrilysin:0 | 46/138,393 | 2,573/26,262,527 | 3.39 | 4.89e-12 | 5.26e-11 |
| Myopathy:0 | 13/138,393 | 17,500/26,262,527 | 0.14 | 1.31e-24 | 2.70e-23 |
| Glial:0 | 2/138,393 | 4,556/26,262,527 | 0.08 | 2.60e-08 | 2.00e-07 |
| Crystallins:0 | 2/138,393 | 6,197/26,262,527 | 0.06 | 7.27e-12 | 7.70e-11 |
| procollagen type I carboxy terminal peptide:0 | 25/138,393 | 983/26,262,527 | 4.83 | 4.02e-10 | 3.69e-09 |
| Weaning:0 | 1/138,393 | 8,914/26,262,527 | 0.02 | 4.15e-19 | 6.80e-18 |
| LIPOPROTEIN LIPASE|LPL:0 | 10/138,393 | 11,404/26,262,527 | 0.17 | 4.11e-15 | 5.45e-14 |
| Abdominal aorta structure:0 | 2/138,393 | 8,042/26,262,527 | 0.05 | 1.01e-15 | 1.39e-14 |
| CDC25C:0 | 21/138,393 | 813/26,262,527 | 4.90 | 7.45e-09 | 6.11e-08 |
| Plant Leaves:0 | 16/138,393 | 11,247/26,262,527 | 0.27 | 6.24e-11 | 6.11e-10 |
| Null cell:0 | 43/138,393 | 1,976/26,262,527 | 4.13 | 4.86e-14 | 6.05e-13 |
| Glyburide:0 | 4/138,393 | 11,347/26,262,527 | 0.07 | 1.76e-20 | 3.07e-19 |
| ETV4 gene|ETV4:0 | 23/138,393 | 120/26,262,527 | 36.38 | 4.30e-27 | 9.77e-26 |
| copolymer 1:0 | 1/138,393 | 3,362/26,262,527 | 0.06 | 9.23e-07 | 6.01e-06 |
| Antimicrobial susceptibility:0 | 675/138,393 | 87,620/26,262,527 | 1.46 | 1.87e-20 | 3.25e-19 |
| Peptidoglycan:0 | 1/138,393 | 8,463/26,262,527 | 0.02 | 3.65e-18 | 5.71e-17 |
| stricture; bladder, neck:0 | 7/138,393 | 24/26,262,527 | 55.35 | 2.56e-10 | 2.39e-09 |
| Gene Fusion:0 | 20/138,393 | 311/26,262,527 | 12.21 | 2.96e-15 | 3.96e-14 |
| Relative Risk:0 | 22/138,393 | 880/26,262,527 | 4.74 | 5.86e-09 | 4.85e-08 |
| Hereditary hemochromatosis:0 | 1/138,393 | 3,812/26,262,527 | 0.05 | 6.94e-08 | 5.10e-07 |
| Catecholamines:0 | 12/138,393 | 26,511/26,262,527 | 0.09 | 6.68e-44 | 2.55e-42 |
| Herpesvirus 4, Human:0 | 9/138,393 | 18,480/26,262,527 | 0.09 | 3.33e-30 | 8.42e-29 |
| Intestinal Mucosa:0 | 6/138,393 | 8,614/26,262,527 | 0.13 | 5.25e-13 | 6.04e-12 |
| Renin|REN:0 | 1/138,393 | 8,207/26,262,527 | 0.02 | 1.62e-17 | 2.45e-16 |
| Learning Disabilities:0 | 2/138,393 | 7,426/26,262,527 | 0.05 | 1.66e-14 | 2.12e-13 |
| Milk, Human:0 | 7/138,393 | 6,072/26,262,527 | 0.22 | 2.74e-07 | 1.89e-06 |
| Osteogenesis Imperfecta:0 | 4/138,393 | 5,864/26,262,527 | 0.13 | 3.61e-09 | 3.05e-08 |
| Gelatinase A:0 | 213/138,393 | 17,325/26,262,527 | 2.34 | 3.40e-27 | 7.75e-26 |
| Long-Term Survivors:0 | 101/138,393 | 5,500/26,262,527 | 3.49 | 2.87e-25 | 6.06e-24 |
| Major Histocompatibility Complex:0 | 9/138,393 | 11,754/26,262,527 | 0.15 | 1.39e-16 | 2.00e-15 |
| Dehydration:0 | 4/138,393 | 9,966/26,262,527 | 0.08 | 1.41e-17 | 2.13e-16 |
| Synapses:0 | 3/138,393 | 18,932/26,262,527 | 0.03 | 1.70e-38 | 5.62e-37 |
| indole-3-carbinol:0 | 29/138,393 | 747/26,262,527 | 7.37 | 7.07e-16 | 9.76e-15 |
| diagnostic procedure:0 | 95/138,393 | 9,671/26,262,527 | 1.86 | 3.39e-08 | 2.57e-07 |
| Immunocompromised Host:0 | 12/138,393 | 13,348/26,262,527 | 0.17 | 2.42e-17 | 3.63e-16 |
| angiogram:0 | 15/138,393 | 36,525/26,262,527 | 0.08 | 1.10e-61 | 6.01e-60 |
| Ecosystem:0 | 3/138,393 | 6,302/26,262,527 | 0.09 | 4.48e-11 | 4.46e-10 |
| Neurologic Deficits:0 | 15/138,393 | 10,791/26,262,527 | 0.26 | 9.60e-11 | 9.28e-10 |
| Molar tooth:0 | 2/138,393 | 12,708/26,262,527 | 0.03 | 3.94e-26 | 8.61e-25 |
| ZD1839:0 | 31/138,393 | 1,097/26,262,527 | 5.36 | 2.58e-13 | 3.03e-12 |
| FGFR1 gene|FGFR1:0 | 30/138,393 | 1,083/26,262,527 | 5.26 | 9.99e-13 | 1.12e-11 |
| Antiviral Agents:0 | 1/138,393 | 7,865/26,262,527 | 0.02 | 1.04e-16 | 1.50e-15 |
| FOLH1 gene|FOLH1:0 | 147/138,393 | 607/26,262,527 | 46.00 | 2.94e-177 | 5.01e-175 |
| CNS disorder:0 | 5/138,393 | 6,238/26,262,527 | 0.15 | 3.97e-09 | 3.34e-08 |
| SPDEF:0 | 31/138,393 | 201/26,262,527 | 29.27 | 2.30e-33 | 6.46e-32 |
| HIV-1:0 | 12/138,393 | 34,936/26,262,527 | 0.07 | 8.94e-62 | 4.90e-60 |
| Liver diseases:0 | 48/138,393 | 37,138/26,262,527 | 0.25 | 2.41e-36 | 7.51e-35 |
| Nutritional status:0 | 5/138,393 | 8,215/26,262,527 | 0.12 | 4.34e-13 | 5.01e-12 |
| Neuronal Transmission:0 | 3/138,393 | 11,694/26,262,527 | 0.05 | 1.85e-22 | 3.50e-21 |
| Bradycardia:0 | 1/138,393 | 6,199/26,262,527 | 0.03 | 4.39e-13 | 5.08e-12 |
| RRBP1|RHBDL1:0 | 27/138,393 | 113/26,262,527 | 45.35 | 8.32e-34 | 2.37e-32 |
| PREDICTED:0 | 98/138,393 | 5,726/26,262,527 | 3.25 | 1.78e-22 | 3.38e-21 |
| CYP3A4 gene|CYP3A4:0 | 28/138,393 | 975/26,262,527 | 5.45 | 2.46e-12 | 2.69e-11 |
| Colonic mucous membrane:0 | 11/138,393 | 8,486/26,262,527 | 0.25 | 4.51e-09 | 3.77e-08 |
| Myelin:0 | 1/138,393 | 8,722/26,262,527 | 0.02 | 1.29e-18 | 2.07e-17 |
| Zonal:0 | 507/138,393 | 67,299/26,262,527 | 1.43 | 2.84e-14 | 3.59e-13 |
| Toll-Like Receptor 2:0 | 1/138,393 | 4,321/26,262,527 | 0.04 | 5.52e-09 | 4.58e-08 |
| platelet-derived growth factor BB:0 | 5/138,393 | 4,991/26,262,527 | 0.19 | 1.07e-06 | 6.91e-06 |
| Local disease:0 | 623/138,393 | 4,549/26,262,527 | 26.10 | 0.00e+00 | 0.00e+00 |
| Bacteria:0 | 70/138,393 | 122,648/26,262,527 | 0.11 | 2.08e-184 | 3.74e-182 |
| Entire midbrain:0 | 2/138,393 | 14,841/26,262,527 | 0.03 | 7.10e-31 | 1.84e-29 |
| Uroflowmetry:0 | 16/138,393 | 309/26,262,527 | 9.83 | 3.60e-11 | 3.60e-10 |
| Myositis:0 | 4/138,393 | 5,809/26,262,527 | 0.13 | 5.21e-09 | 4.33e-08 |
| N-telopeptide:0 | 8/138,393 | 142/26,262,527 | 10.69 | 1.55e-06 | 9.78e-06 |
| Rifampin:0 | 3/138,393 | 15,580/26,262,527 | 0.04 | 4.29e-31 | 1.12e-29 |
| Processed meat:0 | 11/138,393 | 189/26,262,527 | 11.05 | 1.28e-08 | 1.02e-07 |
| Acetylcysteine|ELANE:0 | 9/138,393 | 4/26,262,527 | 427.01 | 2.10e-18 | 3.32e-17 |
| Prosthesis:0 | 36/138,393 | 32,796/26,262,527 | 0.21 | 2.93e-36 | 9.11e-35 |
| MULTISECTION:FINDING:POINT IN TIME:PROSTATE:NARRATIVE:COMPUTERIZED TOMOGRAPHY:0 | 8/138,393 | 9/26,262,527 | 168.69 | 1.33e-14 | 1.71e-13 |
| Prostatic Tissue:0 | 2,253/138,393 | 5,110/26,262,527 | 85.04 | 0.00e+00 | 0.00e+00 |
| selective intervention:0 | 17/138,393 | 202/26,262,527 | 15.97 | 5.70e-15 | 7.51e-14 |
| Ethnic group:0 | 231/138,393 | 23,819/26,262,527 | 1.84 | 3.65e-17 | 5.44e-16 |
| 2,2'-azobis(2-(2-imidazolin-2-yl) propane) dihydrochloride:0 | 7/138,393 | 20/26,262,527 | 66.42 | 8.81e-11 | 8.54e-10 |
| associated disease:0 | 5/138,393 | 5,594/26,262,527 | 0.17 | 7.96e-08 | 5.81e-07 |
| TAP-144|SCTR:0 | 8/138,393 | 53/26,262,527 | 28.65 | 1.31e-09 | 1.15e-08 |
| Lanugo:0 | 85/138,393 | 6,845/26,262,527 | 2.36 | 4.89e-12 | 5.26e-11 |
| Endocardium:0 | 4/138,393 | 5,546/26,262,527 | 0.14 | 1.37e-08 | 1.09e-07 |
| Buserelin:0 | 84/138,393 | 2,378/26,262,527 | 6.71 | 6.26e-40 | 2.17e-38 |
| Scaffold:0 | 11/138,393 | 7,461/26,262,527 | 0.28 | 2.15e-07 | 1.50e-06 |
| Mesenchymal Stem Cells:0 | 46/138,393 | 30,359/26,262,527 | 0.29 | 4.49e-26 | 9.79e-25 |
| Cricetinae:0 | 47/138,393 | 36,063/26,262,527 | 0.25 | 5.74e-35 | 1.70e-33 |
| Drosophila melanogaster:0 | 1/138,393 | 6,056/26,262,527 | 0.03 | 9.10e-13 | 1.03e-11 |
| IL2-inducible T-cell kinase|ITK|SLC22A3:0 | 38/138,393 | 2,053/26,262,527 | 3.51 | 1.26e-10 | 1.21e-09 |
| Adverse drug effect:0 | 8/138,393 | 6,278/26,262,527 | 0.24 | 4.50e-07 | 3.02e-06 |
| Phosphatidylethanolamines:0 | 12/138,393 | 11,423/26,262,527 | 0.20 | 1.06e-13 | 1.28e-12 |
| water channel:0 | 7/138,393 | 6,030/26,262,527 | 0.22 | 2.62e-07 | 1.82e-06 |
| Clofibrate:0 | 4/138,393 | 4,888/26,262,527 | 0.16 | 2.81e-07 | 1.94e-06 |
| caspase-8:0 | 119/138,393 | 5,662/26,262,527 | 3.99 | 1.62e-34 | 4.69e-33 |
| Mouse Pancreatic Intraepithelial Neoplasia-2:0 | 52/138,393 | 2,783/26,262,527 | 3.55 | 4.17e-14 | 5.20e-13 |
| Candidate Disease Gene:0 | 878/138,393 | 53,728/26,262,527 | 3.11 | 9.22e-175 | 1.54e-172 |
| alpha-Melanocyte stimulating hormone:0 | 1/138,393 | 4,699/26,262,527 | 0.04 | 9.14e-10 | 8.13e-09 |
| Parenchyma:0 | 65/138,393 | 31,429/26,262,527 | 0.39 | 9.00e-19 | 1.45e-17 |
| Bone Screws:0 | 2/138,393 | 15,853/26,262,527 | 0.02 | 4.38e-33 | 1.22e-31 |
| Parenteral Nutrition, Total:0 | 1/138,393 | 6,115/26,262,527 | 0.03 | 6.27e-13 | 7.16e-12 |
| pars compacta:0 | 1/138,393 | 8,800/26,262,527 | 0.02 | 9.13e-19 | 1.48e-17 |
| Transitional cell carcinoma of bladder:0 | 53/138,393 | 1,282/26,262,527 | 7.85 | 6.71e-29 | 1.62e-27 |
| Thermal techniques:0 | 51/138,393 | 752/26,262,527 | 12.87 | 1.80e-37 | 5.77e-36 |
| Platelet-Derived Growth Factor Receptor|PDGFRB:0 | 14/138,393 | 493/26,262,527 | 5.39 | 7.58e-07 | 4.99e-06 |
| diallyl trisulfide:0 | 22/138,393 | 929/26,262,527 | 4.49 | 1.49e-08 | 1.18e-07 |
| Tool:0 | 389/138,393 | 55,288/26,262,527 | 1.34 | 5.23e-08 | 3.88e-07 |
| Octreotide:0 | 37/138,393 | 17,483/26,262,527 | 0.40 | 1.27e-10 | 1.22e-09 |
| Invasive Malignant Neoplasm:0 | 141/138,393 | 4,876/26,262,527 | 5.49 | 1.02e-55 | 4.94e-54 |
| Shock:0 | 34/138,393 | 43,186/26,262,527 | 0.15 | 2.41e-57 | 1.21e-55 |
| Fibrin:0 | 19/138,393 | 11,501/26,262,527 | 0.31 | 9.01e-10 | 8.03e-09 |
| Systemic arterial pressure:0 | 34/138,393 | 84,167/26,262,527 | 0.08 | 2.19e-141 | 2.78e-139 |
| Chest:0 | 88/138,393 | 44,721/26,262,527 | 0.37 | 6.20e-28 | 1.45e-26 |
| Trunk of posterior segmental artery:0 | 24/138,393 | 1,223/26,262,527 | 3.72 | 1.03e-07 | 7.46e-07 |
| ILK gene|ILK:0 | 13/138,393 | 320/26,262,527 | 7.71 | 3.74e-08 | 2.82e-07 |
| Antimitotic Agents:0 | 20/138,393 | 990/26,262,527 | 3.83 | 7.41e-07 | 4.88e-06 |
| Cyclooxygenase 2 Inhibitors:0 | 129/138,393 | 10,626/26,262,527 | 2.31 | 8.38e-17 | 1.22e-15 |
| Lactic acid:0 | 7/138,393 | 6,523/26,262,527 | 0.20 | 4.12e-08 | 3.10e-07 |
| Cell marker:0 | 55/138,393 | 3,239/26,262,527 | 3.22 | 3.22e-13 | 3.76e-12 |
| Xanthine Oxidase:0 | 9/138,393 | 7,663/26,262,527 | 0.22 | 7.56e-09 | 6.19e-08 |
| Fibrous capsule of kidney:0 | 25/138,393 | 1,429/26,262,527 | 3.32 | 4.51e-07 | 3.03e-06 |
| alpha 1-Antitrypsin:0 | 17/138,393 | 9,780/26,262,527 | 0.33 | 5.27e-08 | 3.91e-07 |
| Urinary Incontinence:0 | 306/138,393 | 14,456/26,262,527 | 4.02 | 1.61e-86 | 1.22e-84 |
| RNA, Small Interfering:0 | 655/138,393 | 33,696/26,262,527 | 3.70 | 2.95e-165 | 4.51e-163 |
| Radiotherapy department:0 | 7/138,393 | 82/26,262,527 | 16.20 | 5.15e-07 | 3.44e-06 |
| PTRF:0 | 9/138,393 | 139/26,262,527 | 12.29 | 1.14e-07 | 8.15e-07 |
| Metastasis Suppressor Genes:0 | 68/138,393 | 355/26,262,527 | 36.37 | 6.97e-77 | 4.70e-75 |
| Smoking:0 | 169/138,393 | 52,024/26,262,527 | 0.62 | 1.18e-11 | 1.23e-10 |
| Lymph node excision:0 | 203/138,393 | 8,391/26,262,527 | 4.60 | 5.70e-67 | 3.38e-65 |
| Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:0 | 262/138,393 | 344/26,262,527 | 144.80 | 0.00e+00 | 0.00e+00 |
| Ketoconazole:0 | 171/138,393 | 10,163/26,262,527 | 3.20 | 5.11e-37 | 1.63e-35 |
| Alanine:0 | 28/138,393 | 14,629/26,262,527 | 0.36 | 2.29e-10 | 2.15e-09 |
| Entire hippocampus:0 | 16/138,393 | 102,020/26,262,527 | 0.03 | 2.30e-203 | 4.40e-201 |
| Flagellin:0 | 1/138,393 | 3,795/26,262,527 | 0.05 | 1.06e-07 | 7.64e-07 |
| Adaptation:0 | 20/138,393 | 19,257/26,262,527 | 0.20 | 1.40e-22 | 2.66e-21 |
| Therapeutic vaccine:0 | 73/138,393 | 1,464/26,262,527 | 9.47 | 2.79e-44 | 1.07e-42 |
| Zona Pellucida:0 | 1/138,393 | 3,500/26,262,527 | 0.05 | 4.43e-07 | 2.98e-06 |
| Problem, prostate:0 | 10/138,393 | 26/26,262,527 | 72.99 | 3.52e-15 | 4.69e-14 |
| Nitric Oxide Synthase Type I:0 | 3/138,393 | 6,261/26,262,527 | 0.09 | 6.46e-11 | 6.32e-10 |
| Neurites:0 | 5/138,393 | 5,025/26,262,527 | 0.19 | 7.55e-07 | 4.97e-06 |
| Cooley's anemia:0 | 2/138,393 | 5,768/26,262,527 | 0.07 | 6.19e-11 | 6.07e-10 |
| Hepatitis, Chronic:0 | 2/138,393 | 10,561/26,262,527 | 0.04 | 2.10e-21 | 3.81e-20 |
| Pneumonia, Pneumocystis carinii:0 | 1/138,393 | 5,524/26,262,527 | 0.03 | 1.80e-11 | 1.84e-10 |
| Enterocytes:0 | 3/138,393 | 10,101/26,262,527 | 0.06 | 4.75e-19 | 7.76e-18 |
| Uterus - Cervix (MMHCC):0 | 103/138,393 | 10,435/26,262,527 | 1.87 | 7.06e-09 | 5.80e-08 |
| Motility:0 | 183/138,393 | 22,771/26,262,527 | 1.53 | 1.01e-07 | 7.28e-07 |
| Synaptic Vesicles:0 | 1/138,393 | 5,057/26,262,527 | 0.04 | 1.49e-10 | 1.42e-09 |
| cohort:0 | 1,939/138,393 | 121,378/26,262,527 | 3.06 | 0.00e+00 | 0.00e+00 |
| Magnetic Resonance Imaging:0 | 1,843/138,393 | 130,520/26,262,527 | 2.70 | 1.13e-289 | 3.06e-287 |
| Donor person:0 | 61/138,393 | 32,687/26,262,527 | 0.35 | 3.22e-22 | 6.02e-21 |
| Removal of endotracheal tube:0 | 1/138,393 | 3,445/26,262,527 | 0.06 | 6.61e-07 | 4.37e-06 |
| Torsades de Pointes:0 | 1/138,393 | 3,811/26,262,527 | 0.05 | 6.94e-08 | 5.10e-07 |
| Itraconazole:0 | 7/138,393 | 8,032/26,262,527 | 0.17 | 4.41e-11 | 4.39e-10 |
| Urinary outflow obstruction:0 | 9/138,393 | 61/26,262,527 | 28.00 | 1.46e-10 | 1.39e-09 |
| Chemotactic Factors:0 | 16/138,393 | 9,160/26,262,527 | 0.33 | 1.47e-07 | 1.05e-06 |
| Leptocyte:0 | 147/138,393 | 15,796/26,262,527 | 1.77 | 2.92e-10 | 2.71e-09 |
| Caries:0 | 1/138,393 | 13,263/26,262,527 | 0.01 | 8.26e-29 | 1.99e-27 |
| Sodium:0 | 26/138,393 | 34,109/26,262,527 | 0.14 | 2.55e-46 | 1.03e-44 |
| inhibitor-of-apoptosis protein:0 | 17/138,393 | 555/26,262,527 | 5.81 | 1.82e-08 | 1.43e-07 |
| thymolphthalein monophosphate:0 | 5/138,393 | 11/26,262,527 | 86.26 | 1.65e-08 | 1.30e-07 |
| Cryosurgery:0 | 335/138,393 | 6,267/26,262,527 | 10.17 | 2.59e-205 | 4.98e-203 |
| Southwest Oncology Group:0 | 34/138,393 | 731/26,262,527 | 8.83 | 1.24e-20 | 2.19e-19 |
| Anesthetics:0 | 36/138,393 | 32,847/26,262,527 | 0.21 | 2.09e-36 | 6.55e-35 |
| Reporter:0 | 133/138,393 | 11,671/26,262,527 | 2.16 | 2.79e-15 | 3.75e-14 |
| Proscar:0 | 8/138,393 | 101/26,262,527 | 15.03 | 1.35e-07 | 9.66e-07 |
| Chemokine (C-C Motif) Receptor 5|CCR5:0 | 12/138,393 | 7,674/26,262,527 | 0.30 | 3.23e-07 | 2.21e-06 |
| Zidovudine:0 | 6/138,393 | 16,903/26,262,527 | 0.07 | 3.36e-30 | 8.49e-29 |
| Siderophores:0 | 1/138,393 | 3,843/26,262,527 | 0.05 | 7.09e-08 | 5.21e-07 |
| epitheliasin|TMPRSS2:0 | 63/138,393 | 246/26,262,527 | 48.62 | 2.45e-78 | 1.69e-76 |
| Refractory Neoplasm:0 | 22/138,393 | 318/26,262,527 | 13.13 | 2.99e-17 | 4.46e-16 |
| Endometrioid carcinoma of prostate:0 | 29/138,393 | 46/26,262,527 | 119.66 | 2.95e-46 | 1.19e-44 |
| Skeletal muscle structure:0 | 24/138,393 | 54,023/26,262,527 | 0.08 | 9.08e-89 | 6.95e-87 |
| Interferons:0 | 60/138,393 | 62,340/26,262,527 | 0.18 | 9.46e-74 | 6.07e-72 |
| Androgen Response Element:0 | 100/138,393 | 270/26,262,527 | 70.33 | 5.75e-137 | 7.14e-135 |
| Markers, Radiopaque:0 | 15/138,393 | 400/26,262,527 | 7.12 | 9.62e-09 | 7.77e-08 |
| Nimodipine:0 | 1/138,393 | 5,579/26,262,527 | 0.03 | 1.21e-11 | 1.25e-10 |
| Urologic Oncology:0 | 7/138,393 | 14/26,262,527 | 94.89 | 1.19e-11 | 1.23e-10 |
| 2-pyrrolino-DOX:0 | 4/138,393 | 12/26,262,527 | 63.26 | 1.31e-06 | 8.33e-06 |
| Secondary malignant neoplasm of skin NOS:0 | 38/138,393 | 1,431/26,262,527 | 5.04 | 3.84e-15 | 5.11e-14 |
| BRCA1 gene|BRCA1:0 | 192/138,393 | 11,821/26,262,527 | 3.09 | 2.40e-39 | 8.13e-38 |
| Acidosis, Lactic:0 | 1/138,393 | 4,219/26,262,527 | 0.04 | 1.20e-08 | 9.56e-08 |
| Heme Oxygenase-1:0 | 27/138,393 | 12,744/26,262,527 | 0.40 | 5.48e-08 | 4.06e-07 |
| Total cholesterol:0 | 35/138,393 | 16,388/26,262,527 | 0.41 | 7.60e-10 | 6.81e-09 |
| CERS2:0 | 10/138,393 | 73/26,262,527 | 26.00 | 2.69e-11 | 2.71e-10 |
| Testosterone measurement:0 | 73/138,393 | 1,052/26,262,527 | 13.17 | 1.57e-53 | 7.27e-52 |
| Chlorides:0 | 34/138,393 | 17,615/26,262,527 | 0.37 | 4.09e-12 | 4.40e-11 |
| BRCA2 gene|BRCA2:0 | 152/138,393 | 4,922/26,262,527 | 5.87 | 1.94e-63 | 1.09e-61 |
| Histocompatibility Antigens Class II:0 | 9/138,393 | 12,056/26,262,527 | 0.14 | 3.71e-17 | 5.52e-16 |
| Oxytocin:0 | 11/138,393 | 31,200/26,262,527 | 0.07 | 5.93e-55 | 2.82e-53 |
| Motor Neurons:0 | 4/138,393 | 27,207/26,262,527 | 0.03 | 3.19e-55 | 1.53e-53 |
| acidification:0 | 17/138,393 | 11,826/26,262,527 | 0.27 | 2.19e-11 | 2.22e-10 |
| Oligodendroglia:0 | 1/138,393 | 11,923/26,262,527 | 0.02 | 9.01e-26 | 1.94e-24 |
| Pudendal artery:0 | 9/138,393 | 102/26,262,527 | 16.75 | 9.33e-09 | 7.55e-08 |
| Ascorbic Acid:0 | 90/138,393 | 40,315/26,262,527 | 0.42 | 3.90e-21 | 7.00e-20 |
| bicalutamide 150 MG:0 | 24/138,393 | 37/26,262,527 | 123.11 | 9.12e-39 | 3.03e-37 |
| Tumor Necrosis Factor-alpha|TNF:0 | 64/138,393 | 39,958/26,262,527 | 0.30 | 4.39e-32 | 1.18e-30 |
| Kidney biopsy:0 | 6/138,393 | 6,463/26,262,527 | 0.18 | 7.99e-09 | 6.52e-08 |
| Nitroglycerin:0 | 6/138,393 | 12,680/26,262,527 | 0.09 | 3.55e-21 | 6.38e-20 |
| Estrogen Antagonists:0 | 115/138,393 | 9,641/26,262,527 | 2.26 | 1.12e-14 | 1.44e-13 |
| Interleukin-13:0 | 7/138,393 | 8,963/26,262,527 | 0.15 | 8.59e-13 | 9.73e-12 |
| Kidney Failure, Chronic:0 | 22/138,393 | 84,790/26,262,527 | 0.05 | 6.13e-157 | 8.67e-155 |
| Prostatic gland:0 | 6/138,393 | 12/26,262,527 | 94.89 | 3.65e-10 | 3.36e-09 |
| Human Glandular Kallikrein 2:0 | 40/138,393 | 112/26,262,527 | 67.79 | 2.75e-55 | 1.32e-53 |
| Neurotransmitters:0 | 23/138,393 | 25,852/26,262,527 | 0.17 | 9.75e-33 | 2.68e-31 |
| DUSP10:0 | 8/138,393 | 85/26,262,527 | 17.86 | 3.91e-08 | 2.94e-07 |
| Human Cell Line:0 | 2,358/138,393 | 74,082/26,262,527 | 6.13 | 0.00e+00 | 0.00e+00 |
| Insulin|INS:0 | 104/138,393 | 63,586/26,262,527 | 0.31 | 4.05e-49 | 1.74e-47 |
| Cell Proliferation:0 | 2,210/138,393 | 80,896/26,262,527 | 5.25 | 0.00e+00 | 0.00e+00 |
| Rectal examination:0 | 83/138,393 | 310/26,262,527 | 50.84 | 4.92e-104 | 4.47e-102 |
| Corpora amylacea:0 | 9/138,393 | 145/26,262,527 | 11.78 | 1.60e-07 | 1.13e-06 |
| polyestradiol phosphate:0 | 37/138,393 | 156/26,262,527 | 45.02 | 1.25e-45 | 4.97e-44 |
| Inguinal part of abdomen:0 | 11/138,393 | 131/26,262,527 | 15.94 | 3.49e-10 | 3.22e-09 |
| Urothelial carcinoma urethra:0 | 8/138,393 | 26/26,262,527 | 58.39 | 9.17e-12 | 9.61e-11 |
| Transplantation, Homologous:0 | 3/138,393 | 4,154/26,262,527 | 0.14 | 1.43e-06 | 9.10e-06 |
| Proton Pump Inhibitors:0 | 8/138,393 | 10,286/26,262,527 | 0.15 | 1.24e-14 | 1.59e-13 |
| transglutaminase 4|TGM4:0 | 5/138,393 | 24/26,262,527 | 39.54 | 4.23e-07 | 2.86e-06 |
| fluorodeoxyglucose:0 | 34/138,393 | 2,356/26,262,527 | 2.74 | 3.67e-07 | 2.49e-06 |
| Spinal Cord Diseases:0 | 9/138,393 | 8,831/26,262,527 | 0.19 | 4.62e-11 | 4.59e-10 |
| Neoplasms, Experimental:0 | 44/138,393 | 2,685/26,262,527 | 3.11 | 1.99e-10 | 1.88e-09 |
| beta Thalassemia:0 | 2/138,393 | 8,328/26,262,527 | 0.05 | 2.40e-16 | 3.42e-15 |
| Genitourinary Cancer:0 | 145/138,393 | 439/26,262,527 | 62.74 | 1.06e-191 | 1.97e-189 |
| Appendectomy:0 | 3/138,393 | 5,343/26,262,527 | 0.11 | 6.18e-09 | 5.10e-08 |
| mTOR Inhibitor:0 | 25/138,393 | 1,147/26,262,527 | 4.14 | 7.99e-09 | 6.53e-08 |
| Polymerase|ERVK-9|ERVK-19|ERVK-11:0 | 25/138,393 | 12,321/26,262,527 | 0.38 | 3.21e-08 | 2.44e-07 |
| Exercise stress test:0 | 3/138,393 | 14,198/26,262,527 | 0.04 | 6.27e-28 | 1.47e-26 |
| Epidermal Growth Factor|EREG|ESR1:0 | 16/138,393 | 44/26,262,527 | 69.01 | 3.91e-23 | 7.60e-22 |
| Estrogen Receptors:0 | 141/138,393 | 11,006/26,262,527 | 2.43 | 5.26e-20 | 8.93e-19 |
| TMEM37:0 | 24/138,393 | 389/26,262,527 | 11.71 | 1.29e-17 | 1.96e-16 |
| NPPB:0 | 1/138,393 | 5,961/26,262,527 | 0.03 | 1.29e-12 | 1.45e-11 |
| Trabecular substance of bone:0 | 20/138,393 | 10,933/26,262,527 | 0.35 | 2.05e-08 | 1.60e-07 |
| Advice:0 | 125/138,393 | 11,114/26,262,527 | 2.14 | 6.06e-14 | 7.48e-13 |
| Human plasma:0 | 50/138,393 | 23,233/26,262,527 | 0.41 | 1.89e-13 | 2.24e-12 |
| Excitability:0 | 2/138,393 | 18,691/26,262,527 | 0.02 | 1.96e-39 | 6.69e-38 |
| Oat cell carcinoma:0 | 69/138,393 | 2,518/26,262,527 | 5.20 | 6.86e-27 | 1.54e-25 |
| KLK2 gene|KLK2:0 | 19/138,393 | 35/26,262,527 | 103.03 | 7.21e-30 | 1.80e-28 |
| Horseradish Peroxidase:0 | 15/138,393 | 14,752/26,262,527 | 0.19 | 1.02e-17 | 1.57e-16 |
| Single tumor:0 | 25/138,393 | 971/26,262,527 | 4.89 | 3.15e-10 | 2.92e-09 |
| Rod Photoreceptors:0 | 1/138,393 | 5,997/26,262,527 | 0.03 | 1.33e-12 | 1.49e-11 |
| Oxidase:0 | 8/138,393 | 10,784/26,262,527 | 0.14 | 1.80e-15 | 2.44e-14 |
| Rectum:0 | 560/138,393 | 19,685/26,262,527 | 5.42 | 2.21e-212 | 4.41e-210 |
| Gene Amplification:0 | 28/138,393 | 1,378/26,262,527 | 3.86 | 4.63e-09 | 3.86e-08 |
| Medical Imaging:0 | 1,260/138,393 | 145,462/26,262,527 | 1.65 | 8.71e-60 | 4.59e-58 |
| Entire hindlimb:0 | 20/138,393 | 10,047/26,262,527 | 0.38 | 3.88e-07 | 2.64e-06 |
| Tumor Burden:0 | 65/138,393 | 1,857/26,262,527 | 6.65 | 4.42e-31 | 1.16e-29 |
| Fibromyalgia:0 | 4/138,393 | 21,318/26,262,527 | 0.04 | 2.46e-42 | 9.05e-41 |
| Sclera:0 | 1/138,393 | 6,123/26,262,527 | 0.03 | 6.30e-13 | 7.19e-12 |
| Protein-tyrosine kinase inhibitor:0 | 115/138,393 | 12,674/26,262,527 | 1.72 | 8.13e-08 | 5.93e-07 |
| Performance:0 | 191/138,393 | 53,596/26,262,527 | 0.68 | 1.07e-08 | 8.62e-08 |
| Protein Kinase C|SPANXC:0 | 136/138,393 | 50,594/26,262,527 | 0.51 | 1.68e-18 | 2.67e-17 |
| S Phase:0 | 59/138,393 | 4,852/26,262,527 | 2.31 | 1.47e-08 | 1.16e-07 |
| ixabepilone:0 | 24/138,393 | 793/26,262,527 | 5.74 | 3.08e-11 | 3.10e-10 |
| Minor pelvis:0 | 34/138,393 | 592/26,262,527 | 10.90 | 2.33e-23 | 4.57e-22 |
| Paroxysmal nocturnal hemoglobinuria:0 | 3/138,393 | 4,852/26,262,527 | 0.12 | 4.59e-08 | 3.44e-07 |
| Neoplasm progression:0 | 3,611/138,393 | 37,131/26,262,527 | 18.92 | 0.00e+00 | 0.00e+00 |
| Disseminated adenocarcinoma:0 | 8/138,393 | 51/26,262,527 | 29.77 | 9.96e-10 | 8.83e-09 |
| Eosinophilia:0 | 6/138,393 | 9,618/26,262,527 | 0.12 | 6.81e-15 | 8.91e-14 |
| Androgen Antagonists:0 | 1,287/138,393 | 5,655/26,262,527 | 43.58 | 0.00e+00 | 0.00e+00 |
| Insulin-Like Growth Factor Binding Protein 3:0 | 201/138,393 | 6,361/26,262,527 | 6.00 | 6.52e-85 | 4.86e-83 |
| Alcohol consumption:0 | 63/138,393 | 27,727/26,262,527 | 0.43 | 1.47e-14 | 1.88e-13 |
| Mycelium:0 | 2/138,393 | 6,477/26,262,527 | 0.06 | 1.74e-12 | 1.92e-11 |
| Cervical Intraepithelial Neoplasia:0 | 12/138,393 | 7,995/26,262,527 | 0.28 | 1.02e-07 | 7.36e-07 |
| Difluoromethylornithine|TH:0 | 5/138,393 | 14/26,262,527 | 67.78 | 4.33e-08 | 3.25e-07 |
| Stress Fractures:0 | 2/138,393 | 4,860/26,262,527 | 0.08 | 6.51e-09 | 5.36e-08 |
| Receptors, IgE|FCER2:0 | 1/138,393 | 3,840/26,262,527 | 0.05 | 7.07e-08 | 5.19e-07 |
| AKR1C1|AKR1C1:0 | 11/138,393 | 228/26,262,527 | 9.16 | 7.93e-08 | 5.79e-07 |
| Neisseria meningitidis:0 | 1/138,393 | 4,594/26,262,527 | 0.04 | 2.03e-09 | 1.75e-08 |
| Integrin alpha6|ITGA6:0 | 14/138,393 | 341/26,262,527 | 7.79 | 9.98e-09 | 8.05e-08 |
| Immunotherapy, Active:0 | 37/138,393 | 897/26,262,527 | 7.83 | 1.20e-20 | 2.12e-19 |
| Deamino Arginine Vasopressin:0 | 1/138,393 | 4,023/26,262,527 | 0.05 | 3.70e-08 | 2.80e-07 |
| Stage B:0 | 5/138,393 | 32/26,262,527 | 29.65 | 1.50e-06 | 9.49e-06 |
| Embolization, Therapeutic:0 | 41/138,393 | 29,910/26,262,527 | 0.26 | 4.66e-28 | 1.10e-26 |
| Scoliosis, unspecified:0 | 1/138,393 | 8,508/26,262,527 | 0.02 | 3.87e-18 | 6.06e-17 |
| Acoustic Neuroma:0 | 4/138,393 | 6,496/26,262,527 | 0.12 | 1.65e-10 | 1.57e-09 |
| Genistein:0 | 340/138,393 | 20,100/26,262,527 | 3.22 | 2.81e-72 | 1.77e-70 |
| Sorbitol:0 | 4/138,393 | 5,129/26,262,527 | 0.15 | 1.05e-07 | 7.57e-07 |
| Milk:0 | 14/138,393 | 15,301/26,262,527 | 0.17 | 1.46e-19 | 2.44e-18 |
| Entire pelvic cavity:0 | 13/138,393 | 444/26,262,527 | 5.56 | 1.34e-06 | 8.55e-06 |
| NCOA2 gene|NCOA2:0 | 15/138,393 | 435/26,262,527 | 6.54 | 2.79e-08 | 2.14e-07 |
| Decubitus ulcer:0 | 2/138,393 | 8,423/26,262,527 | 0.05 | 1.08e-16 | 1.56e-15 |
| Staff:0 | 19/138,393 | 13,285/26,262,527 | 0.27 | 1.17e-12 | 1.31e-11 |
| Debridement:0 | 12/138,393 | 15,279/26,262,527 | 0.15 | 4.75e-21 | 8.51e-20 |
| Hybrids:0 | 31/138,393 | 13,859/26,262,527 | 0.42 | 5.24e-08 | 3.89e-07 |
| Secondary malignant neoplasm of liver:0 | 87/138,393 | 29,191/26,262,527 | 0.57 | 6.33e-09 | 5.21e-08 |
| E2F3:0 | 14/138,393 | 441/26,262,527 | 6.02 | 2.10e-07 | 1.47e-06 |
| Urethral Neoplasms:0 | 18/138,393 | 127/26,262,527 | 26.90 | 1.98e-19 | 3.29e-18 |
| BCL2 gene|BCL2:0 | 73/138,393 | 3,721/26,262,527 | 3.72 | 3.02e-20 | 5.18e-19 |
| Physical findings:0 | 181/138,393 | 66,188/26,262,527 | 0.52 | 7.74e-23 | 1.49e-21 |
| Image analysis:0 | 94/138,393 | 6,124/26,262,527 | 2.91 | 1.22e-18 | 1.96e-17 |
| Propylthiouracil:0 | 2/138,393 | 4,114/26,262,527 | 0.09 | 2.12e-07 | 1.48e-06 |
| Pericarditis:0 | 2/138,393 | 3,734/26,262,527 | 0.10 | 1.20e-06 | 7.70e-06 |
| Tumor Suppression:0 | 52/138,393 | 1,050/26,262,527 | 9.40 | 6.57e-32 | 1.76e-30 |
| Nephrogenic adenoma:0 | 24/138,393 | 450/26,262,527 | 10.12 | 2.83e-16 | 4.01e-15 |
| Transcriptional Regulation:0 | 108/138,393 | 9,809/26,262,527 | 2.09 | 7.79e-12 | 8.21e-11 |
| Buprenorphine:0 | 1/138,393 | 9,591/26,262,527 | 0.02 | 1.67e-20 | 2.92e-19 |
| Green Fluorescent Proteins|UBTF:0 | 3/138,393 | 2/26,262,527 | 284.66 | 1.43e-06 | 9.07e-06 |
| GTP-Binding Proteins:0 | 38/138,393 | 20,571/26,262,527 | 0.35 | 1.04e-14 | 1.35e-13 |
| glucose transport:0 | 5/138,393 | 7,869/26,262,527 | 0.12 | 2.42e-12 | 2.65e-11 |
| Peripheral Stem Cell Transplantation:0 | 2/138,393 | 4,000/26,262,527 | 0.09 | 4.53e-07 | 3.04e-06 |
| Peplomycin|PAEP|PREP|PTPN22:0 | 6/138,393 | 3/26,262,527 | 379.55 | 1.72e-12 | 1.91e-11 |
| Pericardial sac structure:0 | 2/138,393 | 5,342/26,262,527 | 0.07 | 5.26e-10 | 4.78e-09 |
| Somatic mutation:0 | 64/138,393 | 4,263/26,262,527 | 2.85 | 8.06e-13 | 9.13e-12 |
| Duodenal Ulcer:0 | 189/138,393 | 19,063/26,262,527 | 1.88 | 3.71e-15 | 4.94e-14 |
| Luteal Cells:0 | 2/138,393 | 3,836/26,262,527 | 0.10 | 8.78e-07 | 5.73e-06 |
| Lignin:0 | 1/138,393 | 4,851/26,262,527 | 0.04 | 4.47e-10 | 4.09e-09 |
| Rectum finding:0 | 4/138,393 | 6/26,262,527 | 126.52 | 1.55e-07 | 1.09e-06 |
| Magnetic resonance imaging of pelvis:0 | 8/138,393 | 115/26,262,527 | 13.20 | 3.44e-07 | 2.35e-06 |
| Estrogenic:0 | 89/138,393 | 5,465/26,262,527 | 3.09 | 2.93e-19 | 4.82e-18 |
| Bacterial Infections:0 | 24/138,393 | 20,604/26,262,527 | 0.22 | 2.25e-22 | 4.23e-21 |
| Nuclear Matrix-Associated Proteins:0 | 37/138,393 | 672/26,262,527 | 10.45 | 1.12e-24 | 2.31e-23 |
| Breast neoplasm screening:0 | 19/138,393 | 806/26,262,527 | 4.47 | 1.48e-07 | 1.05e-06 |
| Ptosis:0 | 14/138,393 | 12,843/26,262,527 | 0.21 | 5.66e-15 | 7.46e-14 |
| GPX1:0 | 13/138,393 | 354/26,262,527 | 6.97 | 1.15e-07 | 8.22e-07 |
| leukemia inhibitory factor|LIF:0 | 5/138,393 | 6,137/26,262,527 | 0.15 | 8.22e-09 | 6.69e-08 |
| cancer surgery:0 | 24/138,393 | 1,254/26,262,527 | 3.63 | 1.61e-07 | 1.13e-06 |
| Risk factor, cardiovascular:0 | 36/138,393 | 18,667/26,262,527 | 0.37 | 8.98e-13 | 1.02e-11 |
| Phytotherapy:0 | 22/138,393 | 792/26,262,527 | 5.27 | 9.23e-10 | 8.21e-09 |
| Phospholipase A2:0 | 22/138,393 | 14,755/26,262,527 | 0.28 | 1.69e-13 | 2.02e-12 |
| rosiglitazone:0 | 15/138,393 | 13,610/26,262,527 | 0.21 | 1.14e-15 | 1.56e-14 |
| Intoxication:0 | 4/138,393 | 6,208/26,262,527 | 0.12 | 6.47e-10 | 5.83e-09 |
| Biliary Atresia:0 | 1/138,393 | 6,116/26,262,527 | 0.03 | 6.27e-13 | 7.17e-12 |
| Insurance Coverage:0 | 51/138,393 | 3,386/26,262,527 | 2.86 | 1.37e-10 | 1.31e-09 |
| ERBB2 gene|ERBB2:0 | 133/138,393 | 11,298/26,262,527 | 2.24 | 2.73e-16 | 3.86e-15 |
| SRD5A1:0 | 14/138,393 | 113/26,262,527 | 23.51 | 1.05e-14 | 1.36e-13 |
| MAP9:0 | 13/138,393 | 52/26,262,527 | 47.45 | 2.87e-17 | 4.29e-16 |
| Microscopy, Electron, Scanning:0 | 4/138,393 | 9,467/26,262,527 | 0.08 | 1.67e-16 | 2.40e-15 |
| research study:0 | 220/138,393 | 60,117/26,262,527 | 0.69 | 1.13e-08 | 9.11e-08 |
| Prostate and urinary bladder:0 | 9/138,393 | 24/26,262,527 | 71.17 | 1.03e-13 | 1.25e-12 |
| CpG Islands:0 | 111/138,393 | 3,724/26,262,527 | 5.66 | 1.94e-45 | 7.66e-44 |
| Methane:0 | 3/138,393 | 5,714/26,262,527 | 0.10 | 1.11e-09 | 9.79e-09 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase activity:0 | 9/138,393 | 62/26,262,527 | 27.55 | 1.66e-10 | 1.58e-09 |
| Laceration:0 | 9/138,393 | 11,561/26,262,527 | 0.15 | 2.58e-16 | 3.66e-15 |
| Sensors:0 | 43/138,393 | 22,174/26,262,527 | 0.37 | 7.65e-15 | 9.98e-14 |
| Thromboembolism:0 | 78/138,393 | 30,590/26,262,527 | 0.48 | 6.12e-13 | 7.01e-12 |
| Plenaxis:0 | 5/138,393 | 9/26,262,527 | 105.43 | 7.62e-09 | 6.24e-08 |
| Comorbidity:0 | 35/138,393 | 1,771/26,262,527 | 3.75 | 1.24e-10 | 1.20e-09 |
| fluoroethylcholine:0 | 12/138,393 | 30/26,262,527 | 75.91 | 4.11e-18 | 6.43e-17 |
| Magnesium:0 | 12/138,393 | 21,165/26,262,527 | 0.11 | 9.13e-33 | 2.51e-31 |
| Zymosan:0 | 2/138,393 | 4,961/26,262,527 | 0.08 | 3.04e-09 | 2.58e-08 |
| Tinnitus:0 | 2/138,393 | 9,270/26,262,527 | 0.04 | 1.41e-18 | 2.26e-17 |
| Cataract:0 | 10/138,393 | 23,097/26,262,527 | 0.08 | 8.41e-39 | 2.80e-37 |
| Pneumonia:0 | 26/138,393 | 83,170/26,262,527 | 0.06 | 2.04e-148 | 2.73e-146 |
| Somatotropin:0 | 312/138,393 | 40,499/26,262,527 | 1.46 | 3.05e-10 | 2.83e-09 |
| Proto-Oncogene Proteins c-myc|MYC:0 | 72/138,393 | 5,926/26,262,527 | 2.31 | 4.79e-10 | 4.36e-09 |
| apoptogenic cytochrome c release channel activity:0 | 172/138,393 | 5,269/26,262,527 | 6.20 | 6.18e-75 | 4.05e-73 |
| X-Ray Computed Tomography:0 | 239/138,393 | 28,334/26,262,527 | 1.60 | 1.45e-11 | 1.50e-10 |
| CA2:0 | 90/138,393 | 129,513/26,262,527 | 0.13 | 6.79e-180 | 1.18e-177 |
| Gastrointestinal Hemorrhage:0 | 9/138,393 | 9,079/26,262,527 | 0.19 | 1.82e-11 | 1.86e-10 |
| loss; bone:0 | 239/138,393 | 18,786/26,262,527 | 2.42 | 1.51e-32 | 4.13e-31 |
| Rhabdomyosarcoma:0 | 150/138,393 | 11,067/26,262,527 | 2.57 | 1.56e-23 | 3.09e-22 |
| beta catenin:0 | 289/138,393 | 29,409/26,262,527 | 1.87 | 9.89e-22 | 1.82e-20 |
| High-Risk Cancer:0 | 1,296/138,393 | 7,468/26,262,527 | 33.23 | 0.00e+00 | 0.00e+00 |
| Hydrocortisone:0 | 136/138,393 | 53,406/26,262,527 | 0.48 | 1.03e-21 | 1.90e-20 |
| Androstanediol:0 | 13/138,393 | 323/26,262,527 | 7.64 | 4.15e-08 | 3.12e-07 |
| Tomato sauce:0 | 7/138,393 | 18/26,262,527 | 73.80 | 4.81e-11 | 4.76e-10 |
| prostate stem cell antigen:0 | 80/138,393 | 193/26,262,527 | 78.71 | 3.56e-113 | 3.53e-111 |
| Chinese Hamster Ovary Cell:0 | 28/138,393 | 18,602/26,262,527 | 0.29 | 1.48e-16 | 2.13e-15 |
| Radical retropubic prostatectomy:0 | 963/138,393 | 2,101/26,262,527 | 87.58 | 0.00e+00 | 0.00e+00 |
| Gene Expression:0 | 538/138,393 | 59,582/26,262,527 | 1.72 | 2.01e-30 | 5.14e-29 |
| Choroid:0 | 20/138,393 | 15,645/26,262,527 | 0.24 | 4.28e-16 | 6.00e-15 |
| Syringes:0 | 2/138,393 | 4,316/26,262,527 | 0.09 | 7.29e-08 | 5.34e-07 |
| UGT2B17:0 | 15/138,393 | 149/26,262,527 | 19.11 | 1.96e-14 | 2.50e-13 |
| Extent of disease:0 | 5/138,393 | 11/26,262,527 | 86.26 | 1.65e-08 | 1.30e-07 |
| Mice, Obese:0 | 4/138,393 | 5,133/26,262,527 | 0.15 | 1.06e-07 | 7.61e-07 |
| Entire bile duct:0 | 15/138,393 | 10,634/26,262,527 | 0.27 | 1.74e-10 | 1.65e-09 |
| Glutamate Receptor:0 | 3/138,393 | 8,278/26,262,527 | 0.07 | 3.37e-15 | 4.50e-14 |
| MAP1LC3B:0 | 12/138,393 | 343/26,262,527 | 6.64 | 5.70e-07 | 3.80e-06 |
| Utilities:0 | 65/138,393 | 4,126/26,262,527 | 2.99 | 6.86e-14 | 8.44e-13 |
| Irradiation cystitis:0 | 32/138,393 | 283/26,262,527 | 21.46 | 1.64e-30 | 4.19e-29 |
| Seizures:0 | 46/138,393 | 57,336/26,262,527 | 0.15 | 4.62e-75 | 3.03e-73 |
| Venography - procedure:0 | 5/138,393 | 5,022/26,262,527 | 0.19 | 7.55e-07 | 4.97e-06 |
| PAK6 gene|PAK6:0 | 9/138,393 | 170/26,262,527 | 10.05 | 5.69e-07 | 3.79e-06 |
| amidronate:0 | 103/138,393 | 7,720/26,262,527 | 2.53 | 3.23e-16 | 4.56e-15 |
| Locally Advanced Malignant Neoplasm:0 | 898/138,393 | 13,570/26,262,527 | 12.63 | 0.00e+00 | 0.00e+00 |
| Diversion procedure:0 | 57/138,393 | 4,464/26,262,527 | 2.42 | 5.45e-09 | 4.52e-08 |
| S-Phase Fraction:0 | 52/138,393 | 2,829/26,262,527 | 3.49 | 7.67e-14 | 9.41e-13 |
| Glutamic Acid:0 | 6/138,393 | 5,424/26,262,527 | 0.21 | 7.26e-07 | 4.78e-06 |
| Multiple Sclerosis:0 | 25/138,393 | 93,770/26,262,527 | 0.05 | 1.15e-172 | 1.84e-170 |
| Hemoglobin:0 | 76/138,393 | 43,112/26,262,527 | 0.33 | 5.39e-31 | 1.40e-29 |
| Cerebellum:0 | 21/138,393 | 59,113/26,262,527 | 0.07 | 7.27e-103 | 6.55e-101 |
| Virus:0 | 92/138,393 | 67,078/26,262,527 | 0.26 | 2.71e-61 | 1.48e-59 |
| FK-506:0 | 10/138,393 | 11,219/26,262,527 | 0.17 | 7.58e-15 | 9.89e-14 |
| Thromboxane A2:0 | 4/138,393 | 6,297/26,262,527 | 0.12 | 4.66e-10 | 4.25e-09 |
| Organism:0 | 86/138,393 | 94,684/26,262,527 | 0.17 | 2.57e-115 | 2.62e-113 |
| epithelial to mesenchymal transition:0 | 84/138,393 | 2,290/26,262,527 | 6.96 | 4.40e-41 | 1.57e-39 |
| Aspiration-action:0 | 24/138,393 | 12,456/26,262,527 | 0.37 | 6.29e-09 | 5.19e-08 |
| Facilitation:0 | 5/138,393 | 8,321/26,262,527 | 0.11 | 3.17e-13 | 3.71e-12 |
| STEAP1:0 | 30/138,393 | 136/26,262,527 | 41.87 | 1.78e-36 | 5.59e-35 |
| Diabetic Retinopathy:0 | 14/138,393 | 21,356/26,262,527 | 0.12 | 2.20e-31 | 5.80e-30 |
| Free testosterone:0 | 92/138,393 | 2,177/26,262,527 | 8.02 | 1.26e-49 | 5.46e-48 |
| Pregnancy:0 | 31/138,393 | 98,117/26,262,527 | 0.06 | 1.36e-174 | 2.24e-172 |
| delta-catenin:0 | 14/138,393 | 331/26,262,527 | 8.03 | 6.97e-09 | 5.72e-08 |
| External auditory canal structure:0 | 1/138,393 | 4,711/26,262,527 | 0.04 | 9.28e-10 | 8.25e-09 |
| Stents:0 | 46/138,393 | 51,189/26,262,527 | 0.17 | 2.96e-63 | 1.67e-61 |
| European American:0 | 27/138,393 | 1,338/26,262,527 | 3.83 | 9.89e-09 | 7.98e-08 |
| Measurable Disease:0 | 144/138,393 | 1,465/26,262,527 | 18.67 | 2.47e-123 | 2.70e-121 |
| Systemic Therapy:0 | 199/138,393 | 10,219/26,262,527 | 3.70 | 1.19e-51 | 5.34e-50 |
| Tracheophyta:0 | 1/138,393 | 3,965/26,262,527 | 0.05 | 3.38e-08 | 2.56e-07 |
| Probes:0 | 442/138,393 | 56,887/26,262,527 | 1.48 | 1.77e-14 | 2.26e-13 |
| Hormone Antagonists:0 | 33/138,393 | 438/26,262,527 | 14.30 | 3.51e-26 | 7.68e-25 |
| terazosine:0 | 38/138,393 | 1,907/26,262,527 | 3.78 | 1.65e-11 | 1.70e-10 |
| Small prostate:0 | 63/138,393 | 181/26,262,527 | 66.08 | 1.61e-85 | 1.20e-83 |
| Lidocaine:0 | 52/138,393 | 23,145/26,262,527 | 0.43 | 1.77e-12 | 1.96e-11 |
| Estramustine phosphate:0 | 262/138,393 | 906/26,262,527 | 54.98 | 0.00e+00 | 0.00e+00 |
| Intracranial:0 | 28/138,393 | 18,191/26,262,527 | 0.29 | 8.75e-16 | 1.20e-14 |
| Bilirubin:0 | 4/138,393 | 8,559/26,262,527 | 0.09 | 1.04e-14 | 1.35e-13 |
| overdiagnosis:0 | 60/138,393 | 278/26,262,527 | 40.97 | 8.60e-71 | 5.31e-69 |
| Posterior Fossa:0 | 1/138,393 | 5,325/26,262,527 | 0.04 | 3.43e-11 | 3.44e-10 |
| Premature Birth:0 | 1/138,393 | 15,951/26,262,527 | 0.01 | 7.03e-35 | 2.08e-33 |
| PGR gene|PGR:0 | 29/138,393 | 1,592/26,262,527 | 3.46 | 2.51e-08 | 1.93e-07 |
| Brucellosis:0 | 1/138,393 | 8,283/26,262,527 | 0.02 | 1.13e-17 | 1.73e-16 |
| Prothrombin:0 | 5/138,393 | 6,335/26,262,527 | 0.15 | 2.91e-09 | 2.48e-08 |
| Cyclins:0 | 56/138,393 | 3,194/26,262,527 | 3.33 | 5.70e-14 | 7.05e-13 |
| Suspected prostate cancer:0 | 151/138,393 | 190/26,262,527 | 150.98 | 3.14e-245 | 7.45e-243 |
| Hyperglycemia:0 | 33/138,393 | 35,522/26,262,527 | 0.18 | 1.82e-43 | 6.88e-42 |
| CAMKK2:0 | 7/138,393 | 91/26,262,527 | 14.60 | 9.92e-07 | 6.42e-06 |
| Macrophage Chemotactic Factors:0 | 89/138,393 | 4,288/26,262,527 | 3.94 | 6.63e-26 | 1.43e-24 |
| Short Bowel Syndrome:0 | 1/138,393 | 4,315/26,262,527 | 0.04 | 5.51e-09 | 4.57e-08 |
| Transplantation:0 | 96/138,393 | 113,545/26,262,527 | 0.16 | 1.79e-143 | 2.33e-141 |
| Orchiectomy:0 | 534/138,393 | 3,377/26,262,527 | 30.12 | 0.00e+00 | 0.00e+00 |
| Disease recurrence:0 | 154/138,393 | 2,600/26,262,527 | 11.25 | 1.77e-101 | 1.55e-99 |
| V 70:0 | 21/138,393 | 44/26,262,527 | 90.58 | 6.26e-32 | 1.68e-30 |
| ghrelin:0 | 21/138,393 | 20,943/26,262,527 | 0.19 | 6.56e-25 | 1.37e-23 |
| epitheliasin:0 | 5/138,393 | 20/26,262,527 | 47.44 | 1.93e-07 | 1.35e-06 |
| Subcutaneous Fat:0 | 4/138,393 | 5,638/26,262,527 | 0.13 | 9.91e-09 | 8.00e-08 |
| Pulmonary Embolism:0 | 51/138,393 | 28,204/26,262,527 | 0.34 | 3.94e-20 | 6.73e-19 |
| Polypeptides:0 | 69/138,393 | 39,224/26,262,527 | 0.33 | 2.35e-28 | 5.58e-27 |
| Podocytes:0 | 2/138,393 | 8,393/26,262,527 | 0.05 | 1.65e-16 | 2.36e-15 |
| Steroid therapy:0 | 20/138,393 | 10,834/26,262,527 | 0.35 | 2.67e-08 | 2.05e-07 |
| Estramustine Phosphate Sodium:0 | 9/138,393 | 45/26,262,527 | 37.96 | 1.28e-11 | 1.33e-10 |
| Serum Prostate Specific Antigen Test:0 | 7/138,393 | 8/26,262,527 | 166.06 | 6.74e-13 | 7.67e-12 |
| expression vector:0 | 66/138,393 | 5,125/26,262,527 | 2.44 | 2.39e-10 | 2.24e-09 |
| MSR1 gene|MSR1:0 | 11/138,393 | 55/26,262,527 | 37.96 | 6.77e-14 | 8.34e-13 |
| Lysosomal Storage Diseases:0 | 1/138,393 | 4,476/26,262,527 | 0.04 | 2.69e-09 | 2.30e-08 |
| Spondylarthritis:0 | 1/138,393 | 6,137/26,262,527 | 0.03 | 6.40e-13 | 7.30e-12 |
| Saccharomycetales:0 | 1/138,393 | 4,992/26,262,527 | 0.04 | 2.16e-10 | 2.03e-09 |
| Cardiac Hypertrophy:0 | 1/138,393 | 9,792/26,262,527 | 0.02 | 5.38e-21 | 9.61e-20 |
| BTG1 gene|BTG1|PPBP:0 | 303/138,393 | 777/26,262,527 | 74.16 | 0.00e+00 | 0.00e+00 |
| athlete:0 | 6/138,393 | 38,102/26,262,527 | 0.03 | 2.01e-76 | 1.35e-74 |
| parent:0 | 88/138,393 | 56,632/26,262,527 | 0.29 | 3.44e-46 | 1.38e-44 |
| Coagulating gland:0 | 12/138,393 | 275/26,262,527 | 8.28 | 5.89e-08 | 4.35e-07 |
| Entire pulmonary artery:0 | 4/138,393 | 17,317/26,262,527 | 0.04 | 1.47e-33 | 4.16e-32 |
| Ligaments:0 | 3/138,393 | 8,086/26,262,527 | 0.07 | 1.00e-14 | 1.30e-13 |
| Phyllodes Tumor:0 | 44/138,393 | 1,772/26,262,527 | 4.71 | 2.88e-16 | 4.08e-15 |
| Recombinant Erythropoietin:0 | 17/138,393 | 23,175/26,262,527 | 0.14 | 1.85e-32 | 5.02e-31 |
| responsibility:0 | 7/138,393 | 7,464/26,262,527 | 0.18 | 6.08e-10 | 5.50e-09 |
| Exposure to:0 | 39/138,393 | 16,060/26,262,527 | 0.46 | 5.44e-08 | 4.03e-07 |
| Diaphragm (Anatomy):0 | 2/138,393 | 4,826/26,262,527 | 0.08 | 6.20e-09 | 5.12e-08 |
| Rheumatism:0 | 18/138,393 | 21,671/26,262,527 | 0.16 | 1.17e-28 | 2.81e-27 |
| Encephalopathies:0 | 9/138,393 | 12,372/26,262,527 | 0.14 | 6.56e-18 | 1.01e-16 |
| KCNK3:0 | 2/138,393 | 6,396/26,262,527 | 0.06 | 2.48e-12 | 2.70e-11 |
| Disintegration:0 | 23/138,393 | 10,961/26,262,527 | 0.40 | 4.15e-07 | 2.81e-06 |
| Peripheral Vascular Diseases:0 | 11/138,393 | 23,565/26,262,527 | 0.09 | 8.75e-39 | 2.91e-37 |
| Hepatic:0 | 220/138,393 | 63,591/26,262,527 | 0.66 | 2.83e-11 | 2.85e-10 |
| taxane:0 | 166/138,393 | 4,211/26,262,527 | 7.49 | 9.09e-84 | 6.66e-82 |
| Cyproterone:0 | 13/138,393 | 259/26,262,527 | 9.53 | 3.43e-09 | 2.90e-08 |
| Dutasteride:0 | 169/138,393 | 1,443/26,262,527 | 22.25 | 5.36e-156 | 7.55e-154 |
| Serine:0 | 31/138,393 | 15,515/26,262,527 | 0.38 | 2.52e-10 | 2.36e-09 |
| Sensorineural Hearing Loss:0 | 1/138,393 | 9,588/26,262,527 | 0.02 | 1.66e-20 | 2.89e-19 |
| Sheep:0 | 16/138,393 | 64,650/26,262,527 | 0.05 | 7.12e-121 | 7.55e-119 |
| Cell of bone:0 | 61/138,393 | 2,831/26,262,527 | 4.09 | 4.94e-19 | 8.06e-18 |
| Gleason grading system for prostatic cancer:0 | 677/138,393 | 887/26,262,527 | 145.55 | 0.00e+00 | 0.00e+00 |
| Mannose:0 | 2/138,393 | 5,474/26,262,527 | 0.07 | 2.55e-10 | 2.39e-09 |
| Sarcoplasmic Reticulum:0 | 5/138,393 | 15,289/26,262,527 | 0.06 | 8.39e-28 | 1.96e-26 |
| Apoptosis Inducing Proteins:0 | 36/138,393 | 1,136/26,262,527 | 6.02 | 1.14e-16 | 1.66e-15 |
| Bone Resorption:0 | 137/138,393 | 11,701/26,262,527 | 2.22 | 1.71e-16 | 2.45e-15 |
| Abuse:0 | 3/138,393 | 13,648/26,262,527 | 0.04 | 7.36e-27 | 1.65e-25 |
| AIDS related complex:0 | 152/138,393 | 9,047/26,262,527 | 3.19 | 4.83e-33 | 1.34e-31 |
| Carcinoma of the Large Intestine:0 | 763/138,393 | 102,181/26,262,527 | 1.42 | 8.81e-20 | 1.49e-18 |
| Omentum:0 | 8/138,393 | 6,650/26,262,527 | 0.23 | 9.54e-08 | 6.92e-07 |
| BAK1 gene|BAK1:0 | 52/138,393 | 2,986/26,262,527 | 3.31 | 5.56e-13 | 6.38e-12 |
| Dairy Products:0 | 35/138,393 | 827/26,262,527 | 8.03 | 5.94e-20 | 1.01e-18 |
| Sensitized cell:0 | 52/138,393 | 1,905/26,262,527 | 5.18 | 1.30e-20 | 2.28e-19 |
| Neurofilament:0 | 1/138,393 | 3,291/26,262,527 | 0.06 | 1.33e-06 | 8.45e-06 |
| Atypical proliferation:0 | 64/138,393 | 300/26,262,527 | 40.50 | 4.13e-75 | 2.71e-73 |
| Chromosomes, Human:0 | 44/138,393 | 3,110/26,262,527 | 2.69 | 1.40e-08 | 1.11e-07 |
| Core needle biopsy:0 | 470/138,393 | 4,763/26,262,527 | 18.79 | 0.00e+00 | 0.00e+00 |
| Interleukin-1 alpha:0 | 39/138,393 | 25,507/26,262,527 | 0.29 | 8.16e-22 | 1.51e-20 |
| hepsin:0 | 7/138,393 | 33/26,262,527 | 40.26 | 1.74e-09 | 1.51e-08 |
| African American:0 | 530/138,393 | 24,443/26,262,527 | 4.13 | 1.45e-152 | 1.99e-150 |
| Carbon:0 | 30/138,393 | 25,351/26,262,527 | 0.22 | 5.76e-27 | 1.30e-25 |
| Neoplasms, Epithelial:0 | 92/138,393 | 3,740/26,262,527 | 4.67 | 7.14e-32 | 1.91e-30 |
| Visual Acuity:0 | 1/138,393 | 12,489/26,262,527 | 0.02 | 4.76e-27 | 1.08e-25 |
| Sotalol:0 | 2/138,393 | 4,144/26,262,527 | 0.09 | 2.24e-07 | 1.56e-06 |
| Dopamine D2 Receptor:0 | 1/138,393 | 3,826/26,262,527 | 0.05 | 6.97e-08 | 5.13e-07 |
| oncoprotein p21|CDKN1A|TCEAL1|NSG1|H3F3AP6:0 | 27/138,393 | 543/26,262,527 | 9.44 | 2.15e-17 | 3.24e-16 |
| Zea mays:0 | 2/138,393 | 12,948/26,262,527 | 0.03 | 1.37e-26 | 3.05e-25 |
| Gestational Age:0 | 2/138,393 | 10,552/26,262,527 | 0.04 | 2.10e-21 | 3.81e-20 |
| Insulin Resistance:0 | 83/138,393 | 63,707/26,262,527 | 0.25 | 7.20e-61 | 3.89e-59 |
| Ethylene:0 | 1/138,393 | 10,953/26,262,527 | 0.02 | 9.85e-24 | 1.96e-22 |
| Malignant tumor of colon:0 | 595/138,393 | 38,289/26,262,527 | 2.96 | 2.25e-110 | 2.16e-108 |
| Left ventricular structure:0 | 24/138,393 | 38,888/26,262,527 | 0.12 | 1.35e-57 | 6.82e-56 |
| Endurance:0 | 6/138,393 | 5,961/26,262,527 | 0.19 | 7.81e-08 | 5.71e-07 |
| Cyclic GMP:0 | 27/138,393 | 28,710/26,262,527 | 0.18 | 3.49e-35 | 1.04e-33 |
| Closure:0 | 8/138,393 | 11,006/26,262,527 | 0.14 | 6.62e-16 | 9.15e-15 |
| Neck Carcinoma:0 | 15/138,393 | 574/26,262,527 | 4.96 | 8.49e-07 | 5.56e-06 |
| Proteasome inhibitor:0 | 107/138,393 | 5,913/26,262,527 | 3.44 | 3.50e-26 | 7.66e-25 |
| Specimen from prostate:0 | 659/138,393 | 1,141/26,262,527 | 110.12 | 0.00e+00 | 0.00e+00 |
| E2F1 gene|E2F1|UBE2L3:0 | 65/138,393 | 3,878/26,262,527 | 3.18 | 4.51e-15 | 5.97e-14 |
| Infections, Upper Respiratory:0 | 2/138,393 | 5,419/26,262,527 | 0.07 | 3.71e-10 | 3.41e-09 |
| Therapeutic agent (substance):0 | 192/138,393 | 11,388/26,262,527 | 3.20 | 1.88e-41 | 6.76e-40 |
| Coughing:0 | 8/138,393 | 13,509/26,262,527 | 0.11 | 4.37e-21 | 7.84e-20 |
| Lichen Planus:0 | 1/138,393 | 4,129/26,262,527 | 0.05 | 1.67e-08 | 1.31e-07 |
| Fibroblast Growth Factor 8:0 | 20/138,393 | 314/26,262,527 | 12.09 | 3.51e-15 | 4.68e-14 |
| Ribosomal RNA:0 | 21/138,393 | 25,593/26,262,527 | 0.16 | 8.33e-34 | 2.37e-32 |
| Gastroesophageal reflux disease:0 | 8/138,393 | 31,922/26,262,527 | 0.05 | 3.89e-60 | 2.07e-58 |
| Low Birth Weights:0 | 1/138,393 | 12,477/26,262,527 | 0.02 | 4.63e-27 | 1.05e-25 |
| Macrolide Antibiotics:0 | 3/138,393 | 6,582/26,262,527 | 0.09 | 1.68e-11 | 1.72e-10 |
| BRCA1 Protein|BRCA1:0 | 13/138,393 | 319/26,262,527 | 7.73 | 3.61e-08 | 2.73e-07 |
| Digestion:0 | 17/138,393 | 10,205/26,262,527 | 0.32 | 9.53e-09 | 7.70e-08 |
| Congenital absence:0 | 2/138,393 | 3,940/26,262,527 | 0.10 | 4.18e-07 | 2.82e-06 |
| Adiponectin:0 | 60/138,393 | 35,021/26,262,527 | 0.32 | 2.80e-26 | 6.17e-25 |
| Tumor Necrosis Factor Receptor Superfamily, Member 10B:0 | 34/138,393 | 934/26,262,527 | 6.91 | 1.55e-17 | 2.35e-16 |
| Status Epilepticus:0 | 1/138,393 | 10,565/26,262,527 | 0.02 | 9.36e-23 | 1.80e-21 |
| Metals:0 | 45/138,393 | 35,880/26,262,527 | 0.24 | 5.85e-36 | 1.79e-34 |
| Endothelium:0 | 79/138,393 | 28,952/26,262,527 | 0.52 | 8.45e-11 | 8.21e-10 |
| TroVax:0 | 7/138,393 | 47/26,262,527 | 28.26 | 1.55e-08 | 1.23e-07 |
| Amines:0 | 22/138,393 | 14,045/26,262,527 | 0.30 | 3.22e-12 | 3.49e-11 |
| Plication:0 | 2/138,393 | 4,956/26,262,527 | 0.08 | 3.04e-09 | 2.58e-08 |
| S Phase Arrest:0 | 17/138,393 | 662/26,262,527 | 4.87 | 2.07e-07 | 1.44e-06 |
| Phosphatidylethanolamine Binding Protein:0 | 23/138,393 | 1,037/26,262,527 | 4.21 | 2.27e-08 | 1.77e-07 |
| Solid organ:0 | 44/138,393 | 1,914/26,262,527 | 4.36 | 3.98e-15 | 5.29e-14 |
| Stanolone:0 | 1,054/138,393 | 15,050/26,262,527 | 13.38 | 0.00e+00 | 0.00e+00 |
| Microscopes, Electron, Scanning:0 | 14/138,393 | 8,645/26,262,527 | 0.31 | 9.40e-08 | 6.83e-07 |
| Hereditary angioneurotic edema:0 | 1/138,393 | 3,319/26,262,527 | 0.06 | 8.70e-07 | 5.69e-06 |
| Cyclin-Dependent Kinases:0 | 70/138,393 | 5,126/26,262,527 | 2.59 | 6.19e-12 | 6.59e-11 |
| Actuary:0 | 37/138,393 | 713/26,262,527 | 9.85 | 7.65e-24 | 1.53e-22 |
| Hemospermia:0 | 34/138,393 | 342/26,262,527 | 18.87 | 1.32e-30 | 3.40e-29 |
| Amputation of penis NOS:0 | 12/138,393 | 298/26,262,527 | 7.64 | 1.35e-07 | 9.66e-07 |
| Hypophysectomy:0 | 37/138,393 | 1,280/26,262,527 | 5.49 | 7.03e-16 | 9.71e-15 |
| Superoxide Dismutase:0 | 54/138,393 | 50,281/26,262,527 | 0.20 | 8.03e-56 | 3.91e-54 |
| Bone lesion:0 | 108/138,393 | 2,182/26,262,527 | 9.40 | 2.43e-64 | 1.38e-62 |
| Fingers:0 | 9/138,393 | 11,085/26,262,527 | 0.15 | 2.73e-15 | 3.67e-14 |
| TNF-related apoptosis-inducing ligand:0 | 72/138,393 | 2,823/26,262,527 | 4.84 | 3.30e-26 | 7.23e-25 |
| FASN gene|FASN:0 | 42/138,393 | 427/26,262,527 | 18.67 | 3.05e-37 | 9.77e-36 |
| Probiotics:0 | 1/138,393 | 3,347/26,262,527 | 0.06 | 8.97e-07 | 5.85e-06 |
| Thymus Gland:0 | 4/138,393 | 10,586/26,262,527 | 0.07 | 5.60e-19 | 9.12e-18 |
| Delayed Hypersensitivity:0 | 15/138,393 | 9,053/26,262,527 | 0.31 | 8.02e-08 | 5.85e-07 |
| neuroimaging:0 | 4/138,393 | 4,788/26,262,527 | 0.16 | 3.88e-07 | 2.63e-06 |
| Zoonoses:0 | 1/138,393 | 7,914/26,262,527 | 0.02 | 6.91e-17 | 1.02e-15 |
| Nucleotides:0 | 36/138,393 | 17,874/26,262,527 | 0.38 | 1.24e-11 | 1.28e-10 |
| glutathione S-transferase pi|GSTP1:0 | 14/138,393 | 350/26,262,527 | 7.59 | 1.37e-08 | 1.08e-07 |
| Chronic Kidney Insufficiency:0 | 4/138,393 | 4,963/26,262,527 | 0.15 | 2.01e-07 | 1.41e-06 |
| Albendazole:0 | 3/138,393 | 5,026/26,262,527 | 0.11 | 2.36e-08 | 1.83e-07 |
| Trigona:0 | 12/138,393 | 245/26,262,527 | 9.30 | 1.76e-08 | 1.38e-07 |
| [D]Acute retention of urine:0 | 129/138,393 | 1,570/26,262,527 | 15.61 | 1.17e-101 | 1.03e-99 |
| Hyperhomocysteinemia:0 | 1/138,393 | 7,498/26,262,527 | 0.03 | 6.30e-16 | 8.72e-15 |
| Phentolamine:0 | 4/138,393 | 7,319/26,262,527 | 0.10 | 3.80e-12 | 4.11e-11 |
| Neoplasm Metastasis:0 | 4,189/138,393 | 100,066/26,262,527 | 8.16 | 0.00e+00 | 0.00e+00 |
| Peritoneal Dialysis:0 | 2/138,393 | 8,453/26,262,527 | 0.04 | 1.12e-16 | 1.63e-15 |
| Systemic vasculitis:0 | 1/138,393 | 3,600/26,262,527 | 0.05 | 2.05e-07 | 1.43e-06 |
| Denervation:0 | 6/138,393 | 7,924/26,262,527 | 0.14 | 1.59e-11 | 1.64e-10 |
| Question of pregnancy:0 | 6/138,393 | 15,517/26,262,527 | 0.07 | 2.73e-27 | 6.24e-26 |
| Cell Cycle Progression:0 | 293/138,393 | 12,819/26,262,527 | 4.34 | 2.88e-90 | 2.26e-88 |
| Ascites:0 | 13/138,393 | 11,299/26,262,527 | 0.22 | 6.42e-13 | 7.32e-12 |
| PIK3CB:0 | 12/138,393 | 295/26,262,527 | 7.72 | 1.22e-07 | 8.72e-07 |
| Sarcosine:0 | 57/138,393 | 812/26,262,527 | 13.33 | 1.94e-42 | 7.16e-41 |
| Endophthalmitis:0 | 2/138,393 | 4,752/26,262,527 | 0.08 | 8.82e-09 | 7.15e-08 |
| High Density Lipoproteins:0 | 19/138,393 | 18,325/26,262,527 | 0.20 | 1.28e-21 | 2.34e-20 |
| Hospitalization:0 | 60/138,393 | 32,690/26,262,527 | 0.35 | 1.02e-22 | 1.96e-21 |
| Uric Acid:0 | 9/138,393 | 9,097/26,262,527 | 0.19 | 1.26e-11 | 1.31e-10 |
| Glycogen:0 | 7/138,393 | 22,218/26,262,527 | 0.06 | 2.00e-40 | 7.02e-39 |
| Metamorphosis, Biological:0 | 1/138,393 | 4,136/26,262,527 | 0.05 | 1.68e-08 | 1.32e-07 |
| Sleep:0 | 13/138,393 | 32,212/26,262,527 | 0.08 | 8.54e-55 | 4.05e-53 |
| Biopsy sampling:0 | 19/138,393 | 234/26,262,527 | 15.41 | 2.73e-16 | 3.87e-15 |
| antitumor agent:0 | 44/138,393 | 1,733/26,262,527 | 4.82 | 1.34e-16 | 1.94e-15 |
| FOXA1:0 | 47/138,393 | 621/26,262,527 | 14.37 | 1.14e-36 | 3.60e-35 |
| Congenital bladder neck stenosis:0 | 34/138,393 | 191/26,262,527 | 33.79 | 2.52e-38 | 8.27e-37 |
| Hemoglobinopathies:0 | 1/138,393 | 3,996/26,262,527 | 0.05 | 3.49e-08 | 2.64e-07 |
| External radiotherapy NOS:0 | 110/138,393 | 1,058/26,262,527 | 19.75 | 4.47e-97 | 3.80e-95 |
| Heart Arrest:0 | 10/138,393 | 20,516/26,262,527 | 0.09 | 1.57e-33 | 4.43e-32 |
| Elastases:0 | 7/138,393 | 8,179/26,262,527 | 0.16 | 2.28e-11 | 2.31e-10 |
| 17q12:0 | 14/138,393 | 126/26,262,527 | 21.09 | 4.15e-14 | 5.18e-13 |
| Living Donors:0 | 2/138,393 | 4,004/26,262,527 | 0.09 | 2.94e-07 | 2.03e-06 |
| Congenital Heart Defects:0 | 2/138,393 | 9,029/26,262,527 | 0.04 | 6.30e-18 | 9.74e-17 |
| Difficulty passing urine:0 | 17/138,393 | 384/26,262,527 | 8.40 | 9.10e-11 | 8.81e-10 |
| Hydrolysis:0 | 46/138,393 | 20,599/26,262,527 | 0.42 | 2.15e-11 | 2.18e-10 |
| Nerve sparing:0 | 74/138,393 | 162/26,262,527 | 86.73 | 2.29e-107 | 2.12e-105 |
| Petroleum:0 | 2/138,393 | 4,664/26,262,527 | 0.08 | 1.25e-08 | 9.94e-08 |
| Transitional epithelial cell:0 | 43/138,393 | 1,507/26,262,527 | 5.42 | 5.37e-18 | 8.34e-17 |
| Order Coleoptera:0 | 1/138,393 | 3,602/26,262,527 | 0.05 | 2.05e-07 | 1.43e-06 |
| Gastroenteritis:0 | 1/138,393 | 10,404/26,262,527 | 0.02 | 1.88e-22 | 3.56e-21 |
| Estrogen Receptor beta|ESR2:0 | 62/138,393 | 3,735/26,262,527 | 3.15 | 2.83e-14 | 3.57e-13 |
| male germ cell-associated kinase:0 | 4/138,393 | 11/26,262,527 | 69.01 | 9.84e-07 | 6.38e-06 |
| Column:0 | 78/138,393 | 52,747/26,262,527 | 0.28 | 2.81e-45 | 1.11e-43 |
| Cystography:0 | 30/138,393 | 1,169/26,262,527 | 4.87 | 6.21e-12 | 6.60e-11 |
| Prostatic secretions:0 | 75/138,393 | 461/26,262,527 | 30.89 | 7.05e-80 | 4.96e-78 |
| Back:0 | 6/138,393 | 13,410/26,262,527 | 0.08 | 1.10e-22 | 2.10e-21 |
| Ureter:0 | 154/138,393 | 16,388/26,262,527 | 1.78 | 5.22e-11 | 5.15e-10 |
| Blood Glucose:0 | 12/138,393 | 18,895/26,262,527 | 0.12 | 3.52e-28 | 8.32e-27 |
| Ultrasonography:0 | 733/138,393 | 80,080/26,262,527 | 1.74 | 1.34e-42 | 4.95e-41 |
| granule cell:0 | 2/138,393 | 13,954/26,262,527 | 0.03 | 8.57e-29 | 2.07e-27 |
| Triptorelin|GNRH1:0 | 20/138,393 | 43/26,262,527 | 88.28 | 2.67e-30 | 6.76e-29 |
| Brill-Zinsser Disease:0 | 9/138,393 | 53/26,262,527 | 32.23 | 4.72e-11 | 4.68e-10 |
| Entire dentate gyrus:0 | 1/138,393 | 17,677/26,262,527 | 0.01 | 6.73e-39 | 2.25e-37 |
| Neuron-Specific Enolase:0 | 66/138,393 | 5,541/26,262,527 | 2.26 | 4.70e-09 | 3.92e-08 |
| Prostate Neuroendocrine Neoplasm:0 | 4/138,393 | 4/26,262,527 | 189.77 | 5.20e-08 | 3.86e-07 |
| apical membrane:0 | 14/138,393 | 8,105/26,262,527 | 0.33 | 6.83e-07 | 4.51e-06 |
| Primary biliary cirrhosis:0 | 4/138,393 | 15,551/26,262,527 | 0.05 | 1.20e-29 | 2.97e-28 |
| Natural Killer Cells:0 | 74/138,393 | 30,947/26,262,527 | 0.45 | 9.05e-15 | 1.17e-13 |
| Rhinitis:0 | 1/138,393 | 7,479/26,262,527 | 0.03 | 6.15e-16 | 8.53e-15 |
| PAWR gene|PAWR:0 | 58/138,393 | 947/26,262,527 | 11.63 | 4.26e-40 | 1.48e-38 |
| human old age (65+):0 | 72/138,393 | 3,570/26,262,527 | 3.83 | 1.26e-20 | 2.22e-19 |
| Exercise:0 | 104/138,393 | 37,589/26,262,527 | 0.52 | 3.44e-13 | 4.00e-12 |
| Cancer pain:0 | 64/138,393 | 5,164/26,262,527 | 2.35 | 2.03e-09 | 1.76e-08 |
| Chronic heart failure:0 | 2/138,393 | 28,381/26,262,527 | 0.01 | 2.94e-61 | 1.60e-59 |
| Acceptors:0 | 5/138,393 | 4,975/26,262,527 | 0.19 | 1.05e-06 | 6.81e-06 |
| Common Neoplasm:0 | 107/138,393 | 4,325/26,262,527 | 4.70 | 5.53e-37 | 1.76e-35 |
| CD4 gene|CD4:0 | 86/138,393 | 54,893/26,262,527 | 0.30 | 1.98e-44 | 7.65e-43 |
| Wounds, Penetrating:0 | 3/138,393 | 5,366/26,262,527 | 0.11 | 4.12e-09 | 3.45e-08 |
| Antigen-Antibody Complex:0 | 15/138,393 | 17,771/26,262,527 | 0.16 | 1.68e-23 | 3.32e-22 |
| Androcur:0 | 8/138,393 | 66/26,262,527 | 23.00 | 6.32e-09 | 5.20e-08 |
| Joints:0 | 6/138,393 | 13,974/26,262,527 | 0.08 | 6.49e-24 | 1.31e-22 |
| Registration:0 | 67/138,393 | 2,704/26,262,527 | 4.70 | 7.53e-24 | 1.51e-22 |
| Phenols:0 | 6/138,393 | 8,835/26,262,527 | 0.13 | 1.91e-13 | 2.26e-12 |
| ITIH4:0 | 3/138,393 | 7,597/26,262,527 | 0.07 | 1.23e-13 | 1.48e-12 |
| IFI27|PSMD9|SSSCA1|DCTN6|TMED7:0 | 275/138,393 | 11,061/26,262,527 | 4.73 | 1.45e-92 | 1.17e-90 |
| Glaucoma:0 | 5/138,393 | 37,749/26,262,527 | 0.03 | 3.13e-77 | 2.13e-75 |
| Tissue, Paraffin:0 | 95/138,393 | 4,656/26,262,527 | 3.87 | 5.18e-27 | 1.17e-25 |
| Finasteride:0 | 405/138,393 | 5,752/26,262,527 | 13.40 | 1.10e-290 | 3.01e-288 |
| KLK4:0 | 22/138,393 | 293/26,262,527 | 14.25 | 5.97e-18 | 9.24e-17 |
| Prostate-specific antigen monitoring:0 | 4/138,393 | 4/26,262,527 | 189.77 | 5.20e-08 | 3.86e-07 |
| Pseudoaneurysm:0 | 5/138,393 | 13,070/26,262,527 | 0.07 | 3.22e-23 | 6.28e-22 |
| Fox Chase Cancer Center:0 | 10/138,393 | 18/26,262,527 | 105.43 | 1.89e-16 | 2.70e-15 |
| AKR1C2:0 | 17/138,393 | 300/26,262,527 | 10.75 | 2.31e-12 | 2.53e-11 |
| Nerve Endings:0 | 1/138,393 | 3,979/26,262,527 | 0.05 | 3.41e-08 | 2.59e-07 |
| prior radiation therapy:0 | 29/138,393 | 556/26,262,527 | 9.90 | 4.31e-19 | 7.05e-18 |
| Myocytes, Cardiac:0 | 9/138,393 | 46,918/26,262,527 | 0.04 | 1.03e-91 | 8.18e-90 |
| Iron deficiency anemia:0 | 10/138,393 | 9,238/26,262,527 | 0.21 | 4.63e-11 | 4.59e-10 |
| Chloramphenicol:0 | 5/138,393 | 9,730/26,262,527 | 0.10 | 4.78e-16 | 6.66e-15 |
| Arterial pulse pressure:0 | 2/138,393 | 10,552/26,262,527 | 0.04 | 2.10e-21 | 3.81e-20 |
| Caregiver:0 | 21/138,393 | 14,764/26,262,527 | 0.27 | 4.51e-14 | 5.61e-13 |
| Palatine Tonsil:0 | 5/138,393 | 8,501/26,262,527 | 0.11 | 1.10e-13 | 1.33e-12 |
| Carcinoma of Male Breast:0 | 49/138,393 | 1,350/26,262,527 | 6.89 | 1.69e-24 | 3.48e-23 |
| Captopril:0 | 4/138,393 | 25,594/26,262,527 | 0.03 | 8.74e-52 | 3.95e-50 |
| IGFBP2 protein, human|IGFBP2:0 | 44/138,393 | 2,229/26,262,527 | 3.75 | 6.06e-13 | 6.95e-12 |
| Organic solvent product:0 | 1/138,393 | 4,626/26,262,527 | 0.04 | 1.31e-09 | 1.15e-08 |
| Alpha-hemolytic streptococcus:0 | 13/138,393 | 242/26,262,527 | 10.19 | 1.58e-09 | 1.37e-08 |
| Thrombosis:0 | 41/138,393 | 49,816/26,262,527 | 0.16 | 1.38e-64 | 7.89e-63 |
| Bile Acids:0 | 20/138,393 | 17,226/26,262,527 | 0.22 | 6.70e-19 | 1.09e-17 |
| Acute leukemia:0 | 30/138,393 | 20,009/26,262,527 | 0.28 | 1.11e-17 | 1.69e-16 |
| INPP4B:0 | 8/138,393 | 112/26,262,527 | 13.56 | 2.84e-07 | 1.96e-06 |
| vitamin E succinate:0 | 23/138,393 | 658/26,262,527 | 6.63 | 5.01e-12 | 5.38e-11 |
| follow-up:0 | 520/138,393 | 34,503/26,262,527 | 2.87 | 3.36e-92 | 2.71e-90 |
| Focused Ultrasound Therapy:0 | 32/138,393 | 152/26,262,527 | 39.96 | 3.13e-38 | 1.03e-36 |
| Hematoma:0 | 24/138,393 | 12,810/26,262,527 | 0.36 | 2.20e-09 | 1.89e-08 |
| Cesarean section:0 | 1/138,393 | 14,989/26,262,527 | 0.01 | 7.94e-33 | 2.19e-31 |
| Radical perineal prostatectomy:0 | 119/138,393 | 262/26,262,527 | 86.27 | 2.49e-171 | 3.94e-169 |
| Carotid Arteries:0 | 3/138,393 | 17,221/26,262,527 | 0.03 | 1.03e-34 | 3.04e-33 |
| 17-(allylamino)-17-demethoxygeldanamycin:0 | 39/138,393 | 1,928/26,262,527 | 3.84 | 5.87e-12 | 6.25e-11 |
| PSCA gene|PSCA:0 | 111/138,393 | 276/26,262,527 | 76.38 | 3.93e-155 | 5.49e-153 |
| CDK2 protein, human|CDK2:0 | 23/138,393 | 850/26,262,527 | 5.14 | 6.32e-10 | 5.70e-09 |
| Thyroid Diseases:0 | 7/138,393 | 8,810/26,262,527 | 0.15 | 1.66e-12 | 1.84e-11 |
| Arthritis:0 | 28/138,393 | 43,348/26,262,527 | 0.12 | 6.47e-63 | 3.61e-61 |
| Choline:0 | 202/138,393 | 12,346/26,262,527 | 3.11 | 9.91e-42 | 3.60e-40 |
| Free prostate specific antigen level:0 | 17/138,393 | 21/26,262,527 | 153.64 | 4.41e-29 | 1.07e-27 |
| Discharge, Body Substance:0 | 20/138,393 | 17,536/26,262,527 | 0.22 | 1.95e-19 | 3.25e-18 |
| Therapeutic Mobilization:0 | 18/138,393 | 11,579/26,262,527 | 0.29 | 1.93e-10 | 1.83e-09 |
| Dyspepsia:0 | 4/138,393 | 5,383/26,262,527 | 0.14 | 2.68e-08 | 2.05e-07 |
| WASF3:0 | 9/138,393 | 115/26,262,527 | 14.85 | 2.46e-08 | 1.90e-07 |
| TNFSF10 gene|TNFSF10:0 | 51/138,393 | 1,354/26,262,527 | 7.15 | 4.04e-26 | 8.82e-25 |
| Alcohol dehydrogenase:0 | 2/138,393 | 7,880/26,262,527 | 0.05 | 2.00e-15 | 2.70e-14 |
| Plain x-ray:0 | 73/138,393 | 36,461/26,262,527 | 0.38 | 1.76e-22 | 3.33e-21 |
| Tea:0 | 63/138,393 | 2,382/26,262,527 | 5.02 | 6.25e-24 | 1.26e-22 |
| Arthrogram:0 | 1/138,393 | 3,353/26,262,527 | 0.06 | 9.06e-07 | 5.91e-06 |
| 3-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene:0 | 4/138,393 | 6/26,262,527 | 126.52 | 1.55e-07 | 1.09e-06 |
| Multileaf collimator:0 | 50/138,393 | 644/26,262,527 | 14.74 | 2.14e-39 | 7.29e-38 |
| Residual Cancer:0 | 87/138,393 | 1,181/26,262,527 | 13.99 | 1.81e-65 | 1.05e-63 |
| Goiter:0 | 7/138,393 | 7,167/26,262,527 | 0.19 | 2.22e-09 | 1.91e-08 |
| Malaria:0 | 16/138,393 | 53,071/26,262,527 | 0.06 | 7.13e-96 | 5.96e-94 |
| organic disorders:0 | 275/138,393 | 2,762/26,262,527 | 18.93 | 3.85e-235 | 8.63e-233 |
| Cholesterol Esters:0 | 9/138,393 | 8,526/26,262,527 | 0.20 | 1.65e-10 | 1.57e-09 |
| Adenosine Triphosphate:0 | 14/138,393 | 13,012/26,262,527 | 0.20 | 3.08e-15 | 4.13e-14 |
| Thyroglobulin|TG:0 | 2/138,393 | 6,967/26,262,527 | 0.05 | 2.22e-13 | 2.62e-12 |
| alcohol use disorder:0 | 1/138,393 | 3,881/26,262,527 | 0.05 | 4.83e-08 | 3.61e-07 |
| Pyruvate:0 | 20/138,393 | 11,220/26,262,527 | 0.34 | 6.80e-09 | 5.59e-08 |
| Receptor Activation:0 | 146/138,393 | 10,199/26,262,527 | 2.72 | 3.84e-25 | 8.07e-24 |
| Spironolactone:0 | 11/138,393 | 7,333/26,262,527 | 0.28 | 3.96e-07 | 2.69e-06 |
| Asians:0 | 130/138,393 | 12,979/26,262,527 | 1.90 | 3.98e-11 | 3.97e-10 |
| ERBB3 gene|ERBB3:0 | 46/138,393 | 2,633/26,262,527 | 3.32 | 1.03e-11 | 1.08e-10 |
| Weight Gain:0 | 40/138,393 | 19,069/26,262,527 | 0.40 | 1.34e-11 | 1.38e-10 |
| Movement:0 | 65/138,393 | 44,897/26,262,527 | 0.27 | 1.54e-39 | 5.27e-38 |
| pN1 category:0 | 32/138,393 | 720/26,262,527 | 8.44 | 5.76e-19 | 9.37e-18 |
| Receptor Protein-Tyrosine Kinases:0 | 184/138,393 | 13,263/26,262,527 | 2.63 | 1.20e-29 | 2.98e-28 |
| Intestines, Small:0 | 122/138,393 | 65,075/26,262,527 | 0.36 | 8.19e-43 | 3.06e-41 |
| Venous Thrombosis:0 | 15/138,393 | 9,182/26,262,527 | 0.31 | 4.43e-08 | 3.32e-07 |
| Invasive bladder cancer:0 | 146/138,393 | 4,949/26,262,527 | 5.60 | 1.19e-58 | 6.12e-57 |
| Sulfur:0 | 5/138,393 | 9,845/26,262,527 | 0.10 | 2.27e-16 | 3.23e-15 |
| Entire male genitourinary tract:0 | 6/138,393 | 26/26,262,527 | 43.79 | 1.67e-08 | 1.32e-07 |
| Binge Eating:0 | 1/138,393 | 5,756/26,262,527 | 0.03 | 3.87e-12 | 4.18e-11 |
| Prostate Leiomyosarcoma:0 | 4/138,393 | 8/26,262,527 | 94.89 | 3.61e-07 | 2.46e-06 |
| ETS Family Gene:0 | 8/138,393 | 37/26,262,527 | 41.03 | 1.03e-10 | 9.99e-10 |
| HIV Seropositivity:0 | 35/138,393 | 51,207/26,262,527 | 0.13 | 2.31e-72 | 1.46e-70 |
| Adrenergic beta-Agonists:0 | 3/138,393 | 6,136/26,262,527 | 0.09 | 1.34e-10 | 1.28e-09 |
| Corticotropin|CALCA|PCYT1A:0 | 4/138,393 | 6/26,262,527 | 126.52 | 1.55e-07 | 1.09e-06 |
| Acinar Prostate Adenocarcinoma, Sarcomatoid Variant:0 | 8/138,393 | 15/26,262,527 | 101.22 | 2.61e-13 | 3.06e-12 |
| Ion Channel:0 | 25/138,393 | 12,217/26,262,527 | 0.39 | 4.09e-08 | 3.08e-07 |
| Proton therapy:0 | 166/138,393 | 2,031/26,262,527 | 15.53 | 6.36e-130 | 7.31e-128 |
| glucose uptake:0 | 13/138,393 | 12,463/26,262,527 | 0.20 | 5.82e-15 | 7.65e-14 |
| Climate:0 | 4/138,393 | 8,104/26,262,527 | 0.09 | 8.30e-14 | 1.02e-12 |
| VDR gene|VDR:0 | 20/138,393 | 240/26,262,527 | 15.82 | 2.86e-17 | 4.28e-16 |
| Flutamide:0 | 616/138,393 | 5,619/26,262,527 | 20.89 | 0.00e+00 | 0.00e+00 |
| Dehiscence:0 | 3/138,393 | 5,232/26,262,527 | 0.11 | 8.27e-09 | 6.73e-08 |
| PTPN11 gene|PTPN11:0 | 9/138,393 | 7,313/26,262,527 | 0.23 | 2.48e-08 | 1.92e-07 |
| Substance Use Disorders:0 | 2/138,393 | 6,578/26,262,527 | 0.06 | 1.25e-12 | 1.40e-11 |
| Obsessive-Compulsive Disorder:0 | 1/138,393 | 19,821/26,262,527 | 0.01 | 1.09e-43 | 4.15e-42 |
| Epidemiologic Studies:0 | 54/138,393 | 4,844/26,262,527 | 2.12 | 8.20e-07 | 5.38e-06 |
| Growth Factor:0 | 756/138,393 | 60,756/26,262,527 | 2.37 | 1.17e-94 | 9.68e-93 |
| Very low density lipoprotein:0 | 3/138,393 | 7,196/26,262,527 | 0.08 | 6.73e-13 | 7.66e-12 |
| Superior mesenteric artery structure:0 | 2/138,393 | 4,410/26,262,527 | 0.09 | 5.26e-08 | 3.90e-07 |
| Body Weight:0 | 16/138,393 | 10,773/26,262,527 | 0.28 | 3.62e-10 | 3.33e-09 |
| Adenoviruses:0 | 172/138,393 | 14,506/26,262,527 | 2.25 | 6.78e-21 | 1.20e-19 |
| Chronic infectious disease:0 | 13/138,393 | 16,102/26,262,527 | 0.15 | 7.21e-22 | 1.33e-20 |
| Shoulder:0 | 7/138,393 | 29,434/26,262,527 | 0.05 | 6.35e-56 | 3.10e-54 |
| Cell Survival:0 | 780/138,393 | 34,166/26,262,527 | 4.35 | 7.73e-237 | 1.75e-234 |
| EZH2 protein, human|EZH2:0 | 33/138,393 | 524/26,262,527 | 11.95 | 6.87e-24 | 1.38e-22 |
| Marfan Syndrome:0 | 1/138,393 | 7,771/26,262,527 | 0.02 | 1.44e-16 | 2.07e-15 |
| Antihypertensive Agents:0 | 24/138,393 | 16,478/26,262,527 | 0.28 | 3.94e-15 | 5.23e-14 |
| Medullary:0 | 21/138,393 | 18,370/26,262,527 | 0.22 | 2.87e-20 | 4.93e-19 |
| glycitein:0 | 14/138,393 | 220/26,262,527 | 12.08 | 4.59e-11 | 4.56e-10 |
| dopaminergic neuron:0 | 2/138,393 | 20,951/26,262,527 | 0.02 | 1.59e-44 | 6.17e-43 |
| Alcohol abuse:0 | 3/138,393 | 5,751/26,262,527 | 0.10 | 7.39e-10 | 6.63e-09 |
| Neostriatum:0 | 7/138,393 | 83,814/26,262,527 | 0.02 | 2.52e-177 | 4.32e-175 |
| Chronic venous insufficiency NOS:0 | 1/138,393 | 3,332/26,262,527 | 0.06 | 8.79e-07 | 5.74e-06 |
| Tumorigenesis:0 | 1,450/138,393 | 42,358/26,262,527 | 6.55 | 0.00e+00 | 0.00e+00 |
| Granulomatous prostatitis:0 | 41/138,393 | 124/26,262,527 | 62.76 | 1.79e-55 | 8.66e-54 |
| Robot:0 | 79/138,393 | 5,128/26,262,527 | 2.92 | 5.12e-16 | 7.13e-15 |
| Alzheimer's Disease:0 | 58/138,393 | 105,318/26,262,527 | 0.10 | 1.79e-160 | 2.62e-158 |
| Acrosome Reaction:0 | 2/138,393 | 3,801/26,262,527 | 0.10 | 8.42e-07 | 5.52e-06 |
| Upper gastrointestinal hemorrhage:0 | 2/138,393 | 5,860/26,262,527 | 0.06 | 4.44e-11 | 4.42e-10 |
| Antilipemic Agents:0 | 1/138,393 | 4,183/26,262,527 | 0.05 | 1.14e-08 | 9.16e-08 |
| Chromosomes:0 | 44/138,393 | 16,159/26,262,527 | 0.52 | 1.50e-06 | 9.51e-06 |
| Abnormal shape:0 | 18/138,393 | 9,074/26,262,527 | 0.38 | 1.39e-06 | 8.82e-06 |
| Fracture:0 | 206/138,393 | 110,090/26,262,527 | 0.35 | 1.44e-71 | 8.96e-70 |
| Prostatectomy, Suprapubic:0 | 34/138,393 | 225/26,262,527 | 28.68 | 3.64e-36 | 1.13e-34 |
| PHOSPHATE BUFFERS:0 | 3/138,393 | 5,031/26,262,527 | 0.11 | 2.37e-08 | 1.84e-07 |
| Applicator - device:0 | 40/138,393 | 1,002/26,262,527 | 7.58 | 1.06e-21 | 1.94e-20 |
| Human serum albumin:0 | 11/138,393 | 10,167/26,262,527 | 0.21 | 3.40e-12 | 3.68e-11 |
| Metabolic syndrome:0 | 162/138,393 | 56,986/26,262,527 | 0.54 | 3.27e-18 | 5.14e-17 |
| Transposition procedure:0 | 1/138,393 | 5,414/26,262,527 | 0.04 | 2.41e-11 | 2.44e-10 |
| Ejaculatory duct structure:0 | 16/138,393 | 119/26,262,527 | 25.52 | 4.16e-17 | 6.18e-16 |
| Adrenal Medulla:0 | 6/138,393 | 8,069/26,262,527 | 0.14 | 8.10e-12 | 8.52e-11 |
| dichlorobis(ethylenediamine)rhodium(III):0 | 10/138,393 | 246/26,262,527 | 7.71 | 1.36e-06 | 8.63e-06 |
| MONONUCLEAR CELLS:0 | 31/138,393 | 24,481/26,262,527 | 0.24 | 9.99e-25 | 2.07e-23 |
| Kidney Failure:0 | 59/138,393 | 28,963/26,262,527 | 0.39 | 1.08e-17 | 1.66e-16 |
| Hay fever:0 | 6/138,393 | 9,530/26,262,527 | 0.12 | 9.32e-15 | 1.21e-13 |
| Carcinoma of bladder:0 | 22/138,393 | 717/26,262,527 | 5.82 | 1.55e-10 | 1.48e-09 |
| Radioactive destruction:0 | 13/138,393 | 71/26,262,527 | 34.75 | 9.98e-16 | 1.37e-14 |
| trophoblast:0 | 7/138,393 | 8,256/26,262,527 | 0.16 | 1.64e-11 | 1.69e-10 |
| HSPA5:0 | 72/138,393 | 4,293/26,262,527 | 3.18 | 1.57e-16 | 2.26e-15 |
| Aneurysm:0 | 12/138,393 | 51,128/26,262,527 | 0.04 | 1.19e-96 | 1.01e-94 |
| Cyst:0 | 52/138,393 | 35,040/26,262,527 | 0.28 | 1.69e-30 | 4.31e-29 |
| Rheumatoid Factor:0 | 1/138,393 | 6,749/26,262,527 | 0.03 | 2.35e-14 | 2.97e-13 |
| Leukocyte Elastase:0 | 1/138,393 | 8,839/26,262,527 | 0.02 | 5.95e-19 | 9.67e-18 |
| Leucine:0 | 43/138,393 | 17,568/26,262,527 | 0.46 | 1.45e-08 | 1.15e-07 |
| Oncogene Proteins:0 | 119/138,393 | 8,427/26,262,527 | 2.68 | 2.24e-20 | 3.90e-19 |
| Interleukin-12:0 | 58/138,393 | 21,433/26,262,527 | 0.51 | 2.12e-08 | 1.65e-07 |
| Spinal Cord:0 | 51/138,393 | 88,108/26,262,527 | 0.11 | 5.22e-132 | 6.19e-130 |
| Therapeutic immunosuppression:0 | 15/138,393 | 9,241/26,262,527 | 0.31 | 3.29e-08 | 2.51e-07 |
| End Point:0 | 307/138,393 | 12,560/26,262,527 | 4.65 | 2.38e-101 | 2.08e-99 |
| Radiolabeled Monoclonal Antibodies:0 | 19/138,393 | 452/26,262,527 | 7.98 | 1.72e-11 | 1.76e-10 |
| insulin secretion:0 | 3/138,393 | 20,758/26,262,527 | 0.03 | 2.06e-42 | 7.62e-41 |
| Entire aortic arch:0 | 1/138,393 | 7,019/26,262,527 | 0.03 | 8.47e-15 | 1.10e-13 |
| mating:0 | 1/138,393 | 6,731/26,262,527 | 0.03 | 3.62e-14 | 4.54e-13 |
| depolarization:0 | 14/138,393 | 16,218/26,262,527 | 0.16 | 3.02e-21 | 5.45e-20 |
| Menopausal hot flushes:0 | 85/138,393 | 2,823/26,262,527 | 5.72 | 1.60e-35 | 4.86e-34 |
| L-Selectin:0 | 1/138,393 | 4,219/26,262,527 | 0.04 | 1.20e-08 | 9.56e-08 |
| Nicotine:0 | 3/138,393 | 35,007/26,262,527 | 0.02 | 2.46e-74 | 1.59e-72 |
| Oncogenes:0 | 226/138,393 | 9,037/26,262,527 | 4.75 | 7.26e-77 | 4.89e-75 |
| fluorescence activated cell sorter device:0 | 66/138,393 | 4,177/26,262,527 | 3.00 | 3.90e-14 | 4.88e-13 |
| Combination Drug Therapy:0 | 133/138,393 | 14,765/26,262,527 | 1.71 | 1.53e-08 | 1.21e-07 |
| Sugars:0 | 22/138,393 | 27,157/26,262,527 | 0.15 | 4.74e-36 | 1.46e-34 |
| Cell Communication:0 | 116/138,393 | 11,487/26,262,527 | 1.92 | 2.82e-10 | 2.62e-09 |
| Chromatography, Gel:0 | 15/138,393 | 9,061/26,262,527 | 0.31 | 5.78e-08 | 4.27e-07 |
| BMX Non-Receptor Tyrosine Kinase|BMX|EPHA3:0 | 13/138,393 | 204/26,262,527 | 12.09 | 2.20e-10 | 2.07e-09 |
| Saw palmetto extract:0 | 12/138,393 | 249/26,262,527 | 9.15 | 2.09e-08 | 1.63e-07 |
| Polycystic Kidney, Autosomal Dominant:0 | 2/138,393 | 7,546/26,262,527 | 0.05 | 8.02e-15 | 1.05e-13 |
| Opioid Receptor:0 | 5/138,393 | 10,380/26,262,527 | 0.09 | 2.09e-17 | 3.14e-16 |
| Retinoblastoma Protein|RB1:0 | 72/138,393 | 6,726/26,262,527 | 2.03 | 7.76e-08 | 5.67e-07 |
| Pain Threshold:0 | 1/138,393 | 5,011/26,262,527 | 0.04 | 2.23e-10 | 2.09e-09 |
| Nicotinic Acid:0 | 1/138,393 | 8,824/26,262,527 | 0.02 | 5.87e-19 | 9.54e-18 |
| Anura:0 | 8/138,393 | 23,958/26,262,527 | 0.06 | 6.21e-43 | 2.33e-41 |
| Fasting:0 | 10/138,393 | 9,138/26,262,527 | 0.21 | 6.17e-11 | 6.05e-10 |
| T-Cell Lymphoma:0 | 8/138,393 | 6,257/26,262,527 | 0.24 | 4.42e-07 | 2.97e-06 |
| Medical pathologist:0 | 83/138,393 | 2,558/26,262,527 | 6.16 | 6.21e-37 | 1.97e-35 |
| BMP6 gene|BMP6:0 | 12/138,393 | 221/26,262,527 | 10.30 | 5.92e-09 | 4.89e-08 |
| Gut:0 | 36/138,393 | 33,438/26,262,527 | 0.20 | 1.68e-37 | 5.41e-36 |
| ERBB2:0 | 34/138,393 | 1,338/26,262,527 | 4.82 | 3.35e-13 | 3.91e-12 |
| Molecular Target:0 | 31/138,393 | 1,757/26,262,527 | 3.35 | 1.71e-08 | 1.35e-07 |
| Leukemia, Lymphocytic, Acute:0 | 41/138,393 | 35,808/26,262,527 | 0.22 | 2.21e-38 | 7.27e-37 |
| Cardiac function:0 | 4/138,393 | 16,044/26,262,527 | 0.05 | 9.61e-31 | 2.48e-29 |
| Clinic Activities:0 | 57/138,393 | 1,429/26,262,527 | 7.57 | 3.39e-30 | 8.56e-29 |
| NEPHROTOXICITY:0 | 10/138,393 | 7,705/26,262,527 | 0.25 | 2.26e-08 | 1.75e-07 |
| Disease Progression:0 | 877/138,393 | 28,836/26,262,527 | 5.80 | 0.00e+00 | 0.00e+00 |
| Gonadotropin-Releasing Hormone Receptor:0 | 124/138,393 | 3,242/26,262,527 | 7.26 | 1.13e-61 | 6.16e-60 |
| Laser Delivery Systems, Fiberoptic:0 | 10/138,393 | 249/26,262,527 | 7.62 | 1.51e-06 | 9.52e-06 |
| Strabismus:0 | 1/138,393 | 5,707/26,262,527 | 0.03 | 5.68e-12 | 6.06e-11 |
| Plaque (lesion):0 | 8/138,393 | 6,355/26,262,527 | 0.24 | 3.31e-07 | 2.26e-06 |
| Structure of mucous membrane of nose:0 | 1/138,393 | 7,586/26,262,527 | 0.03 | 4.53e-16 | 6.32e-15 |
| adjuvant therapy:0 | 331/138,393 | 14,336/26,262,527 | 4.39 | 7.93e-103 | 7.11e-101 |
| Hepatic Vein Thrombosis:0 | 1/138,393 | 4,127/26,262,527 | 0.05 | 1.66e-08 | 1.31e-07 |
| Radiation Oncologist:0 | 9/138,393 | 87/26,262,527 | 19.63 | 2.57e-09 | 2.20e-08 |
| Dose-Rate:0 | 10/138,393 | 89/26,262,527 | 21.32 | 1.60e-10 | 1.52e-09 |
| Muramidase:0 | 4/138,393 | 8,247/26,262,527 | 0.09 | 4.14e-14 | 5.16e-13 |
| Energy Metabolism:0 | 37/138,393 | 23,658/26,262,527 | 0.30 | 6.13e-20 | 1.04e-18 |
| Asparagine:0 | 3/138,393 | 4,486/26,262,527 | 0.13 | 2.54e-07 | 1.76e-06 |
| Insulin-Like Growth-Factor-Binding Proteins:0 | 107/138,393 | 6,799/26,262,527 | 2.99 | 9.62e-22 | 1.77e-20 |
| Nonulcer dyspepsia:0 | 1/138,393 | 6,995/26,262,527 | 0.03 | 8.06e-15 | 1.05e-13 |
| Hand:0 | 100/138,393 | 62,883/26,262,527 | 0.30 | 4.79e-50 | 2.09e-48 |
| Trifluoperazine:0 | 2/138,393 | 3,738/26,262,527 | 0.10 | 1.20e-06 | 7.73e-06 |
| TRANSCRIPTION FACTOR:0 | 715/138,393 | 73,851/26,262,527 | 1.84 | 2.94e-49 | 1.26e-47 |
| Small cell carcinoma of lung:0 | 371/138,393 | 29,877/26,262,527 | 2.36 | 3.62e-47 | 1.50e-45 |
| targeting:0 | 667/138,393 | 34,735/26,262,527 | 3.66 | 1.05e-165 | 1.62e-163 |
| HSP90 Heat-Shock Proteins:0 | 48/138,393 | 3,597/26,262,527 | 2.53 | 2.32e-08 | 1.80e-07 |
| Bladder tumour resection:0 | 6/138,393 | 48/26,262,527 | 23.72 | 4.32e-07 | 2.91e-06 |
| Gastritis, Atrophic:0 | 4/138,393 | 5,270/26,262,527 | 0.14 | 5.34e-08 | 3.96e-07 |
| Urokinase|PLAU|PRAP1:0 | 114/138,393 | 5,281/26,262,527 | 4.10 | 3.95e-34 | 1.13e-32 |
| Myalgia:0 | 3/138,393 | 4,627/26,262,527 | 0.12 | 1.28e-07 | 9.14e-07 |
| Negative Lymph Node:0 | 31/138,393 | 698/26,262,527 | 8.43 | 2.05e-18 | 3.25e-17 |
| Gastrectomy:0 | 5/138,393 | 19,080/26,262,527 | 0.05 | 5.01e-36 | 1.55e-34 |
| Suicide:0 | 38/138,393 | 20,793/26,262,527 | 0.35 | 6.32e-15 | 8.29e-14 |
| Papillary thyroid carcinoma:0 | 28/138,393 | 12,965/26,262,527 | 0.41 | 5.31e-08 | 3.93e-07 |
| Hematuria:0 | 176/138,393 | 5,153/26,262,527 | 6.49 | 1.70e-79 | 1.19e-77 |
| Oral anticoagulants:0 | 3/138,393 | 6,256/26,262,527 | 0.09 | 6.43e-11 | 6.29e-10 |
| SPINK1 gene|SPINK1:0 | 19/138,393 | 642/26,262,527 | 5.62 | 4.67e-09 | 3.90e-08 |
| Acute proctitis:0 | 14/138,393 | 76/26,262,527 | 34.96 | 7.36e-17 | 1.08e-15 |
| Laser enucleation of the prostate:0 | 12/138,393 | 281/26,262,527 | 8.10 | 7.37e-08 | 5.39e-07 |
| IGA Glomerulonephritis:0 | 3/138,393 | 11,801/26,262,527 | 0.05 | 8.56e-23 | 1.65e-21 |
| Malignant Carcinoid Syndrome:0 | 19/138,393 | 430/26,262,527 | 8.39 | 7.59e-12 | 8.02e-11 |
| Buserelin|EREG|ESR1:0 | 15/138,393 | 5/26,262,527 | 569.36 | 9.37e-31 | 2.42e-29 |
| tat Genes|TAT:0 | 10/138,393 | 8,432/26,262,527 | 0.23 | 1.02e-09 | 9.03e-09 |
| Vascular occlusion:0 | 1/138,393 | 3,358/26,262,527 | 0.06 | 9.15e-07 | 5.96e-06 |
| Hospitalized Patients:0 | 25/138,393 | 24,149/26,262,527 | 0.20 | 4.13e-28 | 9.75e-27 |
| Entire head:0 | 18/138,393 | 21,044/26,262,527 | 0.16 | 2.35e-27 | 5.39e-26 |
| Ubiquitination:0 | 48/138,393 | 3,620/26,262,527 | 2.52 | 2.65e-08 | 2.03e-07 |
| Succinylcholine:0 | 1/138,393 | 3,556/26,262,527 | 0.05 | 3.01e-07 | 2.07e-06 |
| Parkinsonian Disorders:0 | 1/138,393 | 11,267/26,262,527 | 0.02 | 2.35e-24 | 4.80e-23 |
| Urticaria:0 | 2/138,393 | 5,923/26,262,527 | 0.06 | 3.07e-11 | 3.09e-10 |
| GABA Receptor:0 | 2/138,393 | 4,769/26,262,527 | 0.08 | 8.98e-09 | 7.27e-08 |
| Decision Making:0 | 19/138,393 | 616/26,262,527 | 5.85 | 2.45e-09 | 2.11e-08 |
| CD14 gene|CD14:0 | 13/138,393 | 9,873/26,262,527 | 0.25 | 2.23e-10 | 2.09e-09 |
| Prognosis bad:0 | 392/138,393 | 18,684/26,262,527 | 3.99 | 3.63e-109 | 3.43e-107 |
| Postherpetic neuralgia:0 | 1/138,393 | 3,509/26,262,527 | 0.05 | 4.52e-07 | 3.03e-06 |
| Liver Cirrhosis, Alcoholic:0 | 1/138,393 | 4,965/26,262,527 | 0.04 | 2.11e-10 | 1.99e-09 |
| spouse:0 | 56/138,393 | 4,915/26,262,527 | 2.16 | 3.24e-07 | 2.21e-06 |
| Ventricular Function, Left:0 | 1/138,393 | 16,525/26,262,527 | 0.01 | 3.78e-36 | 1.17e-34 |
| Microscopy:0 | 63/138,393 | 22,451/26,262,527 | 0.53 | 3.51e-08 | 2.66e-07 |
| TRPV6:0 | 19/138,393 | 561/26,262,527 | 6.43 | 5.61e-10 | 5.08e-09 |
| Adenocarcinoma, Mucinous:0 | 96/138,393 | 4,467/26,262,527 | 4.08 | 6.95e-29 | 1.68e-27 |
| Whole-Body Scintigraphy:0 | 13/138,393 | 357/26,262,527 | 6.91 | 1.26e-07 | 9.00e-07 |
| RASSF1A|RASSF1:0 | 32/138,393 | 1,874/26,262,527 | 3.24 | 2.13e-08 | 1.66e-07 |
| Osteolysis:0 | 63/138,393 | 4,226/26,262,527 | 2.83 | 1.61e-12 | 1.78e-11 |
| GSTP1 gene|GSTP1:0 | 128/138,393 | 1,800/26,262,527 | 13.51 | 1.08e-93 | 8.84e-92 |
| Entire prostatic glandular tissue:0 | 18/138,393 | 32/26,262,527 | 106.76 | 1.37e-28 | 3.28e-27 |
| FGF7 gene|FGF7:0 | 18/138,393 | 838/26,262,527 | 4.08 | 1.12e-06 | 7.25e-06 |
| Structure of retinal pigment epithelium:0 | 3/138,393 | 16,254/26,262,527 | 0.04 | 1.71e-32 | 4.64e-31 |
| Prostate specific antigen measurement:0 | 498/138,393 | 674/26,262,527 | 140.72 | 0.00e+00 | 0.00e+00 |
| Human Volunteers:0 | 1/138,393 | 3,569/26,262,527 | 0.05 | 3.07e-07 | 2.11e-06 |
| Hematopoietic stem cells:0 | 42/138,393 | 18,647/26,262,527 | 0.43 | 2.59e-10 | 2.42e-09 |
| Sputum:0 | 1/138,393 | 4,242/26,262,527 | 0.04 | 7.92e-09 | 6.47e-08 |
| EGF gene|EGF:0 | 150/138,393 | 9,344/26,262,527 | 3.05 | 1.25e-30 | 3.22e-29 |
| Skp2 Proteins|SKP2:0 | 38/138,393 | 1,192/26,262,527 | 6.05 | 1.38e-17 | 2.10e-16 |
| Factor Xa:0 | 4/138,393 | 4,933/26,262,527 | 0.15 | 2.98e-07 | 2.05e-06 |
| Cerebrum:0 | 3/138,393 | 5,555/26,262,527 | 0.10 | 2.16e-09 | 1.86e-08 |
| Growth Inhibitors:0 | 268/138,393 | 6,962/26,262,527 | 7.32 | 1.06e-131 | 1.25e-129 |
| rituximab:0 | 12/138,393 | 31,592/26,262,527 | 0.07 | 1.53e-54 | 7.20e-53 |
| Pulmonary Fibrosis:0 | 5/138,393 | 10,785/26,262,527 | 0.09 | 2.46e-18 | 3.88e-17 |
| Coronary angiography:0 | 2/138,393 | 14,476/26,262,527 | 0.03 | 4.37e-30 | 1.10e-28 |
| Pituitary cell:0 | 10/138,393 | 8,012/26,262,527 | 0.24 | 6.65e-09 | 5.47e-08 |
| paracrine:0 | 134/138,393 | 5,903/26,262,527 | 4.31 | 5.25e-42 | 1.92e-40 |
| Tissue, Fresh:0 | 62/138,393 | 2,353/26,262,527 | 5.00 | 1.69e-23 | 3.34e-22 |
| sevoflurane:0 | 3/138,393 | 11,791/26,262,527 | 0.05 | 8.51e-23 | 1.64e-21 |
| Propofol:0 | 10/138,393 | 29,500/26,262,527 | 0.06 | 2.00e-52 | 9.11e-51 |
| Gonadorelin|GHRH:0 | 129/138,393 | 1,835/26,262,527 | 13.35 | 7.75e-94 | 6.37e-92 |
| Saccharomyces cerevisiae:0 | 86/138,393 | 119,916/26,262,527 | 0.14 | 2.72e-164 | 4.08e-162 |
| Brain natriuretic peptide:0 | 1/138,393 | 13,578/26,262,527 | 0.01 | 1.24e-29 | 3.08e-28 |
| Pituitary-dependent Cushing's disease:0 | 3/138,393 | 5,746/26,262,527 | 0.10 | 7.35e-10 | 6.60e-09 |
| Secondary malignant neoplasm of lymph node:0 | 782/138,393 | 27,056/26,262,527 | 5.51 | 3.31e-300 | 9.19e-298 |
| Urothelium:0 | 301/138,393 | 9,808/26,262,527 | 5.83 | 4.56e-123 | 4.96e-121 |
| Lupus Erythematosus, Systemic:0 | 23/138,393 | 84,201/26,262,527 | 0.05 | 1.85e-154 | 2.58e-152 |
| Immune Sera|HSD3B1:0 | 11/138,393 | 8/26,262,527 | 260.95 | 5.97e-21 | 1.06e-19 |
| daidzein:0 | 88/138,393 | 3,062/26,262,527 | 5.46 | 2.85e-35 | 8.54e-34 |
| Alcohols:0 | 6/138,393 | 8,101/26,262,527 | 0.14 | 5.53e-12 | 5.92e-11 |
| Advance:0 | 43/138,393 | 2,581/26,262,527 | 3.16 | 1.94e-10 | 1.84e-09 |
| METHYLATE:0 | 41/138,393 | 1,957/26,262,527 | 3.98 | 5.93e-13 | 6.80e-12 |
| Electromagnetic Energy:0 | 173/138,393 | 12,737/26,262,527 | 2.58 | 5.40e-27 | 1.22e-25 |
| Outpatients:0 | 88/138,393 | 41,949/26,262,527 | 0.40 | 4.92e-24 | 9.94e-23 |
| Klebsiella pneumonia bacterium:0 | 4/138,393 | 5,531/26,262,527 | 0.14 | 1.36e-08 | 1.08e-07 |
| Prostatic specific antigen decreased:0 | 23/138,393 | 32/26,262,527 | 136.42 | 5.61e-38 | 1.83e-36 |
| Osteoblasts:0 | 390/138,393 | 25,527/26,262,527 | 2.90 | 4.01e-71 | 2.48e-69 |
| Pulmonary Surfactants:0 | 4/138,393 | 21,691/26,262,527 | 0.03 | 4.09e-43 | 1.54e-41 |
| DNA, Single-Stranded:0 | 5/138,393 | 5,318/26,262,527 | 0.18 | 3.05e-07 | 2.09e-06 |
| Echocardiography, Transesophageal:0 | 1/138,393 | 8,043/26,262,527 | 0.02 | 3.29e-17 | 4.90e-16 |
| tumor growth:0 | 2,313/138,393 | 48,672/26,262,527 | 9.15 | 0.00e+00 | 0.00e+00 |
| Prostate examination:0 | 33/138,393 | 50/26,262,527 | 125.28 | 6.39e-53 | 2.93e-51 |
| Prostate implantation:0 | 25/138,393 | 41/26,262,527 | 115.73 | 8.27e-40 | 2.85e-38 |
| Granulomatous Disease, Chronic:0 | 1/138,393 | 4,955/26,262,527 | 0.04 | 3.33e-10 | 3.08e-09 |
| Androgen therapy:0 | 2,129/138,393 | 5,391/26,262,527 | 76.10 | 0.00e+00 | 0.00e+00 |
| neutrophil:0 | 36/138,393 | 104,336/26,262,527 | 0.07 | 6.93e-182 | 1.22e-179 |
| Paraquat:0 | 3/138,393 | 5,432/26,262,527 | 0.10 | 2.91e-09 | 2.48e-08 |
| Medulla:0 | 10/138,393 | 20,620/26,262,527 | 0.09 | 1.14e-33 | 3.25e-32 |
| Hormones:0 | 431/138,393 | 31,814/26,262,527 | 2.58 | 3.36e-64 | 1.90e-62 |
| Degenerative disorder:0 | 10/138,393 | 8,540/26,262,527 | 0.22 | 7.61e-10 | 6.81e-09 |
| Heart tissue:0 | 4/138,393 | 7,124/26,262,527 | 0.11 | 1.10e-11 | 1.15e-10 |
| host:0 | 158/138,393 | 74,147/26,262,527 | 0.40 | 1.31e-40 | 4.62e-39 |
| Anthelmintics:0 | 3/138,393 | 5,541/26,262,527 | 0.10 | 2.11e-09 | 1.82e-08 |
| Soluble ErbB-1|EGFR:0 | 85/138,393 | 5,981/26,262,527 | 2.70 | 3.45e-15 | 4.60e-14 |
| Atherosclerosis:0 | 59/138,393 | 73,537/26,262,527 | 0.15 | 7.20e-96 | 6.01e-94 |
| Citrate:0 | 101/138,393 | 7,857/26,262,527 | 2.44 | 5.46e-15 | 7.20e-14 |
| Local Therapy:0 | 175/138,393 | 3,804/26,262,527 | 8.74 | 2.93e-98 | 2.51e-96 |
| Heparitin Sulfate:0 | 9/138,393 | 8,669/26,262,527 | 0.20 | 8.68e-11 | 8.42e-10 |
| SPOP:0 | 19/138,393 | 117/26,262,527 | 30.82 | 1.98e-21 | 3.59e-20 |
| Disability NOS:0 | 29/138,393 | 67,403/26,262,527 | 0.08 | 1.77e-111 | 1.72e-109 |
| Population at Risk:0 | 40/138,393 | 2,570/26,262,527 | 2.95 | 5.10e-09 | 4.24e-08 |
| Diltiazem:0 | 5/138,393 | 12,124/26,262,527 | 0.08 | 4.80e-21 | 8.60e-20 |
| Heart Valves:0 | 6/138,393 | 29,405/26,262,527 | 0.04 | 3.13e-57 | 1.57e-55 |
| Markers, Bone:0 | 51/138,393 | 2,040/26,262,527 | 4.75 | 1.04e-18 | 1.67e-17 |
| Ampicillin:0 | 8/138,393 | 9,506/26,262,527 | 0.16 | 4.88e-13 | 5.61e-12 |
| Estrogens, Synthetic:0 | 35/138,393 | 952/26,262,527 | 6.98 | 3.93e-18 | 6.15e-17 |
| Sulfuric Acid Esters:0 | 14/138,393 | 10,853/26,262,527 | 0.24 | 1.76e-11 | 1.80e-10 |
| Central incisor:0 | 1/138,393 | 4,837/26,262,527 | 0.04 | 4.40e-10 | 4.03e-09 |
| Histone Deacetylase:0 | 115/138,393 | 6,467/26,262,527 | 3.38 | 2.14e-27 | 4.92e-26 |
| Glucagon|GCG:0 | 3/138,393 | 11,322/26,262,527 | 0.05 | 1.08e-21 | 1.99e-20 |
| Patient Selection:0 | 101/138,393 | 3,966/26,262,527 | 4.84 | 5.30e-36 | 1.63e-34 |
| Malignant Epithelial Cell:0 | 237/138,393 | 5,936/26,262,527 | 7.59 | 7.03e-120 | 7.37e-118 |
| Females:0 | 19/138,393 | 13,672/26,262,527 | 0.26 | 2.67e-13 | 3.13e-12 |
| Metastatic Lesion:0 | 178/138,393 | 4,588/26,262,527 | 7.37 | 1.22e-88 | 9.31e-87 |
| Cell Transformation, Neoplastic:0 | 93/138,393 | 4,022/26,262,527 | 4.39 | 2.84e-30 | 7.20e-29 |
| Atypical antipsychotic:0 | 1/138,393 | 7,328/26,262,527 | 0.03 | 1.27e-15 | 1.73e-14 |
| TNF-related apoptosis-inducing ligand|TNFSF10:0 | 180/138,393 | 9,521/26,262,527 | 3.59 | 3.09e-45 | 1.21e-43 |
| Microsomes:0 | 49/138,393 | 36,336/26,262,527 | 0.26 | 2.73e-34 | 7.88e-33 |
| Ductal Breast Carcinoma:0 | 68/138,393 | 1,672/26,262,527 | 7.72 | 3.55e-36 | 1.10e-34 |
| Biological Markers:0 | 37/138,393 | 468/26,262,527 | 15.01 | 7.52e-30 | 1.88e-28 |
| fMRI:0 | 17/138,393 | 9,015/26,262,527 | 0.36 | 6.03e-07 | 4.00e-06 |
| Celiac Disease:0 | 6/138,393 | 32,918/26,262,527 | 0.03 | 4.12e-65 | 2.38e-63 |
| Diffusion Magnetic Resonance Imaging:0 | 121/138,393 | 3,123/26,262,527 | 7.36 | 8.41e-61 | 4.52e-59 |
| Heroin:0 | 2/138,393 | 5,596/26,262,527 | 0.07 | 1.94e-10 | 1.83e-09 |
| Bone Wires:0 | 11/138,393 | 8,529/26,262,527 | 0.24 | 3.21e-09 | 2.72e-08 |
| cancer care:0 | 52/138,393 | 970/26,262,527 | 10.18 | 1.79e-33 | 5.03e-32 |
| Dissociation:0 | 53/138,393 | 23,638/26,262,527 | 0.43 | 8.26e-13 | 9.35e-12 |
| Negative Finding:0 | 53/138,393 | 1,293/26,262,527 | 7.78 | 9.89e-29 | 2.38e-27 |
| Strontium-89:0 | 79/138,393 | 217/26,262,527 | 69.12 | 4.35e-108 | 4.06e-106 |
| ZD4054:0 | 7/138,393 | 54/26,262,527 | 24.60 | 3.70e-08 | 2.80e-07 |
| Optic Disk:0 | 3/138,393 | 7,570/26,262,527 | 0.08 | 1.17e-13 | 1.41e-12 |
| AMACR:0 | 31/138,393 | 113/26,262,527 | 52.07 | 3.42e-40 | 1.19e-38 |
| Orthologous Gene:0 | 39/138,393 | 15,839/26,262,527 | 0.47 | 8.51e-08 | 6.20e-07 |
| Needle biopsy procedure:0 | 943/138,393 | 5,778/26,262,527 | 31.18 | 0.00e+00 | 0.00e+00 |
| Angiotensin II:0 | 30/138,393 | 65,381/26,262,527 | 0.09 | 4.09e-106 | 3.75e-104 |
| Filament:0 | 9/138,393 | 11,916/26,262,527 | 0.14 | 7.34e-17 | 1.08e-15 |
| HIF1A gene|HIF1A:0 | 36/138,393 | 965/26,262,527 | 7.08 | 8.51e-19 | 1.38e-17 |
| Ovaro-:0 | 383/138,393 | 39,578/26,262,527 | 1.84 | 3.42e-27 | 7.79e-26 |
| Diphosphonates:0 | 736/138,393 | 22,913/26,262,527 | 6.12 | 4.24e-310 | 1.21e-307 |
| NELFCD:0 | 12/138,393 | 9,351/26,262,527 | 0.24 | 4.59e-10 | 4.19e-09 |
| Macular retinal edema:0 | 1/138,393 | 5,330/26,262,527 | 0.04 | 3.44e-11 | 3.45e-10 |
| Lymphocyte:0 | 205/138,393 | 112,902/26,262,527 | 0.34 | 2.85e-76 | 1.90e-74 |
| flavopiridol:0 | 30/138,393 | 1,625/26,262,527 | 3.50 | 1.09e-08 | 8.80e-08 |
| EP300 protein, human|EP300:0 | 57/138,393 | 5,267/26,262,527 | 2.05 | 9.58e-07 | 6.23e-06 |
| Falls:0 | 55/138,393 | 31,118/26,262,527 | 0.34 | 9.60e-23 | 1.84e-21 |
| Paget's Disease:0 | 48/138,393 | 3,871/26,262,527 | 2.35 | 1.76e-07 | 1.24e-06 |
| Kidney Diseases:0 | 31/138,393 | 51,721/26,262,527 | 0.11 | 4.78e-77 | 3.23e-75 |
| prostatitis:0 | 240/138,393 | 2,194/26,262,527 | 20.79 | 2.66e-214 | 5.41e-212 |
| Antirheumatic Drugs, Disease-Modifying:0 | 2/138,393 | 4,029/26,262,527 | 0.09 | 2.97e-07 | 2.05e-06 |
| lamotrigine:0 | 2/138,393 | 7,022/26,262,527 | 0.05 | 1.49e-13 | 1.79e-12 |
| Invasive Carcinoma:0 | 114/138,393 | 6,954/26,262,527 | 3.11 | 2.10e-24 | 4.30e-23 |
| Chronic urticaria:0 | 1/138,393 | 3,993/26,262,527 | 0.05 | 3.47e-08 | 2.63e-07 |
| Argipressin:0 | 11/138,393 | 31,837/26,262,527 | 0.07 | 2.45e-56 | 1.21e-54 |
| Nucleocapsid:0 | 1/138,393 | 3,271/26,262,527 | 0.06 | 1.28e-06 | 8.16e-06 |
| Liver Failure:0 | 7/138,393 | 8,149/26,262,527 | 0.16 | 3.27e-11 | 3.28e-10 |
| Airway device:0 | 1/138,393 | 7,166/26,262,527 | 0.03 | 4.13e-15 | 5.47e-14 |
| Infectious Mononucleosis:0 | 2/138,393 | 4,397/26,262,527 | 0.09 | 5.17e-08 | 3.85e-07 |
| Restenosis:0 | 2/138,393 | 13,333/26,262,527 | 0.03 | 1.48e-27 | 3.42e-26 |
| Brain Injuries:0 | 1/138,393 | 22,308/26,262,527 | 0.01 | 2.79e-49 | 1.20e-47 |
| Clinical Trials, Phase I:0 | 15/138,393 | 402/26,262,527 | 7.08 | 1.02e-08 | 8.26e-08 |
| GRP gene|GRP:0 | 22/138,393 | 356/26,262,527 | 11.73 | 2.73e-16 | 3.87e-15 |
| Aortic valve replacement NOS:0 | 2/138,393 | 13,121/26,262,527 | 0.03 | 4.42e-27 | 1.00e-25 |
| Calcium:0 | 274/138,393 | 140,538/26,262,527 | 0.37 | 3.53e-86 | 2.66e-84 |
| Decidua:0 | 2/138,393 | 5,482/26,262,527 | 0.07 | 2.57e-10 | 2.40e-09 |
| PTPN6 protein, human|PTPN6:0 | 8/138,393 | 132/26,262,527 | 11.50 | 9.21e-07 | 6.00e-06 |
| Botulinum Toxins:0 | 9/138,393 | 14,127/26,262,527 | 0.12 | 2.00e-21 | 3.64e-20 |
| Urinary tract:0 | 130/138,393 | 4,833/26,262,527 | 5.11 | 2.99e-48 | 1.26e-46 |
| Health care facility:0 | 587/138,393 | 25,395/26,262,527 | 4.40 | 4.39e-181 | 7.68e-179 |
| Hypertrophy:0 | 122/138,393 | 47,545/26,262,527 | 0.49 | 3.16e-19 | 5.20e-18 |
| Zebrafish:0 | 20/138,393 | 23,008/26,262,527 | 0.16 | 1.47e-29 | 3.65e-28 |
| degarelix:0 | 68/138,393 | 202/26,262,527 | 63.91 | 2.44e-91 | 1.93e-89 |
| beta-Endorphin:0 | 4/138,393 | 14,065/26,262,527 | 0.05 | 2.28e-26 | 5.04e-25 |
| Natriuretic Peptides:0 | 4/138,393 | 5,714/26,262,527 | 0.13 | 7.09e-09 | 5.82e-08 |
| Andropause:0 | 15/138,393 | 140/26,262,527 | 20.33 | 8.47e-15 | 1.10e-13 |
| Ambulatory Care Facilities:0 | 300/138,393 | 30,271/26,262,527 | 1.88 | 4.92e-23 | 9.54e-22 |
| Venoms:0 | 9/138,393 | 10,523/26,262,527 | 0.16 | 2.63e-14 | 3.32e-13 |
| cyclopamine:0 | 31/138,393 | 656/26,262,527 | 8.97 | 3.87e-19 | 6.35e-18 |
| E2F1 Transcription Factor:0 | 15/138,393 | 430/26,262,527 | 6.62 | 2.41e-08 | 1.86e-07 |
| Prostatic duct:0 | 82/138,393 | 164/26,262,527 | 94.94 | 2.25e-121 | 2.40e-119 |
| Seminoma:0 | 66/138,393 | 5,152/26,262,527 | 2.43 | 2.79e-10 | 2.59e-09 |
| Cancer Relapse:0 | 70/138,393 | 538/26,262,527 | 24.70 | 1.40e-68 | 8.52e-67 |
| Superficial ulcer:0 | 18/138,393 | 12,451/26,262,527 | 0.27 | 7.92e-12 | 8.34e-11 |
| cell body (neuron):0 | 43/138,393 | 22,299/26,262,527 | 0.37 | 6.00e-15 | 7.88e-14 |
| Bladder Neoplasm:0 | 240/138,393 | 6,440/26,262,527 | 7.08 | 2.68e-115 | 2.72e-113 |
| Late pregnancy:0 | 2/138,393 | 4,370/26,262,527 | 0.09 | 5.09e-08 | 3.79e-07 |
| Nycturia:0 | 46/138,393 | 2,529/26,262,527 | 3.45 | 2.79e-12 | 3.03e-11 |
| Carbohydrates:0 | 63/138,393 | 28,492/26,262,527 | 0.42 | 1.65e-15 | 2.24e-14 |
| Transcranial Magnetic Stimulation, Repetitive:0 | 1/138,393 | 5,543/26,262,527 | 0.03 | 1.15e-11 | 1.20e-10 |
| Urogenital diaphragm:0 | 7/138,393 | 34/26,262,527 | 39.07 | 2.09e-09 | 1.80e-08 |
| Tumor Suppressor Genes:0 | 1,209/138,393 | 33,756/26,262,527 | 6.85 | 0.00e+00 | 0.00e+00 |
| Patient in hospital:0 | 4/138,393 | 6,275/26,262,527 | 0.12 | 4.59e-10 | 4.19e-09 |
| Microorganism:0 | 13/138,393 | 27,143/26,262,527 | 0.09 | 3.53e-44 | 1.36e-42 |
| Steroids:0 | 631/138,393 | 56,869/26,262,527 | 2.11 | 4.30e-62 | 2.37e-60 |
| Dexamethasone:0 | 164/138,393 | 85,229/26,262,527 | 0.36 | 9.93e-54 | 4.63e-52 |
| Vasospasm:0 | 4/138,393 | 13,074/26,262,527 | 0.06 | 3.49e-24 | 7.08e-23 |
| Green Fluorescent Proteins|HSPA9:0 | 3/138,393 | 1/26,262,527 | 569.32 | 5.74e-07 | 3.82e-06 |
| Basal Ganglia:0 | 4/138,393 | 14,679/26,262,527 | 0.05 | 8.69e-28 | 2.02e-26 |
| Leukemia, Myelocytic, Acute:0 | 93/138,393 | 65,224/26,262,527 | 0.27 | 1.26e-57 | 6.38e-56 |
| Optic Nerve:0 | 4/138,393 | 14,125/26,262,527 | 0.05 | 1.56e-26 | 3.47e-25 |
| Biomedical tape:0 | 3/138,393 | 6,276/26,262,527 | 0.09 | 6.59e-11 | 6.45e-10 |
| TRPM8:0 | 28/138,393 | 905/26,262,527 | 5.87 | 4.48e-13 | 5.18e-12 |
| Brucella:0 | 1/138,393 | 5,882/26,262,527 | 0.03 | 2.93e-12 | 3.17e-11 |
| Chronic pain:0 | 16/138,393 | 29,017/26,262,527 | 0.10 | 4.47e-45 | 1.75e-43 |
| Multiple tumors:0 | 79/138,393 | 4,324/26,262,527 | 3.47 | 5.12e-20 | 8.70e-19 |
| Erythropoietin:0 | 12/138,393 | 14,560/26,262,527 | 0.16 | 1.33e-19 | 2.23e-18 |
| General Population:0 | 326/138,393 | 43,258/26,262,527 | 1.43 | 1.12e-09 | 9.90e-09 |
| cancer complication:0 | 5/138,393 | 30/26,262,527 | 31.63 | 1.13e-06 | 7.26e-06 |
| [M]Neoplasm morphology NOS:0 | 13/138,393 | 395/26,262,527 | 6.25 | 3.81e-07 | 2.59e-06 |
| androsterone glucuronide:0 | 8/138,393 | 63/26,262,527 | 24.10 | 4.52e-09 | 3.78e-08 |
| DNMT3B gene|DNMT3B:0 | 21/138,393 | 1,114/26,262,527 | 3.58 | 1.16e-06 | 7.46e-06 |
| Urokinase Plasminogen Activator Receptor:0 | 33/138,393 | 2,312/26,262,527 | 2.71 | 6.80e-07 | 4.49e-06 |
| Nulliparous:0 | 3/138,393 | 6,300/26,262,527 | 0.09 | 6.92e-11 | 6.76e-10 |
| Strontium 89 therapy:0 | 13/138,393 | 35/26,262,527 | 70.49 | 3.67e-19 | 6.03e-18 |
| Bronchioles:0 | 3/138,393 | 4,427/26,262,527 | 0.13 | 3.60e-07 | 2.45e-06 |
| P-Glycoprotein:0 | 88/138,393 | 28,525/26,262,527 | 0.59 | 5.82e-08 | 4.30e-07 |
| AGR2 gene|AGR2:0 | 9/138,393 | 149/26,262,527 | 11.46 | 1.99e-07 | 1.39e-06 |
| Glycolipids:0 | 6/138,393 | 7,470/26,262,527 | 0.15 | 1.15e-10 | 1.11e-09 |
| Cell Wall:0 | 5/138,393 | 26,558/26,262,527 | 0.04 | 1.82e-52 | 8.31e-51 |
| Daughter:0 | 23/138,393 | 11,440/26,262,527 | 0.38 | 8.85e-08 | 6.44e-07 |
| Bladder outlet obstruction:0 | 117/138,393 | 3,058/26,262,527 | 7.27 | 2.60e-58 | 1.33e-56 |
| Renal pelvis:0 | 63/138,393 | 5,357/26,262,527 | 2.23 | 1.55e-08 | 1.22e-07 |
| 17q24.3:0 | 5/138,393 | 11/26,262,527 | 86.26 | 1.65e-08 | 1.30e-07 |
| Primary Neoplasm:0 | 850/138,393 | 35,552/26,262,527 | 4.56 | 5.51e-271 | 1.41e-268 |
| Workers:0 | 109/138,393 | 59,811/26,262,527 | 0.35 | 8.93e-41 | 3.16e-39 |
| Localized Malignant Neoplasm:0 | 297/138,393 | 2,195/26,262,527 | 25.73 | 2.01e-289 | 5.39e-287 |
| Interferon-beta:0 | 27/138,393 | 15,291/26,262,527 | 0.33 | 8.42e-12 | 8.85e-11 |
| Pathogenicity:0 | 44/138,393 | 40,066/26,262,527 | 0.21 | 5.73e-44 | 2.19e-42 |
| S-Adenosylmethionine:0 | 6/138,393 | 7,321/26,262,527 | 0.16 | 2.23e-10 | 2.09e-09 |
| Therapeutic radiology procedure:0 | 57/138,393 | 116/26,262,527 | 93.29 | 1.50e-84 | 1.11e-82 |
| Glutamate Decarboxylase:0 | 1/138,393 | 5,135/26,262,527 | 0.04 | 1.04e-10 | 1.01e-09 |
| Epiphysial cartilage:0 | 2/138,393 | 10,354/26,262,527 | 0.04 | 6.25e-21 | 1.11e-19 |
| Renal Blood Flow:0 | 1/138,393 | 6,470/26,262,527 | 0.03 | 1.01e-13 | 1.23e-12 |
| Nitroprusside:0 | 1/138,393 | 3,797/26,262,527 | 0.05 | 1.07e-07 | 7.67e-07 |
| Lymphoproliferative Disorders:0 | 19/138,393 | 10,468/26,262,527 | 0.34 | 3.33e-08 | 2.54e-07 |
| Reserpine:0 | 1/138,393 | 6,617/26,262,527 | 0.03 | 4.89e-14 | 6.07e-13 |
| Embolism:0 | 16/138,393 | 11,507/26,262,527 | 0.26 | 2.65e-11 | 2.68e-10 |
| Active monitoring:0 | 22/138,393 | 336/26,262,527 | 12.43 | 8.80e-17 | 1.28e-15 |
| Malignant neoplasm of ureter:0 | 12/138,393 | 221/26,262,527 | 10.30 | 5.92e-09 | 4.89e-08 |
| Chlamydia:0 | 2/138,393 | 5,957/26,262,527 | 0.06 | 3.28e-11 | 3.29e-10 |
| Soft Tissue Infections:0 | 3/138,393 | 4,436/26,262,527 | 0.13 | 3.63e-07 | 2.47e-06 |
| specific immunity:0 | 89/138,393 | 6,902/26,262,527 | 2.45 | 2.38e-13 | 2.80e-12 |
| Zoladex:0 | 117/138,393 | 673/26,262,527 | 33.02 | 1.36e-126 | 1.51e-124 |
| Prostatic Adenoma:0 | 91/138,393 | 697/26,262,527 | 24.79 | 9.85e-89 | 7.52e-87 |
| Thyroidectomy:0 | 4/138,393 | 5,957/26,262,527 | 0.13 | 2.65e-09 | 2.27e-08 |
| Offspring:0 | 67/138,393 | 44,530/26,262,527 | 0.29 | 6.71e-38 | 2.19e-36 |
| Movement Disorders:0 | 2/138,393 | 8,207/26,262,527 | 0.05 | 3.17e-16 | 4.47e-15 |
| Transurethral Resection of Prostate:0 | 472/138,393 | 3,795/26,262,527 | 23.68 | 0.00e+00 | 0.00e+00 |
| FOXO3A gene|FOXO3:0 | 32/138,393 | 2,286/26,262,527 | 2.66 | 1.47e-06 | 9.34e-06 |
| P-Selectin:0 | 11/138,393 | 8,483/26,262,527 | 0.25 | 4.49e-09 | 3.76e-08 |
| IGHE:0 | 2/138,393 | 35,388/26,262,527 | 0.01 | 4.52e-77 | 3.06e-75 |
| Drug abuse:0 | 1/138,393 | 10,984/26,262,527 | 0.02 | 1.02e-23 | 2.03e-22 |
| Bupropion:0 | 1/138,393 | 4,495/26,262,527 | 0.04 | 2.75e-09 | 2.35e-08 |
| Silicon Dioxide:0 | 3/138,393 | 9,475/26,262,527 | 0.06 | 1.23e-17 | 1.87e-16 |
| Screw:0 | 4/138,393 | 14,678/26,262,527 | 0.05 | 8.68e-28 | 2.02e-26 |
| Diaphyses:0 | 6/138,393 | 5,470/26,262,527 | 0.21 | 7.63e-07 | 5.02e-06 |
| Vaccine Therapy:0 | 27/138,393 | 463/26,262,527 | 11.07 | 4.89e-19 | 7.99e-18 |
| CD44 gene|CD44:0 | 163/138,393 | 13,111/26,262,527 | 2.36 | 8.59e-22 | 1.59e-20 |
| KIAA0101:0 | 1/138,393 | 3,244/26,262,527 | 0.06 | 1.24e-06 | 7.98e-06 |
| Senility:0 | 48/138,393 | 3,577/26,262,527 | 2.55 | 2.10e-08 | 1.64e-07 |
| Electroresection:0 | 11/138,393 | 118/26,262,527 | 17.69 | 1.24e-10 | 1.19e-09 |
| Histidine:0 | 8/138,393 | 9,429/26,262,527 | 0.16 | 6.75e-13 | 7.67e-12 |
| Esophageal carcinoma:0 | 86/138,393 | 27,062/26,262,527 | 0.60 | 4.24e-07 | 2.86e-06 |
| Baclofen:0 | 1/138,393 | 8,810/26,262,527 | 0.02 | 9.40e-19 | 1.52e-17 |
| Elderly man:0 | 23/138,393 | 1,297/26,262,527 | 3.37 | 1.02e-06 | 6.58e-06 |
| Metal stent:0 | 12/138,393 | 9,702/26,262,527 | 0.23 | 1.42e-10 | 1.36e-09 |
| Ephrin Receptor EphB1:0 | 22/138,393 | 10,819/26,262,527 | 0.39 | 2.43e-07 | 1.69e-06 |
| Microfilaments:0 | 16/138,393 | 9,184/26,262,527 | 0.33 | 1.51e-07 | 1.07e-06 |
| Human Chorionic Gonadotropin|CTSG:0 | 5/138,393 | 5/26,262,527 | 189.77 | 9.76e-10 | 8.66e-09 |
| Echocardiography:0 | 5/138,393 | 27,963/26,262,527 | 0.03 | 2.07e-55 | 9.98e-54 |
| Chronic Lymphocytic Leukemia:0 | 71/138,393 | 29,445/26,262,527 | 0.46 | 6.40e-14 | 7.90e-13 |
| Hepatitis C:0 | 9/138,393 | 16,014/26,262,527 | 0.11 | 4.21e-25 | 8.82e-24 |
| Angiotensinogen:0 | 1/138,393 | 7,436/26,262,527 | 0.03 | 9.24e-16 | 1.27e-14 |
| Neurodegenerative Disorders:0 | 21/138,393 | 37,203/26,262,527 | 0.11 | 6.67e-57 | 3.33e-55 |
| cyclin-dependent kinase inhibitor 1B|CDKN1B|CIB1:0 | 13/138,393 | 139/26,262,527 | 17.75 | 2.51e-12 | 2.74e-11 |
| Malignant neoplasm of testis:0 | 164/138,393 | 5,830/26,262,527 | 5.34 | 6.35e-63 | 3.55e-61 |
| Saline:0 | 11/138,393 | 9,208/26,262,527 | 0.23 | 2.01e-10 | 1.90e-09 |
| tocilizumab:0 | 1/138,393 | 4,240/26,262,527 | 0.04 | 1.26e-08 | 1.00e-07 |
| Catechol Oxidase:0 | 3/138,393 | 4,615/26,262,527 | 0.12 | 1.93e-07 | 1.35e-06 |
| Atypical adenomatous hyperplasia:0 | 44/138,393 | 521/26,262,527 | 16.03 | 2.58e-36 | 8.05e-35 |
| Dental caries:0 | 18/138,393 | 17,659/26,262,527 | 0.19 | 4.62e-21 | 8.28e-20 |
| Testosterone Propionate:0 | 61/138,393 | 3,786/26,262,527 | 3.06 | 1.55e-13 | 1.86e-12 |
| Hyperbilirubinemia:0 | 2/138,393 | 5,452/26,262,527 | 0.07 | 3.95e-10 | 3.63e-09 |
| Neck Dissection:0 | 5/138,393 | 5,096/26,262,527 | 0.19 | 8.10e-07 | 5.31e-06 |
| Gonorrhea:0 | 10/138,393 | 8,214/26,262,527 | 0.23 | 2.59e-09 | 2.22e-08 |
| Luciferases|EREG|ESR1:0 | 132/138,393 | 154/26,262,527 | 162.81 | 9.98e-218 | 2.04e-215 |
| Lack of sensation:0 | 16/138,393 | 27,759/26,262,527 | 0.11 | 1.51e-42 | 5.57e-41 |
| Behavior:0 | 193/138,393 | 73,977/26,262,527 | 0.49 | 3.83e-28 | 9.05e-27 |
| Quantitative Reverse Transcriptase PCR:0 | 65/138,393 | 2,358/26,262,527 | 5.23 | 1.45e-25 | 3.09e-24 |
| Surgical margins:0 | 430/138,393 | 7,620/26,262,527 | 10.74 | 7.24e-272 | 1.88e-269 |
| ZNF135:0 | 61/138,393 | 370/26,262,527 | 31.30 | 1.30e-65 | 7.56e-64 |
| Triton X-100:0 | 4/138,393 | 7,424/26,262,527 | 0.10 | 2.82e-12 | 3.06e-11 |
| established cell line:0 | 89/138,393 | 2,688/26,262,527 | 6.29 | 4.04e-40 | 1.41e-38 |
| Laparotomy:0 | 27/138,393 | 15,551/26,262,527 | 0.33 | 3.73e-12 | 4.03e-11 |
| Congenital heart disease:0 | 4/138,393 | 25,865/26,262,527 | 0.03 | 2.03e-52 | 9.25e-51 |
| Biopsy sample:0 | 494/138,393 | 27,682/26,262,527 | 3.40 | 4.51e-112 | 4.43e-110 |
| Abnormal renal function:0 | 18/138,393 | 11,831/26,262,527 | 0.29 | 8.19e-11 | 7.96e-10 |
| Receptor, EphA2|EPHA2:0 | 7/138,393 | 60/26,262,527 | 22.14 | 7.18e-08 | 5.27e-07 |
| HLA-E:0 | 11/138,393 | 8,618/26,262,527 | 0.24 | 2.39e-09 | 2.06e-08 |
| Salicylic Acid:0 | 5/138,393 | 9,292/26,262,527 | 0.10 | 3.79e-15 | 5.05e-14 |
| Female Breast Carcinoma:0 | 46/138,393 | 1,318/26,262,527 | 6.63 | 1.92e-22 | 3.62e-21 |
| Schizophrenia:0 | 20/138,393 | 118,708/26,262,527 | 0.03 | 1.74e-234 | 3.84e-232 |
| Laser Capture Microdissection:0 | 13/138,393 | 383/26,262,527 | 6.44 | 2.72e-07 | 1.88e-06 |
| Ki-67 Antigen|MKI67|PIEZO1|MIB1:0 | 34/138,393 | 700/26,262,527 | 9.22 | 3.45e-21 | 6.21e-20 |
| Rats, Inbred SHR:0 | 2/138,393 | 35,149/26,262,527 | 0.01 | 2.13e-76 | 1.43e-74 |
| Bilateral Malignant Neoplasm:0 | 12/138,393 | 156/26,262,527 | 14.60 | 1.43e-10 | 1.37e-09 |
| Periodontal Diseases:0 | 9/138,393 | 12,116/26,262,527 | 0.14 | 2.59e-17 | 3.89e-16 |
| Microdissection:0 | 38/138,393 | 1,969/26,262,527 | 3.66 | 4.01e-11 | 4.00e-10 |
| Microsurgery:0 | 3/138,393 | 4,594/26,262,527 | 0.12 | 1.86e-07 | 1.31e-06 |
| Pheromone:0 | 2/138,393 | 3,945/26,262,527 | 0.10 | 4.19e-07 | 2.83e-06 |
| Opportunistic Infections:0 | 2/138,393 | 9,686/26,262,527 | 0.04 | 2.52e-19 | 4.16e-18 |
| Psoriasis:0 | 18/138,393 | 46,513/26,262,527 | 0.07 | 1.65e-79 | 1.16e-77 |
| Common Variable Immunodeficiency:0 | 2/138,393 | 4,979/26,262,527 | 0.08 | 3.08e-09 | 2.61e-08 |
| ERCC8|CSH1|HSPA9:0 | 1/138,393 | 6,119/26,262,527 | 0.03 | 6.28e-13 | 7.18e-12 |
| Entire putamen:0 | 1/138,393 | 4,411/26,262,527 | 0.04 | 3.89e-09 | 3.27e-08 |
| PRSS8 protein, human|PRSS8:0 | 16/138,393 | 598/26,262,527 | 5.08 | 2.75e-07 | 1.90e-06 |
| Fruit:0 | 66/138,393 | 5,782/26,262,527 | 2.17 | 2.07e-08 | 1.61e-07 |
| melanoma:0 | 789/138,393 | 96,656/26,262,527 | 1.55 | 1.98e-30 | 5.07e-29 |
| Algae, Green:0 | 1/138,393 | 4,596/26,262,527 | 0.04 | 2.04e-09 | 1.76e-08 |
| KLK13:0 | 6/138,393 | 37/26,262,527 | 30.77 | 1.07e-07 | 7.69e-07 |
| Platelet Activating Factor:0 | 4/138,393 | 18,317/26,262,527 | 0.04 | 9.52e-36 | 2.90e-34 |
| Phenobarbital:0 | 5/138,393 | 16,024/26,262,527 | 0.06 | 1.58e-29 | 3.90e-28 |
| Gland structure:0 | 568/138,393 | 17,877/26,262,527 | 6.05 | 1.65e-237 | 3.75e-235 |
| Roentgen Rays:0 | 37/138,393 | 18,812/26,262,527 | 0.37 | 1.58e-12 | 1.75e-11 |
| Nerve Growth Factors:0 | 60/138,393 | 34,072/26,262,527 | 0.33 | 7.58e-25 | 1.58e-23 |
| Surrogate Endpoints:0 | 33/138,393 | 300/26,262,527 | 20.88 | 4.65e-31 | 1.22e-29 |
| Twin Multiple Birth:0 | 17/138,393 | 10,643/26,262,527 | 0.30 | 2.39e-09 | 2.06e-08 |
| Neural Network Simulation:0 | 22/138,393 | 996/26,262,527 | 4.19 | 4.86e-08 | 3.63e-07 |
| mast cell:0 | 14/138,393 | 34,610/26,262,527 | 0.08 | 1.12e-58 | 5.77e-57 |
| Fatty Liver:0 | 7/138,393 | 15,346/26,262,527 | 0.09 | 1.08e-25 | 2.32e-24 |
| Radiation therapist:0 | 15/138,393 | 177/26,262,527 | 16.08 | 2.01e-13 | 2.38e-12 |
| Androstenedione:0 | 124/138,393 | 6,243/26,262,527 | 3.77 | 1.18e-33 | 3.35e-32 |
| Fibrinogen:0 | 21/138,393 | 21,648/26,262,527 | 0.18 | 2.53e-26 | 5.59e-25 |
| JV 1-38:0 | 7/138,393 | 39/26,262,527 | 34.06 | 4.87e-09 | 4.06e-08 |
| Bone structure of calcaneum:0 | 2/138,393 | 7,674/26,262,527 | 0.05 | 5.98e-15 | 7.85e-14 |
| nitric oxide receptor:0 | 5/138,393 | 5,299/26,262,527 | 0.18 | 2.96e-07 | 2.04e-06 |
| Teleradiotherapy procedure:0 | 989/138,393 | 4,838/26,262,527 | 39.06 | 0.00e+00 | 0.00e+00 |
| Medical Patients:0 | 1/138,393 | 4,006/26,262,527 | 0.05 | 3.56e-08 | 2.69e-07 |
| Diabetes Mellitus:0 | 141/138,393 | 70,996/26,262,527 | 0.38 | 4.77e-43 | 1.79e-41 |
| Vesicorectal fistula:0 | 8/138,393 | 89/26,262,527 | 17.06 | 5.44e-08 | 4.03e-07 |
| Depressive Symptoms:0 | 34/138,393 | 26,906/26,262,527 | 0.24 | 4.38e-27 | 9.95e-26 |
| Structure of parenchyma of lung:0 | 36/138,393 | 23,974/26,262,527 | 0.28 | 5.36e-21 | 9.57e-20 |
| Hematopoiesis:0 | 18/138,393 | 10,842/26,262,527 | 0.31 | 3.44e-09 | 2.90e-08 |
| Parietal Cells, Gastric:0 | 1/138,393 | 4,267/26,262,527 | 0.04 | 8.03e-09 | 6.55e-08 |
| Isoproterenol:0 | 7/138,393 | 33,933/26,262,527 | 0.04 | 8.83e-66 | 5.17e-64 |
| Ferrets:0 | 4/138,393 | 4,583/26,262,527 | 0.17 | 1.05e-06 | 6.81e-06 |
| Proto-Oncogenes:0 | 93/138,393 | 8,723/26,262,527 | 2.02 | 1.36e-09 | 1.19e-08 |
| Tract:0 | 304/138,393 | 40,586/26,262,527 | 1.42 | 6.46e-09 | 5.32e-08 |
| satraplatin:0 | 31/138,393 | 192/26,262,527 | 30.65 | 6.47e-34 | 1.85e-32 |
| Microcirculation:0 | 14/138,393 | 15,386/26,262,527 | 0.17 | 1.07e-19 | 1.79e-18 |
| KLF6 gene|KLF6:0 | 22/138,393 | 243/26,262,527 | 17.18 | 1.48e-19 | 2.47e-18 |
| Amyloid:0 | 11/138,393 | 19,620/26,262,527 | 0.11 | 1.10e-30 | 2.82e-29 |
| Prostate-Specific Antigen:0 | 5,760/138,393 | 14,799/26,262,527 | 77.02 | 0.00e+00 | 0.00e+00 |
| Selenium Compounds:0 | 20/138,393 | 644/26,262,527 | 5.89 | 8.45e-10 | 7.56e-09 |
| Chromosomes, Human, Pair 10:0 | 79/138,393 | 3,182/26,262,527 | 4.71 | 7.28e-28 | 1.70e-26 |
| inhibitors:0 | 143/138,393 | 13,592/26,262,527 | 2.00 | 1.16e-13 | 1.41e-12 |
| Hepatitis B, Chronic:0 | 1/138,393 | 20,245/26,262,527 | 0.01 | 1.20e-44 | 4.65e-43 |
| insulin sensitivity:0 | 35/138,393 | 21,054/26,262,527 | 0.32 | 7.87e-17 | 1.15e-15 |
| Electrolytes:0 | 9/138,393 | 12,629/26,262,527 | 0.14 | 2.48e-18 | 3.92e-17 |
| Wrist:0 | 10/138,393 | 13,192/26,262,527 | 0.14 | 1.53e-18 | 2.44e-17 |
| Analyzer:0 | 7/138,393 | 6,295/26,262,527 | 0.21 | 1.06e-07 | 7.64e-07 |
| Mucous Membrane:0 | 98/138,393 | 82,184/26,262,527 | 0.23 | 6.23e-84 | 4.57e-82 |
| Total excision of bladder NOS:0 | 22/138,393 | 650/26,262,527 | 6.42 | 2.60e-11 | 2.62e-10 |
| Corticosterone:0 | 17/138,393 | 27,362/26,262,527 | 0.12 | 8.39e-41 | 2.98e-39 |
| Epithelial Cells:0 | 2,268/138,393 | 126,298/26,262,527 | 3.45 | 0.00e+00 | 0.00e+00 |
| Body Weight decreased:0 | 46/138,393 | 24,712/26,262,527 | 0.35 | 3.29e-17 | 4.90e-16 |
| Fibroblast Growth Factor 8b:0 | 6/138,393 | 58/26,262,527 | 19.63 | 1.20e-06 | 7.70e-06 |
| Glucose concentration, test strip measurement:0 | 1/138,393 | 5,689/26,262,527 | 0.03 | 5.58e-12 | 5.96e-11 |
| Streptococcus Group B:0 | 2/138,393 | 5,518/26,262,527 | 0.07 | 2.73e-10 | 2.54e-09 |
| Process:0 | 55/138,393 | 20,052/26,262,527 | 0.52 | 8.96e-08 | 6.52e-07 |
| SYK gene|SYK:0 | 2/138,393 | 3,771/26,262,527 | 0.10 | 1.26e-06 | 8.07e-06 |
| Immunoglobulins|WDR20:0 | 6/138,393 | 19/26,262,527 | 59.93 | 3.37e-09 | 2.85e-08 |
| Blood Platelets:0 | 20/138,393 | 32,989/26,262,527 | 0.11 | 2.55e-49 | 1.10e-47 |
| Neoplasms, Second Primary:0 | 93/138,393 | 1,846/26,262,527 | 9.57 | 2.78e-56 | 1.36e-54 |
| Chromogranin A:0 | 163/138,393 | 5,036/26,262,527 | 6.15 | 1.28e-70 | 7.92e-69 |
| Edema:0 | 157/138,393 | 60,264/26,262,527 | 0.49 | 2.68e-23 | 5.24e-22 |
| hearing impairment:0 | 6/138,393 | 29,245/26,262,527 | 0.04 | 6.22e-57 | 3.11e-55 |
| Urethrorectal fistula:0 | 22/138,393 | 90/26,262,527 | 46.39 | 5.06e-28 | 1.19e-26 |
| Amyloid beta-Protein Precursor:0 | 4/138,393 | 13,048/26,262,527 | 0.06 | 3.29e-24 | 6.69e-23 |
| Urethral Stricture:0 | 59/138,393 | 2,335/26,262,527 | 4.80 | 1.35e-21 | 2.47e-20 |
| Male pelvis:0 | 6/138,393 | 37/26,262,527 | 30.77 | 1.07e-07 | 7.69e-07 |
| Open prostatectomy:0 | 86/138,393 | 440/26,262,527 | 37.11 | 1.98e-97 | 1.69e-95 |
| Malignant neoplasm of lung:0 | 1,111/138,393 | 85,433/26,262,527 | 2.48 | 1.06e-150 | 1.43e-148 |
| Dizziness:0 | 3/138,393 | 5,160/26,262,527 | 0.11 | 1.17e-08 | 9.36e-08 |
| Decompressive incision:0 | 19/138,393 | 14,752/26,262,527 | 0.24 | 4.03e-15 | 5.36e-14 |
| Tumor focality:0 | 49/138,393 | 228/26,262,527 | 40.80 | 4.76e-58 | 2.43e-56 |
| hyperkalemia:0 | 2/138,393 | 4,310/26,262,527 | 0.09 | 7.26e-08 | 5.33e-07 |
| Dihydroxycholecalciferols:0 | 52/138,393 | 2,980/26,262,527 | 3.31 | 5.17e-13 | 5.94e-12 |
| Algae:0 | 4/138,393 | 10,824/26,262,527 | 0.07 | 2.01e-19 | 3.33e-18 |
| Surgical Flaps:0 | 15/138,393 | 18,703/26,262,527 | 0.15 | 2.29e-25 | 4.87e-24 |
| Prostate Leiomyoma:0 | 5/138,393 | 10/26,262,527 | 94.89 | 1.14e-08 | 9.13e-08 |
| Amine Oxidase (Copper-Containing):0 | 3/138,393 | 4,167/26,262,527 | 0.14 | 1.47e-06 | 9.29e-06 |
| Cecum:0 | 7/138,393 | 10,600/26,262,527 | 0.13 | 5.49e-16 | 7.62e-15 |
| benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone:0 | 32/138,393 | 1,880/26,262,527 | 3.23 | 2.28e-08 | 1.77e-07 |
| Female:0 | 371/138,393 | 148,039/26,262,527 | 0.47 | 9.10e-60 | 4.79e-58 |
| cell invasion:0 | 265/138,393 | 6,448/26,262,527 | 7.81 | 1.21e-136 | 1.49e-134 |
| Flagella:0 | 2/138,393 | 3,878/26,262,527 | 0.10 | 5.96e-07 | 3.96e-06 |
| Etidronate:0 | 43/138,393 | 3,579/26,262,527 | 2.28 | 1.52e-06 | 9.64e-06 |
| Prostaglandins:0 | 113/138,393 | 47,445/26,262,527 | 0.45 | 4.80e-22 | 8.93e-21 |
| Entire tendon:0 | 1/138,393 | 19,900/26,262,527 | 0.01 | 7.64e-44 | 2.91e-42 |
| Thrombin:0 | 40/138,393 | 41,771/26,262,527 | 0.18 | 4.58e-50 | 2.00e-48 |
| Lesion of stomach:0 | 1/138,393 | 3,715/26,262,527 | 0.05 | 1.50e-07 | 1.06e-06 |
| Acute prostatitis:0 | 22/138,393 | 168/26,262,527 | 24.85 | 9.87e-23 | 1.89e-21 |
| Bone plates:0 | 22/138,393 | 28,749/26,262,527 | 0.15 | 4.84e-39 | 1.63e-37 |
| Wall of rectum:0 | 68/138,393 | 614/26,262,527 | 21.03 | 2.19e-62 | 1.21e-60 |
| radiologist:0 | 69/138,393 | 5,528/26,262,527 | 2.37 | 3.59e-10 | 3.30e-09 |
| kallikrein 4:0 | 16/138,393 | 125/26,262,527 | 24.29 | 8.44e-17 | 1.23e-15 |
| Intercellular adhesion molecule 1:0 | 28/138,393 | 21,551/26,262,527 | 0.25 | 1.96e-21 | 3.57e-20 |
| hen egg lysozyme:0 | 1/138,393 | 3,257/26,262,527 | 0.06 | 1.26e-06 | 8.04e-06 |
| Bacterial Prostatitis:0 | 18/138,393 | 383/26,262,527 | 8.92 | 1.02e-11 | 1.06e-10 |
| Ulcer:0 | 30/138,393 | 32,858/26,262,527 | 0.17 | 9.87e-41 | 3.49e-39 |
| Human cells:0 | 213/138,393 | 27,570/26,262,527 | 1.47 | 1.49e-07 | 1.06e-06 |
| Extracellular:0 | 277/138,393 | 93,383/26,262,527 | 0.56 | 6.32e-26 | 1.37e-24 |
| Gonadotropins|HSD3B1:0 | 4/138,393 | 3/26,262,527 | 253.03 | 2.61e-08 | 2.01e-07 |
| Autophagy:0 | 236/138,393 | 31,557/26,262,527 | 1.42 | 3.38e-07 | 2.31e-06 |
| Egtazic Acid:0 | 2/138,393 | 6,473/26,262,527 | 0.06 | 1.73e-12 | 1.92e-11 |
| Swelling:0 | 19/138,393 | 14,367/26,262,527 | 0.25 | 1.82e-14 | 2.31e-13 |
| nursing home resident:0 | 4/138,393 | 5,398/26,262,527 | 0.14 | 2.69e-08 | 2.06e-07 |
| Respiratory distress:0 | 2/138,393 | 4,958/26,262,527 | 0.08 | 3.04e-09 | 2.58e-08 |
| AKR1C3|AKR1A1|PCA3:0 | 25/138,393 | 87/26,262,527 | 54.54 | 3.77e-33 | 1.05e-31 |
| Secretin|SCT:0 | 1/138,393 | 3,360/26,262,527 | 0.06 | 9.19e-07 | 5.99e-06 |
| Papio:0 | 13/138,393 | 10,793/26,262,527 | 0.23 | 5.69e-12 | 6.07e-11 |
| Catfish:0 | 1/138,393 | 3,623/26,262,527 | 0.05 | 2.08e-07 | 1.45e-06 |
| Cancer Promoting Genes:0 | 178/138,393 | 3,424/26,262,527 | 9.88 | 3.98e-108 | 3.73e-106 |
| Prostatic epithelium:0 | 515/138,393 | 924/26,262,527 | 106.16 | 0.00e+00 | 0.00e+00 |
| Cardiopulmonary:0 | 1/138,393 | 6,633/26,262,527 | 0.03 | 4.96e-14 | 6.16e-13 |
| Hole:0 | 4/138,393 | 6,157/26,262,527 | 0.12 | 9.28e-10 | 8.24e-09 |
| Entire sciatic nerve:0 | 4/138,393 | 12,769/26,262,527 | 0.06 | 1.39e-23 | 2.75e-22 |
| Elastin|ELN:0 | 3/138,393 | 5,067/26,262,527 | 0.11 | 1.63e-08 | 1.29e-07 |
| Bladder Tissue:0 | 26/138,393 | 1,196/26,262,527 | 4.13 | 4.29e-09 | 3.59e-08 |
| Preservation, Biological:0 | 379/138,393 | 25,524/26,262,527 | 2.82 | 3.82e-66 | 2.25e-64 |
| high-LET neutron therapy:0 | 12/138,393 | 150/26,262,527 | 15.18 | 9.36e-11 | 9.06e-10 |
| Diastolic blood pressure:0 | 3/138,393 | 6,761/26,262,527 | 0.08 | 5.54e-12 | 5.92e-11 |
| Inverse:0 | 202/138,393 | 15,399/26,262,527 | 2.49 | 2.62e-29 | 6.44e-28 |
| Radiopharmaceuticals:0 | 163/138,393 | 3,274/26,262,527 | 9.46 | 1.66e-96 | 1.40e-94 |
| lipoteichoic acid:0 | 1/138,393 | 3,287/26,262,527 | 0.06 | 1.31e-06 | 8.38e-06 |
| Tumor Antigens:0 | 230/138,393 | 8,591/26,262,527 | 5.09 | 1.54e-83 | 1.12e-81 |
| Ammonia:0 | 5/138,393 | 14,241/26,262,527 | 0.07 | 1.14e-25 | 2.44e-24 |
| craniofacial:0 | 2/138,393 | 6,752/26,262,527 | 0.06 | 6.51e-13 | 7.42e-12 |
| Electron Microscopy:0 | 58/138,393 | 21,451/26,262,527 | 0.51 | 1.68e-08 | 1.32e-07 |
| S100A9 gene|S100A9:0 | 25/138,393 | 1,244/26,262,527 | 3.81 | 3.67e-08 | 2.77e-07 |
| Malignant neoplasm of penis:0 | 36/138,393 | 1,128/26,262,527 | 6.06 | 9.28e-17 | 1.35e-15 |
| Paroxetine:0 | 3/138,393 | 7,480/26,262,527 | 0.08 | 1.64e-13 | 1.95e-12 |
| Solutions:0 | 15/138,393 | 13,844/26,262,527 | 0.21 | 4.51e-16 | 6.30e-15 |
| Gonadorelin|ZBTB7A|CREBRF:0 | 107/138,393 | 214/26,262,527 | 94.96 | 7.84e-158 | 1.12e-155 |
| Memantine:0 | 2/138,393 | 5,002/26,262,527 | 0.08 | 3.19e-09 | 2.70e-08 |
| Cyclin E:0 | 68/138,393 | 4,214/26,262,527 | 3.06 | 6.26e-15 | 8.21e-14 |
| Suprapubic:0 | 19/138,393 | 314/26,262,527 | 11.48 | 4.02e-14 | 5.03e-13 |
| Left ventricular assist device:0 | 1/138,393 | 6,866/26,262,527 | 0.03 | 1.71e-14 | 2.19e-13 |
| Endocrine therapy:0 | 1,910/138,393 | 16,687/26,262,527 | 22.01 | 0.00e+00 | 0.00e+00 |
| Sexual function:0 | 303/138,393 | 6,404/26,262,527 | 9.00 | 6.79e-172 | 1.08e-169 |
| CD82 gene|CD82:0 | 63/138,393 | 1,272/26,262,527 | 9.40 | 2.69e-38 | 8.84e-37 |
| 5-Trimethoxyamphetamine:0 | 13/138,393 | 440/26,262,527 | 5.61 | 1.22e-06 | 7.82e-06 |
| Tissue specimen from prostate:0 | 170/138,393 | 282/26,262,527 | 114.54 | 1.56e-260 | 3.91e-258 |
| Valproate:0 | 3/138,393 | 9,256/26,262,527 | 0.06 | 3.54e-17 | 5.28e-16 |
| calcification:0 | 54/138,393 | 24,449/26,262,527 | 0.42 | 1.46e-13 | 1.75e-12 |
| FAVOR:0 | 339/138,393 | 33,561/26,262,527 | 1.92 | 3.49e-27 | 7.96e-26 |
| Immunoglobulins, Intravenous:0 | 4/138,393 | 25,544/26,262,527 | 0.03 | 1.29e-51 | 5.79e-50 |
| Choline Kinase:0 | 24/138,393 | 1,352/26,262,527 | 3.37 | 5.90e-07 | 3.93e-06 |
| Duct (organ) structure:0 | 100/138,393 | 6,329/26,262,527 | 3.00 | 1.51e-20 | 2.63e-19 |
| Phagocytosis:0 | 19/138,393 | 23,618/26,262,527 | 0.15 | 1.29e-31 | 3.43e-30 |
| Bone pain:0 | 230/138,393 | 2,005/26,262,527 | 21.80 | 9.88e-210 | 1.94e-207 |
| Durapatite:0 | 9/138,393 | 11,392/26,262,527 | 0.15 | 7.40e-16 | 1.02e-14 |
| Heart failure:0 | 46/138,393 | 124,773/26,262,527 | 0.07 | 6.41e-214 | 1.30e-211 |
| IGFBP3 gene|IGFBP3:0 | 14/138,393 | 335/26,262,527 | 7.93 | 8.06e-09 | 6.57e-08 |
| snail transcription factors:0 | 7/138,393 | 46/26,262,527 | 28.88 | 1.36e-08 | 1.08e-07 |
| Immunoglobulin G:0 | 29/138,393 | 16,900/26,262,527 | 0.33 | 2.70e-13 | 3.17e-12 |
| Squamous cell carcinoma:0 | 370/138,393 | 99,673/26,262,527 | 0.70 | 1.10e-12 | 1.24e-11 |
| Well adult:0 | 22/138,393 | 12,321/26,262,527 | 0.34 | 1.52e-09 | 1.33e-08 |
| Numbers:0 | 124/138,393 | 10,848/26,262,527 | 2.17 | 1.90e-14 | 2.41e-13 |
| [D]Extravasation of urine:0 | 40/138,393 | 802/26,262,527 | 9.47 | 4.86e-25 | 1.02e-23 |
| Silence:0 | 272/138,393 | 16,378/26,262,527 | 3.16 | 9.93e-57 | 4.94e-55 |
| Genitourinary Neoplasms:0 | 15/138,393 | 49/26,262,527 | 58.10 | 7.76e-21 | 1.37e-19 |
| Left ventricular systolic dysfunction:0 | 1/138,393 | 3,527/26,262,527 | 0.05 | 2.94e-07 | 2.03e-06 |
| Infusion procedures:0 | 34/138,393 | 15,781/26,262,527 | 0.41 | 2.07e-09 | 1.79e-08 |
| External Beam Radiation Therapy:0 | 952/138,393 | 4,794/26,262,527 | 37.94 | 0.00e+00 | 0.00e+00 |
| Increased Cellular Death:0 | 19/138,393 | 777/26,262,527 | 4.64 | 8.57e-08 | 6.24e-07 |
| Acute diarrhea:0 | 4/138,393 | 4,756/26,262,527 | 0.16 | 5.54e-07 | 3.70e-06 |
| Factor VIIa:0 | 6/138,393 | 10,779/26,262,527 | 0.11 | 2.81e-17 | 4.20e-16 |
| Vinblastine:0 | 87/138,393 | 8,453/26,262,527 | 1.95 | 1.94e-08 | 1.52e-07 |
| Hospitals, Cancer:0 | 17/138,393 | 292/26,262,527 | 11.05 | 1.54e-12 | 1.71e-11 |
| Protoplasts:0 | 2/138,393 | 5,070/26,262,527 | 0.07 | 2.22e-09 | 1.91e-08 |
| Inositol:0 | 12/138,393 | 8,291/26,262,527 | 0.27 | 3.11e-08 | 2.37e-07 |
| Pancreatitis:0 | 23/138,393 | 48,636/26,262,527 | 0.09 | 1.71e-78 | 1.18e-76 |
| Portal vein thrombosis:0 | 2/138,393 | 4,560/26,262,527 | 0.08 | 2.62e-08 | 2.01e-07 |
| BIRC4 gene|XIAP:0 | 61/138,393 | 3,802/26,262,527 | 3.05 | 1.85e-13 | 2.19e-12 |
| HOXD3:0 | 7/138,393 | 70/26,262,527 | 18.98 | 1.90e-07 | 1.33e-06 |
| Cytomegalovirus:0 | 33/138,393 | 25,497/26,262,527 | 0.25 | 2.41e-25 | 5.10e-24 |
| procaspase-3:0 | 19/138,393 | 848/26,262,527 | 4.25 | 3.12e-07 | 2.13e-06 |
| Tachycardia:0 | 3/138,393 | 12,243/26,262,527 | 0.05 | 1.00e-23 | 2.00e-22 |
| Dysmenorrhea:0 | 1/138,393 | 3,323/26,262,527 | 0.06 | 8.72e-07 | 5.70e-06 |
| Glucokinase:0 | 1/138,393 | 4,685/26,262,527 | 0.04 | 9.03e-10 | 8.05e-09 |
| CLU:0 | 19/138,393 | 720/26,262,527 | 5.01 | 2.72e-08 | 2.09e-07 |
| Prostate feature:0 | 9/138,393 | 10/26,262,527 | 170.80 | 2.63e-16 | 3.74e-15 |
| Intracranial Hemorrhages:0 | 1/138,393 | 6,566/26,262,527 | 0.03 | 7.19e-14 | 8.83e-13 |
| Gamma Rays:0 | 7/138,393 | 7,423/26,262,527 | 0.18 | 8.78e-10 | 7.84e-09 |
| parathyroid hormone-related protein:0 | 92/138,393 | 8,021/26,262,527 | 2.18 | 4.78e-11 | 4.74e-10 |
| ATPase, Aminophospholipid Transporter-Like, Class I, Type 8A, Member 2|ATP8A2:0 | 125/138,393 | 83,193/26,262,527 | 0.28 | 1.29e-69 | 7.92e-68 |
| endoscopy:0 | 43/138,393 | 19,117/26,262,527 | 0.43 | 1.59e-10 | 1.51e-09 |
| Cardiac Output:0 | 2/138,393 | 10,003/26,262,527 | 0.04 | 3.84e-20 | 6.57e-19 |
| Demented:0 | 2/138,393 | 6,153/26,262,527 | 0.06 | 1.08e-11 | 1.12e-10 |
| Contraceptives, Oral:0 | 10/138,393 | 12,461/26,262,527 | 0.15 | 2.82e-17 | 4.22e-16 |
| Large Intestine:0 | 50/138,393 | 3,747/26,262,527 | 2.53 | 1.17e-08 | 9.34e-08 |
| Nitrous Oxide:0 | 3/138,393 | 8,101/26,262,527 | 0.07 | 1.03e-14 | 1.33e-13 |
| Amenorrhea:0 | 3/138,393 | 4,288/26,262,527 | 0.13 | 7.16e-07 | 4.72e-06 |
| Immune Sera|EREG|ESR1:0 | 9/138,393 | 34/26,262,527 | 50.24 | 1.43e-12 | 1.60e-11 |
| Mental disorders:0 | 24/138,393 | 65,111/26,262,527 | 0.07 | 4.33e-112 | 4.27e-110 |
| Enoxaparin:0 | 4/138,393 | 7,071/26,262,527 | 0.11 | 1.05e-11 | 1.10e-10 |
| Signaling Molecule:0 | 107/138,393 | 11,831/26,262,527 | 1.72 | 3.24e-07 | 2.21e-06 |
| Anogenital region:0 | 81/138,393 | 5,300/26,262,527 | 2.90 | 3.39e-16 | 4.78e-15 |
| 3' Untranslated Regions:0 | 109/138,393 | 8,846/26,262,527 | 2.34 | 7.03e-15 | 9.19e-14 |
| Extensor:0 | 2/138,393 | 9,340/26,262,527 | 0.04 | 9.84e-19 | 1.58e-17 |
| Respiratory Syncytial Virus Infections:0 | 3/138,393 | 5,320/26,262,527 | 0.11 | 5.95e-09 | 4.91e-08 |
| Gray matter:0 | 1/138,393 | 6,656/26,262,527 | 0.03 | 5.17e-14 | 6.40e-13 |
| SB 75:0 | 11/138,393 | 68/26,262,527 | 30.70 | 5.35e-13 | 6.15e-12 |
| Adenocarcinoma of prostate:0 | 1,309/138,393 | 2,164/26,262,527 | 115.88 | 0.00e+00 | 0.00e+00 |
| prostate cancer prevention:0 | 92/138,393 | 114/26,262,527 | 153.25 | 1.48e-150 | 1.99e-148 |
| TGFBR2 protein, human|TGFBR2:0 | 17/138,393 | 376/26,262,527 | 8.58 | 6.67e-11 | 6.52e-10 |
| abnormal glucose tolerance test:0 | 3/138,393 | 8,714/26,262,527 | 0.07 | 4.02e-16 | 5.64e-15 |
| Reflex action:0 | 6/138,393 | 6,496/26,262,527 | 0.18 | 8.19e-09 | 6.67e-08 |
| Eukaryota:0 | 38/138,393 | 42,726/26,262,527 | 0.17 | 2.46e-53 | 1.13e-51 |
| Aldosterone:0 | 9/138,393 | 24,374/26,262,527 | 0.07 | 1.08e-42 | 3.99e-41 |
| Cell Cycle Proteins:0 | 69/138,393 | 2,773/26,262,527 | 4.72 | 1.31e-24 | 2.70e-23 |
| Instillation, Bladder:0 | 38/138,393 | 1,716/26,262,527 | 4.20 | 8.23e-13 | 9.33e-12 |
| Serologic tests:0 | 4/138,393 | 6,321/26,262,527 | 0.12 | 4.81e-10 | 4.39e-09 |
| Hamartoma:0 | 8/138,393 | 7,271/26,262,527 | 0.21 | 7.94e-09 | 6.49e-08 |
| Testicular ablation:0 | 11/138,393 | 23/26,262,527 | 90.77 | 2.10e-17 | 3.16e-16 |
| Refractory Carcinoma:0 | 253/138,393 | 2,419/26,262,527 | 19.88 | 2.33e-221 | 4.85e-219 |
| Blood Flow Velocity:0 | 1/138,393 | 9,052/26,262,527 | 0.02 | 1.98e-19 | 3.30e-18 |
| Radiation proctitis:0 | 51/138,393 | 357/26,262,527 | 27.12 | 2.68e-52 | 1.22e-50 |
| Brain region:0 | 1/138,393 | 10,064/26,262,527 | 0.02 | 1.21e-21 | 2.22e-20 |
| Vancomycin:0 | 1/138,393 | 16,806/26,262,527 | 0.01 | 8.63e-37 | 2.73e-35 |
| Tooth structure:0 | 11/138,393 | 33,921/26,262,527 | 0.06 | 8.36e-61 | 4.50e-59 |
| Anxiety:0 | 7/138,393 | 7,526/26,262,527 | 0.18 | 4.36e-10 | 3.99e-09 |
| Scopolamine:0 | 2/138,393 | 6,672/26,262,527 | 0.06 | 9.12e-13 | 1.03e-11 |
| Ureteral obstruction:0 | 73/138,393 | 4,651/26,262,527 | 2.98 | 2.56e-15 | 3.44e-14 |
| Emcyt:0 | 14/138,393 | 37/26,262,527 | 71.81 | 1.27e-20 | 2.24e-19 |
| Hepatocyte:0 | 91/138,393 | 119,633/26,262,527 | 0.14 | 2.03e-159 | 2.94e-157 |
| Mucositis:0 | 5/138,393 | 4,970/26,262,527 | 0.19 | 1.05e-06 | 6.79e-06 |
| Supraventricular tachycardia:0 | 2/138,393 | 4,962/26,262,527 | 0.08 | 3.04e-09 | 2.58e-08 |
| Monozygotic twins:0 | 3/138,393 | 4,936/26,262,527 | 0.12 | 3.27e-08 | 2.49e-07 |
| Interleukin 2 receptor, soluble:0 | 1/138,393 | 3,379/26,262,527 | 0.06 | 6.04e-07 | 4.00e-06 |
| Receptors, Nuclear:0 | 178/138,393 | 10,571/26,262,527 | 3.20 | 1.69e-38 | 5.58e-37 |
| Secondary malignant neoplasm of vertebral column:0 | 62/138,393 | 2,051/26,262,527 | 5.74 | 1.81e-26 | 4.02e-25 |
| The science and art of healing:0 | 127/138,393 | 8,531/26,262,527 | 2.83 | 1.78e-23 | 3.50e-22 |
| Polymorphism, Genetic:0 | 500/138,393 | 50,498/26,262,527 | 1.88 | 2.75e-37 | 8.80e-36 |
| URINARY OBSTRUCTIVE SYMPTOMS:0 | 16/138,393 | 25/26,262,527 | 121.47 | 2.96e-26 | 6.51e-25 |
| Residual urine:0 | 16/138,393 | 401/26,262,527 | 7.57 | 1.34e-09 | 1.18e-08 |
| Undifferentiated carcinoma:0 | 36/138,393 | 2,628/26,262,527 | 2.60 | 5.60e-07 | 3.73e-06 |
| Molecular Fingerprint of Tumor:0 | 18/138,393 | 629/26,262,527 | 5.43 | 1.92e-08 | 1.50e-07 |
| Vitamin D3 Receptor:0 | 193/138,393 | 9,185/26,262,527 | 3.99 | 8.07e-55 | 3.83e-53 |
| Gram-Negative Bacteria:0 | 5/138,393 | 15,174/26,262,527 | 0.06 | 1.13e-27 | 2.61e-26 |
| Carcinoma of Nasopharynx:0 | 38/138,393 | 20,311/26,262,527 | 0.35 | 3.14e-14 | 3.95e-13 |
| Chronic lung disease:0 | 1/138,393 | 6,629/26,262,527 | 0.03 | 4.94e-14 | 6.13e-13 |
| PROM1:0 | 59/138,393 | 4,420/26,262,527 | 2.53 | 5.39e-10 | 4.90e-09 |
| differentiation therapy:0 | 14/138,393 | 482/26,262,527 | 5.51 | 5.86e-07 | 3.90e-06 |
| Leukemia, Lymphocytic, Acute, L1:0 | 1/138,393 | 4,535/26,262,527 | 0.04 | 1.86e-09 | 1.61e-08 |
| hip bone:0 | 22/138,393 | 749/26,262,527 | 5.57 | 3.41e-10 | 3.15e-09 |
| Neoplasms, Multiple Primary:0 | 17/138,393 | 518/26,262,527 | 6.23 | 6.90e-09 | 5.67e-08 |
| Yohimbe Preparation:0 | 3/138,393 | 6,691/26,262,527 | 0.09 | 7.88e-12 | 8.30e-11 |
| Cancer of Intestines:0 | 20/138,393 | 1,033/26,262,527 | 3.67 | 1.39e-06 | 8.83e-06 |
| Enterobacteriaceae:0 | 1/138,393 | 7,164/26,262,527 | 0.03 | 4.11e-15 | 5.45e-14 |
| Salmonella typhimurium:0 | 5/138,393 | 8,695/26,262,527 | 0.11 | 5.80e-14 | 7.16e-13 |
| Desipramine:0 | 8/138,393 | 9,141/26,262,527 | 0.17 | 2.54e-12 | 2.77e-11 |
| KLK11 gene|KLK11:0 | 15/138,393 | 86/26,262,527 | 33.10 | 1.21e-17 | 1.84e-16 |
| Femur:0 | 140/138,393 | 63,970/26,262,527 | 0.41 | 1.05e-33 | 2.98e-32 |
| Urinary catheter:0 | 21/138,393 | 847/26,262,527 | 4.71 | 1.47e-08 | 1.16e-07 |
| Arteriovenous malformation:0 | 3/138,393 | 5,050/26,262,527 | 0.11 | 2.45e-08 | 1.89e-07 |
| Melanins:0 | 20/138,393 | 9,938/26,262,527 | 0.38 | 6.73e-07 | 4.45e-06 |
| Testis:0 | 454/138,393 | 54,670/26,262,527 | 1.58 | 2.03e-19 | 3.37e-18 |
| Glycosaminoglycans:0 | 27/138,393 | 18,198/26,262,527 | 0.28 | 2.39e-16 | 3.41e-15 |
| Astrocytes:0 | 20/138,393 | 48,573/26,262,527 | 0.08 | 1.14e-81 | 8.11e-80 |
| PMEPA1:0 | 21/138,393 | 117/26,262,527 | 34.07 | 2.44e-24 | 4.96e-23 |
| Intermittent Positive-Pressure Ventilation:0 | 1/138,393 | 4,512/26,262,527 | 0.04 | 2.84e-09 | 2.42e-08 |
| Polymyxin B:0 | 1/138,393 | 3,782/26,262,527 | 0.05 | 1.04e-07 | 7.47e-07 |
| Autoantibodies:0 | 72/138,393 | 44,201/26,262,527 | 0.31 | 1.20e-34 | 3.52e-33 |
| Atropine:0 | 4/138,393 | 18,127/26,262,527 | 0.04 | 2.87e-35 | 8.58e-34 |
| Tachyarrhythmia:0 | 1/138,393 | 6,172/26,262,527 | 0.03 | 6.90e-13 | 7.84e-12 |
| Solvents:0 | 6/138,393 | 10,156/26,262,527 | 0.11 | 4.18e-16 | 5.86e-15 |
| Entire trunk:0 | 20/138,393 | 23,197/26,262,527 | 0.16 | 5.29e-30 | 1.33e-28 |
| Budesonide:0 | 2/138,393 | 8,707/26,262,527 | 0.04 | 2.54e-17 | 3.81e-16 |
| Pseudocyst:0 | 1/138,393 | 3,484/26,262,527 | 0.05 | 4.32e-07 | 2.91e-06 |
| Evolution:0 | 66/138,393 | 34,278/26,262,527 | 0.37 | 2.34e-22 | 4.41e-21 |
| Lambda:0 | 1/138,393 | 4,902/26,262,527 | 0.04 | 3.04e-10 | 2.83e-09 |
| GB virus C:0 | 1/138,393 | 3,491/26,262,527 | 0.05 | 4.36e-07 | 2.94e-06 |
| Equilibrium:0 | 19/138,393 | 9,510/26,262,527 | 0.38 | 8.36e-07 | 5.48e-06 |
| Onset of illness:0 | 16/138,393 | 16,607/26,262,527 | 0.18 | 1.65e-20 | 2.89e-19 |
| Lipids:0 | 213/138,393 | 113,403/26,262,527 | 0.36 | 2.15e-73 | 1.38e-71 |
| Phytochemical:0 | 63/138,393 | 2,601/26,262,527 | 4.60 | 4.81e-22 | 8.95e-21 |
| Receptor Gene:0 | 250/138,393 | 9,534/26,262,527 | 4.98 | 7.46e-89 | 5.72e-87 |
| Androgenic precursors:0 | 13/138,393 | 157/26,262,527 | 15.71 | 1.04e-11 | 1.09e-10 |
| resistin|RETN:0 | 2/138,393 | 6,791/26,262,527 | 0.06 | 4.25e-13 | 4.92e-12 |
| Grade:0 | 140/138,393 | 10,108/26,262,527 | 2.63 | 6.66e-23 | 1.29e-21 |
| steroid hormone metabolism:0 | 7/138,393 | 73/26,262,527 | 18.20 | 2.47e-07 | 1.71e-06 |
| Nicotinamide adenine dinucleotide (NAD):0 | 24/138,393 | 12,928/26,262,527 | 0.35 | 1.26e-09 | 1.10e-08 |
| Magnetic Resonance Spectroscopy:0 | 195/138,393 | 13,704/26,262,527 | 2.70 | 1.18e-32 | 3.23e-31 |
| Mice, Nude:0 | 1,332/138,393 | 29,179/26,262,527 | 8.74 | 0.00e+00 | 0.00e+00 |
| rams:0 | 2/138,393 | 4,590/26,262,527 | 0.08 | 1.77e-08 | 1.39e-07 |
| Brain Death:0 | 2/138,393 | 5,008/26,262,527 | 0.08 | 3.23e-09 | 2.74e-08 |
| Urethra:0 | 258/138,393 | 7,201/26,262,527 | 6.81 | 4.27e-120 | 4.49e-118 |
| Ostium:0 | 6/138,393 | 9,850/26,262,527 | 0.12 | 1.63e-15 | 2.22e-14 |
| Telomerase:0 | 120/138,393 | 9,443/26,262,527 | 2.41 | 3.69e-17 | 5.50e-16 |
| Diagnosis:0 | 1,205/138,393 | 141,324/26,262,527 | 1.62 | 5.74e-54 | 2.69e-52 |
| Mucous body substance:0 | 1/138,393 | 6,907/26,262,527 | 0.03 | 1.14e-14 | 1.47e-13 |
| Cholangiocarcinoma:0 | 20/138,393 | 10,631/26,262,527 | 0.36 | 6.11e-08 | 4.50e-07 |
| Anatomic Sites:0 | 23/138,393 | 1,128/26,262,527 | 3.87 | 9.80e-08 | 7.10e-07 |
| Instability:0 | 32/138,393 | 19,923/26,262,527 | 0.30 | 1.35e-16 | 1.95e-15 |
| Adenosine:0 | 17/138,393 | 43,565/26,262,527 | 0.07 | 2.21e-74 | 1.43e-72 |
| Microscopy, Atomic Force:0 | 4/138,393 | 5,908/26,262,527 | 0.13 | 2.52e-09 | 2.16e-08 |
| Suspected malignancy:0 | 32/138,393 | 1,415/26,262,527 | 4.29 | 2.94e-11 | 2.96e-10 |
| Tumor Oxygenation:0 | 17/138,393 | 394/26,262,527 | 8.19 | 1.33e-10 | 1.27e-09 |
| STEAP2:0 | 5/138,393 | 25/26,262,527 | 37.95 | 5.06e-07 | 3.38e-06 |
| [M]Papillary neoplasms:0 | 43/138,393 | 2,725/26,262,527 | 3.00 | 9.46e-10 | 8.40e-09 |
| Malignant transformation:0 | 242/138,393 | 10,470/26,262,527 | 4.39 | 8.69e-76 | 5.77e-74 |
| Bronchoscopy:0 | 5/138,393 | 5,055/26,262,527 | 0.19 | 7.66e-07 | 5.03e-06 |
| prognostic:0 | 40/138,393 | 1,294/26,262,527 | 5.87 | 5.51e-18 | 8.54e-17 |
| FK506 binding protein 5|FKBP4|FKBP5:0 | 15/138,393 | 437/26,262,527 | 6.51 | 2.95e-08 | 2.26e-07 |
| Transplantation, Autologous:0 | 1/138,393 | 11,546/26,262,527 | 0.02 | 5.38e-25 | 1.13e-23 |
| hydroxyflutamide:0 | 88/138,393 | 458/26,262,527 | 36.48 | 4.50e-99 | 3.90e-97 |
| GOLM1:0 | 8/138,393 | 86/26,262,527 | 17.65 | 4.25e-08 | 3.20e-07 |
| Colon:0 | 1,337/138,393 | 104,980/26,262,527 | 2.43 | 4.11e-174 | 6.72e-172 |
| Lipid A:0 | 2/138,393 | 3,905/26,262,527 | 0.10 | 6.15e-07 | 4.07e-06 |
| Proliferating Cell Nuclear Antigen|PCNA:0 | 30/138,393 | 1,774/26,262,527 | 3.21 | 7.02e-08 | 5.16e-07 |
| pulmonary function:0 | 1/138,393 | 9,053/26,262,527 | 0.02 | 1.99e-19 | 3.30e-18 |
| Punch:0 | 55/138,393 | 3,977/26,262,527 | 2.63 | 5.41e-10 | 4.91e-09 |
| CDK6:0 | 28/138,393 | 1,101/26,262,527 | 4.83 | 3.74e-11 | 3.74e-10 |
| Smoke:0 | 2/138,393 | 4,606/26,262,527 | 0.08 | 1.78e-08 | 1.40e-07 |
| Minocycline:0 | 4/138,393 | 6,560/26,262,527 | 0.12 | 1.17e-10 | 1.12e-09 |
| Adrenal Gland Hyperfunction:0 | 2/138,393 | 3,808/26,262,527 | 0.10 | 8.46e-07 | 5.55e-06 |
| Percent Free Prostate-Specific Antigen:0 | 70/138,393 | 125/26,262,527 | 106.32 | 1.37e-106 | 1.26e-104 |
| zoledronate:0 | 45/138,393 | 1,436/26,262,527 | 5.95 | 3.01e-20 | 5.18e-19 |
| Foreign Bodies:0 | 7/138,393 | 12,681/26,262,527 | 0.10 | 2.61e-20 | 4.51e-19 |
| adenosinetriphosphatase activity:0 | 3/138,393 | 4,761/26,262,527 | 0.12 | 9.75e-08 | 7.06e-07 |
| NOS3 protein, human|NOS3:0 | 75/138,393 | 45,385/26,262,527 | 0.31 | 5.28e-35 | 1.57e-33 |
| Phospholipase D:0 | 9/138,393 | 7,429/26,262,527 | 0.23 | 1.90e-08 | 1.49e-07 |
| Increase in blood pressure:0 | 3/138,393 | 5,169/26,262,527 | 0.11 | 1.18e-08 | 9.44e-08 |
| Oncologist:0 | 55/138,393 | 1,533/26,262,527 | 6.81 | 4.67e-27 | 1.06e-25 |
| monoclonal antibody J591:0 | 10/138,393 | 17/26,262,527 | 111.64 | 1.22e-16 | 1.76e-15 |
| trait:0 | 16/138,393 | 11,237/26,262,527 | 0.27 | 6.19e-11 | 6.07e-10 |
| Bilateral subcapsular orchidectomy:0 | 5/138,393 | 7/26,262,527 | 135.55 | 3.04e-09 | 2.58e-08 |
| Entire scalp:0 | 23/138,393 | 16,302/26,262,527 | 0.27 | 1.80e-15 | 2.45e-14 |
| Respiratory Tract Infections:0 | 5/138,393 | 16,251/26,262,527 | 0.06 | 5.44e-30 | 1.37e-28 |
| Follicle Stimulating Hormone:0 | 114/138,393 | 11,840/26,262,527 | 1.83 | 4.24e-09 | 3.55e-08 |
| Aminoglycosides:0 | 2/138,393 | 5,426/26,262,527 | 0.07 | 3.75e-10 | 3.44e-09 |
| Estramustinphosphate:0 | 4/138,393 | 4/26,262,527 | 189.77 | 5.20e-08 | 3.86e-07 |
| HPC1 gene|STX1A:0 | 4/138,393 | 4/26,262,527 | 189.77 | 5.20e-08 | 3.86e-07 |
| neuropeptide Y|NPY:0 | 13/138,393 | 23,568/26,262,527 | 0.10 | 7.83e-37 | 2.48e-35 |
| Normal pregnancy:0 | 5/138,393 | 5,020/26,262,527 | 0.19 | 1.12e-06 | 7.20e-06 |
| Stress:0 | 127/138,393 | 69,387/26,262,527 | 0.35 | 7.09e-47 | 2.90e-45 |
| caspase activation:0 | 51/138,393 | 3,835/26,262,527 | 2.52 | 8.94e-09 | 7.25e-08 |
| 5alphaR:0 | 5/138,393 | 30/26,262,527 | 31.63 | 1.13e-06 | 7.26e-06 |
| Single Nucleotide Polymorphism:0 | 725/138,393 | 57,483/26,262,527 | 2.40 | 2.22e-93 | 1.81e-91 |
| Prior Therapy:0 | 29/138,393 | 871/26,262,527 | 6.32 | 3.00e-14 | 3.77e-13 |
| Isoenzymes:0 | 61/138,393 | 5,812/26,262,527 | 1.99 | 1.20e-06 | 7.73e-06 |
| Posture:0 | 1/138,393 | 3,931/26,262,527 | 0.05 | 5.07e-08 | 3.78e-07 |
| Chronic radiation proctitis:0 | 16/138,393 | 123/26,262,527 | 24.69 | 6.69e-17 | 9.86e-16 |
| Rare Diseases:0 | 24/138,393 | 18,702/26,262,527 | 0.24 | 4.81e-19 | 7.86e-18 |
| Thiobarbituric Acid Reactive Substances:0 | 4/138,393 | 6,996/26,262,527 | 0.11 | 2.28e-11 | 2.31e-10 |
| anakinra:0 | 5/138,393 | 8,545/26,262,527 | 0.11 | 1.14e-13 | 1.38e-12 |
| Vaccines, Peptide:0 | 28/138,393 | 953/26,262,527 | 5.58 | 1.46e-12 | 1.63e-11 |
| Vasoconstrictor Agents:0 | 2/138,393 | 5,151/26,262,527 | 0.07 | 1.59e-09 | 1.38e-08 |
| Green Fluorescent Proteins|PDC:0 | 3/138,393 | 1/26,262,527 | 569.32 | 5.74e-07 | 3.82e-06 |
| Western Blot:0 | 345/138,393 | 21,808/26,262,527 | 3.01 | 1.45e-66 | 8.56e-65 |
| Herceptin|EREG|ESR1:0 | 6/138,393 | 56/26,262,527 | 20.33 | 9.92e-07 | 6.42e-06 |
| bacteriocin:0 | 1/138,393 | 3,897/26,262,527 | 0.05 | 4.86e-08 | 3.63e-07 |
| Fibrosis:0 | 122/138,393 | 92,404/26,262,527 | 0.25 | 8.89e-87 | 6.76e-85 |
| Hepatitis C, Chronic:0 | 5/138,393 | 38,514/26,262,527 | 0.02 | 5.55e-79 | 3.86e-77 |
| Sinus:0 | 18/138,393 | 15,746/26,262,527 | 0.22 | 1.75e-17 | 2.64e-16 |
| Vascular Endothelial Growth Factor Receptor-2:0 | 40/138,393 | 2,848/26,262,527 | 2.67 | 7.37e-08 | 5.39e-07 |
| Candida:0 | 1/138,393 | 4,064/26,262,527 | 0.05 | 2.42e-08 | 1.87e-07 |
| PTH gene|PTH:0 | 15/138,393 | 10,885/26,262,527 | 0.26 | 7.24e-11 | 7.06e-10 |
| Acetone:0 | 11/138,393 | 7,765/26,262,527 | 0.27 | 6.55e-08 | 4.82e-07 |
| APP gene|APP:0 | 8/138,393 | 20,752/26,262,527 | 0.07 | 5.34e-36 | 1.64e-34 |
| Research Personnel:0 | 163/138,393 | 17,588/26,262,527 | 1.76 | 4.15e-11 | 4.14e-10 |
| cancer recurrence:0 | 88/138,393 | 1,480/26,262,527 | 11.29 | 6.44e-59 | 3.34e-57 |
| Population-Based Registry:0 | 9/138,393 | 45/26,262,527 | 37.96 | 1.28e-11 | 1.33e-10 |
| Epidermal Growth Factor Receptor|EGFR:0 | 324/138,393 | 33,803/26,262,527 | 1.82 | 1.21e-22 | 2.31e-21 |
| Esophageal Varices:0 | 2/138,393 | 5,481/26,262,527 | 0.07 | 2.57e-10 | 2.40e-09 |
| Malaise:0 | 16/138,393 | 19,587/26,262,527 | 0.15 | 3.68e-26 | 8.05e-25 |
| Allergic rhinitis NOS:0 | 1/138,393 | 20,679/26,262,527 | 0.01 | 1.33e-45 | 5.28e-44 |
| quorum sensing:0 | 2/138,393 | 3,779/26,262,527 | 0.10 | 1.28e-06 | 8.20e-06 |
| Hypotension, Orthostatic:0 | 1/138,393 | 3,736/26,262,527 | 0.05 | 1.57e-07 | 1.11e-06 |
| annual screening:0 | 17/138,393 | 209/26,262,527 | 15.44 | 9.60e-15 | 1.24e-13 |
| Gonadotropin-Releasing Hormone Analog:0 | 792/138,393 | 7,747/26,262,527 | 19.51 | 0.00e+00 | 0.00e+00 |
| Girls:0 | 12/138,393 | 84,654/26,262,527 | 0.03 | 6.72e-171 | 1.06e-168 |
| Pleural effusion disorder:0 | 22/138,393 | 11,659/26,262,527 | 0.36 | 1.31e-08 | 1.04e-07 |
| Mollusca:0 | 4/138,393 | 5,242/26,262,527 | 0.14 | 5.24e-08 | 3.89e-07 |
| Cimetidine:0 | 7/138,393 | 15,694/26,262,527 | 0.08 | 1.83e-26 | 4.06e-25 |
| Multicenter Trials:0 | 29/138,393 | 1,846/26,262,527 | 2.98 | 4.95e-07 | 3.31e-06 |
| Tail:0 | 80/138,393 | 31,799/26,262,527 | 0.48 | 9.28e-14 | 1.13e-12 |
| Gas Chromatography:0 | 13/138,393 | 8,888/26,262,527 | 0.28 | 1.09e-08 | 8.79e-08 |
| HDAC9:0 | 38/138,393 | 2,349/26,262,527 | 3.07 | 4.50e-09 | 3.76e-08 |
| Vacuum Pump:0 | 30/138,393 | 1,017/26,262,527 | 5.60 | 2.17e-13 | 2.57e-12 |
| Structure of parietal fascia of pelvis:0 | 7/138,393 | 67/26,262,527 | 19.83 | 1.44e-07 | 1.02e-06 |
| Cancer Center:0 | 49/138,393 | 1,238/26,262,527 | 7.51 | 4.68e-26 | 1.02e-24 |
| Prostate Sarcoma:0 | 35/138,393 | 88/26,262,527 | 75.49 | 6.13e-50 | 2.66e-48 |
| Metastatic bone pain:0 | 45/138,393 | 220/26,262,527 | 38.83 | 1.35e-52 | 6.18e-51 |
| Milk Thistle:0 | 19/138,393 | 359/26,262,527 | 10.04 | 3.81e-13 | 4.42e-12 |
| Obturator lymph node group:0 | 9/138,393 | 40/26,262,527 | 42.70 | 5.08e-12 | 5.45e-11 |
| Oryza sativa:0 | 2/138,393 | 15,727/26,262,527 | 0.02 | 9.35e-33 | 2.57e-31 |
| Lymphoma, Non-Hodgkin's:0 | 228/138,393 | 25,472/26,262,527 | 1.70 | 1.98e-13 | 2.35e-12 |
| Smooth muscle (tissue):0 | 137/138,393 | 56,345/26,262,527 | 0.46 | 5.57e-25 | 1.16e-23 |
| Azathioprine:0 | 8/138,393 | 15,738/26,262,527 | 0.10 | 1.50e-25 | 3.20e-24 |
| Muscarinic Acetylcholine Receptor:0 | 8/138,393 | 16,514/26,262,527 | 0.09 | 3.22e-27 | 7.36e-26 |
| Fenofibrate:0 | 4/138,393 | 7,901/26,262,527 | 0.10 | 2.38e-13 | 2.80e-12 |
| Acid phosphatase level:0 | 10/138,393 | 37/26,262,527 | 51.29 | 6.80e-14 | 8.37e-13 |
| Plasma Exchange:0 | 4/138,393 | 7,622/26,262,527 | 0.10 | 9.66e-13 | 1.09e-11 |
| Androgenic steroid:0 | 18/138,393 | 315/26,262,527 | 10.85 | 4.63e-13 | 5.34e-12 |
| probasin:0 | 74/138,393 | 189/26,262,527 | 74.34 | 2.63e-103 | 2.38e-101 |
| Aldehydes:0 | 8/138,393 | 9,184/26,262,527 | 0.17 | 1.77e-12 | 1.96e-11 |
| Glomerular Basement Membrane:0 | 3/138,393 | 5,556/26,262,527 | 0.10 | 2.17e-09 | 1.86e-08 |
| Raised prostate specific antigen:0 | 579/138,393 | 829/26,262,527 | 133.09 | 0.00e+00 | 0.00e+00 |
| Therapists:0 | 1/138,393 | 4,063/26,262,527 | 0.05 | 2.41e-08 | 1.87e-07 |
| docetaxel/estramustine:0 | 26/138,393 | 56/26,262,527 | 88.12 | 6.34e-39 | 2.13e-37 |
| CRH gene|CRH:0 | 1/138,393 | 3,742/26,262,527 | 0.05 | 9.96e-08 | 7.21e-07 |
| Baresthesia:0 | 66/138,393 | 73,279/26,262,527 | 0.17 | 6.60e-90 | 5.13e-88 |
| Serum testosterone measurement:0 | 30/138,393 | 287/26,262,527 | 19.84 | 8.77e-28 | 2.04e-26 |
| Acid Phosphatase:0 | 776/138,393 | 9,888/26,262,527 | 14.97 | 0.00e+00 | 0.00e+00 |
| S100B:0 | 1/138,393 | 8,641/26,262,527 | 0.02 | 1.83e-18 | 2.90e-17 |
| Primary Health Care:0 | 10/138,393 | 7,068/26,262,527 | 0.27 | 2.48e-07 | 1.72e-06 |
| Ruminants:0 | 2/138,393 | 7,566/26,262,527 | 0.05 | 8.09e-15 | 1.05e-13 |
| FGFR2 gene|FGFR2:0 | 26/138,393 | 1,185/26,262,527 | 4.16 | 3.57e-09 | 3.02e-08 |
| Ouabain:0 | 16/138,393 | 15,353/26,262,527 | 0.20 | 3.85e-18 | 6.03e-17 |
| Acute graft-versus-host disease:0 | 1/138,393 | 5,063/26,262,527 | 0.04 | 1.50e-10 | 1.43e-09 |
| Clinic:0 | 98/138,393 | 10,848/26,262,527 | 1.71 | 8.30e-07 | 5.44e-06 |
| Uterine Contraction:0 | 1/138,393 | 3,439/26,262,527 | 0.06 | 6.51e-07 | 4.30e-06 |
| Corneal Diseases:0 | 8/138,393 | 14,102/26,262,527 | 0.11 | 2.83e-22 | 5.31e-21 |
| Amiodarone:0 | 4/138,393 | 13,985/26,262,527 | 0.05 | 3.21e-26 | 7.03e-25 |
| RELB:0 | 20/138,393 | 934/26,262,527 | 4.06 | 3.09e-07 | 2.12e-06 |
| hypoglycemia:0 | 7/138,393 | 22,467/26,262,527 | 0.06 | 7.17e-41 | 2.55e-39 |
| Fatty Streak, Arterial:0 | 3/138,393 | 14,037/26,262,527 | 0.04 | 1.25e-27 | 2.88e-26 |
| Tumor Initiation:0 | 80/138,393 | 1,693/26,262,527 | 8.97 | 9.87e-47 | 4.01e-45 |
| no positive axillary nodes:0 | 38/138,393 | 2,406/26,262,527 | 3.00 | 8.32e-09 | 6.76e-08 |
| Methionine:0 | 49/138,393 | 19,454/26,262,527 | 0.48 | 7.26e-09 | 5.96e-08 |
| Epothilones:0 | 24/138,393 | 468/26,262,527 | 9.73 | 6.47e-16 | 8.94e-15 |
| connective tissue growth factor:0 | 7/138,393 | 6,693/26,262,527 | 0.20 | 1.51e-08 | 1.19e-07 |
| Myxoma:0 | 2/138,393 | 3,773/26,262,527 | 0.10 | 1.27e-06 | 8.10e-06 |
| Gangrene:0 | 1/138,393 | 4,859/26,262,527 | 0.04 | 4.53e-10 | 4.14e-09 |
| Antiphospholipid Antibodies:0 | 1/138,393 | 5,657/26,262,527 | 0.03 | 8.49e-12 | 8.92e-11 |
| Thermoluminescent Dosimetry:0 | 6/138,393 | 46/26,262,527 | 24.75 | 3.43e-07 | 2.35e-06 |
| Cerebral cortex:0 | 9/138,393 | 44,230/26,262,527 | 0.04 | 9.70e-86 | 7.27e-84 |
| Thyrotoxicosis:0 | 5/138,393 | 5,770/26,262,527 | 0.16 | 2.88e-08 | 2.20e-07 |
| Salvage Therapy:0 | 248/138,393 | 3,540/26,262,527 | 13.32 | 2.79e-178 | 4.81e-176 |
| Auxins:0 | 1/138,393 | 7,285/26,262,527 | 0.03 | 1.89e-15 | 2.55e-14 |
| KLK10:0 | 11/138,393 | 136/26,262,527 | 15.35 | 5.05e-10 | 4.60e-09 |
| Chemotaxis:0 | 54/138,393 | 19,238/26,262,527 | 0.53 | 4.21e-07 | 2.85e-06 |
| Psychotherapy:0 | 5/138,393 | 9,265/26,262,527 | 0.10 | 3.62e-15 | 4.82e-14 |
| arginine methyl ester:0 | 1/138,393 | 7,092/26,262,527 | 0.03 | 5.90e-15 | 7.76e-14 |
| Vaccines, Inactivated:0 | 1/138,393 | 3,669/26,262,527 | 0.05 | 1.43e-07 | 1.02e-06 |
| Ganglion cell:0 | 6/138,393 | 7,120/26,262,527 | 0.16 | 6.23e-10 | 5.63e-09 |
| N-Methyl-D-Aspartate Receptors:0 | 3/138,393 | 17,486/26,262,527 | 0.03 | 3.76e-35 | 1.12e-33 |
| Clostridium perfringens:0 | 1/138,393 | 3,244/26,262,527 | 0.06 | 1.24e-06 | 7.98e-06 |
| maspin:0 | 12/138,393 | 204/26,262,527 | 11.16 | 2.53e-09 | 2.17e-08 |
| FRA16D:0 | 8/138,393 | 94/26,262,527 | 16.15 | 8.07e-08 | 5.88e-07 |
| Neck Neoplasms:0 | 18/138,393 | 838/26,262,527 | 4.08 | 1.12e-06 | 7.25e-06 |
| Arabidopsis thaliana:0 | 3/138,393 | 13,218/26,262,527 | 0.04 | 6.39e-26 | 1.38e-24 |
| Kininogenase|KLK4:0 | 117/138,393 | 3,819/26,262,527 | 5.82 | 6.26e-49 | 2.67e-47 |
| Acute coronary syndrome:0 | 3/138,393 | 34,413/26,262,527 | 0.02 | 4.44e-73 | 2.82e-71 |
| Graft Rejection:0 | 2/138,393 | 3,714/26,262,527 | 0.10 | 1.19e-06 | 7.64e-06 |
| Neuromuscular Diseases:0 | 2/138,393 | 6,978/26,262,527 | 0.05 | 1.42e-13 | 1.70e-12 |
| establishment and maintenance of substrate location:0 | 252/138,393 | 29,151/26,262,527 | 1.64 | 3.63e-13 | 4.22e-12 |
| rosuvastatin:0 | 1/138,393 | 7,141/26,262,527 | 0.03 | 3.91e-15 | 5.20e-14 |
| Chromosome 10 Short Arm:0 | 9/138,393 | 144/26,262,527 | 11.86 | 1.51e-07 | 1.07e-06 |
| Obstetric Patient:0 | 1/138,393 | 4,625/26,262,527 | 0.04 | 1.31e-09 | 1.15e-08 |
| Calcium Channel Blockers:0 | 20/138,393 | 27,809/26,262,527 | 0.14 | 6.85e-39 | 2.29e-37 |
| Gram-Positive Bacteria:0 | 3/138,393 | 7,920/26,262,527 | 0.07 | 1.98e-14 | 2.51e-13 |
| MMP2 gene|MMP2:0 | 15/138,393 | 439/26,262,527 | 6.48 | 3.13e-08 | 2.39e-07 |
| biological adaptation to stress:0 | 45/138,393 | 16,830/26,262,527 | 0.51 | 4.79e-07 | 3.21e-06 |
| Urethral Obstruction:0 | 18/138,393 | 775/26,262,527 | 4.41 | 3.81e-07 | 2.59e-06 |
| Immunity:0 | 110/138,393 | 34,764/26,262,527 | 0.60 | 8.02e-09 | 6.54e-08 |
| Lactate Dehydrogenase:0 | 38/138,393 | 17,356/26,262,527 | 0.42 | 4.43e-10 | 4.05e-09 |
| MUC7|MCOLN1:0 | 2/138,393 | 15,060/26,262,527 | 0.03 | 2.39e-31 | 6.28e-30 |
| Spectrin:0 | 1/138,393 | 4,409/26,262,527 | 0.04 | 3.88e-09 | 3.27e-08 |
| DNA-Directed RNA Polymerase|ERVK-9|ERVK-19|ERVK-11:0 | 7/138,393 | 11,649/26,262,527 | 0.11 | 3.16e-18 | 4.96e-17 |
| N-Methylaspartate:0 | 2/138,393 | 22,056/26,262,527 | 0.02 | 7.06e-47 | 2.89e-45 |
| Neck:0 | 708/138,393 | 74,015/26,262,527 | 1.82 | 3.70e-47 | 1.53e-45 |
| Body Regions:0 | 38/138,393 | 2,951/26,262,527 | 2.44 | 1.32e-06 | 8.44e-06 |
| Neuropathic pain:0 | 9/138,393 | 12,654/26,262,527 | 0.13 | 2.60e-18 | 4.10e-17 |
| Dyskinetic syndrome:0 | 1/138,393 | 8,220/26,262,527 | 0.02 | 1.66e-17 | 2.51e-16 |
| Tetrodotoxin:0 | 12/138,393 | 9,023/26,262,527 | 0.25 | 1.54e-09 | 1.34e-08 |
| prostein:0 | 8/138,393 | 21/26,262,527 | 72.30 | 2.22e-12 | 2.43e-11 |
| Tissue Model:0 | 27/138,393 | 1,167/26,262,527 | 4.39 | 6.05e-10 | 5.47e-09 |
| activated p21cdc42Hs kinase|TNK2:0 | 11/138,393 | 239/26,262,527 | 8.73 | 1.25e-07 | 8.91e-07 |
| TLR4 protein, human|TLR4:0 | 21/138,393 | 13,017/26,262,527 | 0.31 | 3.64e-11 | 3.64e-10 |
| Inflammation Mediators:0 | 15/138,393 | 10,210/26,262,527 | 0.28 | 1.06e-09 | 9.37e-09 |
| Wegener's Granulomatosis:0 | 1/138,393 | 5,513/26,262,527 | 0.03 | 1.75e-11 | 1.80e-10 |
| PROSTATE NODULAR:0 | 5/138,393 | 9/26,262,527 | 105.43 | 7.62e-09 | 6.24e-08 |
| bosentan:0 | 2/138,393 | 5,498/26,262,527 | 0.07 | 2.62e-10 | 2.44e-09 |
| Omeprazole:0 | 3/138,393 | 11,901/26,262,527 | 0.05 | 6.21e-23 | 1.20e-21 |
| Immune Sera:0 | 120/138,393 | 56,235/26,262,527 | 0.40 | 4.97e-31 | 1.30e-29 |
| CHRFAM7A:0 | 14/138,393 | 403/26,262,527 | 6.59 | 7.31e-08 | 5.36e-07 |
| CRISP-3 protein:0 | 11/138,393 | 60/26,262,527 | 34.79 | 1.57e-13 | 1.88e-12 |
| Secondary carcinoma NOS:0 | 14/138,393 | 371/26,262,527 | 7.16 | 2.74e-08 | 2.10e-07 |
| imatinib:0 | 45/138,393 | 23,558/26,262,527 | 0.36 | 5.90e-16 | 8.20e-15 |
| Castration, Male:0 | 160/138,393 | 367/26,262,527 | 82.83 | 2.13e-227 | 4.58e-225 |
| Hemorrhage:0 | 268/138,393 | 86,376/26,262,527 | 0.59 | 3.28e-21 | 5.91e-20 |
| Estradurin:0 | 15/138,393 | 48/26,262,527 | 59.31 | 5.97e-21 | 1.06e-19 |
| neurodevelopment:0 | 1/138,393 | 5,158/26,262,527 | 0.04 | 1.09e-10 | 1.05e-09 |
| disease stage:0 | 26/138,393 | 717/26,262,527 | 6.88 | 9.61e-14 | 1.17e-12 |
| Serine Proteinase Inhibitors:0 | 53/138,393 | 3,945/26,262,527 | 2.55 | 3.58e-09 | 3.02e-08 |
| Metastatic Carcinoma:0 | 316/138,393 | 9,353/26,262,527 | 6.42 | 6.05e-140 | 7.65e-138 |
| Pulmonary Edema:0 | 2/138,393 | 11,072/26,262,527 | 0.03 | 1.67e-22 | 3.18e-21 |
| Buccal pouch:0 | 1/138,393 | 3,559/26,262,527 | 0.05 | 3.02e-07 | 2.08e-06 |
| [M]Adenocarcinoma, metastatic, NOS:0 | 166/138,393 | 3,099/26,262,527 | 10.18 | 7.40e-103 | 6.65e-101 |
| dopamine transporter:0 | 2/138,393 | 7,798/26,262,527 | 0.05 | 2.81e-15 | 3.77e-14 |
| Prostatic Diseases:0 | 632/138,393 | 1,332/26,262,527 | 90.45 | 0.00e+00 | 0.00e+00 |
| Tumor Angiogenesis:0 | 213/138,393 | 6,207/26,262,527 | 6.52 | 3.66e-96 | 3.07e-94 |
| Urethral anastomosis:0 | 19/138,393 | 70/26,262,527 | 51.52 | 3.74e-25 | 7.86e-24 |
| Prostate cancer stage IV:0 | 71/138,393 | 114/26,262,527 | 118.25 | 1.26e-110 | 1.21e-108 |
| Renal Cell Carcinoma:0 | 520/138,393 | 39,892/26,262,527 | 2.48 | 8.47e-72 | 5.30e-70 |
| Protozoa:0 | 3/138,393 | 6,555/26,262,527 | 0.09 | 1.60e-11 | 1.65e-10 |
| clusterin antisense oligonucleotide:0 | 6/138,393 | 28/26,262,527 | 40.67 | 2.46e-08 | 1.90e-07 |
| Globus Pallidus:0 | 2/138,393 | 7,844/26,262,527 | 0.05 | 1.91e-15 | 2.59e-14 |
| Prostate Cancer Prevention Trial:0 | 16/138,393 | 16/26,262,527 | 189.79 | 1.80e-28 | 4.30e-27 |
| Ephrins:0 | 24/138,393 | 1,294/26,262,527 | 3.52 | 2.78e-07 | 1.92e-06 |
| Cations:0 | 7/138,393 | 10,161/26,262,527 | 0.13 | 4.18e-15 | 5.53e-14 |
| Alcoholic Liver Diseases:0 | 3/138,393 | 6,594/26,262,527 | 0.09 | 1.11e-11 | 1.15e-10 |
| Course:0 | 16/138,393 | 10,482/26,262,527 | 0.29 | 1.18e-09 | 1.03e-08 |
| New Agents:0 | 13/138,393 | 324/26,262,527 | 7.61 | 4.29e-08 | 3.23e-07 |
| Rats, Zucker:0 | 2/138,393 | 9,247/26,262,527 | 0.04 | 2.15e-18 | 3.40e-17 |
| nerve supply:0 | 16/138,393 | 14,663/26,262,527 | 0.21 | 6.48e-17 | 9.56e-16 |
| purification:0 | 35/138,393 | 22,046/26,262,527 | 0.30 | 1.97e-18 | 3.13e-17 |
| DNA Modification Methylases:0 | 26/138,393 | 1,397/26,262,527 | 3.53 | 8.55e-08 | 6.22e-07 |
| Allopurinol:0 | 7/138,393 | 9,554/26,262,527 | 0.14 | 5.96e-14 | 7.35e-13 |
| Intestinal Obstruction:0 | 11/138,393 | 7,861/26,262,527 | 0.27 | 4.94e-08 | 3.69e-07 |
| Urological examination:0 | 6/138,393 | 40/26,262,527 | 28.47 | 1.62e-07 | 1.14e-06 |
| Chromium:0 | 5/138,393 | 8,221/26,262,527 | 0.12 | 4.35e-13 | 5.03e-12 |
| Structural protein:0 | 11/138,393 | 7,600/26,262,527 | 0.27 | 1.18e-07 | 8.45e-07 |
| Tolbutamide:0 | 1/138,393 | 3,379/26,262,527 | 0.06 | 6.04e-07 | 4.00e-06 |
| CA1|S100A10:0 | 1/138,393 | 7,227/26,262,527 | 0.03 | 2.79e-15 | 3.75e-14 |
| Glutamate:0 | 29/138,393 | 51,339/26,262,527 | 0.11 | 3.42e-78 | 2.35e-76 |
| cardiac arrhythmia:0 | 7/138,393 | 24,895/26,262,527 | 0.05 | 3.83e-46 | 1.53e-44 |
| Chronic Disease:0 | 126/138,393 | 43,394/26,262,527 | 0.55 | 1.75e-13 | 2.08e-12 |
| Quinazolines:0 | 16/138,393 | 515/26,262,527 | 5.90 | 3.91e-08 | 2.95e-07 |
| LY 294002:0 | 116/138,393 | 6,913/26,262,527 | 3.19 | 1.34e-25 | 2.87e-24 |
| outer membrane:0 | 7/138,393 | 15,714/26,262,527 | 0.08 | 1.23e-26 | 2.73e-25 |
| Immunologic function:0 | 28/138,393 | 13,952/26,262,527 | 0.38 | 2.48e-09 | 2.13e-08 |
| Photosynthesis:0 | 5/138,393 | 10,523/26,262,527 | 0.09 | 1.03e-17 | 1.59e-16 |
| Bronchitis, Chronic:0 | 2/138,393 | 7,519/26,262,527 | 0.05 | 1.20e-14 | 1.54e-13 |
| Bombesin:0 | 196/138,393 | 6,130/26,262,527 | 6.07 | 1.13e-83 | 8.29e-82 |
| Nucleus Accumbens:0 | 1/138,393 | 22,934/26,262,527 | 0.01 | 9.94e-51 | 4.42e-49 |
| Tomography, Emission-Computed:0 | 118/138,393 | 4,214/26,262,527 | 5.32 | 1.31e-45 | 5.20e-44 |
| Receptors, Nuclear|AR:0 | 30/138,393 | 115/26,262,527 | 49.52 | 2.22e-38 | 7.29e-37 |
| Repeat Surgery:0 | 23/138,393 | 15,947/26,262,527 | 0.27 | 8.13e-15 | 1.06e-13 |
| Hemagglutinin:0 | 5/138,393 | 10,516/26,262,527 | 0.09 | 1.02e-17 | 1.57e-16 |
| tumor protein D52|TPD52:0 | 9/138,393 | 83/26,262,527 | 20.58 | 1.75e-09 | 1.52e-08 |
| TOOKAD:0 | 12/138,393 | 37/26,262,527 | 61.55 | 3.32e-17 | 4.95e-16 |
| Robotic Systems:0 | 34/138,393 | 1,098/26,262,527 | 5.88 | 1.50e-15 | 2.04e-14 |
| Ovarian Follicle:0 | 9/138,393 | 25,782/26,262,527 | 0.07 | 1.39e-45 | 5.48e-44 |
| osteoblast cadherin:0 | 15/138,393 | 552/26,262,527 | 5.16 | 5.30e-07 | 3.54e-06 |
| Plants, Transgenic:0 | 1/138,393 | 3,346/26,262,527 | 0.06 | 8.96e-07 | 5.84e-06 |
| Reticulocytes:0 | 2/138,393 | 6,400/26,262,527 | 0.06 | 2.48e-12 | 2.70e-11 |
| Serum specimen:0 | 141/138,393 | 8,689/26,262,527 | 3.08 | 2.42e-29 | 5.95e-28 |
| Alcoholic Intoxication:0 | 356/138,393 | 1,286/26,262,527 | 52.67 | 0.00e+00 | 0.00e+00 |
| Arsenic:0 | 37/138,393 | 14,506/26,262,527 | 0.48 | 9.22e-07 | 6.01e-06 |
| Immune Sera|ESR1|ERAL1:0 | 3/138,393 | 1/26,262,527 | 569.32 | 5.74e-07 | 3.82e-06 |
| Antidepressive Agents:0 | 30/138,393 | 52,115/26,262,527 | 0.11 | 8.35e-79 | 5.79e-77 |
| Knee bone:0 | 1/138,393 | 11,498/26,262,527 | 0.02 | 8.16e-25 | 1.70e-23 |
| Leptin|LEP:0 | 62/138,393 | 61,776/26,262,527 | 0.19 | 3.20e-71 | 1.99e-69 |
| Sleep Apnea, Obstructive:0 | 8/138,393 | 46,337/26,262,527 | 0.03 | 8.27e-92 | 6.59e-90 |
| Recurrent disease:0 | 190/138,393 | 10,145/26,262,527 | 3.56 | 4.31e-47 | 1.79e-45 |
| Phenylephrine:0 | 6/138,393 | 15,635/26,262,527 | 0.07 | 2.01e-27 | 4.62e-26 |
| src-Family Kinases:0 | 49/138,393 | 3,795/26,262,527 | 2.45 | 3.69e-08 | 2.79e-07 |
| Pes:0 | 32/138,393 | 29,601/26,262,527 | 0.20 | 3.17e-33 | 8.87e-32 |
| Diuretics:0 | 11/138,393 | 15,653/26,262,527 | 0.13 | 1.02e-22 | 1.95e-21 |
| Urinary organ:0 | 18/138,393 | 178/26,262,527 | 19.19 | 4.69e-17 | 6.95e-16 |
| Entire aortic valve:0 | 1/138,393 | 6,517/26,262,527 | 0.03 | 1.08e-13 | 1.31e-12 |
| Muscle Cells:0 | 11/138,393 | 35,238/26,262,527 | 0.06 | 1.41e-63 | 7.94e-62 |
| Cold Therapy:0 | 193/138,393 | 5,442/26,262,527 | 6.74 | 1.29e-89 | 1.00e-87 |
| microbial:0 | 19/138,393 | 33,087/26,262,527 | 0.11 | 1.75e-50 | 7.76e-49 |
| Lysosomes:0 | 32/138,393 | 14,143/26,262,527 | 0.43 | 5.16e-08 | 3.84e-07 |
| Neural Stem Cell:0 | 5/138,393 | 7,668/26,262,527 | 0.12 | 6.89e-12 | 7.31e-11 |
| particle:0 | 24/138,393 | 19,212/26,262,527 | 0.24 | 8.09e-20 | 1.36e-18 |
| Observation parameter:0 | 634/138,393 | 97,956/26,262,527 | 1.23 | 5.21e-07 | 3.48e-06 |
| Neoplastic Epithelial Cell:0 | 39/138,393 | 492/26,262,527 | 15.05 | 2.05e-31 | 5.41e-30 |
| Capromab Pendetide:0 | 72/138,393 | 160/26,262,527 | 85.44 | 3.93e-104 | 3.58e-102 |
| Dosimeter:0 | 43/138,393 | 2,755/26,262,527 | 2.96 | 1.30e-09 | 1.14e-08 |
| MET gene|MET|RNMT|SLTM:0 | 36/138,393 | 1,343/26,262,527 | 5.09 | 1.51e-14 | 1.94e-13 |
| Endobronchial metastases:0 | 10/138,393 | 139/26,262,527 | 13.65 | 8.82e-09 | 7.15e-08 |
| Globo-H:0 | 8/138,393 | 62/26,262,527 | 24.49 | 4.03e-09 | 3.39e-08 |
| Organelles:0 | 30/138,393 | 13,229/26,262,527 | 0.43 | 1.41e-07 | 1.00e-06 |
| SAMARIUM Sm153:0 | 14/138,393 | 39/26,262,527 | 68.13 | 2.35e-20 | 4.07e-19 |
| Second Degree Relative:0 | 22/138,393 | 497/26,262,527 | 8.40 | 1.71e-13 | 2.04e-12 |
| Viral Proteins:0 | 11/138,393 | 9,749/26,262,527 | 0.21 | 2.29e-11 | 2.32e-10 |
| Carcinoma, Endometrioid:0 | 32/138,393 | 1,628/26,262,527 | 3.73 | 8.49e-10 | 7.59e-09 |
| Endothelial dysfunction:0 | 6/138,393 | 24,571/26,262,527 | 0.05 | 8.84e-47 | 3.61e-45 |
| Kininogenase:0 | 83/138,393 | 3,416/26,262,527 | 4.61 | 1.39e-28 | 3.33e-27 |
| MICE:0 | 116/138,393 | 2,602/26,262,527 | 8.47 | 2.10e-64 | 1.19e-62 |
| Inspiration function:0 | 5/138,393 | 17,447/26,262,527 | 0.05 | 1.94e-32 | 5.25e-31 |
| Fundus:0 | 4/138,393 | 12,581/26,262,527 | 0.06 | 2.69e-23 | 5.26e-22 |
| Health:0 | 190/138,393 | 52,500/26,262,527 | 0.69 | 4.40e-08 | 3.30e-07 |
| Clinical Trials, Phase III:0 | 45/138,393 | 798/26,262,527 | 10.70 | 4.57e-30 | 1.15e-28 |
| Embryo:0 | 63/138,393 | 92,742/26,262,527 | 0.13 | 2.00e-130 | 2.32e-128 |
| CLDN4 gene|CLDN4:0 | 10/138,393 | 225/26,262,527 | 8.43 | 6.26e-07 | 4.14e-06 |
| Tramadol:0 | 5/138,393 | 5,832/26,262,527 | 0.16 | 3.04e-08 | 2.32e-07 |
| Myenteric Plexus:0 | 1/138,393 | 4,963/26,262,527 | 0.04 | 2.11e-10 | 1.99e-09 |
| External Ear:0 | 2/138,393 | 4,510/26,262,527 | 0.08 | 3.90e-08 | 2.94e-07 |
| Cardiomyopathies, Primary:0 | 1/138,393 | 4,083/26,262,527 | 0.05 | 2.50e-08 | 1.93e-07 |
| Breast Feeding:0 | 33/138,393 | 31,935/26,262,527 | 0.20 | 8.54e-37 | 2.70e-35 |
| Brachytherapy implant:0 | 50/138,393 | 349/26,262,527 | 27.20 | 2.31e-51 | 1.03e-49 |
| Superantigens:0 | 1/138,393 | 5,475/26,262,527 | 0.03 | 1.66e-11 | 1.71e-10 |
| Aspartate:0 | 9/138,393 | 9,520/26,262,527 | 0.18 | 2.60e-12 | 2.83e-11 |
| Acids:0 | 67/138,393 | 36,663/26,262,527 | 0.35 | 1.80e-25 | 3.83e-24 |
| Entire substantia nigra:0 | 2/138,393 | 24,998/26,262,527 | 0.02 | 1.35e-53 | 6.26e-52 |
| Hypertrophy, Left Ventricular:0 | 2/138,393 | 19,124/26,262,527 | 0.02 | 2.21e-40 | 7.76e-39 |
| SV40 T Proteins:0 | 15/138,393 | 564/26,262,527 | 5.05 | 6.87e-07 | 4.53e-06 |
| Insulin-Like Growth Factor II:0 | 120/138,393 | 12,901/26,262,527 | 1.77 | 1.26e-08 | 1.01e-07 |
| KRT6A|PCSK1|BTG2|ACTR1B|CBX8:0 | 6/138,393 | 20/26,262,527 | 56.93 | 4.37e-09 | 3.65e-08 |
| Metabolic acidosis:0 | 3/138,393 | 5,117/26,262,527 | 0.11 | 1.72e-08 | 1.35e-07 |
| Streptococcus:0 | 3/138,393 | 14,108/26,262,527 | 0.04 | 8.68e-28 | 2.02e-26 |
| Androgen-Insensitivity Syndrome:0 | 24/138,393 | 611/26,262,527 | 7.46 | 1.64e-13 | 1.95e-12 |
| Three dimensional treatment planning:0 | 10/138,393 | 87/26,262,527 | 21.81 | 1.30e-10 | 1.25e-09 |
| Lymphocyte Function-Associated Antigen-1:0 | 1/138,393 | 4,758/26,262,527 | 0.04 | 6.29e-10 | 5.68e-09 |
| Growth retardation:0 | 105/138,393 | 8,305/26,262,527 | 2.40 | 4.97e-15 | 6.57e-14 |
| Stroke prevention:0 | 1/138,393 | 4,359/26,262,527 | 0.04 | 5.75e-09 | 4.76e-08 |
| Lysine:0 | 36/138,393 | 20,740/26,262,527 | 0.33 | 8.04e-16 | 1.11e-14 |
| Hydrochlorothiazide:0 | 1/138,393 | 7,383/26,262,527 | 0.03 | 1.39e-15 | 1.90e-14 |
| Dermis:0 | 9/138,393 | 9,975/26,262,527 | 0.17 | 3.76e-13 | 4.36e-12 |
| Medical oncologist:0 | 13/138,393 | 292/26,262,527 | 8.45 | 1.34e-08 | 1.06e-07 |
| Erythrocyte Membrane:0 | 7/138,393 | 9,271/26,262,527 | 0.14 | 2.31e-13 | 2.73e-12 |
| survivin:0 | 154/138,393 | 6,503/26,262,527 | 4.50 | 3.68e-50 | 1.62e-48 |
| Cerebrospinal Fluid:0 | 15/138,393 | 30,415/26,262,527 | 0.09 | 5.65e-49 | 2.42e-47 |
| brain function:0 | 3/138,393 | 6,062/26,262,527 | 0.09 | 1.89e-10 | 1.79e-09 |
| Intestines:0 | 388/138,393 | 144,853/26,262,527 | 0.51 | 8.89e-51 | 3.96e-49 |
| Dietary Fats:0 | 64/138,393 | 5,493/26,262,527 | 2.21 | 2.20e-08 | 1.71e-07 |
| Allergic Reaction:0 | 4/138,393 | 7,061/26,262,527 | 0.11 | 1.59e-11 | 1.64e-10 |
| Death, Sudden:0 | 4/138,393 | 15,478/26,262,527 | 0.05 | 1.71e-29 | 4.21e-28 |
| Esophagectomy:0 | 1/138,393 | 8,944/26,262,527 | 0.02 | 4.41e-19 | 7.22e-18 |
| Peplomycin:0 | 31/138,393 | 849/26,262,527 | 6.93 | 3.65e-16 | 5.14e-15 |
| Acupuncture procedure:0 | 19/138,393 | 21,766/26,262,527 | 0.17 | 4.72e-28 | 1.11e-26 |
| Death, Sudden, Cardiac:0 | 5/138,393 | 8,811/26,262,527 | 0.11 | 2.81e-14 | 3.55e-13 |
| Peroxynitrite:0 | 2/138,393 | 7,056/26,262,527 | 0.05 | 9.92e-14 | 1.21e-12 |
| sterol esterase:0 | 1/138,393 | 3,956/26,262,527 | 0.05 | 3.37e-08 | 2.56e-07 |
| omega-N-Methylarginine:0 | 1/138,393 | 5,204/26,262,527 | 0.04 | 7.22e-11 | 7.04e-10 |
| Virulence Factors:0 | 4/138,393 | 12,825/26,262,527 | 0.06 | 9.48e-24 | 1.89e-22 |
| Heart Atrium:0 | 4/138,393 | 23,374/26,262,527 | 0.03 | 6.71e-47 | 2.75e-45 |
| Buffaloes:0 | 2/138,393 | 5,558/26,262,527 | 0.07 | 1.81e-10 | 1.72e-09 |
| Anterior Cruciate Ligament:0 | 1/138,393 | 5,302/26,262,527 | 0.04 | 5.27e-11 | 5.19e-10 |
| Hypotensive:0 | 2/138,393 | 6,073/26,262,527 | 0.06 | 1.52e-11 | 1.57e-10 |
| Physiologic pulse:0 | 7/138,393 | 6,465/26,262,527 | 0.21 | 3.92e-08 | 2.95e-07 |
| Caspase Inhibitor:0 | 52/138,393 | 2,751/26,262,527 | 3.59 | 2.71e-14 | 3.43e-13 |
| Flexion:0 | 1/138,393 | 4,678/26,262,527 | 0.04 | 9.01e-10 | 8.03e-09 |
| Lamella:0 | 1/138,393 | 5,860/26,262,527 | 0.03 | 2.79e-12 | 3.03e-11 |
| In complete remission:0 | 120/138,393 | 11,670/26,262,527 | 1.95 | 4.53e-11 | 4.51e-10 |
| Obturator fossa:0 | 9/138,393 | 40/26,262,527 | 42.70 | 5.08e-12 | 5.45e-11 |
| Tissue Engineering:0 | 1/138,393 | 3,656/26,262,527 | 0.05 | 2.21e-07 | 1.54e-06 |
| Lamina Propria:0 | 10/138,393 | 8,681/26,262,527 | 0.22 | 4.04e-10 | 3.71e-09 |
| Calculators:0 | 12/138,393 | 340/26,262,527 | 6.70 | 5.21e-07 | 3.49e-06 |
| Lower Extremity:0 | 71/138,393 | 51,015/26,262,527 | 0.26 | 2.07e-46 | 8.36e-45 |
| Embryonic Stem Cell:0 | 38/138,393 | 18,337/26,262,527 | 0.39 | 2.18e-11 | 2.22e-10 |
| Atelectasis:0 | 2/138,393 | 3,859/26,262,527 | 0.10 | 5.91e-07 | 3.93e-06 |
| Hysterectomy:0 | 11/138,393 | 10,537/26,262,527 | 0.20 | 6.96e-13 | 7.90e-12 |
| Pain, Postoperative:0 | 16/138,393 | 9,698/26,262,527 | 0.31 | 2.06e-08 | 1.61e-07 |
| Maxilla:0 | 14/138,393 | 27,002/26,262,527 | 0.10 | 8.51e-43 | 3.17e-41 |
| Ileal conduit procedure:0 | 48/138,393 | 1,183/26,262,527 | 7.70 | 5.33e-26 | 1.16e-24 |
| Ribavirin:0 | 4/138,393 | 25,217/26,262,527 | 0.03 | 8.45e-51 | 3.77e-49 |
| PROTECTION:0 | 121/138,393 | 50,769/26,262,527 | 0.45 | 1.85e-23 | 3.64e-22 |
| Contracture:0 | 4/138,393 | 11,852/26,262,527 | 0.06 | 1.47e-21 | 2.69e-20 |
| Follicle:0 | 5/138,393 | 8,990/26,262,527 | 0.11 | 1.47e-14 | 1.89e-13 |
| Endoplasmic Reticulum:0 | 84/138,393 | 27,366/26,262,527 | 0.58 | 7.93e-08 | 5.79e-07 |
| alpha Catenin:0 | 25/138,393 | 1,261/26,262,527 | 3.76 | 4.71e-08 | 3.53e-07 |
| CD40LG:0 | 13/138,393 | 23,367/26,262,527 | 0.11 | 2.23e-36 | 6.96e-35 |
| Raynaud Phenomenon:0 | 1/138,393 | 3,772/26,262,527 | 0.05 | 1.02e-07 | 7.36e-07 |
| Anatomical zone:0 | 9/138,393 | 59/26,262,527 | 28.95 | 1.11e-10 | 1.07e-09 |
| Endothelial Cells:0 | 312/138,393 | 114,443/26,262,527 | 0.52 | 7.18e-39 | 2.39e-37 |
| CAP - NOS:0 | 526/138,393 | 2,768/26,262,527 | 36.20 | 0.00e+00 | 0.00e+00 |
| Radiotherapy, Intensity-Modulated:0 | 406/138,393 | 5,010/26,262,527 | 15.42 | 1.42e-313 | 4.09e-311 |
| GGN:0 | 12/138,393 | 81/26,262,527 | 28.12 | 1.21e-13 | 1.46e-12 |
| CATALASE|CAT:0 | 13/138,393 | 10,215/26,262,527 | 0.24 | 6.82e-11 | 6.66e-10 |
| Bone marrow scintigraphy:0 | 10/138,393 | 128/26,262,527 | 14.83 | 4.21e-09 | 3.53e-08 |
| Androgen Receptor Antagonists:0 | 9/138,393 | 26/26,262,527 | 65.69 | 1.87e-13 | 2.22e-12 |
| Cancer Patient:0 | 1,253/138,393 | 46,816/26,262,527 | 5.12 | 0.00e+00 | 0.00e+00 |
| Familial Mediterranean Fever:0 | 1/138,393 | 6,438/26,262,527 | 0.03 | 1.53e-13 | 1.83e-12 |
| trastuzumab|ERBB2:0 | 24/138,393 | 195/26,262,527 | 23.36 | 4.47e-24 | 9.04e-23 |
| Fructose:0 | 6/138,393 | 10,648/26,262,527 | 0.11 | 5.75e-17 | 8.51e-16 |
| Cytokeratin 18:0 | 16/138,393 | 356/26,262,527 | 8.53 | 2.60e-10 | 2.42e-09 |
| PLAB Protein:0 | 36/138,393 | 822/26,262,527 | 8.31 | 6.16e-21 | 1.10e-19 |
| Calcidiol 1-Monooxygenase|CYP27B1:0 | 24/138,393 | 757/26,262,527 | 6.02 | 1.23e-11 | 1.28e-10 |
| Testosterone 5-alpha-Reductase|SRD5A2:0 | 21/138,393 | 92/26,262,527 | 43.32 | 2.84e-26 | 6.27e-25 |
| Vaccines, Attenuated:0 | 4/138,393 | 7,504/26,262,527 | 0.10 | 2.03e-12 | 2.23e-11 |
| Estrus:0 | 3/138,393 | 6,722/26,262,527 | 0.08 | 8.24e-12 | 8.66e-11 |
| Immunoglobulin Idiotypes:0 | 1/138,393 | 3,314/26,262,527 | 0.06 | 8.68e-07 | 5.67e-06 |
| Platelet function:0 | 1/138,393 | 5,787/26,262,527 | 0.03 | 4.00e-12 | 4.31e-11 |
| CD28 gene|CD28:0 | 3/138,393 | 6,438/26,262,527 | 0.09 | 3.39e-11 | 3.40e-10 |
| casein kinase II:0 | 46/138,393 | 3,560/26,262,527 | 2.45 | 9.39e-08 | 6.82e-07 |
| Gonadorelin|RHCE|RHD:0 | 31/138,393 | 12/26,262,527 | 490.34 | 2.90e-61 | 1.58e-59 |
| Franzen needle:0 | 7/138,393 | 8/26,262,527 | 166.06 | 6.74e-13 | 7.67e-12 |
| IgG1:0 | 29/138,393 | 12,698/26,262,527 | 0.43 | 2.98e-07 | 2.05e-06 |
| Entire condyle:0 | 2/138,393 | 19,650/26,262,527 | 0.02 | 1.83e-41 | 6.59e-40 |
| EPHB2|MAPK1:0 | 259/138,393 | 30,102/26,262,527 | 1.63 | 3.45e-13 | 4.01e-12 |
| MCM7 gene|MCM7:0 | 11/138,393 | 266/26,262,527 | 7.85 | 3.46e-07 | 2.36e-06 |
| Bone necrosis:0 | 156/138,393 | 15,665/26,262,527 | 1.89 | 7.06e-13 | 8.01e-12 |
| isoflavonoids:0 | 19/138,393 | 861/26,262,527 | 4.19 | 3.89e-07 | 2.64e-06 |
| Antibiotics, Aminoglycoside:0 | 3/138,393 | 6,756/26,262,527 | 0.08 | 5.52e-12 | 5.91e-11 |
| Nursing Homes:0 | 1/138,393 | 4,932/26,262,527 | 0.04 | 3.16e-10 | 2.92e-09 |
| Apnea:0 | 1/138,393 | 8,456/26,262,527 | 0.02 | 3.64e-18 | 5.71e-17 |
| Polyarthritis:0 | 1/138,393 | 4,572/26,262,527 | 0.04 | 1.93e-09 | 1.67e-08 |
| MRSA - Methicillin resistant Staphylococcus aureus infection:0 | 2/138,393 | 17,112/26,262,527 | 0.02 | 6.01e-36 | 1.84e-34 |
| Herpes Simplex Infections:0 | 1/138,393 | 4,144/26,262,527 | 0.05 | 1.71e-08 | 1.34e-07 |
| Glucose Intolerance:0 | 4/138,393 | 5,960/26,262,527 | 0.13 | 2.67e-09 | 2.28e-08 |
| Apolipoprotein A-I:0 | 8/138,393 | 10,133/26,262,527 | 0.15 | 2.41e-14 | 3.05e-13 |
| tumor-associated antigen 72:0 | 20/138,393 | 358/26,262,527 | 10.60 | 3.59e-14 | 4.50e-13 |
| Proliferating Cell Nuclear Antigen:0 | 137/138,393 | 12,130/26,262,527 | 2.14 | 2.10e-15 | 2.84e-14 |
| Transplanted organ and tissue status:0 | 14/138,393 | 10,161/26,262,527 | 0.26 | 2.65e-10 | 2.47e-09 |
| Progesterone:0 | 141/138,393 | 56,234/26,262,527 | 0.48 | 1.45e-23 | 2.88e-22 |
| Prostatic stent:0 | 11/138,393 | 130/26,262,527 | 16.06 | 3.23e-10 | 2.99e-09 |
| innate immune response:0 | 8/138,393 | 7,826/26,262,527 | 0.19 | 6.00e-10 | 5.43e-09 |
| Pelvic floor exercises:0 | 15/138,393 | 457/26,262,527 | 6.23 | 5.18e-08 | 3.85e-07 |
| SMAD5-AS1:0 | 2/138,393 | 6,061/26,262,527 | 0.06 | 1.50e-11 | 1.54e-10 |
| % uptake:0 | 12/138,393 | 309/26,262,527 | 7.37 | 1.96e-07 | 1.37e-06 |
| Cytokeratin:0 | 107/138,393 | 7,716/26,262,527 | 2.63 | 7.09e-18 | 1.09e-16 |
| Replacement therapy:0 | 164/138,393 | 11,084/26,262,527 | 2.81 | 1.62e-29 | 4.00e-28 |
| Vitamin D:0 | 415/138,393 | 30,917/26,262,527 | 2.55 | 7.27e-61 | 3.92e-59 |
| glutamate carboxypeptidase II, human:0 | 15/138,393 | 38/26,262,527 | 74.92 | 3.21e-22 | 6.02e-21 |
| Methylphenidate:0 | 4/138,393 | 9,770/26,262,527 | 0.08 | 2.66e-17 | 3.99e-16 |
| Nuclease Sensitive Element Binding Protein 1:0 | 11/138,393 | 232/26,262,527 | 9.00 | 9.37e-08 | 6.81e-07 |
| Response Elements:0 | 87/138,393 | 8,833/26,262,527 | 1.87 | 1.42e-07 | 1.01e-06 |
| Malignant neoplasm of cervix uteri:0 | 257/138,393 | 32,720/26,262,527 | 1.49 | 1.87e-09 | 1.62e-08 |
| maspin|SERPINB5:0 | 81/138,393 | 2,364/26,262,527 | 6.51 | 1.13e-37 | 3.65e-36 |
| Radical therapy:0 | 84/138,393 | 500/26,262,527 | 31.90 | 2.71e-90 | 2.13e-88 |
| Benzodiazepines:0 | 7/138,393 | 18,899/26,262,527 | 0.07 | 2.39e-33 | 6.70e-32 |
| Survivors:0 | 528/138,393 | 59,275/26,262,527 | 1.69 | 1.38e-28 | 3.31e-27 |
| Pelvis:0 | 1,027/138,393 | 29,285/26,262,527 | 6.70 | 0.00e+00 | 0.00e+00 |
| [X]Disorder of vein, unspecified:0 | 1/138,393 | 3,772/26,262,527 | 0.05 | 1.02e-07 | 7.36e-07 |
| Negative Staining:0 | 17/138,393 | 524/26,262,527 | 6.16 | 8.12e-09 | 6.62e-08 |
| Drowsiness:0 | 2/138,393 | 4,046/26,262,527 | 0.09 | 3.03e-07 | 2.08e-06 |
| RIBOSOMAL:0 | 5/138,393 | 6,172/26,262,527 | 0.15 | 5.58e-09 | 4.62e-08 |
| Horns:0 | 14/138,393 | 8,949/26,262,527 | 0.30 | 2.97e-08 | 2.27e-07 |
| hyperthermia treatment:0 | 16/138,393 | 481/26,262,527 | 6.31 | 1.58e-08 | 1.25e-07 |
| Japanese Population:0 | 89/138,393 | 6,281/26,262,527 | 2.69 | 9.41e-16 | 1.29e-14 |
| beta-defensin-2:0 | 1/138,393 | 3,616/26,262,527 | 0.05 | 2.07e-07 | 1.45e-06 |
| Endotoxins:0 | 5/138,393 | 29,183/26,262,527 | 0.03 | 2.73e-58 | 1.40e-56 |
| Eating:0 | 25/138,393 | 28,099/26,262,527 | 0.17 | 1.65e-35 | 4.98e-34 |
| Cannulation:0 | 1/138,393 | 4,189/26,262,527 | 0.05 | 1.15e-08 | 9.19e-08 |
| 5-aza-2'-deoxycytidine:0 | 93/138,393 | 5,033/26,262,527 | 3.51 | 1.39e-23 | 2.75e-22 |
| Stilphostrol:0 | 10/138,393 | 19/26,262,527 | 99.88 | 2.86e-16 | 4.06e-15 |
| Tendinopathy:0 | 1/138,393 | 5,385/26,262,527 | 0.04 | 3.77e-11 | 3.77e-10 |
| SYP gene|SYP:0 | 11/138,393 | 254/26,262,527 | 8.22 | 2.23e-07 | 1.55e-06 |
| Verumontanum:0 | 19/138,393 | 112/26,262,527 | 32.20 | 9.43e-22 | 1.74e-20 |
| Filters:0 | 43/138,393 | 23,597/26,262,527 | 0.35 | 6.23e-17 | 9.20e-16 |
| Hemostatic function:0 | 15/138,393 | 9,681/26,262,527 | 0.29 | 5.82e-09 | 4.82e-08 |
| IGF1 gene|IGF1:0 | 24/138,393 | 669/26,262,527 | 6.81 | 1.04e-12 | 1.17e-11 |
| Obesity, Morbid:0 | 7/138,393 | 9,292/26,262,527 | 0.14 | 1.58e-13 | 1.88e-12 |
| Spinal Injuries:0 | 1/138,393 | 4,044/26,262,527 | 0.05 | 2.36e-08 | 1.83e-07 |
| Surgical Procedures, Elective:0 | 4/138,393 | 4,718/26,262,527 | 0.16 | 5.41e-07 | 3.61e-06 |
| Relapse:0 | 38/138,393 | 2,188/26,262,527 | 3.30 | 7.00e-10 | 6.30e-09 |
| high-risk group:0 | 105/138,393 | 5,712/26,262,527 | 3.49 | 3.12e-26 | 6.86e-25 |
| GNRH1 gene|GNRH1:0 | 78/138,393 | 2,701/26,262,527 | 5.48 | 1.35e-31 | 3.59e-30 |
| Sex Hormone-Binding Globulin:0 | 108/138,393 | 5,209/26,262,527 | 3.94 | 5.08e-31 | 1.32e-29 |
| brca gene:0 | 9/138,393 | 161/26,262,527 | 10.61 | 3.69e-07 | 2.51e-06 |
| caspase activity:0 | 17/138,393 | 607/26,262,527 | 5.32 | 6.33e-08 | 4.66e-07 |
| Hemangioma, Cavernous:0 | 1/138,393 | 6,912/26,262,527 | 0.03 | 1.14e-14 | 1.47e-13 |
| Amyotrophic Lateral Sclerosis:0 | 8/138,393 | 35,595/26,262,527 | 0.04 | 4.46e-68 | 2.68e-66 |
| anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody:0 | 9/138,393 | 155/26,262,527 | 11.02 | 2.72e-07 | 1.88e-06 |
| comatose:0 | 2/138,393 | 9,338/26,262,527 | 0.04 | 9.83e-19 | 1.58e-17 |
| Arthroplasty:0 | 5/138,393 | 11,697/26,262,527 | 0.08 | 2.57e-20 | 4.43e-19 |
| pertuzumab|EREG|ESR1:0 | 3/138,393 | 1/26,262,527 | 569.32 | 5.74e-07 | 3.82e-06 |
| Feces:0 | 10/138,393 | 8,812/26,262,527 | 0.22 | 2.14e-10 | 2.01e-09 |
| alanosine:0 | 7/138,393 | 5,691/26,262,527 | 0.23 | 1.30e-06 | 8.26e-06 |
| Bacteria, Anaerobic:0 | 1/138,393 | 4,876/26,262,527 | 0.04 | 4.69e-10 | 4.28e-09 |
| Peroxidase:0 | 25/138,393 | 17,800/26,262,527 | 0.27 | 7.08e-17 | 1.04e-15 |
| Braces-Orthopedic appliances:0 | 1/138,393 | 4,917/26,262,527 | 0.04 | 3.09e-10 | 2.86e-09 |
| Toxic effect:0 | 1,503/138,393 | 110,241/26,262,527 | 2.60 | 3.33e-222 | 7.03e-220 |
| Pineal gland:0 | 16/138,393 | 9,217/26,262,527 | 0.33 | 1.10e-07 | 7.92e-07 |
| Face:0 | 37/138,393 | 21,665/26,262,527 | 0.32 | 9.59e-17 | 1.40e-15 |
| Menstrual cycle:0 | 8/138,393 | 10,568/26,262,527 | 0.14 | 3.26e-15 | 4.36e-14 |
| Catechol Oxidase|TYR:0 | 3/138,393 | 6,689/26,262,527 | 0.09 | 7.87e-12 | 8.29e-11 |
| Bladder volume:0 | 14/138,393 | 334/26,262,527 | 7.96 | 7.78e-09 | 6.36e-08 |
| NFKB1:0 | 66/138,393 | 5,144/26,262,527 | 2.44 | 2.66e-10 | 2.48e-09 |
| Periodicals:0 | 299/138,393 | 26,251/26,262,527 | 2.16 | 3.92e-32 | 1.06e-30 |
| cancer prevention:0 | 118/138,393 | 1,566/26,262,527 | 14.31 | 3.57e-89 | 2.75e-87 |
| Vitellogenins:0 | 2/138,393 | 5,245/26,262,527 | 0.07 | 7.37e-10 | 6.61e-09 |
| MDM2 gene|MDM2:0 | 89/138,393 | 7,650/26,262,527 | 2.21 | 4.62e-11 | 4.58e-10 |
| Induction:0 | 691/138,393 | 86,627/26,262,527 | 1.52 | 2.04e-24 | 4.19e-23 |
| Gunshot wound:0 | 2/138,393 | 4,452/26,262,527 | 0.09 | 3.59e-08 | 2.72e-07 |
| PS 341:0 | 15/138,393 | 451/26,262,527 | 6.31 | 4.39e-08 | 3.29e-07 |
| EDN1 gene|EDN1:0 | 15/138,393 | 317/26,262,527 | 8.98 | 4.76e-10 | 4.34e-09 |
| TGFB1I1:0 | 18/138,393 | 112/26,262,527 | 30.50 | 2.61e-20 | 4.51e-19 |
| Prostate size:0 | 103/138,393 | 347/26,262,527 | 56.37 | 1.22e-132 | 1.46e-130 |
| Phosphotransferases:0 | 628/138,393 | 85,057/26,262,527 | 1.40 | 1.22e-15 | 1.67e-14 |
| cyclin-dependent kinase inhibitor 1B|CDKN1B:0 | 49/138,393 | 2,591/26,262,527 | 3.59 | 1.43e-13 | 1.72e-12 |
| Fossa:0 | 63/138,393 | 3,429/26,262,527 | 3.49 | 2.06e-16 | 2.94e-15 |
| Cancer of Urinary Tract:0 | 245/138,393 | 773/26,262,527 | 60.25 | 7.47e-319 | 2.21e-316 |
| Salmonella:0 | 8/138,393 | 11,714/26,262,527 | 0.13 | 2.19e-17 | 3.29e-16 |
| Retroperitoneal lymph node dissection:0 | 27/138,393 | 1,528/26,262,527 | 3.35 | 1.33e-07 | 9.51e-07 |
| Vacuole:0 | 17/138,393 | 13,667/26,262,527 | 0.24 | 1.60e-14 | 2.05e-13 |
| Depot Preparations:0 | 15/138,393 | 213/26,262,527 | 13.37 | 2.43e-12 | 2.66e-11 |
| prostatic binding protein|PEBP1:0 | 17/138,393 | 426/26,262,527 | 7.57 | 4.16e-10 | 3.81e-09 |
| methylselenic acid:0 | 43/138,393 | 293/26,262,527 | 27.86 | 8.20e-45 | 3.20e-43 |
| Leuprolide:0 | 244/138,393 | 1,928/26,262,527 | 24.06 | 9.38e-232 | 2.05e-229 |
| Tomatoes:0 | 35/138,393 | 504/26,262,527 | 13.18 | 1.46e-26 | 3.25e-25 |
| Erythropoietin|EPO:0 | 12/138,393 | 14,627/26,262,527 | 0.16 | 9.48e-20 | 1.60e-18 |
| Oxygen:0 | 81/138,393 | 69,439/26,262,527 | 0.22 | 3.10e-72 | 1.95e-70 |
| Quinidine:0 | 2/138,393 | 6,111/26,262,527 | 0.06 | 1.03e-11 | 1.08e-10 |
| Induction of Apoptosis:0 | 27/138,393 | 1,412/26,262,527 | 3.63 | 2.88e-08 | 2.20e-07 |
| DNA Sequence:0 | 311/138,393 | 102,730/26,262,527 | 0.57 | 7.24e-27 | 1.62e-25 |
| Rectal symptoms:0 | 10/138,393 | 54/26,262,527 | 35.14 | 1.83e-12 | 2.03e-11 |
| Cystoscopy:0 | 76/138,393 | 2,310/26,262,527 | 6.25 | 2.40e-34 | 6.94e-33 |
| Coronary angioplasty:0 | 1/138,393 | 3,783/26,262,527 | 0.05 | 1.04e-07 | 7.48e-07 |
| Prefrontal Cortex:0 | 2/138,393 | 27,943/26,262,527 | 0.01 | 4.30e-60 | 2.29e-58 |
| Testicular Neoplasms:0 | 71/138,393 | 3,064/26,262,527 | 4.40 | 1.42e-23 | 2.81e-22 |
| Positive Lymph Node:0 | 219/138,393 | 4,862/26,262,527 | 8.56 | 9.63e-121 | 1.02e-118 |
| Dopamine Agonists:0 | 7/138,393 | 11,840/26,262,527 | 0.11 | 1.67e-18 | 2.66e-17 |
| Methanol:0 | 15/138,393 | 14,312/26,262,527 | 0.20 | 4.71e-17 | 6.99e-16 |
| Cancer Detection:0 | 360/138,393 | 776/26,262,527 | 88.26 | 0.00e+00 | 0.00e+00 |
| insulin-like growth factor binding protein-related protein 1:0 | 10/138,393 | 189/26,262,527 | 10.04 | 1.36e-07 | 9.70e-07 |
| ropivacaine:0 | 4/138,393 | 4,661/26,262,527 | 0.16 | 7.58e-07 | 4.99e-06 |
| Limb structure:0 | 46/138,393 | 42,287/26,262,527 | 0.21 | 9.75e-47 | 3.97e-45 |
| Normal saline:0 | 7/138,393 | 7,778/26,262,527 | 0.17 | 1.68e-10 | 1.60e-09 |
| Severe Acute Respiratory Syndrome:0 | 2/138,393 | 6,894/26,262,527 | 0.06 | 3.17e-13 | 3.70e-12 |
| Carcinogenesis:0 | 2,030/138,393 | 60,832/26,262,527 | 6.41 | 0.00e+00 | 0.00e+00 |
| Heme Oxygenase (Decyclizing):0 | 4/138,393 | 5,536/26,262,527 | 0.14 | 1.36e-08 | 1.08e-07 |
| ACAT1|SLC25A5:0 | 20/138,393 | 479/26,262,527 | 7.92 | 5.75e-12 | 6.13e-11 |
| Postoperative analgesia:0 | 9/138,393 | 6,310/26,262,527 | 0.27 | 1.29e-06 | 8.22e-06 |
| Zometa:0 | 27/138,393 | 133/26,262,527 | 38.53 | 3.95e-32 | 1.06e-30 |
| Amiloride:0 | 10/138,393 | 8,363/26,262,527 | 0.23 | 1.39e-09 | 1.22e-08 |
| Hyaluronic Acid:0 | 35/138,393 | 14,054/26,262,527 | 0.47 | 8.21e-07 | 5.38e-06 |
| West Nile virus:0 | 1/138,393 | 4,025/26,262,527 | 0.05 | 2.34e-08 | 1.82e-07 |
| Dopa:0 | 9/138,393 | 7,168/26,262,527 | 0.24 | 4.62e-08 | 3.46e-07 |
| Diclofenac:0 | 12/138,393 | 9,571/26,262,527 | 0.24 | 1.83e-10 | 1.73e-09 |
| Intraepithelial Neoplasia:0 | 64/138,393 | 2,261/26,262,527 | 5.37 | 8.67e-26 | 1.87e-24 |
| Bathing:0 | 4/138,393 | 4,713/26,262,527 | 0.16 | 8.11e-07 | 5.32e-06 |
| day:0 | 138/138,393 | 15,966/26,262,527 | 1.64 | 7.47e-08 | 5.47e-07 |
| TPD52:0 | 9/138,393 | 35/26,262,527 | 48.80 | 1.80e-12 | 1.98e-11 |
| ezetimibe:0 | 1/138,393 | 4,409/26,262,527 | 0.04 | 3.88e-09 | 3.27e-08 |
| Dentist:0 | 8/138,393 | 6,664/26,262,527 | 0.23 | 9.68e-08 | 7.02e-07 |
| Sulfasalazine:0 | 6/138,393 | 7,077/26,262,527 | 0.16 | 5.86e-10 | 5.30e-09 |
| Viral hepatitis:0 | 1/138,393 | 5,554/26,262,527 | 0.03 | 1.16e-11 | 1.21e-10 |
| Knowledge acquisition:0 | 13/138,393 | 8,947/26,262,527 | 0.28 | 8.08e-09 | 6.59e-08 |
| Tamoxifen:0 | 189/138,393 | 52,263/26,262,527 | 0.69 | 4.83e-08 | 3.61e-07 |
| Testicular Tissue:0 | 44/138,393 | 3,211/26,262,527 | 2.60 | 3.39e-08 | 2.57e-07 |
| Bone Matrix:0 | 36/138,393 | 2,644/26,262,527 | 2.58 | 6.41e-07 | 4.24e-06 |
| Proliferative diabetic retinopathy:0 | 3/138,393 | 5,719/26,262,527 | 0.10 | 7.27e-10 | 6.53e-09 |
| Breast Carcinoma:0 | 248/138,393 | 21,325/26,262,527 | 2.21 | 3.95e-28 | 9.33e-27 |
| Mastectomy:0 | 13/138,393 | 9,605/26,262,527 | 0.26 | 7.68e-10 | 6.87e-09 |
| Leukotriene C4:0 | 1/138,393 | 4,964/26,262,527 | 0.04 | 2.11e-10 | 1.99e-09 |
| Prednisone:0 | 339/138,393 | 23,824/26,262,527 | 2.70 | 2.83e-55 | 1.36e-53 |
| Topical form corticosteroids:0 | 1/138,393 | 4,065/26,262,527 | 0.05 | 2.42e-08 | 1.87e-07 |
| Fetal Growth:0 | 1/138,393 | 3,910/26,262,527 | 0.05 | 4.91e-08 | 3.67e-07 |
| Pulmonary Surfactant-Associated Protein A:0 | 1/138,393 | 4,368/26,262,527 | 0.04 | 5.86e-09 | 4.85e-08 |
| Myocardial dysfunction:0 | 1/138,393 | 4,095/26,262,527 | 0.05 | 2.58e-08 | 1.99e-07 |
| Prostatic hypertrophy:0 | 244/138,393 | 1,369/26,262,527 | 33.88 | 2.85e-264 | 7.19e-262 |
| LAMC2:0 | 6/138,393 | 13,670/26,262,527 | 0.08 | 2.57e-23 | 5.03e-22 |
| Laryngeal Masks:0 | 1/138,393 | 5,241/26,262,527 | 0.04 | 7.78e-11 | 7.57e-10 |
| Lymphohistiocytosis, Hemophagocytic:0 | 1/138,393 | 4,999/26,262,527 | 0.04 | 2.18e-10 | 2.05e-09 |
| Cytogen 356:0 | 6/138,393 | 8/26,262,527 | 142.33 | 6.01e-11 | 5.91e-10 |
| Nasal Polyps:0 | 2/138,393 | 6,232/26,262,527 | 0.06 | 7.64e-12 | 8.07e-11 |
| Digoxin:0 | 17/138,393 | 14,507/26,262,527 | 0.22 | 5.44e-16 | 7.57e-15 |
| Vasodilation disorder:0 | 3/138,393 | 8,078/26,262,527 | 0.07 | 9.90e-15 | 1.28e-13 |
| Transcriptional Repression:0 | 38/138,393 | 2,379/26,262,527 | 3.03 | 6.23e-09 | 5.14e-08 |
| Colorectal Cancer:0 | 87/138,393 | 5,059/26,262,527 | 3.26 | 2.85e-20 | 4.91e-19 |
| Insecticides:0 | 3/138,393 | 9,378/26,262,527 | 0.06 | 1.67e-17 | 2.52e-16 |
| caspase-9:0 | 119/138,393 | 4,671/26,262,527 | 4.84 | 4.13e-42 | 1.51e-40 |
| Lignans:0 | 52/138,393 | 3,259/26,262,527 | 3.03 | 1.25e-11 | 1.30e-10 |
| Gender:0 | 36/138,393 | 16,201/26,262,527 | 0.42 | 2.53e-09 | 2.17e-08 |
| Fine needle aspiration biopsy:0 | 186/138,393 | 15,091/26,262,527 | 2.34 | 3.50e-24 | 7.10e-23 |
| Femoral Fractures:0 | 2/138,393 | 4,384/26,262,527 | 0.09 | 5.12e-08 | 3.81e-07 |
| Bone structure of tibia:0 | 39/138,393 | 17,330/26,262,527 | 0.43 | 1.18e-09 | 1.04e-08 |
| acetonitrile:0 | 5/138,393 | 6,533/26,262,527 | 0.15 | 1.05e-09 | 9.26e-09 |
| Acetylcholinesterase:0 | 3/138,393 | 20,902/26,262,527 | 0.03 | 1.00e-42 | 3.72e-41 |
| Carcinoma, Cribriform:0 | 6/138,393 | 60/26,262,527 | 18.98 | 1.44e-06 | 9.13e-06 |
| Chemopreventive Agent:0 | 229/138,393 | 3,458/26,262,527 | 12.59 | 8.66e-160 | 1.26e-157 |
| Matrix Metalloproteinases:0 | 217/138,393 | 26,797/26,262,527 | 1.54 | 3.18e-09 | 2.70e-08 |
| ELAC2:0 | 26/138,393 | 60/26,262,527 | 82.25 | 2.71e-38 | 8.88e-37 |
| Iron Overload:0 | 2/138,393 | 10,078/26,262,527 | 0.04 | 2.68e-20 | 4.62e-19 |
| sibling:0 | 62/138,393 | 25,357/26,262,527 | 0.46 | 7.07e-12 | 7.49e-11 |
| Consanguinity:0 | 1/138,393 | 4,255/26,262,527 | 0.04 | 7.95e-09 | 6.49e-08 |
| Methylprednisolone:0 | 9/138,393 | 17,939/26,262,527 | 0.10 | 3.60e-29 | 8.77e-28 |
| Mounts:0 | 124/138,393 | 4,609/26,262,527 | 5.11 | 4.06e-46 | 1.62e-44 |
| proteomic profiling:0 | 16/138,393 | 593/26,262,527 | 5.12 | 2.47e-07 | 1.71e-06 |
| Epithelial-Stromal Communication:0 | 13/138,393 | 125/26,262,527 | 19.74 | 7.24e-13 | 8.21e-12 |
| Stromal Invasion:0 | 26/138,393 | 246/26,262,527 | 20.06 | 2.10e-24 | 4.30e-23 |
| Carcinoma, Transitional Cell:0 | 725/138,393 | 28,571/26,262,527 | 4.84 | 6.40e-246 | 1.53e-243 |
| Entire thoracic aorta:0 | 1/138,393 | 10,284/26,262,527 | 0.02 | 4.09e-22 | 7.62e-21 |
| Genasense:0 | 6/138,393 | 47/26,262,527 | 24.23 | 3.86e-07 | 2.62e-06 |
| Soy Proteins:0 | 135/138,393 | 4,607/26,262,527 | 5.57 | 4.69e-54 | 2.20e-52 |
| Pathological fracture:0 | 76/138,393 | 4,498/26,262,527 | 3.21 | 1.60e-17 | 2.42e-16 |
| Schizosaccharomyces pombe:0 | 4/138,393 | 9,113/26,262,527 | 0.08 | 6.25e-16 | 8.66e-15 |
| Recurrent tumor:0 | 109/138,393 | 4,583/26,262,527 | 4.52 | 3.39e-36 | 1.05e-34 |
| Osteoclasia:0 | 10/138,393 | 178/26,262,527 | 10.66 | 8.00e-08 | 5.83e-07 |
| Asian diet:0 | 7/138,393 | 27/26,262,527 | 49.20 | 5.17e-10 | 4.70e-09 |
| Diabetes Mellitus, Insulin-Dependent:0 | 16/138,393 | 84,579/26,262,527 | 0.04 | 1.22e-164 | 1.84e-162 |
| Anemia, Hemolytic:0 | 2/138,393 | 6,149/26,262,527 | 0.06 | 1.07e-11 | 1.12e-10 |
| Peptide YY|PYY:0 | 3/138,393 | 4,340/26,262,527 | 0.13 | 5.01e-07 | 3.36e-06 |
| Bladder:0 | 2,775/138,393 | 91,053/26,262,527 | 5.88 | 0.00e+00 | 0.00e+00 |
| Tumor Promotion:0 | 33/138,393 | 2,364/26,262,527 | 2.65 | 1.08e-06 | 7.00e-06 |
| CAV1 gene|CAV1:0 | 11/138,393 | 275/26,262,527 | 7.59 | 4.74e-07 | 3.18e-06 |
| Membrane:0 | 296/138,393 | 144,672/26,262,527 | 0.39 | 9.18e-83 | 6.64e-81 |
| Angiogenesis Inhibitors:0 | 305/138,393 | 23,319/26,262,527 | 2.49 | 4.37e-43 | 1.65e-41 |
| Curative treatment:0 | 78/138,393 | 984/26,262,527 | 15.05 | 4.17e-61 | 2.27e-59 |
| Cytosine deaminase:0 | 29/138,393 | 1,029/26,262,527 | 5.35 | 1.57e-12 | 1.75e-11 |
| Salmonella food poisoning:0 | 1/138,393 | 3,450/26,262,527 | 0.05 | 4.21e-07 | 2.85e-06 |
| Somatomedins|BP1:0 | 9/138,393 | 8/26,262,527 | 213.50 | 6.99e-17 | 1.03e-15 |
| Cancer Control:0 | 98/138,393 | 394/26,262,527 | 47.23 | 8.72e-120 | 9.12e-118 |
| Wound Healing:0 | 132/138,393 | 65,923/26,262,527 | 0.38 | 1.11e-39 | 3.83e-38 |
| Glutamate Carboxypeptidase II:0 | 509/138,393 | 1,550/26,262,527 | 62.54 | 0.00e+00 | 0.00e+00 |
| Knee:0 | 5/138,393 | 37,005/26,262,527 | 0.03 | 1.16e-75 | 7.70e-74 |
| Vegetables:0 | 65/138,393 | 2,897/26,262,527 | 4.26 | 4.94e-21 | 8.84e-20 |
| duloxetine:0 | 1/138,393 | 4,235/26,262,527 | 0.04 | 1.24e-08 | 9.90e-08 |
| Cultured skin:0 | 2/138,393 | 4,165/26,262,527 | 0.09 | 1.47e-07 | 1.04e-06 |
| Head:0 | 196/138,393 | 69,184/26,262,527 | 0.54 | 5.27e-22 | 9.80e-21 |
| Regional Blood Flow:0 | 1/138,393 | 24,635/26,262,527 | 0.01 | 1.44e-54 | 6.79e-53 |
| Gonadorelin:0 | 435/138,393 | 23,798/26,262,527 | 3.48 | 4.26e-102 | 3.77e-100 |
| Glomerular Filtration Rate:0 | 13/138,393 | 30,346/26,262,527 | 0.08 | 7.89e-51 | 3.52e-49 |
| Breast Cancer Model:0 | 20/138,393 | 1,001/26,262,527 | 3.79 | 8.74e-07 | 5.71e-06 |
| Additional values:0 | 34/138,393 | 1,004/26,262,527 | 6.43 | 1.21e-16 | 1.76e-15 |
| Radiation Tolerance:0 | 35/138,393 | 1,270/26,262,527 | 5.23 | 1.60e-14 | 2.04e-13 |
| Gynecomastia:0 | 108/138,393 | 2,475/26,262,527 | 8.29 | 3.16e-59 | 1.64e-57 |
| Glycerol:0 | 9/138,393 | 19,608/26,262,527 | 0.09 | 1.22e-32 | 3.34e-31 |
| Ovulation:0 | 10/138,393 | 15,694/26,262,527 | 0.12 | 1.68e-23 | 3.31e-22 |
| Molecular Chaperones|AR:0 | 9/138,393 | 11/26,262,527 | 155.27 | 4.76e-16 | 6.64e-15 |
| Vitamin D Analog:0 | 22/138,393 | 817/26,262,527 | 5.11 | 1.60e-09 | 1.39e-08 |
| Levetiracetam:0 | 2/138,393 | 6,237/26,262,527 | 0.06 | 7.72e-12 | 8.15e-11 |
| Mixed infectious disease:0 | 3/138,393 | 4,449/26,262,527 | 0.13 | 3.69e-07 | 2.51e-06 |
| CYTOKERATIN ANTIBODY:0 | 9/138,393 | 191/26,262,527 | 8.94 | 1.43e-06 | 9.07e-06 |
| Radical cystectomy:0 | 230/138,393 | 6,773/26,262,527 | 6.45 | 8.18e-103 | 7.29e-101 |
| Entire temporomandibular joint:0 | 1/138,393 | 8,680/26,262,527 | 0.02 | 1.22e-18 | 1.96e-17 |
| Endosomes:0 | 22/138,393 | 10,858/26,262,527 | 0.38 | 1.84e-07 | 1.29e-06 |
| Chymosin|REN:0 | 1/138,393 | 10,271/26,262,527 | 0.02 | 3.98e-22 | 7.42e-21 |
| Shock, Cardiogenic:0 | 1/138,393 | 8,397/26,262,527 | 0.02 | 5.27e-18 | 8.19e-17 |
| Parenteral Nutrition:0 | 1/138,393 | 6,156/26,262,527 | 0.03 | 6.62e-13 | 7.55e-12 |
| Recombinant Interferon-gamma:0 | 94/138,393 | 64,386/26,262,527 | 0.28 | 1.22e-55 | 5.92e-54 |
| Hydrocephalus, Normal Pressure:0 | 1/138,393 | 3,741/26,262,527 | 0.05 | 9.96e-08 | 7.21e-07 |
| DKK3:0 | 14/138,393 | 262/26,262,527 | 10.14 | 4.01e-10 | 3.68e-09 |
| Pomegranate:0 | 15/138,393 | 211/26,262,527 | 13.49 | 2.14e-12 | 2.35e-11 |
| Insulin-Like-Growth Factor I Receptor:0 | 129/138,393 | 8,147/26,262,527 | 3.01 | 4.44e-26 | 9.69e-25 |
| Varicosity:0 | 2/138,393 | 17,655/26,262,527 | 0.02 | 5.01e-37 | 1.60e-35 |
| Insulin-Like Growth Factor-Binding Protein-9|NOV:0 | 1/138,393 | 3,312/26,262,527 | 0.06 | 8.67e-07 | 5.67e-06 |
| Theophylline:0 | 8/138,393 | 17,739/26,262,527 | 0.09 | 8.63e-30 | 2.15e-28 |
| GSTM1 gene|GSTM1:0 | 50/138,393 | 2,544/26,262,527 | 3.73 | 2.02e-14 | 2.57e-13 |
| RC 160:0 | 19/138,393 | 309/26,262,527 | 11.67 | 3.07e-14 | 3.87e-13 |
| Antrum:0 | 1/138,393 | 6,417/26,262,527 | 0.03 | 1.48e-13 | 1.77e-12 |
| GLUCOSE TOLERANCE:0 | 5/138,393 | 9,810/26,262,527 | 0.10 | 2.22e-16 | 3.17e-15 |
| Vitiligo:0 | 3/138,393 | 8,763/26,262,527 | 0.06 | 4.39e-16 | 6.14e-15 |
| School (environment):0 | 1/138,393 | 7,432/26,262,527 | 0.03 | 9.16e-16 | 1.26e-14 |
| Percutaneous coronary intervention:0 | 1/138,393 | 27,860/26,262,527 | 0.01 | 5.96e-62 | 3.28e-60 |
| Epidermis:0 | 19/138,393 | 27,452/26,262,527 | 0.13 | 3.88e-39 | 1.31e-37 |
| Clomiphene Citrate:0 | 1/138,393 | 4,981/26,262,527 | 0.04 | 2.13e-10 | 2.01e-09 |
| glucose homeostasis:0 | 5/138,393 | 6,111/26,262,527 | 0.16 | 7.88e-09 | 6.45e-08 |
| Mitochondria, Liver:0 | 4/138,393 | 10,594/26,262,527 | 0.07 | 5.66e-19 | 9.21e-18 |
| Entire tooth:0 | 3/138,393 | 7,931/26,262,527 | 0.07 | 2.00e-14 | 2.54e-13 |
| Neurofibromatosis 1:0 | 4/138,393 | 8,374/26,262,527 | 0.09 | 3.13e-14 | 3.94e-13 |
| Metastron:0 | 8/138,393 | 25/26,262,527 | 60.73 | 7.04e-12 | 7.46e-11 |
| HTATIP protein, human|KAT5:0 | 16/138,393 | 577/26,262,527 | 5.26 | 1.73e-07 | 1.22e-06 |
| gamma-Aminobutyric Acid:0 | 9/138,393 | 56,041/26,262,527 | 0.03 | 7.06e-112 | 6.90e-110 |
| Quantitative Trait Loci:0 | 3/138,393 | 12,329/26,262,527 | 0.05 | 7.17e-24 | 1.44e-22 |
| Electroacupuncture:0 | 3/138,393 | 6,130/26,262,527 | 0.09 | 1.32e-10 | 1.27e-09 |
| Xenograft procedure:0 | 564/138,393 | 11,018/26,262,527 | 9.75 | 0.00e+00 | 0.00e+00 |
| Pregnancy Complications:0 | 1/138,393 | 3,945/26,262,527 | 0.05 | 5.23e-08 | 3.89e-07 |
| sulindac sulfone:0 | 22/138,393 | 381/26,262,527 | 10.96 | 1.02e-15 | 1.40e-14 |
| Augmentation procedure:0 | 22/138,393 | 17,616/26,262,527 | 0.24 | 2.73e-18 | 4.30e-17 |
| disease characteristic:0 | 27/138,393 | 613/26,262,527 | 8.36 | 3.70e-16 | 5.20e-15 |
| RNA:0 | 484/138,393 | 126,350/26,262,527 | 0.73 | 1.63e-13 | 1.94e-12 |
| Receptors, Opioid, kappa:0 | 1/138,393 | 4,701/26,262,527 | 0.04 | 9.16e-10 | 8.14e-09 |
| KLK5 gene|KLK5:0 | 8/138,393 | 65/26,262,527 | 23.36 | 5.66e-09 | 4.69e-08 |
| Plasmapheresis:0 | 3/138,393 | 6,391/26,262,527 | 0.09 | 3.17e-11 | 3.19e-10 |
| HIF1A:0 | 18/138,393 | 641/26,262,527 | 5.33 | 2.53e-08 | 1.95e-07 |
| Acid phosphatase isoenzyme:0 | 8/138,393 | 69/26,262,527 | 22.00 | 8.70e-09 | 7.06e-08 |
| Antibodies, Anticardiolipin:0 | 1/138,393 | 3,403/26,262,527 | 0.06 | 6.12e-07 | 4.06e-06 |
| Recombination, Genetic:0 | 30/138,393 | 16,232/26,262,527 | 0.35 | 7.66e-12 | 8.08e-11 |
| Thrombocythemia, Hemorrhagic:0 | 2/138,393 | 6,159/26,262,527 | 0.06 | 1.09e-11 | 1.14e-10 |
| device aspects:0 | 17/138,393 | 14,898/26,262,527 | 0.22 | 1.17e-16 | 1.69e-15 |
| Clonazepam:0 | 1/138,393 | 3,260/26,262,527 | 0.06 | 1.26e-06 | 8.06e-06 |
| CARBONATE DEHYDRATASE:0 | 7/138,393 | 8,008/26,262,527 | 0.17 | 6.36e-11 | 6.23e-10 |
| Procedures:0 | 668/138,393 | 93,942/26,262,527 | 1.35 | 1.51e-13 | 1.81e-12 |
| Reconstructive Surgical Procedures:0 | 142/138,393 | 65,162/26,262,527 | 0.41 | 1.43e-34 | 4.17e-33 |
| RC 3095:0 | 10/138,393 | 250/26,262,527 | 7.59 | 1.56e-06 | 9.85e-06 |
| Precancerous lesions:0 | 111/138,393 | 5,462/26,262,527 | 3.86 | 4.03e-31 | 1.06e-29 |
| Carbohydrate antigen:0 | 19/138,393 | 779/26,262,527 | 4.63 | 8.90e-08 | 6.48e-07 |
| Proteinuria:0 | 10/138,393 | 24,463/26,262,527 | 0.08 | 1.07e-41 | 3.87e-40 |
| frontal lobe:0 | 6/138,393 | 24,052/26,262,527 | 0.05 | 1.69e-45 | 6.68e-44 |
| Lectin:0 | 60/138,393 | 29,427/26,262,527 | 0.39 | 4.94e-18 | 7.69e-17 |